

WEST Search History

DATE: Friday, August 13, 2004

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L28	L23 AND 514/2.CCLS.	29
<input type="checkbox"/>	L27	= 2000	33
<input type="checkbox"/>	L26	L23 AND inhalation	377
<input type="checkbox"/>	L25	L23 AND CPK-MB	4
<input type="checkbox"/>	L24	L23 AND acute coronary artery disease	2
<input type="checkbox"/>	L23	L22 AND coronary artery disease	793
<input type="checkbox"/>	L22	(FGF-1 OR aFGF OR acidic FGF OR FGF-2 OR bFGF OR basic FGF OR VEGF)	12334
<input type="checkbox"/>	L21	= 2000	44
<input type="checkbox"/>	L20	L19 AND treatment	810
<input type="checkbox"/>	L19	L17 AND nasal	811
<input type="checkbox"/>	L18	L17 AND inhala?	0
<input type="checkbox"/>	L17	L14 AND growth factor	2032
<input type="checkbox"/>	L16	L14 AND growth-factor	41
<input type="checkbox"/>	L15	L14 AND growth fator	3
<input type="checkbox"/>	L14	coronary artery disease	7647
<input type="checkbox"/>	L13	L12 AND growth factor	83
<input type="checkbox"/>	L12	L11 AND coronary artery disease	143
<input type="checkbox"/>	L11	530/300,324,399.CCLS.	8009
<input type="checkbox"/>	L10	L9 AND coronary artery disease	28
<input type="checkbox"/>	L9	424/9.1.CCLS.	907
<input type="checkbox"/>	L8	L7 AND coronary artery disease	67
<input type="checkbox"/>	L7	L6 AND growth factor	2399
<input type="checkbox"/>	L6	(514/2.CCLS.)	6208
<input type="checkbox"/>	L5	Franco-W-P.IN.	3
<input type="checkbox"/>	L4	Franco-Wayne-P.IN.	6
<input type="checkbox"/>	L3	Franco.IN.	6436
<input type="checkbox"/>	L2	Franco-W.IN.	4
<input type="checkbox"/>	L1	(Franco-Wayne.IN.)	0

END OF SEARCH HISTORY

Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Search Results - Record(s) 1 through 67 of 67 returned.

☐ 1. Document ID: US 20040097401 A1

Using default format because multiple data bases are involved.

L8: Entry 1 of 67

File: PGPB

May 20, 2004

PGPUB-DOCUMENT-NUMBER: 20040097401

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040097401 A1

TITLE: Lysine in therapeutic angiogenesis, particularly in treating ischaemic conditions

PUBLICATION-DATE: May 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Datta, Debatosh	Kolkata		IN	

US-CL-CURRENT: 514/2; 514/564, 514/565

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 2. Document ID: US 20040087486 A1

L8: Entry 2 of 67

File: PGPB

May 6, 2004

PGPUB-DOCUMENT-NUMBER: 20040087486

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040087486 A1

TITLE: Methods and compositions for treating platelet-related disorders

PUBLICATION-DATE: May 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hanson, Stephen R.	Stone Mountain	GA	US	

US-CL-CURRENT: 514/2

ABSTRACT:

The invention relates to the prophylactic and therapeutic treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents which reduce the number of circulating platelets to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

h e b b g e e e f e h c e f b e

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 3. Document ID: US 20040082659 A1

L8: Entry 3 of 67

File: PGPB

Apr 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040082659

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040082659 A1

TITLE: Enhancement of vascular function by modulation of endogenous nitric oxide production or activity

PUBLICATION-DATE: April 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cooke, John P.	Palo Alto	CA	US	
Dzau, Victor J.	Newton	MA	US	
Gibbons, Gary H.	Atlanta	GA	US	

US-CL-CURRENT: 514/565; 514/2, 514/564

ABSTRACT:

Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 4. Document ID: US 20040033971 A1

L8: Entry 4 of 67

File: PGPB

Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040033971

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040033971 A1

TITLE: Polypeptides and nucleic acids encoding same

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gangolli, Esha A.	Madison	CT	US	
Patturajan, Meera	Branford	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	

h e b b g e e f e h c e f b e

Kekuda, Ramesh	Norwalk	CT	US
Stone, David J.	Guilford	CT	US
Anderson, David	Branford	CT	US
Shimkets, Richard A.	Guilford	CT	US
Burgess, Catherine E.	Wethersfield	CT	US
Zerhusen, Bryan D.	Branford	CT	US
Liu, Xiaohong	Branford	CT	US
Spytek, Kimberly A.	New Haven	CT	US
Casman, Stacie J.	North Haven	CT	US
Boldog, Ference L.	North Haven	CT	US
Smithson, Glennnda	Guilford	CT	US
Li, Li	Branford	CT	US
Ji, Weizhen	Branford	CT	US
MacDougall, John R.	Hamden	CT	US

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/7.1, 514/2, 530/387.1, 536/23.1

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention farther discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 5. Document ID: US 20040018960 A1

L8: Entry 5 of 67

File: PGPB

Jan 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040018960

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040018960 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	US	
Wallace, Sidney	Houston	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David J.	Sugar Land	TX	US	

US-CL-CURRENT: 514/2; 424/649, 514/185

ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by

h e b b g e e e f e h c e f b e

conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: US 20040002440 A1

L8: Entry 6 of 67

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002440

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002440 A1

TITLE: Novel diagnostic agents of chronic or persistent chlamydial diseases and uses thereof

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Timms, Peter	Queensland		AU	
Mathews, Sarah Anne	Queensland		AU	

US-CL-CURRENT: 514/2; 435/6, 435/7.32, 514/44

ABSTRACT:

The present invention discloses compositions and methods for detecting organisms of the Chlamydiaceae family, including species of Chlamydia and Chlamyclophila, in the persistent phase of their developmental cycle and for the diagnosis of chronic or persistent infections caused by such organisms. The present invention also discloses methods for screening agents that are useful inter alia for modulating a gene whose expression is altered in the persistent phase of the chlamydial developmental cycle or for modulating the level and/or functional activity of an expression product of that gene. Also disclosed are methods and compositions for the treatment and/or prophylaxis of infections, including chronic infections, caused by chlamydial organisms using the aforesaid modulatory agents and optionally agents that are effective in modulating the expression of a gene associated with the lytic phase of said developmental cycle or in modulating the level and/or functional activity of an expression product of that gene. The invention also discloses methods and compositions for the treatment and/or prophylaxis of such infections using a first immunopotentiating agent that elicits the production of elements that are immuno-interactive with an antigen associated with the persistent phase of the chlamydial developmental cycle and a second immunopotentiating agent that elicits the production of elements that are immuno-interactive with an antigen associated with the lytic phase of said developmental cycle.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 7. Document ID: US 20030229003 A1

L8: Entry 7 of 67

File: PGPB

Dec 11, 2003

h e b b g e e f e h c e f b e

PGPUB-DOCUMENT-NUMBER: 20030229003
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030229003 A1

TITLE: Use of transcription factors for treating inflammation and other diseases

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Oettgen, Peter	Brookline	MA	US	
Libermann, Towia	Newton	MA	US	
Goldring, Mary	Auburndale	MA	US	

US-CL-CURRENT: 514/1; 435/4, 435/6, 514/2, 514/44, 514/54

ABSTRACT:

The present invention provides a method of treating inflammation in a mammal comprising altering the activity of a transcription factor involved in the inflammatory response. The invention also relates to the use of transcription factors to screen compounds that are capable of reducing inflammation. The invention also relates to the use of transcription factors in methods of diagnosing the presence of an inflammatory disease in a tissue of a mammal and methods of monitoring the treatment of an inflammatory disease in a tissue of a mammal.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Dram. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

8. Document ID: US 20030215840 A1

L8: Entry 8 of 67

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215840
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030215840 A1

TITLE: Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas J.	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US	
Galvin, Katherine M.	Jamaica Plain	MA	US	
Healy, Aileen	Medford	MA	US	
Acton, Susan L.	Lexington	MA	US	
Donoghue, Mary A.	West Roxbury	MA	US	
Stagliano, Nancy	North Reading	MA	US	

h e b b g e e f e h c ef b e

Perodin, Jacqueline	Arlington	MA	US
Rodrigue-Way, Amelie	Malden	MA	US

US-CL-CURRENT: 435/6; 424/146.1, 435/7.2, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 and 6585 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 9. Document ID: US 20030215452 A1

L8: Entry 9 of 67

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215452

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030215452 A1

TITLE: Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Carroll, Joseph M.	Cambridge	MA	US	
Healy, Aileen	Medford	MA	US	
Weich, Nadine S.	Brookline	MA	US	
Kelly, Louise M.	Brookline	MA	US	

US-CL-CURRENT: 424/146.1; 435/6, 435/7.2, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the

h e b b g e e e f e h c e f b e

differential expression of 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 and 13249 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

10. Document ID: US 20030211472 A1

L8: Entry 10 of 67

File: PGPB

Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211472

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030211472 A1

TITLE: 125 human secreted proteins

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Feng, Ping	Gaithersburg	MD	US	
Ruben, Steven M.	Olney	MD	US	
Rosen, Craig A.	Laytonsville	MD	US	
Ebner, Reinhard	Gaithersburg	MD	US	
Olsen, Henrik S.	Gaithersburg	MD	US	
Ni, Jian	Rockville	MD	US	
Wei, Ying-Fei	Berkeley	CA	US	
Soppet, Daniel R.	Centreville	VA	US	
Moore, Paul A.	Germantown	MD	US	
Kyaw, Hla	Frederick	MD	US	
LaFleur, David W.	Washington	DC	US	
Shi, Yanggu	Gaithersburg	MD	US	
Janat, Fouad	Westerly	RI	US	
Endress, Gregory A.	Potomac	MD	US	
Carter, Kenneth C.	North Potomac	MD	US	

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

h e b b g e e f e h c ef b e

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 11. Document ID: US 20030211095 A1

L8: Entry 11 of 67

File: PGPB

Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211095

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030211095 A1

TITLE: Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Higazi, Abd. Al-Roof	D.N. Shimshon		IL	

US-CL-CURRENT: 424/94.64; 514/2

ABSTRACT:

The present invention relates to compositions of the polypeptide EEIIMI, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents comprising scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prolonging the half lives of the fibrinolytic agents.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 12. Document ID: US 20030199425 A1

L8: Entry 12 of 67

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199425

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030199425 A1

TITLE: Compositions and methods for treatment of hyperplasia

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Desai, Neil P.	Los Angeles	CA	US	
Soon-Shiong, Patrick	Los Angeles	CA	US	

US-CL-CURRENT: 514/2; 424/45, 514/291, 514/365, 514/449

h e b b g e e e f e h c e f b e

ABSTRACT:

In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 13. Document ID: US 20030176320 A1

L8: Entry 13 of 67

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030176320

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030176320 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	US	
Wallace, Sidney	Houston	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David J.	Sugar Land	TX	US	

US-CL-CURRENT: 514/2; 514/8

ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 14. Document ID: US 20030166507 A1

L8: Entry 14 of 67

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166507

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166507 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: September 4, 2003

h e b b g e e e f e h c e f b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	US	
Wallace, Sidney	Houston	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David	Sugar Land	TX	US	

US-CL-CURRENT: 514/2; 514/8, 600/1

ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 15. Document ID: US 20030154504 A1

L8: Entry 15 of 67

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030154504

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030154504 A1

TITLE: Methods and compositions for modulating carbohydrate metabolism

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Farese, Robert V. JR.	San Francisco	CA	US	
Chen, Hubert C.	San Francisco	CA	US	

US-CL-CURRENT: 800/18; 514/2, 514/3

ABSTRACT:

Methods and compositions for modulating carbohydrate metabolism in a host are provided. In the subject methods, diacylglycerol acyltransferase (DGAT) activity (specifically DGAT1 activity) is modulated, e.g., reduced or enhanced, to achieve a desired insulin and/or leptin sensitivity, thereby modulating carbohydrate metabolism, e.g., increasing or decreasing blood glucose levels, glucose uptake into cells and assimilation into glycogen. Also provided are pharmaceutical compositions for practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the treatment of hosts suffering conditions associated with abnormal carbohydrate metabolism, such as obesity or diabetes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 16. Document ID: US 20030152574 A1

L8: Entry 16 of 67

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152574

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030152574 A1

TITLE: Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas Joseph	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US	

US-CL-CURRENT: 424/146.1; 435/7.2, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1419, 58765 or 2210 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 17. Document ID: US 20030130170 A1

L8: Entry 17 of 67

File: PGPB

Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030130170

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030130170 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	US	
Wallace, Sidney	Houston	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David J.	Sugar Land	TX	US	

h e b b g e e e f e h c e f b e

US-CL-CURRENT: 514/2; 514/8, 514/9

ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☒ 18. Document ID: US 20030109420 A1

L8: Entry 18 of 67

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030109420

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030109420 A1

TITLE: Diagnostic markers of acute coronary syndrome and methods of use thereof

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Valkirs, Gunars	Escondido	CA	US	
Dahlen, Jeffrey	San Diego	CA	US	
Buechler, Kenneth F.	Rancho Santa Fe	CA	US	
Kirchick, Howard J.	San Diego	CA	US	

US-CL-CURRENT: 514/2; 435/7.1

ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of acute coronary syndromes. In particular, patient test samples are analyzed for the presence and amount of members of a panel of markers comprising one or more specific markers for myocardial injury and one or more non-specific markers for myocardial injury. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. In various aspects, the invention provides methods for the early detection and differentiation of stable angina, unstable angina, and myocardial infarction. Invention methods provide rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, reduce the costs associated with incorrect diagnosis, and provide important information about the prognosis of the patient.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 19. Document ID: US 20030104977 A1

L8: Entry 19 of 67

File: PGPB

Jun 5, 2003

h e b b g e e e f e h c e f b e

PGPUB-DOCUMENT-NUMBER: 20030104977
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030104977 A1

TITLE: METHODS FOR INDUCING ANGIOGENESIS USING MORPHOGENIC PROTEINS AND STIMULATORY FACTORS

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
RIPAMONTI, UGO	SANDTON		ZA	
RAMOSHEBI, LENTSHA NATHANIEL	JOHANNESBURG		ZA	

US-CL-CURRENT: 514/2

ABSTRACT:

The present invention provides a method for inducing angiogenesis at a target locus in a mammal using morphogenic proteins. In addition, this invention also features a method for improving the angiogenic capability of a morphogenic protein at a target locus in a mammal. In this method, the morphogenic protein is capable of inducing angiogenesis when accessible to a progenitor cell in the mammal, and the morphogenic protein stimulatory factor enhances that capability. The morphogenic protein and morphogenic protein stimulatory factor can be administered simultaneously to the target locus. Alternatively, the two components are administered separately, in any order.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 20. Document ID: US 20030092658 A1

L8: Entry 20 of 67

File: PGPB

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092658
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030092658 A1

TITLE: Novel human enzyme family members and uses thereof

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Meyers, Rachel E.	Newton	MA	US	
Glucksmann, Maria Alexandra	Lexington	MA	US	
Rudolph-Owen, Laura A.	Jamaica Plain	MA	US	

US-CL-CURRENT: 514/44; 424/130.1, 435/6, 514/2

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 33312, 33303, 32579, 21509, 33770, 46638, and 50090 nucleic acid molecules, which encode novel G protein-coupled receptor family members, human thioredoxin family members, human

h e b b g e e e f e h c e f b e

leucine-rich repeat family members, and human ringfinger family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33312, 33303, 32579, 21509, 33770, 46638, or 50090 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33312, 33303, 32579, 21509, 33770, 46638, or 50090 gene has been introduced or disrupted. The invention still further provides isolated 33312, 33303, 32579, 21509, 33770, 46638, or 50090 proteins, fusion proteins, antigenic peptides and anti-33312, 33303, 32579, 21509, 33770, 46638, or 50090 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

21. Document ID: US 20030083231 A1

L8: Entry 21 of 67

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030083231

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030083231 A1

TITLE: Blood cell deficiency treatment method

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ahlem, Clarence N.	San Diego	CA	US	
Reading, Christopher	San Diego	CA	US	
Frincke, James	San Diego	CA	US	
Stickney, Dwight	Granite Bay	CA	US	
Lardy, Henry A.	Madison	WI	US	
Marwah, Padma	Middleton	WI	US	
Marwah, Ashok	Middleton	WI	US	
Prendergast, Patrick T.	Straffan		IE	

US-CL-CURRENT: 514/2; 514/169, 514/173, 514/26, 514/44, 514/63

ABSTRACT:

The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D- -glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstane-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandros- tane that can be used in the treatment method.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

22. Document ID: US 20030073617 A1

L8: Entry 22 of 67

File: PGPB

Apr 17, 2003

h e b b g e e e f e h c e f b e

PGPUB-DOCUMENT-NUMBER: 20030073617
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030073617 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	US	
Wallace, Sidney	Houston	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David J.	Sugar Land	TX	US	

US-CL-CURRENT: 514/2; 514/171, 514/27, 514/283, 514/34, 514/449, 514/8

ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KNOW	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------	-----

☐ 23. Document ID: US 20030073615 A1

L8: Entry 23 of 67

File: PGPB

Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073615
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030073615 A1

TITLE: Water soluble paclitaxel derivatives

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Chun	Missouri City	TX	US	
Wallace, Sidney	Bellaire	TX	US	
Yu, Dong-Fang	Houston	TX	US	
Yang, David J.	Sugar Land	TX	US	

US-CL-CURRENT: 514/2; 514/8

ABSTRACT:

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-

h e b b g e e e f e h c e f b e

glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KNOW	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 24. Document ID: US 20030073118 A1

L8: Entry 24 of 67

File: PGPB

Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073118

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030073118 A1

TITLE: MID 9002, a human sulfatase family member and uses therefor

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Williamson, Mark W.	Saugus	MA	US	

US-CL-CURRENT: 435/6; 424/130.1, 514/1, 514/2, 514/44

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated MID 9002 nucleic acid molecules, which encode novel sulfatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MID 9002 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MID 9002 gene has been introduced or disrupted. The invention still further provides isolated MID 9002 proteins, fusion proteins, antigenic peptides and anti-MID 9002 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KNOW	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 25. Document ID: US 20020151046 A1

L8: Entry 25 of 67

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151046

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020151046 A1

TITLE: 52871, a novel human G protein coupled receptor and uses thereof

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Glucksmann, Maria Alexandra	Lexington	MA	US	

h e b b g e e e f e h c e f b e

Silos-Santiago, Inmaculada Cambridge MA US

US-CL-CURRENT: 435/320.1; 435/325, 435/6, 435/69.1, 435/7.1, 514/2, 530/324,
530/387.7, 536/23.5

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 52871 nucleic acid molecules, which encode novel G-Protein Coupled Receptor molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52871 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52871 gene has been introduced or disrupted. The invention still further provides isolated 52871 proteins, fusion proteins, antigenic peptides and anti-52871 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	INNOV	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	-----------

☐ 26. Document ID: US 20020131959 A1

L8: Entry 26 of 67

File: PGPB

Sep 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020131959

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020131959 A1

TITLE: Means and methods for the modulation of arteriogenesis

PUBLICATION-DATE: September 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Buschmann, Ivo	Freiburg		DE	
Van Royen, Niels	Gundelfingen		DE	
Hofer, Imo	March		DE	

US-CL-CURRENT: 424/93.21; 424/85.1, 424/85.2, 514/2, 514/44

ABSTRACT:

The present invention relates generally to the modulation of arteriogenesis and/or the growth of collateral arteries or other arteries from preexisting arteriolar connections. In particular, the present invention provides a method for enhancing arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting an organ, tissue or cells with transforming growth factor beta 1 (TGF.beta.1) or a nucleic acid molecule encoding TGF.beta.1. The present invention also relates to the use of TGF.beta.1 or a nucleic acid molecule encoding TGF.beta.1 for the preparation of pharmaceutical compositions for enhancing arteriogenesis and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Furthermore, the present invention relates to a method for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGF.beta.1. The present invention further involves the use of an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the

h e b b g e e e f e h c e f b e

biological activity of TGF.beta.1 for the preparation of pharmaceutical compositions for the treatment of tumors.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 27. Document ID: US 20020119913 A1

L8: Entry 27 of 67

File: PGPB

Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119913

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020119913 A1

TITLE: 61833, a novel human pyridoxyl-dependent decarboxylase family member and uses thereof

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Glucksmann, Maria Alexandra	Lexington	MA	US	

US-CL-CURRENT: 514/2; 435/320.1, 435/325, 435/6, 435/69.1, 435/7.2, 530/324, 530/387.9, 536/23.5

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated 61833 nucleic acid molecules, which encode novel pyridoxyl-dependent decarboxylase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 61833 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 61833 gene has been introduced or disrupted. The invention still further provides isolated 61833 proteins, fusion proteins, antigenic peptides and anti-61833 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 28. Document ID: US 20020061521 A1

L8: Entry 28 of 67

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061521

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061521 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

h e b b g e e f e h c e f b e

Barash, Steven C.

Rockville

MD

US

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

ABSTRACT:

The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 29. Document ID: US 20020061294 A1

L8: Entry 29 of 67

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061294

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061294 A1

TITLE: MONONUCLEAR PHAGOCYTES IN THERAPEUTIC DRUG DELIVERY

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LEWIS, CLAIRE E.	SHEFFIELD		GB	
HARRIS, ADRIAN L.	OXFORD		GB	
MARSHALL, JULIAN M	OXFORD		GB	

US-CL-CURRENT: 424/93.21; 424/450, 435/320.1, 435/325, 435/69.1, 514/2, 514/44

ABSTRACT:

The invention relates to the exploitation of the migratory behaviour of mononuclear phagocytes with a view to targeting therapeutic drug delivery. The invention therefore concerns the attachment or incorporation of a therapeutic agent to or into a mononuclear phagocyte and the subsequent migration of the mononuclear phagocyte to a target area.

h e b b g e e f e h c e f b e

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 30. Document ID: US 20020058612 A1

L8: Entry 30 of 67

File: PGPB

May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058612

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020058612 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/2; 424/43

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 31. Document ID: US 20020037832 A1

L8: Entry 31 of 67

File: PGPB

Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037832

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020037832 A1

TITLE: Use of alpha-MSH and EPO for preventing or treating ischemic conditions

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nielsen, Soren	Abyhoj		DK	
Frokiaer, Jorgen	Abyhoj		DK	
Jonassen, Thomas Engelbrecht Norkild	Frederiksberg		DK	
Bjerke, Thorbjorn	Fredensborg		DK	

US-CL-CURRENT: 514/2; 514/169

h e b b g e e e f e h c e f b e

ABSTRACT:

Alpha--melanocyte stimulating hormone (.alpha.-MSH) or an equivalent is used, in conjunction with erythropoietin (EPO) or equivalent, to prevent or treat ischemic conditions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 32. Document ID: US 20020013275 A1

L8: Entry 32 of 67

File: PGPB

Jan 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020013275

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020013275 A1

TITLE: Therapeutic inhibitor of vascular smooth muscle cells

PUBLICATION-DATE: January 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kunz, Lawrence L.	Redmond	WA	US	
Klein, Richard A.	Lynnwood	WA	US	
Reno, John M.	Brier	WA	US	
Grainger, David J.	Cambridge	AL	GB	
Metcalfe, James C.	Cambridge		GB	
Weissberg, Peter L.	Cambridge		GB	
Anderson, Peter G.	Birmingham		US	

US-CL-CURRENT: 514/12; 514/2, 514/411

ABSTRACT:

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

☐ 33. Document ID: US 20020006895 A1

L8: Entry 33 of 67

File: PGPB

Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006895

h e b b g e e e f e h c e f b e

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020006895 A1

TITLE: Method of treatment of cardiovascular injuries

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moulton, Karen S.	Weston	MA	US	
Folkman, Judah	Brookline	MA	US	

US-CL-CURRENT: 514/2; 424/85.6, 424/85.7, 514/326, 514/475

ABSTRACT:

The present invention provides a method for treating cardiovascular ailments. The method involves first screening an individual to determine their risk of having the potential for unstable plaques. Such individuals can be selected by looking at one of the following criteria: (i) increased plaque neovascularization, (ii) area ratio of intima to wall area of a plaque, (iii) evidence of plaque hemorrhage, or (iv) inflammatory cells associated with plaque vessels. Looking at these criteria permits one to select individuals having the potential for unstable plaques. The method then involves treating the selected individual with an effective amount of an angiogenesis inhibitor.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMAC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 34. Document ID: US 20010053357 A1

L8: Entry 34 of 67

File: PGPB

Dec 20, 2001

PGPUB-DOCUMENT-NUMBER: 20010053357

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010053357 A1

TITLE: LIGAND BINDING SITE OF RAGE AND USES THEREOF

PUBLICATION-DATE: December 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
STERN, DAVID	GREAT NECK	NY	US	
YAN, SHI DU	NEW YORK	NY	US	
SCHMIDT, ANN MARIE	FRANKLIN LAKE	NJ	US	
LAMSTER, IRA	WYCKOFF	NJ	US	

US-CL-CURRENT: 424/130.1; 514/12, 514/2, 530/350

ABSTRACT:

The present method provides for an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of a receptor for advanced glycation endproduct (RAGE). The present invention also provides for an isolated peptide having an amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-

h e b b g e e e f e h c e f b e

P-Q-R-L-E-W-K (Seq. I.D. No. 1). The present invention provides for a pharmaceutical composition comprising a therapeutically effect amount of an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of RAGE. The present invention also provides for a method for inhibiting interaction of an amyloid-.beta. peptide with a receptor for advanced glycation end product which is on the surface of a cell, which comprises contacting the cell with the peptide or a functionally equivalent agent, wherein the peptide or agent is capable of inhibiting interaction of the amyloid-.beta. peptide with the receptor for advanced glycation end product, and the peptide or agent is present in an amount effective to inhibit interaction of the amyloid-.beta. peptide with the receptor for advanced glycation endproduct.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 35. Document ID: US 20010029251 A1

L8: Entry 35 of 67

File: PGPB

Oct 11, 2001

PGPUB-DOCUMENT-NUMBER: 20010029251

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010029251 A1

TITLE: Methods and compositions for preventing or retarding the development of a atherosclerotic lesions

PUBLICATION-DATE: October 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gonczol, Eva	Rosemont	PA	US	
Berencsi, Klara	Rosemont	PA	US	

US-CL-CURRENT: 514/44; 514/2

ABSTRACT:

A method for preventing or retarding the development atherosclerotic lesions or restenosis involves administering to a subject, preferably a human, an effective amount of an anti-viral composition directed against CMV, and optionally an anti-microbial composition directed against C. pneumoniae. These compositions may be conventional chemical anti-microbial pharmaceuticals. Alternatively, the compositions may contain a cytomegalovirus (CMV) protein or fragment thereof (or nucleic acid containing compositions expressing such protein or fragment). Such compositions may contain an immunogenic C. pneumoniae protein or fragment thereof (or nucleic acid containing compositions expressing such protein or fragment). The protein/nucleic acid compositions are administered in an amount capable of inducing cell mediated immunity and/or antibody response in the subject.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 36. Document ID: US 6759386 B2

L8: Entry 36 of 67

File: USPT

Jul 6, 2004

US-PAT-NO: 6759386

h e b b g e e e f e h c e f b e

DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Rocky Hill	CT	06067	

US-CL-CURRENT: 514/2; 514/12, 514/14, 514/8, 530/300

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

24 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 37. Document ID: US 6737404 B2

L8: Entry 37 of 67

File: USPT

May 18, 2004

US-PAT-NO: 6737404

DOCUMENT-IDENTIFIER: US 6737404 B2

TITLE: Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137

DATE-ISSUED: May 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Springer; Barry A.	Wilmington	DE		
Pantoliano; Michael W.	Boxford	PA		
Sharp; Celia M.	Doylestown	PA		

US-CL-CURRENT: 514/12; 514/2, 530/399

ABSTRACT:

The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating

h e b b g e e e f e h c e f b e

ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.

30 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 38. Document ID: US 6696063 B1

L8: Entry 38 of 67

File: USPT

Feb 24, 2004

US-PAT-NO: 6696063

DOCUMENT-IDENTIFIER: US 6696063 B1

TITLE: Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDs) with or without lipodystrophy

DATE-ISSUED: February 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Torres; Ramon A.	New York	NY		

US-CL-CURRENT: 424/198.1; 514/2, 530/399

ABSTRACT:

Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDs) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS and other specific medical terms), is treated by administering an effective amount of human growth hormone or other substance which binds to and initiates signalling of the hGH receptor. Alternatively, a substance which stimulates production of endogenous hGH, such as human growth hormone releasing hormone, may be administered. HADDs and related syndromes include abnormal adipose tissue accumulation in the visceral, submandibular, supraclavicular, pectoral, mammary and/or dorsocervical (buffalo hump) area, and/or with subcutaneous lipomas, with or without associated metabolic or other physiologic abnormalities.

27 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 39. Document ID: US 6605592 B2

L8: Entry 39 of 67

File: USPT

Aug 12, 2003

US-PAT-NO: 6605592

DOCUMENT-IDENTIFIER: US 6605592 B2

TITLE: Protein HOFNF53

h e b b g e e f e h c e f b e

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Baker; Kevin P.	Darnestown	MD		
Birse; Charles E.	North Potomac	MD		
Ebner; Reinhard	Gaithersburg	MD		
Fiscella; Michele	Bethesda	MD		
Komatsoulis; George A.	Silver Spring	MD		
LaFleur; David W.	Washington	DC		
Moore; Paul A.	Germantown	MD		
Olsen; Henrik S.	Gaithersburg	MD		
Rosen; Craig A.	Laytonsville	MD		
Ruben; Steven M.	Olney	MD		
Soppet; Daniel R.	Centreville	VA		
Young; Paul E.	Gaithersburg	MD		
Wei; Ping	Brookeville	MD		
Florence; Kimberly A.	Rockville	MD		

US-CL-CURRENT: 514/2; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1, 435/71.1, 435/71.2, 514/12, 514/8, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. In particular, the present application relates to a novel human protein, Protein HOFNF53. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

19 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	COMM	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 40. Document ID: US 6592862 B1

L8: Entry 40 of 67

File: USPT

Jul 15, 2003

US-PAT-NO: 6592862

DOCUMENT-IDENTIFIER: US 6592862 B1

TITLE: Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schäper; Wolfgang	Bad Nauheim/P			DE

h e b b g e e f e h c e f b e

Ito; Wulf D.

Lunenburg

DE

US-CL-CURRENT: 424/85.1; 514/12, 514/2, 514/8

ABSTRACT:

Described is the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting tissue or cells with a monocyte chemotactic protein (MCP) or a nucleic acid molecule encoding said MCP. Furthermore, the use of a MCP or a nucleic acid molecule encoding said MCP for the preparation of pharmaceutical compositions for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described. Also provided are methods for the treatment of tumors comprising contacting tissue or cells with an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the attraction of monocytes. Described is further the use of an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through attraction of monocytes for the preparation of pharmaceutical compositions for the treatment of tumors.

14 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KINC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 41. Document ID: US 6558952 B1

L8: Entry 41 of 67

File: USPT

May 6, 2003

US-PAT-NO: 6558952

DOCUMENT-IDENTIFIER: US 6558952 B1

TITLE: Treatment for diabetes

DATE-ISSUED: May 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Parikh; Indu	Chapel Hill	NC		
Lane; Anne	Westmount			CA
Nardi; Ronald V.	Mahwah	NJ		
Brand; Stephen J.	Lincoln	MA		

US-CL-CURRENT: 435/384; 424/93.1, 435/320.1, 435/325, 435/366, 435/383, 514/2, 514/309, 514/399, 514/44, 514/866, 530/309, 530/399

ABSTRACT:

Methods and compositions for treating diabetes mellitus in a patient in need thereof are provided. The methods include administering to a patient a composition providing a gastrin/CCK receptor ligand, e.g., a gastrin, and/or an epidermal growth factor (EGF) receptor ligand, e.g., TGF- α , in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells

h e b b g e e f e h c e f b e

transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g., a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g., a TGF-.alpha. gene. The methods also include transplanting into a patient cultured pancreatic islets in which mature insulin-secreting beta cells are proliferated by exposure to a gastrin/CCK receptor ligand and an EGF receptor ligand.

3 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 42. Document ID: US 6541224 B2

L8: Entry 42 of 67

File: USPT

Apr 1, 2003

US-PAT-NO: 6541224

DOCUMENT-IDENTIFIER: US 6541224 B2

TITLE: Tumor necrosis factor delta polypeptides

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Germantown	MD		
Gentz; Reiner L.	Rockville	MD		
Dillon; Patrick J.	Carlsbad	CA		

US-CL-CURRENT: 435/69.5; 435/69.1, 435/69.7, 435/7.71, 435/70.1, 514/12, 514/2, 530/350, 530/351

ABSTRACT:

The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

50 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 43. Document ID: US 6541008 B1

L8: Entry 43 of 67

File: USPT

Apr 1, 2003

US-PAT-NO: 6541008

DOCUMENT-IDENTIFIER: US 6541008 B1

h e b b g e e e f e h c e f b e

TITLE: Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wise; Lyn M.	Dunedin			NZ
Mercer; Andrew A.	Dunedin			NZ
Savory; Loreen J.	Dunedin			NZ
Fleming; Stephen B.	Dunedin			NZ
Stacker; Steven A.	Parkville			AU

US-CL-CURRENT: 424/198.1; 514/2, 530/350

ABSTRACT:

The invention is based on the discovery that a viral VEGF-like protein from the orf virus strain NZ2 and from the orf virus strain NZ10 is capable of binding to the extracellular domain of the VEGF receptor-2 to form bioactive complexes which mediate useful cellular responses and/or antagonize undesired biological activities. Disclosed are methods which stimulate or inhibit these biological activities, methods for therapeutic applications and antagonists of ORFV2-VEGF and/or NZ10.

17 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 44. Document ID: US 6521211 B1

L8: Entry 44 of 67

File: USPT

Feb 18, 2003

US-PAT-NO: 6521211

DOCUMENT-IDENTIFIER: US 6521211 B1

TITLE: Methods of imaging and treatment with targeted compositions

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Wu; Yunqiu	Tucson	AZ		

US-CL-CURRENT: 424/9.52; 424/450, 424/9.5, 424/9.51, 514/18, 514/2, 600/431, 600/437

ABSTRACT:

Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of

h e b b g e e e f e h c e f b e

ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

58 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 45. Document ID: US 6518238 B1

L8: Entry 45 of 67

File: USPT

Feb 11, 2003

US-PAT-NO: 6518238
DOCUMENT-IDENTIFIER: US 6518238 B1

TITLE: Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3

DATE-ISSUED: February 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mascarenhas; Desmond	Los Angeles Hills	CA		

US-CL-CURRENT: 514/2; 514/12, 530/399

ABSTRACT:

Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 46. Document ID: US 6518236 B1

L8: Entry 46 of 67

File: USPT

Feb 11, 2003

US-PAT-NO: 6518236
DOCUMENT-IDENTIFIER: US 6518236 B1

h e b b g e e e f c h c e f b e

TITLE: FGF homologs

DATE-ISSUED: February 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deisher; Theresa A.	Seattle	WA		
Conklin; Darrell C.	Seattle	WA		
Raymond; Fenella	Seattle	WA		
Bukowski; Thomas R.	Seattle	WA		
Holderman; Susan D.	Seattle	WA		
Hansen; Birgit	Seattle	WA		
Sheppard; Paul O.	Redmond	WA		

US-CL-CURRENT: 514/2; 435/69.7, 514/12, 530/350, 530/399

ABSTRACT:

The present invention relates to polynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells, in particular cardiac cells and may be used for remodeling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF5 polypeptides.

5 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MM	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	----	------------

☐ 47. Document ID: US 6514937 B1

L8: Entry 47 of 67

File: USPT

Feb 4, 2003

US-PAT-NO: 6514937

DOCUMENT-IDENTIFIER: US 6514937

TITLE: Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mascarenhas; Desmond	Los Hills	CA		

US-CL-CURRENT: 514/12; 424/198, 424/520, 424/537, 424/546, 514/2, 514/3, 514/4, 530/303, 530/324, 530/333

ABSTRACT:

Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3.

h e b b g e e f e h c e f b e

Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided. Also provided are methods for the treatment of polycystic ovarian syndrome (PCOS) by long-term administration of IGF/IGFBP-3 complex.

1 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------

☐ 48. Document ID: US 6514935 B1

L8: Entry 48 of 67

File: USPT

Feb 4, 2003

US-PAT-NO: 6514935

DOCUMENT-IDENTIFIER: US 6514935

TITLE: Methods of treating hypertension

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Mu-En	Newton	MA		
Yet; Shaw-Fang	Los Angeles	CA		

US-CL-CURRENT: 514/2

ABSTRACT:

The invention features a method of inhibiting hypertension in a mammal by administering to the mammal a compound that reduces expression or activity of SmLIM.

3 Claims, 24 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------

☐ 49. Document ID: US 6500798 B1

L8: Entry 49 of 67

File: USPT

Dec 31, 2002

US-PAT-NO: 6500798

DOCUMENT-IDENTIFIER: US 6500798 B1

**** See image for Certificate of Collection ****

TITLE: Use of colostrinin, constituent peptides thereof, and analogs thereof, as oxidative stress regulators

h e b b g e e f e h c e f b e

DATE-ISSUED: December 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stanton; G. John	San Antonio	TX		
Hughes, Jr.; Thomas K.	Galveston	TX		
Boldogh; Istvan	Galveston	TX		

US-CL-CURRENT: 514/2; 424/525, 514/12, 514/13, 514/14, 514/15, 514/16, 514/17,
514/18, 530/300, 530/324, 530/326, 530/327, 530/328, 530/329, 530/334, 530/350

ABSTRACT:

The present invention provides methods that utilize compositions containing colostrinin, an constituent peptide thereof, an active analog thereof, and combinations thereof, as an oxidative stress regulator.

23 Claims, 11 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

☐ 50. Document ID: US 6498144 B1

L8: Entry 50 of 67

File: USPT

Dec 24, 2002

US-PAT-NO: 6498144

DOCUMENT-IDENTIFIER: US 6498144 B1

TITLE: Use of scatter factor to enhance angiogenesis

DATE-ISSUED: December 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Goldberg; Itzhak D.	Englewood	NJ		
Rosen; Eliot M.	Port Washington	NY		

US-CL-CURRENT: 514/12; 514/2, 530/324, 530/350, 530/399

ABSTRACT:

This invention relates to a method of enhancing wound healing and to a method of enhancing organ transplantation utilizing scatter factor, either alone or in combination with a growth factor.

5 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

h e b b g e e f e h c e f b e

☐ 51. Document ID: US 6491922 B1

L8: Entry 51 of 67

File: USPT

Dec 10, 2002

US-PAT-NO: 6491922

DOCUMENT-IDENTIFIER: US 6491922 B1

TITLE: Methods and compounds for treating autoimmune and vascular disease

DATE-ISSUED: December 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ho; John L.	New York	NY		

US-CL-CURRENT: 424/193.1; 424/265.1; 424/269.1, 514/2

ABSTRACT:

The present invention relates to methods of treating inflammatory diseases, inhibiting production of adhesion molecules on endothelial cells, inhibiting production of nitric oxide synthase by macrophages, inhibiting production of tissue factor by endothelial cells, reversing the inhibitory effects of lipophosphoglycan on endothelial cells or macrophages, and targeting a material to endothelial cells, fibroblasts, or monocytes, by administering lipophosphoglycan or lipophosphoglycan analog. Also disclosed is an isolated DNA molecule suitable for connection to a gene capable of transcription where lipophosphoglycan or lipophosphoglycan analogues bind to the DNA molecule and antagonize transcription of the gene.

14 Claims, 42 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 38

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	RWD	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------

☐ 52. Document ID: US 6475796 B1

L8: Entry 52 of 67

File: USPT

Nov 5, 2002

US-PAT-NO: 6475796

DOCUMENT-IDENTIFIER: US 6475796 B1

TITLE: Vascular endothelial growth factor variants

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pollitt; N. Stephen	Los Altos	CA		
Abraham; Judith A.	Santa Jose	CA		

US-CL-CURRENT: 435/455; 424/198.1, 14/2, 530/350

ABSTRACT:

The invention is directed to a method of enhancing the biological activity of

h e b b g e e e f e h c e f b e

vascular endothelial growth factor (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.

17 Claims, 17 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 17

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KNIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 53. Document ID: US 6440934 B1

L8: Entry 53 of 67

File: USPT

Aug 27, 2002

US-PAT-NO: 6440934

DOCUMENT-IDENTIFIER: US 6440934 B1

TITLE: Angiogenically effective use of FGF-2 and method of use

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Whitehouse; Martha Jo	San Francisco	CA		

US-CL-CURRENT: 514/12; 424/423, 424/94.4, 435/69.4, 514/2, 514/358, 514/410, 514/411, 514/51, 514/56, 530/350, 530/380, 530/381, 530/383, 530/399, 536/17.2, 536/21, 604/101.03

ABSTRACT:

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 .mu.g/kg to 48 .mu.g/kg of an FGF-2 of SEQ ID NO. 1, or an angiogenically active fragment or mutein thereof in a pharmaceutical acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts six months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion may play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit via the IV route was unexpected.

58 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KNIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

h e b b g e e f e b c e f b e

54. Document ID: US 6407135 B1

L8: Entry 54 of 67

File: USPT

Jun 18, 2002

US-PAT-NO: 6407135

DOCUMENT-IDENTIFIER: US 6407135 B1

TITLE: Conjugates of dithiocarbamate with pharmacologically active agents and uses therefor

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lai; Ching-San	Encinitas	CA		
Wang; Tingmin	San Marcos	CA		

US-CL-CURRENT: 514/423, 514/2, 514, 530/402, 548/565, 548/573

ABSTRACT:

In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

21 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	PMC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------

55. Document ID: US 6403552 B1

L8: Entry 55 of 67

File: USPT

Jun 11, 2002

US-PAT-NO: 6403552

DOCUMENT-IDENTIFIER: US 6403552 B1

TITLE: Ob receptor and methods for the diagnosis and treatment of body weight disorders

DATE-ISSUED: June 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

h e b b g e e f e b c e f b e

Tartaglia; Louis A.	W	MA
Tepper; Robert I.	W	MA
Culpepper; Janice A.	B	MA
White; David W.	H	MA

US-CL-CURRENT: 514/2; 424/143.1, 435/69.7, 536/23.4

ABSTRACT:

The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.

41 Claims, 40 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 34

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

56. Document ID: US 6235713 B

L8: Entry 56 of 67

File: USPT

May 22, 2001

US-PAT-NO: 6235713

DOCUMENT-IDENTIFIER: US 6235713 B1

TITLE: Vascular endothelial growth factor-D (VEGF-D) polypeptides

DATE-ISSUED: May 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Achen; Marc G.	Fitzroy			AU
Wilks; Andrew F.	South			AU
Stacker; Steven A.	North Fitzroy			AU
Alitalo; Kari	Espoo			FI

US-CL-CURRENT: 514/12; 514/2, 530/ 530/412, 530/413

ABSTRACT:

VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

16 Claims, 22 Drawing figures

h e b b g e e f e h c e f b e

Exemplary Claim Number: 1

Number of Drawing Sheets: 21

Full	Title	Citation	Font	Review	Class	Ref	Reference	Claims	KNOC	Drawing Des
------	-------	----------	------	--------	-------	-----	-----------	--------	------	-------------

☐ 57. Document ID: US 615673

L8: Entry 57 of 67

File: USPT

Dec 5, 2000

US-PAT-NO: 6156731

DOCUMENT-IDENTIFIER: US 6156731

TITLE: Polypeptide composition for administration

DATE-ISSUED: December 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grass; George M.	Mountain View	CA		
Sweetana; Stephanie A.		IN		

US-CL-CURRENT: 514/15; 424/185.1, 514/12, 514/13, 514/14, 514/16, 514/2, 530/300, 530/311, 530/313, 530/326, 530/327, 530/328

ABSTRACT:

There is disclosed a composition containing a biologically active polypeptide selected from LHRH, an LHRH analog, a somatostatin and a somatostatin analog, in a therapeutically effective amount, a permeability enhancing agent, and a protease enzyme inhibitor envelope, and an enteric coating. The composition possesses enhanced bioavailability for oral administration.

16 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Font	Review	Class	Ref	Reference	Claims	KNOC	Drawing Des
------	-------	----------	------	--------	-------	-----	-----------	--------	------	-------------

☐ 58. Document ID: US 603405

L8: Entry 58 of 67

File: USPT

Mar 7, 2000

US-PAT-NO: 6034053

DOCUMENT-IDENTIFIER: US 6034053

TITLE: EGF-isoflavone conjugates for prevention of restenosis

DATE-ISSUED: March 7, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Uckun; Fatih M.	White Bear Lake	MN		
Trieu; Vuong N.	Posey	MN		

h e b b g e e e f h c e f b e

US-CL-CURRENT: 514/2; 424/185.1, 424/193.1, 424/194.1, 424/195.11,
530/391.7

ABSTRACT:

A protein conjugate containing EGF fused to a tyrosine kinase inhibitor such as Genistein, for inhibiting or preventing restenosis following vascular injury.

19 Claims, 35 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Class	Date	Reference	Claims	KMC	Draw	Des
------	-------	----------	-------	--------	-------	------	-----------	--------	-----	------	-----

☐ 59. Document ID: US 6027921

L8: Entry 59 of 67

File: USPT

Feb 22, 2000

US-PAT-NO: 6027921

DOCUMENT-IDENTIFIER: US 6027921

TITLE: Chimeric proteins for use in transport of a selected substance into cells and DNA encoding chimeric proteins

DATE-ISSUED: February 22, 2000

INVENTOR-INFORMATION:

NAME	STATE	ZIP CODE	COUNTRY
Heartlein; Michael W.	MA		
Lemontt; Jeffrey F.	MA		
Concino; Michael F.	MA		

US-CL-CURRENT: 435/69.7; 435/325, 435/366, 514/2, 530/350, 530/399,
536/23.4

ABSTRACT:

Chimeric proteins, which comprise a carrier domain which binds a cell and a binding domain of a first receptor and a second receptor other than the first receptor, useful in transporting a selected substance present in extracellular fluids, such as blood or lymph, into cells; quantitative assays for the selected substance using chimeric proteins; DNA encoding chimeric proteins; plasmids which contain DNA encoding the chimeric proteins; cells, modified to contain DNA encoding the chimeric proteins; a method of producing the chimeric proteins; a method of using the chimeric proteins to assay the selected substance; and a method of reducing extracellular levels of the selected substance through administration of the chimeric proteins which results in transport of the selected substance into cells.

49 Claims, 18 Drawing figures

Exemplary Claim Number:

Number of Drawing Sheets: 17

Full	Title	Citation	Front	Review	Class	Date	Reference	Claims	KMC	Draw	Des
------	-------	----------	-------	--------	-------	------	-----------	--------	-----	------	-----

Methods are provided for treating psychological disorders, metabolic disorders, conditions associated with treating such subjects with IGF. Methods for increasing growth and alleviating symptoms of subjects with diabetes are also provided. Methods for increasing the symptoms of subjects with diabetes are also provided. Methods for increasing the symptoms of subjects with diabetes are also provided.

alleviating the symptoms of subjects with diabetes, chronic stress-related disorders, sleep disorders, senescence, aging, or premature aging by administering IGF either alone or complexed with IGFBP-3. Methods for increasing growth and alleviating the symptoms of subjects with diabetes are also provided. Methods for increasing the symptoms of subjects with diabetes are also provided. Methods for increasing the symptoms of subjects with diabetes are also provided.

6 Claims, 0 Drawing Figures
Exemplary Claim Number

Full	Title	Citation	Front	Review	Class	Date	Reference	Claims	KWC	Draw. Des.
------	-------	----------	-------	--------	-------	------	-----------	--------	-----	------------

☐ 62. Document ID: US 5935924

L8: Entry 62 of 67

File: USPT

Aug 10, 1999

US-PAT-NO: 5935924

DOCUMENT-IDENTIFIER: 5935924

TITLE: Treatment of congestive heart failure

DATE-ISSUED: August 10, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bunting; Stuart	Mont	CA		
Clark; Ross				
Gillett; Nancy	El G	CA		
Jin; Hongkui	Los A	CA		
Yang; Renhui	San F	CA		

US-CL-CURRENT: 514/ 514/522

ABSTRACT:

A mammal with congestive heart failure is treated by administering an effective amount of a growth hormone. The treatment results in increased left ventricular stroke volume, increased end-diastolic pressure, and reduced peripheral vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.

A mammal with congestive heart failure is treated by administering to the mammal an effective amount of a growth hormone. The treatment results in increased left ventricular stroke volume, increased end-diastolic pressure, and reduced peripheral vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.

12 Claims, 5 Drawing Figures
Exemplary Claim Number
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Class	Date	Reference	Claims	KWC	Draw. Des.
------	-------	----------	-------	--------	-------	------	-----------	--------	-----	------------

h e b b g c c f e b c e f b e

☐ 63. Document US 5932540 A

L8: Entry 63 of 67

File: USPT

Aug 3, 1999

US-PAT-NO: 5932540

DOCUMENT-IDENTIFIER: 5932540

** See image for Certificate of Correction **

TITLE: Vascular endothelial growth factor

DATE-ISSUED: August 3, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hu; Jing-Shan	Sunnyvale	CA		
Rosen; Craig A.	Laytonville	MD		
Cao; Liang	Hong Kong			HK

US-CL-CURRENT: 514/27, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402

ABSTRACT:

Disclosed are human VEGF polypeptides, biologically active, diagnostically or therapeutically useful, and derivatives thereof, and DNA(RNA) encoding such VEGF polypeptides. Also disclosed are procedures for producing such polypeptides by recombinant techniques. Antibodies and antagonists against such polypeptides may be used therapeutically for stimulating wound healing and for vascular disease. Also provided are methods of using the antibodies and antagonists to inhibit angiogenesis and thus tumor growth, inflammation, diabetes, osteoporosis, arthritis, and psoriasis.

186 Claims, 22 Drawings
Exemplary Claim Number 1
Number of Drawing Sheets 19

Full	Title	Citation	Form	Serial	Pub	Ref	Reference	Claims	KMC	Draw. Des.
------	-------	----------	------	--------	-----	-----	-----------	--------	-----	------------

☐ 64. Document US 5922322 A

L8: Entry 64 of 67

File: USPT

Jul 13, 1999

US-PAT-NO: 5922322

DOCUMENT-IDENTIFIER: 5922322

TITLE: Fibrin(ogen)olytic activity by fibrinolytic matrix metalloproteinase

DATE-ISSUED: July 13, 1999

INVENTOR-INFORMATION:

NAME	STATE	ZIP CODE	COUNTRY
Bini; Alessandra	NY		

US-CL-CURRENT: 424/94, 424/95, 424/96, 424/97, 424/98, 424/99, 424/100, 424/101, 424/102, 424/103, 424/104, 424/105, 424/106, 424/107, 424/108, 424/109, 424/110, 424/111, 424/112, 424/113, 424/114, 424/115, 424/116, 424/117, 424/118, 424/119, 424/120, 424/121, 424/122, 424/123, 424/124, 424/125, 424/126, 424/127, 424/128, 424/129, 424/130, 424/131, 424/132, 424/133, 424/134, 424/135, 424/136, 424/137, 424/138, 424/139, 424/140, 424/141, 424/142, 424/143, 424/144, 424/145, 424/146, 424/147, 424/148, 424/149, 424/150, 424/151, 424/152, 424/153, 424/154, 424/155, 424/156, 424/157, 424/158, 424/159, 424/160, 424/161, 424/162, 424/163, 424/164, 424/165, 424/166, 424/167, 424/168, 424/169, 424/170, 424/171, 424/172, 424/173, 424/174, 424/175, 424/176, 424/177, 424/178, 424/179, 424/180, 424/181, 424/182, 424/183, 424/184, 424/185, 424/186, 424/187, 424/188, 424/189, 424/190, 424/191, 424/192, 424/193, 424/194, 424/195, 424/196, 424/197, 424/198, 424/199, 424/200, 424/201, 424/202, 424/203, 424/204, 424/205, 424/206, 424/207, 424/208, 424/209, 424/210, 424/211, 424/212, 424/213, 424/214, 424/215, 424/216, 424/217, 424/218, 424/219, 424/220, 424/221, 424/222, 424/223, 424/224, 424/225, 424/226, 424/227, 424/228, 424/229, 424/230, 424/231, 424/232, 424/233, 424/234, 424/235, 424/236, 424/237, 424/238, 424/239, 424/240, 424/241, 424/242, 424/243, 424/244, 424/245, 424/246, 424/247, 424/248, 424/249, 424/250, 424/251, 424/252, 424/253, 424/254, 424/255, 424/256, 424/257, 424/258, 424/259, 424/260, 424/261, 424/262, 424/263, 424/264, 424/265, 424/266, 424/267, 424/268, 424/269, 424/270, 424/271, 424/272, 424/273, 424/274, 424/275, 424/276, 424/277, 424/278, 424/279, 424/280, 424/281, 424/282, 424/283, 424/284, 424/285, 424/286, 424/287, 424/288, 424/289, 424/290, 424/291, 424/292, 424/293, 424/294, 424/295, 424/296, 424/297, 424/298, 424/299, 424/300, 424/301, 424/302, 424/303, 424/304, 424/305, 424/306, 424/307, 424/308, 424/309, 424/310, 424/311, 424/312, 424/313, 424/314, 424/315, 424/316, 424/317, 424/318, 424/319, 424/320, 424/321, 424/322, 424/323, 424/324, 424/325, 424/326, 424/327, 424/328, 424/329, 424/330, 424/331, 424/332, 424/333, 424/334, 424/335, 424/336, 424/337, 424/338, 424/339, 424/340, 424/341, 424/342, 424/343, 424/344, 424/345, 424/346, 424/347, 424/348, 424/349, 424/350, 424/351, 424/352, 424/353, 424/354, 424/355, 424/356, 424/357, 424/358, 424/359, 424/360, 424/361, 424/362, 424/363, 424/364, 424/365, 424/366, 424/367, 424/368, 424/369, 424/370, 424/371, 424/372, 424/373, 424/374, 424/375, 424/376, 424/377, 424/378, 424/379, 424/380, 424/381, 424/382, 424/383, 424/384, 424/385, 424/386, 424/387, 424/388, 424/389, 424/390, 424/391, 424/392, 424/393, 424/394, 424/395, 424/396, 424/397, 424/398, 424/399, 424/400, 424/401, 424/402, 424/403, 424/404, 424/405, 424/406, 424/407, 424/408, 424/409, 424/410, 424/411, 424/412, 424/413, 424/414, 424/415, 424/416, 424/417, 424/418, 424/419, 424/420, 424/421, 424/422, 424/423, 424/424, 424/425, 424/426, 424/427, 424/428, 424/429, 424/430, 424/431, 424/432, 424/433, 424/434, 424/435, 424/436, 424/437, 424/438, 424/439, 424/440, 424/441, 424/442, 424/443, 424/444, 424/445, 424/446, 424/447, 424/448, 424/449, 424/450, 424/451, 424/452, 424/453, 424/454, 424/455, 424/456, 424/457, 424/458, 424/459, 424/460, 424/461, 424/462, 424/463, 424/464, 424/465, 424/466, 424/467, 424/468, 424/469, 424/470, 424/471, 424/472, 424/473, 424/474, 424/475, 424/476, 424/477, 424/478, 424/479, 424/480, 424/481, 424/482, 424/483, 424/484, 424/485, 424/486, 424/487, 424/488, 424/489, 424/490, 424/491, 424/492, 424/493, 424/494, 424/495, 424/496, 424/497, 424/498, 424/499, 424/500, 424/501, 424/502, 424/503, 424/504, 424/505, 424/506, 424/507, 424/508, 424/509, 424/510, 424/511, 424/512, 424/513, 424/514, 424/515, 424/516, 424/517, 424/518, 424/519, 424/520, 424/521, 424/522, 424/523, 424/524, 424/525, 424/526, 424/527, 424/528, 424/529, 424/530, 424/531, 424/532, 424/533, 424/534, 424/535, 424/536, 424/537, 424/538, 424/539, 424/540, 424/541, 424/542, 424/543, 424/544, 424/545, 424/546, 424/547, 424/548, 424/549, 424/550, 424/551, 424/552, 424/553, 424/554, 424/555, 424/556, 424/557, 424/558, 424/559, 424/560, 424/561, 424/562, 424/563, 424/564, 424/565, 424/566, 424/567, 424/568, 424/569, 424/570, 424/571, 424/572, 424/573, 424/574, 424/575, 424/576, 424/577, 424/578, 424/579, 424/580, 424/581, 424/582, 424/583, 424/584, 424/585, 424/586, 424/587, 424/588, 424/589, 424/590, 424/591, 424/592, 424/593, 424/594, 424/595, 424/596, 424/597, 424/598, 424/599, 424/600, 424/601, 424/602, 424/603, 424/604, 424/605, 424/606, 424/607, 424/608, 424/609, 424/610, 424/611, 424/612, 424/613, 424/614, 424/615, 424/616, 424/617, 424/618, 424/619, 424/620, 424/621, 424/622, 424/623, 424/624, 424/625, 424/626, 424/627, 424/628, 424/629, 424/630, 424/631, 424/632, 424/633, 424/634, 424/635, 424/636, 424/637, 424/638, 424/639, 424/640, 424/641, 424/642, 424/643, 424/644, 424/645, 424/646, 424/647, 424/648, 424/649, 424/650, 424/651, 424/652, 424/653, 424/654, 424/655, 424/656, 424/657, 424/658, 424/659, 424/660, 424/661, 424/662, 424/663, 424/664, 424/665, 424/666, 424/667, 424/668, 424/669, 424/670, 424/671, 424/672, 424/673, 424/674, 424/675, 424/676, 424/677, 424/678, 424/679, 424/680, 424/681, 424/682, 424/683, 424/684, 424/685, 424/686, 424/687, 424/688, 424/689, 424/690, 424/691, 424/692, 424/693, 424/694, 424/695, 424/696, 424/697, 424/698, 424/699, 424/700, 424/701, 424/702, 424/703, 424/704, 424/705, 424/706, 424/707, 424/708, 424/709, 424/710, 424/711, 424/712, 424/713, 424/714, 424/715, 424/716, 424/717, 424/718, 424/719, 424/720, 424/721, 424/722, 424/723, 424/724, 424/725, 424/726, 424/727, 424/728, 424/729, 424/730, 424/731, 424/732, 424/733, 424/734, 424/735, 424/736, 424/737, 424/738, 424/739, 424/740, 424/741, 424/742, 424/743, 424/744, 424/745, 424/746, 424/747, 424/748, 424/749, 424/750, 424/751, 424/752, 424/753, 424/754, 424/755, 424/756, 424/757, 424/758, 424/759, 424/760, 424/761, 424/762, 424/763, 424/764, 424/765, 424/766, 424/767, 424/768, 424/769, 424/770, 424/771, 424/772, 424/773, 424/774, 424/775, 424/776, 424/777, 424/778, 424/779, 424/780, 424/781, 424/782, 424/783, 424/784, 424/785, 424/786, 424/787, 424/788, 424/789, 424/790, 424/791, 424/792, 424/793, 424/794, 424/795, 424/796, 424/797, 424/798, 424/799, 424/800, 424/801, 424/802, 424/803, 424/804, 424/805, 424/806, 424/807, 424/808, 424/809, 424/810, 424/811, 424/812, 424/813, 424/814, 424/815, 424/816, 424/817, 424/818, 424/819, 424/820, 424/821, 424/822, 424/823, 424/824, 424/825, 424/826, 424/827, 424/828, 424/829, 424/830, 424/831, 424/832, 424/833, 424/834, 424/835, 424/836, 424/837, 424/838, 424/839, 424/840, 424/841, 424/842, 424/843, 424/844, 424/845, 424/846, 424/847, 424/848, 424/849, 424/850, 424/851, 424/852, 424/853, 424/854, 424/855, 424/856, 424/857, 424/858, 424/859, 424/860, 424/861, 424/862, 424/863, 424/864, 424/865, 424/866, 424/867, 424/868, 424/869, 424/870, 424/871, 424/872, 424/873, 424/874, 424/875, 424/876, 424/877, 424/878, 424/879, 424/880, 424/881, 424/882, 424/883, 424/884, 424/885, 424/886, 424/887, 424/888, 424/889, 424/890, 424/891, 424/892, 424/893, 424/894, 424/895, 424/896, 424/897, 424/898, 424/899, 424/900, 424/901, 424/902, 424/903, 424/904, 424/905, 424/906, 424/907, 424/908, 424/909, 424/910, 424/911, 424/912, 424/913, 424/914, 424/915, 424/916, 424/917, 424/918, 424/919, 424/920, 424/921, 424/922, 424/923, 424/924, 424/925, 424/926, 424/927, 424/928, 424/929, 424/930, 424/931, 424/932, 424/933, 424/934, 424/935, 424/936, 424/937, 424/938, 424/939, 424/940, 424/941, 424/942, 424/943, 424/944, 424/945, 424/946, 424/947, 424/948, 424/949, 424/950, 424/951, 424/952, 424/953, 424/954, 424/955, 424/956, 424/957, 424/958, 424/959, 424/960, 424/961, 424/962, 424/963, 424/964, 424/965, 424/966, 424/967, 424/968, 424/969, 424/970, 424/971, 424/972, 424/973, 424/974, 424/975, 424/976, 424/977, 424/978, 424/979, 424/980, 424/981, 424/982, 424/983, 424/984, 424/985, 424/986, 424/987, 424/988, 424/989, 424/990, 424/991, 424/992, 424/993, 424/994, 424/995, 424/996, 424/997, 424/998, 424/999, 424/1000, 424/1001, 424/1002, 424/1003, 424/1004, 424/1005, 424/1006, 424/1007, 424/1008, 424/1009, 424/1010, 424/1011, 424/1012, 424/1013, 424/1014, 424/1015, 424/1016, 424/1017, 424/1018, 424/1019, 424/1020, 424/1021, 424/1022, 424/1023, 424/1024, 424/1025, 424/1026, 424/1027, 424/1028, 424/1029, 424/1030, 424/1031, 424/1032, 424/1033, 424/1034, 424/1035, 424/1036, 424/1037, 424/1038, 424/1039, 424/1040, 424/1041, 424/1042, 424/1043, 424/1044, 424/1045, 424/1046, 424/1047, 424/1048, 424/1049, 424/1050, 424/1051, 424/1052, 424/1053, 424/1054, 424/1055, 424/1056, 424/1057, 424/1058, 424/1059, 424/1060, 424/1061, 424/1062, 424/1063, 424/1064, 424/1065, 424/1066, 424/1067, 424/1068, 424/1069, 424/1070, 424/1071, 424/1072, 424/1073, 424/1074, 424/1075, 424/1076, 424/1077, 424/1078, 424/1079, 424/1080, 424/1081, 424/1082, 424/1083, 424/1084, 424/1085, 424/1086, 424/1087, 424/1088, 424/1089, 424/1090, 424/1091, 424/1092, 424/1093, 424/1094, 424/1095, 424/1096, 424/1097, 424/1098, 424/1099, 424/1100, 424/1101, 424/1102, 424/1103, 424/1104, 424/1105, 424/1106, 424/1107, 424/1108, 424/1109, 424/1110, 424/1111, 424/1112, 424/1113, 424/1114, 424/1115, 424/1116, 424/1117, 424/1118, 424/1119, 424/1120, 424/1121, 424/1122, 424/1123, 424/1124, 424/1125, 424/1126, 424/1127, 424/1128, 424/1129, 424/1130, 424/1131, 424/1132, 424/1133, 424/1134, 424/1135, 424/1136, 424/1137, 424/1138, 424/1139, 424/1140, 424/1141, 424/1142, 424/1143, 424/1144, 424/1145, 424/1146, 424/1147, 424/1148, 424/1149, 424/1150, 424/1151, 424/1152, 424/1153, 424/1154, 424/1155, 424/1156, 424/1157, 424/1158, 424/1159, 424/1160, 424/1161, 424/1162, 424/1163, 424/1164, 424/1165, 424/1166, 424/1167, 424/1168, 424/1169, 424/1170, 424/1171, 424/1172, 424/1173, 424/1174, 424/1175, 424/1176, 424/1177, 424/1178, 424/1179, 424/1180, 424/1181, 424/1182, 424/1183, 424/1184, 424/1185, 424/1186, 424/1187, 424/1188, 424/1189, 424/1190, 424/1191, 424/1192, 424/1193, 424/1194, 424/1195, 424/1196, 424/1197, 424/1198, 424/1199, 424/1200, 424/1201, 424/1202, 424/1203, 424/1204, 424/1205, 424/1206, 424/1207, 424/1208, 424/1209, 424/1210, 424/1211, 424/1212, 424/1213, 424/1214, 424/1215, 424/1216, 424/1217, 424/1218, 424/1219, 424/1220, 424/1221, 424/1222, 424/1223, 424/1224, 424/1225, 424/1226, 424/1227, 424/1228, 424/1229, 424/1230, 424/1231, 424/1232, 424/1233,

The invention provides a method for causing degradation of fibrin(ogen) (i.e., fibrin, fibrinogen, and related polymers) by means of a fibrinolytic metalloproteinase, preferably an endogenous metalloproteinase such as MMP-3. The method of the invention can be performed in vitro to obtain diagnostic information characterizing fibrin(ogen) and fibrinolytic activity. The method can also be performed in vivo as a method of thrombolytic therapy in which a fibrinolytic metalloproteinase is administered to a subject to dissolve a thrombus in situ. The endogenous fibrinolytic metalloproteinase can be administered in conjunction with other active agents, preferably with agents having thrombolytic activity to improve thrombolytic and fibrinolytic therapy. The invention further provides compositions containing a fibrinolytic metalloproteinase to improve the performance of fibrinolytic or thrombolytic procedures. Also provided are kits that include a fibrinolytic metalloproteinase for performing fibrinolytic or thrombolytic procedures.

Full	Title	Citation	Front	Region	CL	Month	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----	-------	------	-----------	--	--	--------	-----	----------

Full	Title	Citation	From	Bay Area	City	Address	State	Zip	Reference	Remarks	Comments	Drawn Date
------	-------	----------	------	----------	------	---------	-------	-----	-----------	---------	----------	------------

☐ 66. Document 1 S 566 12 A

L8: Entry 66 of 67

File: USPT

Aug 26, 1997

US-PAT-NO: 5661122

DOCUMENT-IDENTIFIER: U 5661122

TITLE: Treatment of congestive heart failure

DATE-ISSUED: August 26, 1997

INVENTOR-INFORMATION:

NAME	STATE	ZIP CODE	COUNTRY
Clark; Ross G.	CA		
Jin; Hongkui	CA		
Paoni; Nicholas F.	CA		
Yang; Renhui	CA		

US-CL-CURRENT: 514/27, 514/28, 514/29

ABSTRACT:

Methods of enhancing myocardial activity and cardiac performance in a mammal with congestive heart failure are provided. In a first method a mammal with congestive heart failure is administered an effective amount of a combination of growth hormone (GH) and insulin-like growth factor (IGF-I). A second method comprises administering to the mammal an effective amount of a combination of GH and IGF-I in the presence of an ACE inhibitor. This method results in enhancement of myocardial activity and cardiac performance above the level achieved with ACE inhibitors. Preferably the mammal is a human.

8 Claims, 13 Drawings
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	From	Class	Date	Reference	Claims	KWIC	Draw. Des.
------	-------	----------	------	-------	------	-----------	--------	------	------------

☐ 67. Document 1 S 56 10134

L8: Entry 67 of 67

File: USPT

Mar 11, 1997

US-PAT-NO: 5610134

DOCUMENT-IDENTIFIER: U 5610134

TITLE: Treatment of congestive heart failure

DATE-ISSUED: March 11, 1997

INVENTOR-INFORMATION:

NAME	STATE	ZIP CODE	COUNTRY
Clark; Ross G.	CA		
Jin; Hongkui	CA		
Paoni; Nicholas F.	CA		
Yang; Renhui	CA		

h e b h c ef b e

US-CL-CURRENT: 514/

ABSTRACT:

Methods of enhancing ability and cardiac performance in a mammal with congestive heart failure. In a first method a mammal with congestive heart failure is administered to the mammal an effective amount of a combination of growth hormone (GH) and insulin-like growth factor (IGF-I). A second method is administered to the mammal an effective amount of a combination of GH and IGF-I in the presence of an ACE inhibitor. This method results in enhancement of myocardial ability and cardiac performance above the level achieved with ACE inhibition. Preferably the mammal is a human.

10 Claims, 13 Drawings
Exemplary Claim Number
Number of Drawing Sheet

Full	Title	Citation	Pub. No.	Date	Reference	Claims	KWIC	Drawn Desc				
<div>Clear Generate Citation Fwd Refs Bkwd Refs Generate OACS</div> <div><table border="1"><tr><td>Terms</td><td>Documents</td></tr><tr><td>L7 AND com</td><td>67</td></tr></table></div>									Terms	Documents	L7 AND com	67
Terms	Documents											
L7 AND com	67											

Display

Change Format

[Next Page](#) [Go to Doc#](#)

Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Search Results - Record(s) 1 through 33 of 33 returned.

☐ 1. Document ID: US 6139819 A

Using default format because multiple data bases are involved.

L27: Entry 1 of 33

File: USPT

Oct 31, 2000

US-PAT-NO: 6139819

DOCUMENT-IDENTIFIER: US 6139819 A

**** See image for Certificate of Correction ****

TITLE: Targeted contrast agents for diagnostic and therapeutic use

DATE-ISSUED: October 31, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Fritz; Thomas A.	Tucson	AZ		
Gertz; Edward W.	Paradise Valley	AZ		

US-CL-CURRENT: 424/9.52; 424/450, 424/9.51

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 2. Document ID: US 6133274 A

L27: Entry 2 of 33

File: USPT

Oct 17, 2000

US-PAT-NO: 6133274

DOCUMENT-IDENTIFIER: US 6133274 A

TITLE: Hydroxyl-containing bicyclic compounds

DATE-ISSUED: October 17, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Underiner; Gail E.	Brier	WA		
Porubek; David	Seattle	WA		
Klein; J. Peter	Vashon Island	WA		
Woodson; Paul	Edmonds	WA		

US-CL-CURRENT: 514/263.36; 544/267

ABSTRACT:

Disclosed are therapeutic compounds having the formula:

h e b b g e e e f e h c e f b e

(R)j-(core moiety),

including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.3 alkyl groups may be unsubstituted or substituted by an hydroxyl, halo or dimethylamino group. The disclosed compounds and therapeutic compositions thereof are useful in treating individuals having a disease or treatment-induced toxicity, mediated by second messenger activity.

13 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RVNC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 3. Document ID: US 6124433 A

L27: Entry 3 of 33

File: USPT

Sep 26, 2000

US-PAT-NO: 6124433

DOCUMENT-IDENTIFIER: US 6124433 A

TITLE: Compositions and methods for treatment and diagnosis of cardiovascular disease

DATE-ISSUED: September 26, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Falb; Dean A.	Wellesley	MA		
Gimbrone, Jr.; Michael A.	Jamaica Plain	MA		

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 530/324, 530/326, 536/23.1, 536/23.5

ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds

h e b b g e e e f e h c e f b e

in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

5 Claims, 53 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 53

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw. Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

4. Document ID: US 6103730 A

L27: Entry 4 of 33

File: USPT

Aug 15, 2000

US-PAT-NO: 6103730

DOCUMENT-IDENTIFIER: US 6103730 A

TITLE: Amine substituted compounds

DATE-ISSUED: August 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	WA		
Ridgers; Lance H.	Bothell	WA		

US-CL-CURRENT: 514/263.2; 514/151, 514/210.21, 514/263.21, 514/263.22, 514/263.23, 514/263.24, 514/263.35, 544/268, 544/269, 544/270, 544/271, 544/272

ABSTRACT:

Compounds and pharmaceutical compositions, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, have the formula:

CORE MOIETY--(R).sub.j

In these compounds, j is an integer from one to three; the core moiety is a cyclic core, the cyclic core being non-cyclic or at least one five- to seven-member non-heterocyclic ring or heterocycle; and R is selected from the group consisting of amine, hydrogen, halogen, hydroxyl, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic group or formula I. At least one R having formula I: ##STR1## In formula I, n is an integer from four to twenty; and each R.sub.1 or R.sub.2 is independently hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxy, C.sub.(2-20) alkenyl or cyclic or heterocyclic group. The compounds are useful in treating or preventing, for example, sepsis syndrome, hematopoietic or organ toxicity, cancer, viral activity, AIDS and AIDS-related indications, alopecia caused by cytotoxic therapies, and progression of an inflammatory or autoimmune disease.

7 Claims, 23 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw. Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

h e b b g e e e f e h c e f b e

☐ 5. Document ID: US 6100271 A

L27: Entry 5 of 33

File: USPT

Aug 8, 2000

US-PAT-NO: 6100271

DOCUMENT-IDENTIFIER: US 6100271 A

TITLE: Therapeutic compounds containing xanthinyl

DATE-ISSUED: August 8, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Leigh; Alistair J.	Brier	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	WA		

US-CL-CURRENT: 514/263.2; 514/210.21, 514/234.2, 514/263.22, 514/263.23, 514/263.24,
514/263.35, 544/268, 544/269, 544/271

ABSTRACT:

Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:

CORE MOIETY --(R).sub.j

wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyallyl; --A(R.sub.5).sub.m, A being N or O, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

14 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Knowl	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	----------

h e b b g e e e f e h c e f b e

☐ 6. Document ID: US 6093743 A

L27: Entry 6 of 33

File: USPT

Jul 25, 2000

US-PAT-NO: 6093743

DOCUMENT-IDENTIFIER: US 6093743 A

TITLE: Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor

DATE-ISSUED: July 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lai; Ching-San	Encinitas	CA		
Vassilev; Vassil	San Diego	CA		

US-CL-CURRENT: 514/599; 514/706, 514/707, 514/851, 514/861, 514/863, 514/866,
514/909, 514/912

ABSTRACT:

The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

51 Claims, 11 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMC	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-------------

☐ 7. Document ID: US 6043250 A

L27: Entry 7 of 33

File: USPT

Mar 28, 2000

US-PAT-NO: 6043250

DOCUMENT-IDENTIFIER: US 6043250 A

TITLE: Methods for using therapeutic compounds containing xanthinyl

DATE-ISSUED: March 28, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

h	e	b	b	g	e	e	e	f	e	h	c	e	f	b	e
---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

Klein; J. Peter	Vashon	WA
Leigh; Alistair J.	Brier	WA
Underiner; Gail E.	Brier	WA
Kumar; Anil M.	Seattle	WA
Rice; Glenn C.	Seattle	WA

US-CL-CURRENT: 514/234.2; 514/210.21, 514/263.2, 514/263.22, 514/263.23, 514/263.35

ABSTRACT:

Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:

CORE MOIETY --(R).sub.j

wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C(.sub.1-10) alkyl, C(.sub.2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C(.sub.1-20) alkyl, C.sub.(1-20) alkoxy, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxy, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxy; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyalkyl; --A(R.sub.5).sub.m, A being N or O, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl, or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

6 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw. Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 8. Document ID: US 6040157 A

L27: Entry 8 of 33

File: USPT

Mar 21, 2000

US-PAT-NO: 6040157

DOCUMENT-IDENTIFIER: US 6040157 A

**** See image for Certificate of Correction ****

TITLE: Vascular endothelial growth factor 2

DATE-ISSUED: March 21, 2000

INVENTOR-INFORMATION:

h e b b g e e e f e h c e f b e

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hu; Jing-Shan	Sunnyvale	CA		
Rosen; Craig A.	Laytonsville	MD		
Cao; Liang	South Horizons			HK

US-CL-CURRENT: 435/69.4; 435/243, 435/320.1, 435/325, 435/7.1, 530/399, 536/23.51

ABSTRACT:

Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically self fragments, analogs, or derivatives thereof, and DNA (RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

75 Claims, 48 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 47

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 9. Document ID: US 6020463 A

L27: Entry 9 of 33

File: USPT

Feb 1, 2000

US-PAT-NO: 6020463

DOCUMENT-IDENTIFIER: US 6020463 A

**** See image for Certificate of Correction ****

TITLE: Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target

DATE-ISSUED: February 1, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Falb; Dean A.	Wellesley	MA		
Gimbrone, Jr.; Michael A.	Jamaica Plain	MA		

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.1

ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as

h e b b g e e e f e h c e f b e

treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

3 Claims, 41 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 53

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KINC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 10. Document ID: US 6020337 A

L27: Entry 10 of 33

File: USPT

Feb 1, 2000

US-PAT-NO: 6020337

DOCUMENT-IDENTIFIER: US 6020337 A

TITLE: Electronegative-substituted long chain xanthine compounds

DATE-ISSUED: February 1, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Leigh; Alistair J.	Brier	WA		
Michnick; John	Seattle	WA		
Kumar; Anil M.	Seattle	WA		
Klein; J. Peter	Vashon	WA		
Underiner; Gail	Malvern	PA		

US-CL-CURRENT: 514/263.34; 514/210.21, 514/263.36, 544/267, 544/272, 544/277

ABSTRACT:

Therapeutic compounds, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, having a formula: ##STR1## wherein R.sub.0 is selected from the group consisting of hydrogen, halo, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic groups, wherein the substituents of substituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl are other than halo; n is an integer from one to sixteen; R.sub.1, R.sub.2, and R.sub.3 are independently selected from the group consisting of a halo; haloacetoxy; hydrogen; hydroxy; oxo; --N.dbd.C.dbd.S; --N.dbd.C.dbd.O; --O--C.tbd.N; --C.tbd.N; --N.dbd.N.dbd.N; and --C--(R.sub.5).sub.3, R.sub.5 being independently a halo or hydrogen, at least one R.sub.5 being halo, at least one of R.sub.1, R.sub.2, and R.sub.3 being halo, cyano, isocyano, isothiocyano, azide or haloacetoxy group; R.sub.4 is hydrogen, C.sub.(1-6) alkyl, C.sub.(1-6) alkenyl, cyclo C.sub.(4-6) alkyl, or phenyl; one or more hydrogen atoms of (CH.sub.2).sub.n --CH.sub.a --CH.sub.b --CH.sub.c may be replaced with: i) at least one of halogen atom, hydroxyl, oxo, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyalkyl, or C.sub.(2-10) alkenyl; or ii) one or more unsaturated bonds; and any two adjacent carbon atoms of (CH.sub.2).sub.n --CH.sub.a --CH.sub.b --CH.sub.c may be instead separated by at least one oxygen atom. These compounds are useful in treating or preventing diseases by inhibiting selective second messenger pathways.

17 Claims, 16 Drawing figures

h e b b g e e f e h c e f b e

Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 11. Document ID: US 6018025 A

L27: Entry 11 of 33

File: USPT

Jan 25, 2000

US-PAT-NO: 6018025

DOCUMENT-IDENTIFIER: US 6018025 A

**** See image for Certificate of Correction ****

TITLE: Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd528 as a target

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Falb; Dean A.	Wellesley	MA		
Gimbrone, Jr.; Michael A.	Jamaica Plain	MA		

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 530/324, 530/326, 536/23.1, 536/23.5

ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

5 Claims, 41 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 53

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 12. Document ID: US 5889011 A

L27: Entry 12 of 33

File: USPT

Mar 30, 1999

h e b b g e e f e h c e f b e

US-PAT-NO: 5889011

DOCUMENT-IDENTIFIER: US 5889011 A

**** See image for Certificate of Correction ****

TITLE: Substituted amino alkyl compounds

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon Island	WA		
Underiner; Gail E.	Brier	WA		
Leigh; Alistair J.	Brier	WA		

US-CL-CURRENT: 514/263.35; 544/264, 544/265, 544/267

ABSTRACT:

Compounds and pharmaceutical compositions thereof comprise the formula:

(R)_j- (core moiety),

including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein J is an integer from one to three, the core moiety is non-cyclic or comprises at least one, five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, alkyl (C.sub.1-6) or alkenyl (C.sub.1-6), and at least one R has the formula I: ##STR1## wherein n is an integer from four to eighteen; each R'.sub.1 and R'.sub.2 is independently hydrogen, alkyl (C.sub.1-4) or alkenyl (C.sub.1-4), the alkyl or alkenyl groups being preferably substituted by a halogen, hydroxyl, ketone or dimethylamino group and/or may be interrupted by an oxygen or hydrogen atom or an alkyl (C.sub.1-4) group; and each R'.sub.3 and R'.sub.4 is independently hydrogen or methyl. Preferably, n is an integer from six to ten, R'.sub.1 and R'.sub.2 are independently hydrogen or methyl and R'.sub.3 and R'.sub.4 are hydrogen. The compounds are useful in treating or preventing, for example, sepsis syndrome, hematopoietic or organ toxicity, baldness, hair loss or alopecia caused by cytotoxic therapies, and progression of an inflammatory or autoimmune disease.

9 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 13. Document ID: US 5882925 A

L27: Entry 13 of 33

File: USPT

Mar 16, 1999

US-PAT-NO: 5882925

DOCUMENT-IDENTIFIER: US 5882925 A

**** See image for Certificate of Correction ****

TITLE: Compositions and method for the treatment and diagnosis of cardiovascular disease using rchd502 as a target

DATE-ISSUED: March 16, 1999

h e b b g e e e f e h c e f b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Falb; Dean A.	Wellesley	MA		

US-CL-CURRENT: 435/325; 435/320.1, 435/455, 435/6, 435/69.1, 536/23.1, 536/24.1, 536/24.3

ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

22 Claims, 53 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 53

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KINC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 14. Document ID: US 5849578 A

L27: Entry 14 of 33

File: USPT

Dec 15, 1998

US-PAT-NO: 5849578

DOCUMENT-IDENTIFIER: US 5849578 A

**** See image for Certificate of Correction ****

TITLE: Compositions and methods for the treatment and diagnosis of cardiovascular using RCHD528 as a target

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Falb; Dean A.	Massachusetts	MA		

US-CL-CURRENT: 435/325; 435/320.1, 435/455, 435/6, 435/69.1, 536/23.1, 536/24.1, 536/24.3

ABSTRACT:

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation.

h e b b g e e f e h c e f b e

Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

21 Claims, 53 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 53

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-------------

☐ 15. Document ID: US 5837703 A

L27: Entry 15 of 33

File: USPT

Nov 17, 1998

US-PAT-NO: 5837703
DOCUMENT-IDENTIFIER: US 5837703 A

TITLE: Amino-alcohol substituted cyclic compounds

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kumar; Anil M.	Seattle	WA		
Michnick; John	Seattle	WA		
Underiner; Gail E.	Brier	WA		
Klein; J. Peter	Vashon Island	WA		
Rice; Glenn C.	Seattle	WA		

US-CL-CURRENT: 514/183, 514/211.15, 514/228.8, 514/241, 514/242, 514/249, 514/256, 514/266.2, 514/266.3, 514/270, 514/274, 514/309, 514/312, 514/315, 514/348, 514/357, 514/374, 514/400, 514/425, 514/427, 540/467, 540/544, 544/216, 544/257, 544/272, 544/286, 544/301, 544/311, 544/335, 546/141, 546/142, 546/157, 546/246, 546/296, 546/334, 546/96, 548/215, 548/340.1, 548/485, 548/546, 548/561

ABSTRACT:

Therapeutic compounds have the formula:

(X)_j-(core moiety),

j being an integer from one to three, the core moiety comprising a core moiety, the core moiety being a heterocycle having one ring or two-fused rings, each ring having five or six ring atoms, A being a carbon atom of the core moiety and attached to a terminal carbon atom of (CH₂)_n, and X has a structure and X being a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or

h e b b g e e f e h c e f b e

more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkyl or alkenyl of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkyl or alkenyl of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxyl group.

9 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 38

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMCC	Drawing Sheet
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------------

16. Document ID: US 5824677 A

L27: Entry 16 of 33

File: USPT

Oct 20, 1998

US-PAT-NO: 5824677

DOCUMENT-IDENTIFIER: US 5824677 A

TITLE: Substituted amino alcohol compounds

DATE-ISSUED: October 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	WA		

US-CL-CURRENT: 514/222.5; 514/223.5, 514/224.5, 514/226.8, 514/227.5, 514/228.8, 514/229.2, 514/230.5, 514/230.8, 514/237.8, 514/248, 514/249, 514/255.02, 514/260.1, 514/274, 514/301, 514/303, 514/311, 514/351, 514/360, 514/361, 514/362, 514/363, 514/364, 514/365, 514/367, 514/372, 514/373, 514/374, 514/375, 514/376, 514/378, 514/379, 514/380, 514/387, 514/395, 514/415, 514/418, 514/424, 514/425, 514/432, 514/433, 514/438, 514/452, 544/127, 544/128, 544/162, 544/2, 544/215, 544/219, 544/229, 544/235, 544/237, 544/255, 544/278, 544/3, 544/311, 544/353, 544/385, 544/5, 544/53, 544/63, 544/65, 544/66, 544/67, 544/8, 544/90, 544/91, 546/113, 546/114, 546/164, 546/300, 548/123, 548/125, 548/131, 548/134, 548/143, 548/146, 548/153, 548/174, 548/207, 548/214, 548/215, 548/217, 548/221, 548/228, 548/229, 548/237, 548/240, 548/241, 548/243, 548/247, 548/267.2, 548/303.7, 548/307.1, 548/453, 548/486, 548/543, 548/546, 549/14, 549/367, 549/368, 549/50, 549/75

ABSTRACT:

Disclosed are compounds having a straight or branched aliphatic hydrocarbon structure

h e b b g e e e f e h c e f b e

of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxy group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocycle. R.sub.3 may be either hydrogen or C.sub.13. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a heterocycle comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

18 Claims, 120 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 89

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

17. Document ID: US 5817662 A

L27: Entry 17 of 33

File: USPT

Oct 6, 1998

US-PAT-NO: 5817662

DOCUMENT-IDENTIFIER: US 5817662 A

TITLE: Substituted amino alkyl compounds

DATE-ISSUED: October 6, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon Island	WA		
Underiner; Gail E.	Brier	WA		
Leigh; Alistair J.	Brier	WA		

US-CL-CURRENT: 514/263.35; 424/824, 424/825

ABSTRACT:

Compounds and pharmaceutical compositions thereof comprise the formula:

(R)_j-(core moiety),

including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein J is an integer from one to three, the core moiety is non-cyclic or comprises at least one, five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, alkyl (C.sub.1-6) or alkenyl (C.sub.1-6), and at least one R has the formula I: ##STR1## wherein n is an integer from four to eighteen; each R'.sub.1 and R'.sub.2 is independently hydrogen, alkyl (C.sub.1-4) or alkenyl (C.sub.1-4), the alkyl or alkenyl groups being preferably substituted by a halogen, hydroxyl, ketone or dimethylamino group and/or may be interrupted by an oxygen or hydrogen atom or an alkyl (C.sub.1-4) group; and each R'.sub.3 and R'.sub.4 is independently hydrogen or methyl. Preferably, n is an integer from six to ten,

h e b b g e e e f e h c e f b e

R'.sub.1 and R'.sub.2 are independently hydrogen or methyl and R'.sub.3 and R'.sub.4 are hydrogen. The compounds are useful in treating or preventing, for example, sepsis syndrome, hematopoietic or organ toxicity, baldness, hair loss or alopecia caused by cytotoxic therapies, and progression of an inflammatory or autoimmune disease.

7 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

18. Document ID: US 5807862 A

L27: Entry 18 of 33

File: USPT

Sep 15, 1998

US-PAT-NO: 5807862

DOCUMENT-IDENTIFIER: US 5807862 A

**** See image for Certificate of Correction ****

TITLE: Therapeutic compounds containing pyrimidinyl moieties

DATE-ISSUED: September 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Leigh; Alistair J.	Brier	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	WA		

US-CL-CURRENT: 514/269; 544/309, 544/310, 544/311, 544/312

ABSTRACT:

Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:

CORE MOIETY--(R).sub.j

wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxy, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxy, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxy; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyalkyl; --A(R.sub.5).sub.m, A being N or O, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl, or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --

h e b b g e e f e h c e f b e

CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

6 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	------------

☐ 19. Document ID: US 5807861 A

L27: Entry 19 of 33

File: USPT

Sep 15, 1998

US-PAT-NO: 5807861

DOCUMENT-IDENTIFIER: US 5807861 A

**** See image for Certificate of Correction ****

TITLE: Amine substituted xanthinyl compounds

DATE-ISSUED: September 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	WA		
Ridgers; Lance H.	Bothell	WA		
Rice; Glenn C.	Seattle	WA		
Leung; David W.	Mercer Island	WA		

US-CL-CURRENT: 514/263.35; 514/151, 514/210.21, 514/263.2, 514/263.22, 514/263.23, 514/81

ABSTRACT:

A method for treating a disease caused by an undesirable cell response mediated by a proliferative intracellular signaling pathway is provided wherein an effective amount of a compound is administered. The compound, resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof, has the formula

CORE MOIETY--(R).sub.j

wherein j is an integer from one to three; the core moiety is xanthinyl; and R is independently selected from the group consisting of amine, hydrogen, halogen, hydroxyl, C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, 2-bromopropyl, 4-chloropentyl, cyclohexyl, cyclopentyl, 3-dimethylaminobutyl, 2-hydroxyethyl, 5-hydroxyhexyl, 3-hydroxy-n-butyl, 3-hydroxypropyl, 2-methoxyethyl, 4-methoxy-n-butyl, phenyl, and formula I, at least one R comprising formula I ##STR1## wherein (CH.sub.2).sub.n is optionally substituted; n is an integer from five to twenty; each R.sub.1 or R.sub.2 is independently hydrogen or an optionally substituted group that is herein defined; and

wherein, when the (CH.sub.2).sub.n, R.sub.1 or R.sub.2 is substituted, a substituent is selected from the group consisting of carbamoyl, primary, secondary and tertiary amino, C.sub.(2-8) alkenyl, C.sub.(1-8) alkyl, C.sub.(1-8) alkoxy, C.sub.(1-8)

h e b b g e e f e h c e f b e

hydroxyalkyl, azido, carbonato, carbonyl, carboxyl, cyano, C.sub.(1-8) haloalkyl, isocyano, isomercaptocyano, phospho, phosphonato, sulfonato, alkylsulfonyl, alkylsulfoxidyl, mercaptocarbonyl, mercaptocarbonato, thioureido and ureido.

21 Claims, 23 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Drawing Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------------

☐ 20. Document ID: US 5804584 A

L27: Entry 20 of 33

File: USPT

Sep 8, 1998

US-PAT-NO: 5804584

DOCUMENT-IDENTIFIER: US 5804584 A

**** See image for Certificate of Correction ****

TITLE: Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms

DATE-ISSUED: September 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Underiner; Gail E.	Brier	WA		
Porubek; David	Seattle	WA		
Klein; J. Peter	Vashon Island	WA		
Woodson; Paul	Edmonds	WA		

US-CL-CURRENT: 514/269; 514/256, 544/242, 544/298, 544/301, 544/302

ABSTRACT:

Disclosed are therapeutic compounds having the formula:

(R)_j-(core moiety),

including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.3 alkyl groups may be unsubstituted or substituted by an hydroxyl, halo or dimethylamino group. The disclosed compounds and therapeutic compositions thereof are useful in treating individuals having a disease or treatment-induced toxicity, mediated by second messenger activity.

9 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

h e b b g e e f c h c e f b e

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KIMC	Dram Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 21. Document ID: US 5801182 A

L27: Entry 21 of 33

File: USPT

Sep 1, 1998

US-PAT-NO: 5801182

DOCUMENT-IDENTIFIER: US 5801182 A

TITLE: Amine substituted compounds

DATE-ISSUED: September 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	WA		
Ridgers; Lance H.	Bothell	WA		

US-CL-CURRENT: 514/269; 514/274, 544/310, 544/311, 544/312

ABSTRACT:

Compounds and pharmaceutical compositions, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, have the formula:

CORE MOIETY --(R).sub.j

In these compounds, j is an integer from one to three; the core moiety is a cyclic core, the cyclic core being non-cyclic or at least one five- to seven-member non-heterocyclic ring or heterocycle; and R is selected from the group consisting of amine, hydrogen, halogen, hydroxyl, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic group or formula I. At least one R having formula I: ##STR1## In formula I, n is an integer from four to twenty; and each R.sub.1 or R.sub.2 is independently hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxy, C.sub.(2-20) alkenyl or cyclic or heterocyclic group. The compounds are useful in treating or preventing, for example, sepsis syndrome, hematopoietic or organ toxicity, cancer, viral activity, AIDS and AIDS-related indications, alopecia caused by cytotoxic therapies, and progression of an inflammatory or autoimmune disease.

16 Claims, 23 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KIMC	Dram Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 22. Document ID: US 5801181 A

L27: Entry 22 of 33

File: USPT

Sep 1, 1998

US-PAT-NO: 5801181

DOCUMENT-IDENTIFIER: US 5801181 A

h e b b g e e e f e h c e f b e

TITLE: Amino alcohol substituted cyclic compounds

DATE-ISSUED: September 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Michnick; John	Seattle	WA		
Underiner; Gail E.	Brier	WA		
Klein; J. Peter	Vashon Island	WA		
Rice; Glenn C.	Seattle	WA		

US-CL-CURRENT: 514/263.35, 514/183, 514/249, 514/266.3, 514/274, 514/309, 514/315,
514/418, 514/425, 514/617, 514/619, 514/626, 514/668, 514/669

ABSTRACT:

Therapeutic compounds have the formula:

(X)_j--(core moiety),

J being an integer from one to three, the core moiety having at least one, five- to seven-membered ring and X being a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkane or alkene of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkane or alkene of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxy group.

45 Claims, 41 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 38

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	NUMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 23. Document ID: US 5785965 A

L27: Entry 23 of 33

File: USPT

Jul 28, 1998

US-PAT-NO: 5785965

DOCUMENT-IDENTIFIER: US 5785965 A

TITLE: VEGF gene transfer into endothelial cells for vascular prosthesis

h e b b g e e f e h c e f b e

DATE-ISSUED: July 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pratt; Richard E.	Palo Alto	CA		
Dzau; Victor J.	Los Altos Hills	CA		

US-CL-CURRENT: 424/93.21; 424/93.1, 424/93.2, 435/325, 435/455, 435/456

ABSTRACT:

Endothelial cells derived from subcutaneous adipose tissue are genetically modified to express the endothelial cell-specific angiogenic factor VEGF. The modified cells are seeded onto a vascular prosthesis for transplantation into an autologous or allogeneic recipient. The method accelerates endothelialization on the luminal surface of the vessel, and promotes collateral circulation in distal ischemic organs.

11 Claims, 4 Drawing figures

Exemplary Claim Number: 1,6

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Know	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 24. Document ID: US 5780476 A

L27: Entry 24 of 33

File: USPT

Jul 14, 1998

US-PAT-NO: 5780476

DOCUMENT-IDENTIFIER: US 5780476 A

TITLE: Hydroxyl-containing xanthine compounds

DATE-ISSUED: July 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Underiner; Gail E.	Brier	WA		
Porubek; David	Seattle	WA		
Klein; J. Peter	Vashon Island	WA		
Woodson; Paul	Edmonds	WA		

US-CL-CURRENT: 514/263.36

ABSTRACT:

Disclosed are therapeutic compounds having the formula:

(R)_j - (core moiety),

including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3

h e b b g e e f c h c e f b e

--CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.3 alkyl groups may be unsubstituted or substituted by an hydroxyl, halo or dimethylamino group. The disclosed compounds and therapeutic compositions thereof are useful in treating individuals having a disease or treatment-induced toxicity, mediated by second messenger activity.

11 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	WAC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 25. Document ID: US 5777117 A

L27: Entry 25 of 33

File: USPT

Jul 7, 1998

US-PAT-NO: 5777117

DOCUMENT-IDENTIFIER: US 5777117 A

TITLE: Method for preparing substituted amino alcohol compounds

DATE-ISSUED: July 7, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	WA		

US-CL-CURRENT: 544/267; 544/257, 544/285, 544/286, 544/287, 544/311, 546/141, 546/243, 546/246, 548/477, 548/546

ABSTRACT:

Disclosed is a process for preparing compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxy group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocycle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a terminal moiety comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

22 Claims, 118 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 92

h e b b g e e f e h c e f b e

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KNOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 26. Document ID: US 5777115 A

L27: Entry 26 of 33

File: USPT

Jul 7, 1998

US-PAT-NO: 5777115

DOCUMENT-IDENTIFIER: US 5777115 A

TITLE: Acetal-and ketal-substituted pyrimidine compounds

DATE-ISSUED: July 7, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Leigh; Alistair	Brier	WA		
Underiner; Gail	Brier	WA		

US-CL-CURRENT: 544/242; 544/267

ABSTRACT:

Acetal-and ketal-substituted compounds and pharmaceutical compositions thereof have the following formula:

CORE MOIETY--(R).sub.j,

including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is non-cyclic or cyclic a monocyclic moiety having at least one nitrogen atom within the ring and R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted alkyl C.sub.(1-6), alkenyl C.sub.(2-6), cyclic or heterocyclic groups, and groups having a structure prescribed by formula I. At least one R has the formula I:

--(CH.sub.2).sub.n --C--(R.sub.1).sub.3 I

wherein n is an integer from three to twenty; R.sub.1 is selected from among hydrogen; halogen; hydroxide; substituted or unsubstituted C.sub.(1-6) alkyl, C.sub.(1-6) alkoxy, C.sub.(2-6) alkenyl, cyclic or heterocyclic group; --OR.sub.2, R.sub.2 being hydrogen or a substituted or unsubstituted C.sub.(1-6) alkyl, C.sub.(2-6) alkenyl, cyclic or heterocyclic group; --(CH.sub.2).sub.p --C(R.sub.3).sub.3 (wherein p is zero or an integer from one to ten, R.sub.3 is hydrogen, halogen, hydroxide, substituted or unsubstituted C.sub.(1-6) alkyl, C.sub.(1-6) alkoxy, C.sub.(2-6) alkenyl, cyclic or heterocyclic group, or --OR.sub.2, R.sub.2 being defined above). The inventive compounds are useful in a large variety of therapeutic indications for treating or preventing disease mediated by intracellular signaling through specific intracellular signaling pathways.

13 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KNOC	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 27. Document ID: US 5770595 A

h e b b g e e e f e h c e f b e

L27: Entry 27 of 33

File: USPT

Jun 23, 1998

US-PAT-NO: 5770595

DOCUMENT-IDENTIFIER: US 5770595 A

TITLE: Oxime substituted therapeutic compounds

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Leigh; Alistair	Brier	WA		

US-CL-CURRENT: 514/263.35; 514/151, 544/271, 544/273

ABSTRACT:

Oxime-substituted compounds are preferably cyclic or heterocyclic compounds. The oxime-substituted compounds and pharmaceutical compositions thereof have the formula:

CORE MOIETY--(R).sub.j

including resolved enantiomers (both syn and anti forms) and/or diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is non-cyclic or cyclic and R may be selected from among: hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10), alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic groups, and formula I. At least one R has the formula I:

--(CH.sub.2).sub.n --C--(R.sub.1).sub.p, I

wherein n is an integer from three to twenty; p is two or three; R.sub.1 is selected from among hydrogen; halogen; hydroxide; substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C.sub.(2-10) alkenyl, cyclic or heterocyclic group; =N--OR.sub.2, R.sub.2 being hydrogen or a substitute or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic group; and --(CH.sub.2).sub.s --C(R.sub.3).sub.t (wherein s is zero or an integer from one to ten, t is two or three, R.sub.3 is hydrogen, halogen, hydroxide, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C(.sub.2-10) alkenyl, cyclic or heterocyclic group, or .dbd.N--OR.sub.2, R.sub.2 being defined above). At least one R.sub.1 or one R.sub.3 is .dbd.N--OR.sub.2, p or t corresponding to the at least one R.sub.1 or one R.sub.3 is two, and a second R.sub.1 or second R.sub.3, bonded to the same --C as the at least one R.sub.1 or one R.sub.3, is other than .dbd.N--OR.sub.2. These disclosed compounds are useful in a large variety of therapeutic indications for treating or preventing disease mediated by intracellular signaling through specific intracellular signaling pathways.

22 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 19

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	NUMC	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 28. Document ID: US 5750575 A

L27: Entry 28 of 33

File: USPT

May 12, 1998

h e b b g e e e f e h c e f b e

US-PAT-NO: 5750575

DOCUMENT-IDENTIFIER: US 5750575 A

**** See image for Certificate of Correction ****

TITLE: Substituted amino alcohol compounds

DATE-ISSUED: May 12, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	WA		

US-CL-CURRENT: 514/617; 514/653, 564/182, 564/355, 564/361

ABSTRACT:

Disclosed are compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxy group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocycle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a carbocycle comprising a substituted or unsubstituted ring system, the ring system having a single ring or two fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

18 Claims, 115 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 90

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	NAME	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	-----------

☐ 29. Document ID: US 5670506 A

L27: Entry 29 of 33

File: USPT

Sep 23, 1997

US-PAT-NO: 5670506

DOCUMENT-IDENTIFIER: US 5670506 A

TITLE: Halogen, isothiocyanate or azide substituted xanthines

DATE-ISSUED: September 23, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Leigh; Alistair	Brier	WA		
Michnick; John	Seattle	WA		

h e b b g e e e f e h c e f b e

Kumar; Anil Seattle WA
Underiner; Gail Brier WA

US-CL-CURRENT: 514/141; 544/267, 544/272, 544/277

ABSTRACT:

There is disclosed a compound having the formula: ##STR1## wherein n is an integer from 5 to 9, wherein the core moiety is a heterocyclic moiety wherein C.sub.a, C.sub.b, and C.sub.c are an R or S enantiomer or racemic mixture and the C.sub.a, C.sub.b, and C.sub.c carbon atoms are bonded together by a single bond, double bond, ether or ester linkages, wherein R.sub.1, R.sub.2 and R.sub.3 are independently halo, hydroxy, hydrogen, keto, isothiocyano, azide or haloacetoxy with the proviso that at least one of R.sub.1, R.sub.2 or R.sub.3 must be a halo, isothiocyano, azide or haloacetoxy group, wherein R.sub.4 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkenyl, cyclo C.sub.4-6 alkyl, or phenyl, and wherein halo refers to fluoro, chloro, bromo and iodo and salts thereof and pharmaceutical compositions thereof.

17 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 30. Document ID: US 5641783 A

L27: Entry 30 of 33

File: USPT

Jun 24, 1997

US-PAT-NO: 5641783
DOCUMENT-IDENTIFIER: US 5641783 A

TITLE: Substituted amino alcohol compounds

DATE-ISSUED: June 24, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Klein; J. Peter	Vashon	WA		
Underiner; Gail E.	Brier	WA		
Kumar; Anil M.	Seattle	WA		

US-CL-CURRENT: 514/263.35; 514/183, 514/222.5, 514/223.5, 514/224.2, 514/226.8,
514/227.5, 514/228.8, 514/229.2, 514/230.5, 514/230.8, 514/237.8, 514/241, 514/242,
514/243, 514/246, 514/247, 514/248, 514/249, 514/252.16, 514/256, 514/259.5,
514/264.1, 514/266.3, 514/270, 514/274, 514/297, 514/300, 514/301, 514/302, 514/303,
514/306, 514/307, 514/311, 514/312, 514/315, 514/345, 514/351, 514/357, 514/359,
514/360, 514/361, 514/362, 514/363, 514/364, 514/365, 514/367, 514/369, 514/372,
514/373, 514/374, 514/375, 514/376, 514/378, 514/379, 514/380, 514/381, 514/383,
514/389, 514/394, 514/395, 514/398, 514/399, 514/401, 514/404, 514/406, 514/413,
514/415, 514/416, 514/418, 514/423, 514/424, 514/425, 514/427, 514/428, 544/1,
544/162, 544/2, 544/215, 544/216, 544/219, 544/220, 544/224, 544/235, 544/239,
544/254, 544/255, 544/257, 544/262, 544/272, 544/277, 544/278, 544/280, 544/283,
544/286, 544/3, 544/301, 544/311, 544/335, 544/336, 544/350, 544/353, 544/385,
544/401, 544/53, 544/63, 544/65, 544/66, 544/67, 544/8, 544/90, 544/91, 546/102,
546/113, 546/114, 546/115, 546/117, 546/118, 546/119, 546/122, 546/138, 546/139,
546/150, 546/153, 546/157, 546/164, 546/176, 546/178, 546/242, 546/243, 546/246,
546/264, 546/300, 546/334, 548/100, 548/123, 548/125, 548/127, 548/128, 548/131,

h e b b g e e f e h c e f b e

548/134, 548/146, 548/153, 548/179, 548/186, 548/207, 548/214, 548/215, 548/217,
548/221, 548/225, 548/228, 548/229, 548/235, 548/237, 548/240, 548/241, 548/243,
548/247, 548/252, 548/267.2, 548/267.8, 548/303.7, 548/306.4, 548/307.1, 548/309.7,
548/319.1, 548/323.5, 548/340.1, 548/348.1, 548/349.1, 548/356.1, 548/370.1,
548/375.1, 548/379.4, 548/452, 548/453, 548/470, 548/482, 548/485, 548/486, 548/491,
548/503, 548/532, 548/543, 548/546, 548/550, 548/565, 548/566

ABSTRACT:

Disclosed are compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocycle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a terminal moiety comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

22 Claims, 115 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 88

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------

☐ 31. Document ID: US 5521315 A

L27: Entry 31 of 33

File: USPT

May 28, 1996

US-PAT-NO: 5521315

DOCUMENT-IDENTIFIER: US 5521315 A

TITLE: Olefin substituted long chain compounds

DATE-ISSUED: May 28, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Underiner; Gail	Brier	WA		
Porubek; David	Seattle	WA		
Klein; J. Peter	Vashon	WA		
Eiseman; Elisa	Seattle	WA		
Leigh; Alistair	Brier	WA		
Kumar; Anil	Seattle	WA		
Michnick; John	Seattle	WA		

US-CL-CURRENT: 546/243; 544/285, 546/242

ABSTRACT:

h e b b g e e e f e h c e f b e

There is disclosed an olefin-substituted compound having the formula:

R--(core moiety),

wherein R is a straight chain hydrocarbon having at least one double bond and a carbon chain length of from about 6 to about 18 carbon atoms, wherein multiple double bonds are separated from each other by at least three carbon atoms, wherein the closest double bond to the core moiety is at least five carbon atoms from the core moiety, and wherein the hydrocarbon chain may be substituted by a hydroxyl, halo, keto or dimethylanimo group and/or interrupted by an oxygen atom and salts thereof and pharmaceutical compositions thereof.

7 Claims, 22 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 32. Document ID: US 5470878 A

L27: Entry 32 of 33

File: USPT

Nov 28, 1995

US-PAT-NO: 5470878

DOCUMENT-IDENTIFIER: US 5470878 A

TITLE: Cell signaling inhibitors

DATE-ISSUED: November 28, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Michnick; John	Seattle	WA		
Underiner; Gail E.	Brier	WA		
Klein; J. Peter	Vashon Island	WA		
Rice; Glenn C.	Seattle	WA		

US-CL-CURRENT: 514/558, 514/274, 514/299, 514/315, 514/418, 514/425, 514/529,
514/552, 514/561, 514/613, 514/617, 514/626, 514/629, 514/669, 544/254, 544/285,
544/301, 546/183, 546/243, 548/486, 548/556

ABSTRACT:

Therapeutic compounds have the formula:

(X)_j-(non-cyclic core moiety),

_j being an integer from one to three, the core moiety is non-cyclic and X is a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkane or alkene of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds

h e b b g e e f e h c e f b e

may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkane or alkene of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms. r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxy group.

10 Claims, 43 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 42

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Drawl Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 33. Document ID: AU 758178 B, WO 200013710 A2, AU 9959095 A, EP 1107791 A2, US 6331309 B1, JP 2002524425 W

L27: Entry 33 of 33

File: DWPI

Mar 20, 2003

DERWENT-ACC-NO: 2000-256866

DERWENT-WEEK: 200329

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Hydrogel compositions useful for controlled delivery of growth factors e.g. in treatment of ischemia and in wound healing

INVENTOR: JENNINGS, R N; PROTTER, A A ; WANG, Y J ; YANG, B

PRIORITY-DATA: 1998US-099168P (September 4, 1998), 1999US-0390164 (September 3, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 758178 B</u>	March 20, 2003		000	A61K047/10
<u>WO 200013710 A2</u>	March 16, 2000	E	027	A61K047/10
<u>AU 9959095 A</u>	March 27, 2000		000	
<u>EP 1107791 A2</u>	June 20, 2001	E	000	A61K047/10
<u>US 6331309 B1</u>	December 18, 2001		000	A61F013/00
<u>JP 2002524425 W</u>	August 6, 2002		033	A61K038/22

INT-CL (IPC): A61 F 13/00; A61 K 9/10; A61 K 9/70; A61 K 38/18; A61 K 38/22; A61 K 47/10; A61 K 47/26; A61 K 47/32; A61 K 47/34; A61 K 47/36; A61 P 9/10; A61 P 17/02

ABSTRACTED-PUB-NO: US 6331309B

BASIC-ABSTRACT:

NOVELTY - Hydrogel composition comprises polypeptide growth factor, water-miscible anionic polymer, water-miscible non-ionic polymeric viscosity controlling agent and water.

DETAILED DESCRIPTION - A hydrogel composition for the controlled release delivery of a polypeptide growth factor comprises: (a) a polypeptide growth factor containing at least one region of positive charge; (b) a water-miscible anionic polymer; (c) a water-miscible non-ionic polymeric viscosity controlling agent; and (d) water.

INDEPENDENT CLAIMS are included for:

h e b b g e e e f e h c e f b e

(A) a hydrogel composition for the controlled release administration of basic fibroblast growth factor comprising: (a) a basic fibroblast growth factor; (b) 0.001-0.1 wt.% water-miscible anionic polymer; (c) 0.5-25 wt.% non-ionic, water-miscible polymeric viscosity controlling agent; and (d) water;

(B) a method for producing a controlled release growth factor composition comprising dispersing in water: (a) a water miscible, non-ionic polymeric viscosity controlling agent; (b) a water miscible, anionic polymer to impart controlled release of the growth factor from the composition; and (c) a polypeptide growth factor having at least one region of positive charge;

(C) a method of treating ischemia comprising administration to a region of ischemic tissue a controlled release hydrogel composition comprising: (a) an angiogenic polypeptide growth factor having at least one region of positive charge; (b) a water-miscible anionic polymer; (c) a water-miscible non-ionic polymer viscosity controlling agent; and (d) water.

ACTIVITY - Vasotropic, Vulnerary.

Male and female Sprague-Dawley rats were briefly anesthetized by inhalation of isoflurane. Gel formulations containing varying dosages of bFGF (e.g. 4.0 mg/ml bFGF, 10% polyoxyethylene-polyoxypropylene and 0.80 % sodium carboxy methyl cellulose), as well as control gel formulations containing no bFGF, were injected subcutaneously. Five days after injection, animals were euthanized. The tissue immediately surrounding the injection site showed substantial angiogenesis in the treated group. In the control group there was no angiogenesis.

MECHANISM OF ACTION - Angiogenesis-Stimulator; FGF-Agonist.

USE - The formulations are useful for the controlled delivery of growth factors. They can be used for the controlled delivery of angiogenic growth factors for the treatment of ischemic tissue and/or for wound healing. The compositions can be used to treat conditions characterized by ischemia in order to restore blood flow to the affected area. Such conditions include coronary artery disease and peripheral vascular disease.

ADVANTAGE - The formulations can be prepared as homogeneous compositions by simple mixing techniques. The water-miscible anionic polymer can be used to impart an efficacious release rate when used at low concentrations.

ABSTRACTED-PUB-NO:

WO 200013710A EQUIVALENT-ABSTRACTS:

NOVELTY - Hydrogel composition comprises polypeptide growth factor, water-miscible anionic polymer, water-miscible non-ionic polymeric viscosity controlling agent and water.

DETAILED DESCRIPTION - A hydrogel composition for the controlled release delivery of a polypeptide growth factor comprises: (a) a polypeptide growth factor containing at least one region of positive charge; (b) a water-miscible anionic polymer; (c) a water-miscible non-ionic polymeric viscosity controlling agent; and (d) water.

INDEPENDENT CLAIMS are included for:

(A) a hydrogel composition for the controlled release administration of basic fibroblast growth factor comprising: (a) a basic fibroblast growth factor; (b) 0.001-0.1 wt.% water-miscible anionic polymer; (c) 0.5-25 wt.% non-ionic, water-miscible polymeric viscosity controlling agent; and (d) water;

(B) a method for producing a controlled release growth factor composition comprising dispersing in water: (a) a water miscible, non-ionic polymeric viscosity controlling agent; (b) a water miscible, anionic polymer to impart controlled release of the growth factor from the composition; and (c) a polypeptide growth factor having at

h e b b g e e e f c h c e f b e

least one region of positive charge;

(C) a method of treating ischemia comprising administration to a region of ischemic tissue a controlled release hydrogel composition comprising: (a) an angiogenic polypeptide growth factor having at least one region of positive charge; (b) a water-miscible anionic polymer; (c) a water-miscible non-ionic polymer viscosity controlling agent; and (d) water.

ACTIVITY - Vasotropic, Vulnerary.

Male and female Sprague-Dawley rats were briefly anesthetized by inhalation of isoflurane. Gel formulations containing varying dosages of bFGF (e.g. 4.0 mg/ml bFGF, 10% polyoxyethylene-polyoxypropylene and 0.80 % sodium carboxy methyl cellulose), as well as control gel formulations containing no bFGF, were injected subcutaneously. Five days after injection, animals were euthanized. The tissue immediately surrounding the injection site showed substantial angiogenesis in the treated group. In the control group there was no angiogenesis.

MECHANISM OF ACTION - Angiogenesis-Stimulator; FGF-Agonist.

USE - The formulations are useful for the controlled delivery of growth factors. They can be used for the controlled delivery of angiogenic growth factors for the treatment of ischemic tissue and/or for wound healing. The compositions can be used to treat conditions characterized by ischemia in order to restore blood flow to the affected area. Such conditions include coronary artery disease and peripheral vascular disease.

ADVANTAGE - The formulations can be prepared as homogeneous compositions by simple mixing techniques. The water-miscible anionic polymer can be used to impart an efficacious release rate when used at low concentrations.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
(L26) AND @PY <= 2000	33

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Search Results - Record(s) 1 through 29 of 29 returned.

☐ 1. Document ID: US 20040097401 A1

Using default format because multiple data bases are involved.

L28: Entry 1 of 29

File: PGPB

May 20, 2004

PGPUB-DOCUMENT-NUMBER: 20040097401

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040097401 A1

TITLE: Lysine in therapeutic angiogenesis, particularly in treating ischaemic conditions

PUBLICATION-DATE: May 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Datta, Debatosh	Kolkata		IN	

US-CL-CURRENT: 514/2; 514/564, 514/565

	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Desc
--	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 2. Document ID: US 20040033971 A1

L28: Entry 2 of 29

File: PGPB

Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040033971

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040033971 A1

TITLE: Polypeptides and nucleic acids encoding same

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gangolli, Esha A.	Madison	CT	US	
Patturajan, Meera	Branford	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Kekuda, Ramesh	Norwalk	CT	US	
Stone, David J.	Guilford	CT	US	
Anderson, David	Branford	CT	US	
Shimkets, Richard A.	Guilford	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	

h e b b g e e e f e h c e f b e

Zerhusen, Bryan D.	Branford	CT	US
Liu, Xiaohong	Branford	CT	US
Spytek, Kimberly A.	New Haven	CT	US
Casman, Stacie J.	North Haven	CT	US
Boldog, Ference L.	North Haven	CT	US
Smithson, Glennnda	Guilford	CT	US
Li, Li	Branford	CT	US
Ji, Weizhen	Branford	CT	US
MacDougall, John R.	Hamden	CT	US

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/7.1, 514/2, 530/387.1, 536/23.1

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention farther discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

.....	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	ENC	Draw Des
-------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 3. Document ID: US 20030229003 A1

L28: Entry 3 of 29

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229003

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030229003 A1

TITLE: Use of transcription factors for treating inflammation and other diseases

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Oettgen, Peter	Brookline	MA	US	
Libermann, Towia	Newton	MA	US	
Goldring, Mary	Auburndale	MA	US	

US-CL-CURRENT: 514/1; 435/4, 435/6, 514/2, 514/44, 514/54

ABSTRACT:

The present invention provides a method of treating inflammation in a mammal comprising altering the activity of a transcription factor involved in the inflammatory response. The invention also relates to the use of transcription factors to screen compounds that are capable of reducing inflammation. The invention also relates to the use of transcription factors in methods of diagnosing the presence of an inflammatory disease in a tissue of a mammal and methods of monitoring the treatment of an inflammatory disease in a tissue of a mammal.

.....	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Des
-------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20030215840 A1

L28: Entry 4 of 29

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215840

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030215840 A1

TITLE: Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas J.	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US	
Galvin, Katherine M.	Jamaica Plain	MA	US	
Healy, Aileen	Medford	MA	US	
Acton, Susan L.	Lexington	MA	US	
Donoghue, Mary A.	West Roxbury	MA	US	
Stagliano, Nancy	North Reading	MA	US	
Perodin, Jacqueline	Arlington	MA	US	
Rodrigue-Way, Amelie	Malden	MA	US	

US-CL-CURRENT: 435/6; 424/146.1, 435/7.2, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 and 6585 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

.....	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Des
-------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 20030199425 A1

L28: Entry 5 of 29

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199425

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030199425 A1

TITLE: Compositions and methods for treatment of hyperplasia

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Desai, Neil P.	Los Angeles	CA	US	
Soon-Shiong, Patrick	Los Angeles	CA	US	

US-CL-CURRENT: 514/2; 424/45, 514/291, 514/365, 514/449

ABSTRACT:

In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent.

Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 6. Document ID: US 20030152574 A1

L28: Entry 6 of 29

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152574

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030152574 A1

TITLE: Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Logan, Thomas Joseph	Springfield	PA	US	
Chun, Miyoung	Belmont	MA	US	

US-CL-CURRENT: 424/146.1; 435/7.2, 514/1, 514/2, 514/44

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial

h e b b g e e e f e h c e f b e

cell disorders. Specifically, the present invention identifies the differential expression of 1419, 58765 or 2210 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.

	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
--	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 7. Document ID: US 20030104977 A1

L28: Entry 7 of 29

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104977

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030104977 A1

TITLE: METHODS FOR INDUCING ANGIOGENESIS USING MORPHOGENIC PROTEINS AND STIMULATORY FACTORS

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
RIPAMONTI, UGO	SANDTON		ZA	
RAMOSHEBI, LENTSHA NATHANIEL	JOHANNESBURG		ZA	

US-CL-CURRENT: 514/2

ABSTRACT:

The present invention provides a method for inducing angiogenesis at a target locus in a mammal using morphogenic proteins. In addition, this invention also features a method for improving the angiogenic capability of a morphogenic protein at a target locus in a mammal. In this method, the morphogenic protein is capable of inducing angiogenesis when accessible to a progenitor cell in the mammal, and the morphogenic protein stimulatory factor enhances that capability. The morphogenic protein and morphogenic protein stimulatory factor can be administered simultaneously to the target locus. Alternatively, the two components are administered separately, in any order.

	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
--	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 8. Document ID: US 20030083231 A1

L28: Entry 8 of 29

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030083231

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030083231 A1

h e b b g e e f e h c e f b e

TITLE: Blood cell deficiency treatment method

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ahlem, Clarence N.	San Diego	CA	US	
Reading, Christopher	San Diego	CA	US	
Frincke, James	San Diego	CA	US	
Stickney, Dwight	Granite Bay	CA	US	
Lardy, Henry A.	Madison	WI	US	
Marwah, Padma	Middleton	WI	US	
Marwah, Ashok	Middleton	WI	US	
Prendergast, Patrick T.	Straffan		IE	

US-CL-CURRENT: 514/2; 514/169, 514/173, 514/26, 514/44, 514/63

ABSTRACT:

The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D- -glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androst-17- -one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost- -4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandros- tane that can be used in the treatment method.

Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KLOC	Draw Des
-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

9. Document ID: US 20020131959 A1

L28: Entry 9 of 29

File: PGPB

Sep 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020131959

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020131959 A1

TITLE: Means and methods for the modulation of arteriogenesis

PUBLICATION-DATE: September 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Buschmann, Ivo	Freiburg		DE	
Van Royen, Niels	Gundelfingen		DE	
Hofer, Imo	March		DE	

US-CL-CURRENT: 424/93.21; 424/85.1, 424/85.2, 514/2, 514/44

ABSTRACT:

The present invention relates generally to the modulation of arteriogenesis and/or the growth of collateral arteries or other arteries from preexisting arteriolar

h e b b g e e e f e h c e f b e

connections. In particular, the present invention provides a method for enhancing arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting an organ, tissue or cells with transforming growth factor beta 1 (TGF.beta.1) or a nucleic acid molecule encoding TGF.beta.1. The present invention also relates to the use of TGF.beta.1 or a nucleic acid molecule encoding TGF.beta.1 for the preparation of pharmaceutical compositions for enhancing arteriogenesis and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Furthermore, the present invention relates to a method for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGF.beta.1. The present invention further involves the use of an agent which suppresses arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of TGF.beta.1 for the preparation of pharmaceutical compositions for the treatment of tumors.

.....	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMK	Draw Des
-------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 10. Document ID: US 20020061521 A1

L28: Entry 10 of 29

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061521

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061521 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/69.1, 514/2, 530/300, 536/23.1

ABSTRACT:

The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods

h e b b g e e e f e h c e f b e

and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc
-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

11. Document ID: US 20020061294 A1

L28: Entry 11 of 29

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061294

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061294 A1

TITLE: MONONUCLEAR PHAGOCYTES IN THERAPEUTIC DRUG DELIVERY

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LEWIS, CLAIRE E.	SHEFFIELD		GB	
HARRIS, ADRIAN L.	OXFORD		GB	
MARSHALL, JULIAN M	OXFORD		GB	

US-CL-CURRENT: 424/93.21; 424/450, 435/320.1, 435/325, 435/69.1, 514/2, 514/44

ABSTRACT:

The invention relates to the exploitation of the migratory behaviour of mononuclear phagocytes with a view to targeting therapeutic drug delivery. The invention therefore concerns the attachment or incorporation of a therapeutic agent to or into a mononuclear phagocyte and the subsequent migration of the mononuclear phagocyte to a target area.

Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc
-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------

12. Document ID: US 20020058612 A1

L28: Entry 12 of 29

File: PGPB

May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058612

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020058612 A1

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franco, Wayne P.	Rocky Hill	CT	US	

US-CL-CURRENT: 514/2; 424/43

h e b b g e e e f e h c e f b e

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

.....	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWOC	Drawn Des
-------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 13. Document ID: US 20020037832 A1

L28: Entry 13 of 29

File: PGPB

Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037832

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020037832 A1

TITLE: Use of alpha-MSH and EPO for preventing or treating ischemic conditions

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nielsen, Soren	Abyhoj		DK	
Frokiaer, Jorgen	Abyhoj		DK	
Jonassen, Thomas Engelbrecht Norkild	Frederiksberg		DK	
Bjerke, Thorbjorn	Fredensborg		DK	

US-CL-CURRENT: 514/2; 514/169

ABSTRACT:

Alpha--melanocyte stimulating hormone (.alpha.-MSH) or an equivalent is used, in conjunction with erythropoietin (EPO) or equivalent, to prevent or treat ischemic conditions.

.....	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWOC	Drawn Des
-------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 14. Document ID: US 20020006895 A1

L28: Entry 14 of 29

File: PGPB

Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006895

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020006895 A1

TITLE: Method of treatment of cardiovascular injuries

PUBLICATION-DATE: January 17, 2002

h e b b g e e e f e h c e f b e

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moulton, Karen S.	Weston	MA	US	
Folkman, Judah	Brookline	MA	US	

US-CL-CURRENT: 514/2; 424/85.6, 424/85.7, 514/326, 514/475

ABSTRACT:

The present invention provides a method for treating cardiovascular ailments. The method involves first screening an individual to determine their risk of having the potential for unstable plaques. Such individuals can be selected by looking at one of the following criteria: (i) increased plaque neovascularization, (ii) area ratio of intima to wall area of a plaque, (iii) evidence of plaque hemorrhage, or (iv) inflammatory cells associated with plaque vessels. Looking at these criteria permits one to select individuals having the potential for unstable plaques. The method then involves treating the selected individual with an effective amount of an angiogenesis inhibitor.

.....	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Dram. Desc.
-------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 15. Document ID: US 6759386 B2

L28: Entry 15 of 29

File: USPT

Jul 6, 2004

US-PAT-NO: 6759386

DOCUMENT-IDENTIFIER: US 6759386 B2

TITLE: Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Franco; Wayne P.	Rocky Hill	CT	06067	

US-CL-CURRENT: 514/2; 514/12, 514/14, 514/8, 530/300

ABSTRACT:

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

24 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

.....	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Dram. Desc.
-------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

h e b b g e e f e h c e f b e

☐ 16. Document ID: US 6737404 B2

L28: Entry 16 of 29

File: USPT

May 18, 2004

US-PAT-NO: 6737404

DOCUMENT-IDENTIFIER: US 6737404 B2

TITLE: Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137

DATE-ISSUED: May 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Springer; Barry A.	Wilmington	DE		
Pantoliano; Michael W.	Boxford	PA		
Sharp; Celia M.	Doylestown	PA		

US-CL-CURRENT: 514/12; 514/2, 530/399

ABSTRACT:

The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.

30 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2.

Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMIC	Draw Desc
-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------

☐ 17. Document ID: US 6605592 B2

L28: Entry 17 of 29

File: USPT

Aug 12, 2003

US-PAT-NO: 6605592

DOCUMENT-IDENTIFIER: US 6605592 B2

TITLE: Protein HOFNF53

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Baker; Kevin P.	Darnestown	MD		
Birse; Charles E.	North Potomac	MD		
Ebner; Reinhard	Gaithersburg	MD		
Fiscella; Michele	Bethesda	MD		

h e b b g e e f e h c ef b e

Komatsoulis; George A.	Silver Spring	MD
LaFleur; David W.	Washington	DC
Moore; Paul A.	Germantown	MD
Olsen; Henrik S.	Gaithersburg	MD
Rosen; Craig A.	Laytonsville	MD
Ruben; Steven M.	Olney	MD
Soppet; Daniel R.	Centreville	VA
Young; Paul E.	Gaithersburg	MD
Wei; Ping	Brookeville	MD
Florence; Kimberly A.	Rockville	MD

US-CL-CURRENT: 514/2; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1,
435/71.1, 435/71.2, 514/12, 514/8, 530/350

ABSTRACT:

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. In particular, the present application relates to a novel human protein, Protein HOFNF53. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

19 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

.....	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Drawl Desc
-------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 18. Document ID: US 6592862 B1

L28: Entry 18 of 29

File: USPT

Jul 15, 2003

US-PAT-NO: 6592862

DOCUMENT-IDENTIFIER: US 6592862 B1

TITLE: Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schaper; Wolfgang	Bad Nauheim/Rodgen			DE
Ito; Wulf D.	Luneburg			DE

US-CL-CURRENT: 424/85.1; 514/12, 514/2, 514/8

ABSTRACT:

Described is the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting tissue or cells with a monocyte chemotactic protein

h e b b g e e e f e h c e f b e

(MCP) or a nucleic acid molecule encoding said MCP. Furthermore, the use of a MCP or a nucleic acid molecule encoding said MCP for the preparation of pharmaceutical compositions for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described, Also provided are methods for the treatment of tumors comprising contacting tissue or cells with an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the attraction of monocytes. Described is further the use of an agent which suppresses the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through attraction of monocytes for the preparation of pharmaceutical compositions for the treatment of tumors.

14 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw Des
--	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

19. Document ID: US 6541224 B2

L28: Entry 19 of 29

File: USPT

Apr 1, 2003

US-PAT-NO: 6541224

DOCUMENT-IDENTIFIER: US 6541224 B2

TITLE: Tumor necrosis factor delta polypeptides

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Germantown	MD		
Gentz; Reiner L.	Rockville	MD		
Dillon; Patrick J.	Carlsbad	CA		

US-CL-CURRENT: 435/69.5; 435/69.1, 435/69.7, 435/7.71, 435/70.1, 514/12, 514/2,
530/350, 530/351

ABSTRACT:

The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

50 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWMC	Draw Des
--	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 20. Document ID: US 6541008 B1

L28: Entry 20 of 29

File: USPT

Apr 1, 2003

US-PAT-NO: 6541008

DOCUMENT-IDENTIFIER: US 6541008 B1

TITLE: Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wise; Lyn M.	Dunedin			NZ
Mercer; Andrew A.	Dunedin			NZ
Savory; Loreen J.	Dunedin			NZ
Fleming; Stephen B.	Dunedin			NZ
Stacker; Steven A.	Parkville			AU

US-CL-CURRENT: 424/198.1; 514/2, 530/350

ABSTRACT:

The invention is based on the discovery that a viral VEGF-like protein from the orf virus strain NZ2 and from the orf virus strain NZ10 is capable of binding to the extracellular domain of the VEGF receptor-2 to form bioactive complexes which mediate useful cellular responses and/or antagonize undesired biological activities. Disclosed are methods which stimulate or inhibit these biological activities, methods for therapeutic applications and antagonists of ORFV2-VEGF and/or NZ10.

17 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Des
-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 21. Document ID: US 6521211 B1

L28: Entry 21 of 29

File: USPT

Feb 18, 2003

US-PAT-NO: 6521211

DOCUMENT-IDENTIFIER: US 6521211 B1

TITLE: Methods of imaging and treatment with targeted compositions

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Wu; Yunqiu	Tucson	AZ		

US-CL-CURRENT: 424/9.52; 424/450, 424/9.5, 424/9.51, 514/18, 514/2, 600/431, 600/437

h e b b g e e e f e h c e f b e

ABSTRACT:

Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIb/IIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

58 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc
-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------

☐ 22. Document ID: US 6518236 B1

L28: Entry 22 of 29

File: USPT

Feb 11, 2003

US-PAT-NO: 6518236

DOCUMENT-IDENTIFIER: US 6518236 B1

TITLE: FGF homologs

DATE-ISSUED: February 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deisher; Theresa A.	Seattle	WA		
Conklin; Darrell C.	Seattle	WA		
Raymond; Fenella	Seattle	WA		
Bukowski; Thomas R.	Seattle	WA		
Holderman; Susan D.	Seattle	WA		
Hansen; Birgit	Seattle	WA		
Sheppard; Paul O.	Redmond	WA		

US-CL-CURRENT: 514/2; 435/69.7, 514/12, 530/350, 530/399

ABSTRACT:

The present invention relates to polynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells, in particular cardiac cells and may be used for remodeling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF5 polypeptides.

5 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc
-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------

h e b b g e e f e h c e f b e

☐ 23. Document ID: US 6514935 B1

L28: Entry 23 of 29

File: USPT

Feb 4, 2003

US-PAT-NO: 6514935

DOCUMENT-IDENTIFIER: US 6514935 B1

TITLE: Methods of treating hypertension

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Mu-En	Newton	MA		
Yet; Shaw-Fang	Andover	MA		

US-CL-CURRENT: 514/2

ABSTRACT:

The invention features a method of inhibiting hypertension in a mammal by administering to the mammal a compound that reduces expression or activity of SmLIM.

3 Claims, 24 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

.....	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Drawing Des.
-------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------------

☐ 24. Document ID: US 6498144 B1

L28: Entry 24 of 29

File: USPT

Dec 24, 2002

US-PAT-NO: 6498144

DOCUMENT-IDENTIFIER: US 6498144 B1

TITLE: Use of scatter factor to enhance angiogenesis

DATE-ISSUED: December 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Goldberg; Itzhak D.	Englewood	NJ		
Rosen; Eliot M.	Port Washington	NY		

US-CL-CURRENT: 514/12; 514/2, 530/324, 530/350, 530/399

ABSTRACT:

This invention relates to a method of enhancing wound healing and to a method of enhancing organ transplantation utilizing scatter factor, either alone or in combination with a growth factor.

5 Claims, 39 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc
-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------

☐ 25. Document ID: US 6475796 B1

L28: Entry 25 of 29

File: USPT

Nov 5, 2002

US-PAT-NO: 6475796
DOCUMENT-IDENTIFIER: US 6475796 B1

TITLE: Vascular endothelial growth factor variants

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pollitt; N. Stephen	Los Altos	CA		
Abraham; Judith A.	San Jose	CA		

US-CL-CURRENT: 435/455; 424/198.1, 514/2, 530/350

ABSTRACT:

The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.

17 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 17

Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc
-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------

☐ 26. Document ID: US 6440934 B1

L28: Entry 26 of 29

File: USPT

Aug 27, 2002

US-PAT-NO: 6440934
DOCUMENT-IDENTIFIER: US 6440934 B1

TITLE: Angiogenically effective unit dose of FGF-2 and method of use

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Whitehouse; Martha Jo	San Francisco	CA		

h e b b g e e e f e h c e f b e

US-CL-CURRENT: 514/12; 424/423, 424/85.2, 424/94.4, 435/69.4, 514/2, 514/358,
514/410, 514/411, 514/54, 514/56, 530/350 , 530/380, 530/381, 530/383, 530/399,
536/17.2, 536/21, 604/101.03

ABSTRACT:

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 .mu.g/kg to 48 .mu.g/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts six months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.

58 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

.....	Title	Citation	Front	Review	Classification	Date	Reference			Claims	INDEX	Draw Des.
-------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	-----------

27. Document ID: US 6235713 B1

L28: Entry 27 of 29

File: USPT

May 22, 2001

US-PAT-NO: 6235713

DOCUMENT-IDENTIFIER: US 6235713 B1

TITLE: Vascular endothelial growth factor-D (VEGF-D) polypeptides

DATE-ISSUED: May 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Achen; Marc G.	Fitzroy			AU
Wilks; Andrew F.	South Yarra			AU
Stacker; Steven A.	North Fitzroy			AU
Alitalo; Kari	Espoo			FI

US-CL-CURRENT: 514/12; 514/2, 530/399, 530/412, 530/413

ABSTRACT:

VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical

h e b b g e e f e h c e f b e

and diagnostic applications.

16 Claims, 22 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 21

Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Des
-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 28. Document ID: US 5932540 A

L28: Entry 28 of 29

File: USPT

Aug 3, 1999

US-PAT-NO: 5932540

DOCUMENT-IDENTIFIER: US 5932540 A

**** See image for Certificate of Correction ****

TITLE: Vascular endothelial growth factor 2

DATE-ISSUED: August 3, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hu; Jing-Shan	Sunnyvale	CA		
Rosen; Craig A.	Laytonsville	MD		
Cao; Liang	Hong Kong			HK

US-CL-CURRENT: 514/2; 530/326, 530/399, 530/402

ABSTRACT:

Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

186 Claims, 22 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 19

Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Des
-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 29. Document ID: US 5824644 A

L28: Entry 29 of 29

File: USPT

Oct 20, 1998

US-PAT-NO: 5824644

DOCUMENT-IDENTIFIER: US 5824644 A

TITLE: Method of attenuating arterial stenosis

h e b b g e e e f e h c ef b e

DATE-ISSUED: October 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Abendschein; Dana R.	St. Louis	MO		

US-CL-CURRENT: 514/12; 424/422, 514/2, 514/21, 530/324, 530/350, 530/380

ABSTRACT:

A method is disclosed for attenuating stenosis after balloon angioplasty. The method comprises administering to a host parenterally or locally to the luminal surface of the blood vessel subjected to said balloon angioplasty an effective amount of tissue factor pathway inhibitor (TFPI) for a prolonged period of time sufficient to substantially reduce the extent of restenosis. An exemplary amount of the TFPI is from about 0.5 mg/kg to about 6 mg/kg during a prolonged administration of about twelve (12) hours to 36 hours.

14 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Desc
-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents


L23 AND (514/2).CCLS.

29

Display Format:

Change Format

[Previous Page](#)[Next Page](#)[Go to Doc#](#)



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books
 Search PubMed for coronary artery disease AND growth factor Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Text Version

Items 1-500 of 548

Page 1 of 2 Next

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: [Schieffer B, Bunte C, Witte J, Hoepfer K, Boger RH, Schwedhelm E, Drexler H.](#) Related Articles, Links

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.
 J Am Coll Cardiol. 2004 Jul 21;44(2):362-8.
 PMID: 15261932 [PubMed - indexed for MEDLINE]

2: [Grunenfelder J, Umbehrl M, Plass A, Bestmann L, Maly FE, Zund G, Turina M.](#) Related Articles, Links

Genetic polymorphisms of apolipoprotein E4 and tumor necrosis factor beta as predisposing factors for increased inflammatory cytokines after cardiopulmonary bypass.
 J Thorac Cardiovasc Surg. 2004 Jul;128(1):92-7.
 PMID: 15224026 [PubMed - indexed for MEDLINE]

3: [Nakajima K, Tabata S, Yamashita T, Kusuhaara M, Arakawa K, Ohmori R, Yonemura A, Higashi K, Ayaori M, Nakamura H, Ohsuzu F.](#) Related Articles, Links

Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease.
 Clin Cardiol. 2004 May;27(5):281-6.
 PMID: 15188944 [PubMed - in process]

4: [Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS.](#) Related Articles, Links

Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support.
 Circulation. 2004 Jun 22;109(24):2986-92. Epub 2004 Jun 07.
 PMID: 15184289 [PubMed - in process]

5: [Lemstrom KB, Nykanen AI, Tikkanen JM, Krebs R, Sihvola RK, Kallio EA, Olivier R, Koskinen PK.](#) Related Articles, Links

Role of angiogenic growth factors in transplant coronary artery disease.
 Ann Med. 2004;36(3):184-93.
 PMID: 15181974 [PubMed - in process]


6: [Penny WF, Hammond HK.](#) Related Articles, Links

Clinical use of intracoronary gene transfer of fibroblast growth factor for coronary artery disease.
 Curr Gene Ther. 2004 Jun;4(2):225-30.
 PMID: 15180588 [PubMed - in process]


7: [Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Antelli A, Canistro D, Francolini G, Macri G, Mastorilli F, Paolini M, Ferrari R.](#) Related Articles, Links


Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction.

J Am Coll Cardiol. 2004 Jun 2;43(11):2000-8.
PMID: 15172404 [PubMed - indexed for MEDLINE]


 **8:** [Choy E.](#)


[Related Articles, Links](#)

 **Clinical experience with inhibition of interleukin-6.**
Rheum Dis Clin North Am. 2004 May;30(2):405-15, viii. Review.
PMID: 15172049 [PubMed - indexed for MEDLINE]


 **9:** [Rosinberg A, Khan TA, Sellke FW, Laham RJ.](#)


[Related Articles, Links](#)

 **Therapeutic angiogenesis for myocardial ischemia.**
Expert Rev Cardiovasc Ther. 2004 Mar;2(2):271-83. Review.
PMID: 15151475 [PubMed - indexed for MEDLINE]


 **10:** [Christiansen JF, Hartwig D, Bechtel JF, Kluter H, Sievers H, Schonbeck U, Bartels C.](#)


[Related Articles, Links](#)

 **Diseased vein grafts express elevated inflammatory cytokine levels compared with atherosclerotic coronary arteries.**
Ann Thorac Surg. 2004 May;77(5):1575-9.
PMID: 15111145 [PubMed - indexed for MEDLINE]


 **11:** [Tentolouris C, Tousoulis D, Antoniadis C, Bosinakou E, Kotsopoulou M, Trikas A, Toutouzas P, Stefanadis C.](#)


[Related Articles, Links](#)

 **Endothelial function and proinflammatory cytokines in patients with ischemic heart disease and dilated cardiomyopathy.**
Int J Cardiol. 2004 Apr;94(2-3):301-5.
PMID: 15093997 [PubMed - indexed for MEDLINE]


 **12:** [Wykretowicz A, Furmaniuk J, Smielecki J, Deskur-Smielecka E, Szczepanik A, Banaszak A, Wysocki H.](#)

[Related Articles, Links](#)

 **The oxygen stress index and levels of circulating interleukin-10 and interleukin-6 in patients with chronic heart failure.**
Int J Cardiol. 2004 Apr;94(2-3):283-7.
PMID: 15093994 [PubMed - indexed for MEDLINE]


 **13:** [Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y, March KL.](#)

[Related Articles, Links](#)

 **Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease.**
J Am Coll Cardiol. 2004 Apr 21;43(8):1383-7.
PMID: 15093871 [PubMed - indexed for MEDLINE]


 **14:** [Poreba R, Skoczynska A, Derkacz A.](#)


[Related Articles, Links](#)

 **[Effect of tobacco smoking on endothelial function in patients with coronary arteriosclerosis]**
Pol Arch Med Wewn. 2004 Jan;111(1):27-36. Polish.
PMID: 15088418 [PubMed - indexed for MEDLINE]


 **15:** [Dimkovic N.](#)


[Related Articles, Links](#)

 **[Erythropoietin administration in the predialysis period]**
Med Pregl. 2003 Nov-Dec;56(11-12):529-35. Review. Serbian.
PMID: 15080045 [PubMed - indexed for MEDLINE]



















 **16:** [Gouni-Berthold I, Sachinidis A.](#)


















[Related Articles, Links](#)




















 **Molecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseases.**
Curr Pharm Des. 2004;10(11):1261-71. Review.
PMID: 15078140 [PubMed - indexed for MEDLINE]


 **17:** [Brydon L, Edwards S, Mohamed-Ali V, Steptoe A.](#)


[Related Articles, Links](#)


-  **Socioeconomic status and stress-induced increases in interleukin-6.**
Brain Behav Immun. 2004 May;18(3):281-90.
PMID: 15050655 [PubMed - indexed for MEDLINE]
-  **18:** [Kovalev IA, Martsinkevich GI, Suslova TE, Sokolov AA.](#) [Related Articles, Links](#)
-  **[Endothelial dysfunction and risk factors of its development in subjects with family history of atherosclerosis]**
Kardiologiia. 2004;44(1):39-42. Russian.
PMID: 15029147 [PubMed - indexed for MEDLINE]
-  **19:** [Llorente-Cortes V, Otero-Vinas M, Berrozpe M, Badimon L.](#) [Related Articles, Links](#)
-  **Intracellular lipid accumulation, low-density lipoprotein receptor-related protein expression, and cell survival in vascular smooth muscle cells derived from normal and atherosclerotic human coronaries.**
Eur J Clin Invest. 2004 Mar;34(3):182-90.
PMID: 15025676 [PubMed - indexed for MEDLINE]
-  **20:** [van Royen N, Voskuil M, Hoefer I, Jost M, de Graaf S, Hedwig F, Andert JP, Wormhoudt TA, Hua J, Hartmann S, Bode C, Buschmann I, Schaper W, van der Neut R, Piek JJ, Pals ST.](#) [Related Articles, Links](#)
-  **CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization.**
Circulation. 2004 Apr 6;109(13):1647-52. Epub 2004 Mar 15.
PMID: 15023889 [PubMed - indexed for MEDLINE]
-  **21:** [Ikonomidis I, Andreotti F, Nihoyannopoulos P.](#) [Related Articles, Links](#)
-  **Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor.**
Heart. 2004 Apr;90(4):389-93.
PMID: 15020512 [PubMed - indexed for MEDLINE]
-  **22:** [Williams MJ, Sutherland WH, Whelan AP, McCormick MP, de Jong SA.](#) [Related Articles, Links](#)
-  **Acute effect of drinking red and white wines on circulating levels of inflammation-sensitive molecules in men with coronary artery disease.**
Metabolism. 2004 Mar;53(3):318-23.
PMID: 15015143 [PubMed - indexed for MEDLINE]
-  **23:** [Yohannes P, Rao M, Burjonrappa S, Sudan R.](#) [Related Articles, Links](#)
-  **Laparoscopic nephron-sparing surgery in a Jehovah's Witness patient.**
J Endourol. 2004 Feb;18(1):59-62.
PMID: 15006056 [PubMed - indexed for MEDLINE]
-  **24:** [Perrin LA, June JE, Rosebury W, Robertson A, Kovacs I, Bruder JT, Kessler PD, Keiser JA, Gordon D.](#) [Related Articles, Links](#)
-  **Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).**
Gene Ther. 2004 Mar;11(6):512-21.
PMID: 14999223 [PubMed - indexed for MEDLINE]
-  **25:** [Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Quiles J, Zouridakis E, Kaski JC.](#) [Related Articles, Links](#)
-  **Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease.**
Am J Cardiol. 2004 Mar 1;93(5):627-9.
PMID: 14996595 [PubMed - indexed for MEDLINE]
-  **26:** [Syed IS, Sanborn TA, Rosengart TK.](#) [Related Articles, Links](#)


-  **Therapeutic angiogenesis: a biologic bypass.**
Cardiology. 2004;101(1-3):131-43. Review.
PMID: 14988635 [PubMed - indexed for MEDLINE]
-  **27:** Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tamok A, Gielen S, Emmrich F, Schuler G, Hambrecht R. [Related Articles](#), [Links](#)
Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.
PMID: 14988094 [PubMed - indexed for MEDLINE]
-  **28:** Chong AY, Caine GJ, Lip GY. [Related Articles](#), [Links](#)
 **Angiopoietin/tie-2 as mediators of angiogenesis: a role in congestive heart failure?**
Eur J Clin Invest. 2004 Jan;34(1):9-13.
PMID: 14984432 [PubMed - indexed for MEDLINE]
-  **29:** Mizia-Stec K, Zahorska-Markiewicz B, Gasior Z. [Related Articles](#), [Links](#)
 **Cigarette smoking and inflammatory indices in coronary artery disease.**
Int J Cardiol. 2004 Feb;93(2-3):169-74.
PMID: 14975543 [PubMed - indexed for MEDLINE]
-  **30:** Brown DL, Desai KK, Vakili BA, Nounch C, Lee HM, Golub LM. [Related Articles](#), [Links](#)
 **Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.**
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):733-8. Epub 2004 Feb 12.
PMID: 14962945 [PubMed - indexed for MEDLINE]
-  **31:** Andreotti F, Crea F, Conti E. [Related Articles](#), [Links](#)
 **Heart-kidney interactions in ischemic syndromes.**
Circulation. 2004 Feb 10;109(5):e31-2; author reply e31-2. No abstract available.
PMID: 14769693 [PubMed - indexed for MEDLINE]
-  **32:** Dubey RK, Gillespie DG, Grogli M, Kloosterboer HJ, Imthurn B. [Related Articles](#), [Links](#)
 **Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: role of estrogen, progesterone, and androgen receptors.**
J Clin Endocrinol Metab. 2004 Feb;89(2):852-9.
PMID: 14764805 [PubMed - indexed for MEDLINE]
-  **33:** Schalch P, Rahman GF, Patejunas G, Goldschmidt RA, Carbray J, Retuerto MA, Kim D, Esser K, Crystal RG, Rosengart TK. [Related Articles](#), [Links](#)
 **Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state.**
J Thorac Cardiovasc Surg. 2004 Feb;127(2):535-40.
PMID: 14762365 [PubMed - indexed for MEDLINE]
-  **34:** Lesperance F, Frasure-Smith N, Theroux P, Irwin M. [Related Articles](#), [Links](#)
 **The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes.**
Am J Psychiatry. 2004 Feb;161(2):271-7.
PMID: 14754776 [PubMed - indexed for MEDLINE]
-  **35:** Biswas SS, Hughes GC, Scarborough JE, Domkowski PW, Diodato L, Smith ML, Landolfo C, Lowe JE, Annex BH, Landolfo KP. [Related Articles](#), [Links](#)


-  **Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study.**
J Thorac Cardiovasc Surg. 2004 Jan;127(1):34-43.
PMID: 14752410 [PubMed - indexed for MEDLINE]
-  **36:** [Symes JF.](#) Related Articles, Links
-  **Gene therapy for ischemic heart disease: therapeutic potential.**
Am J Cardiovasc Drugs. 2001;1(3):159-66. Review.
PMID: 14728030 [PubMed - indexed for MEDLINE]
-  **37:** [Chaladakov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, Ghenev PI, Aloe L.](#) Related Articles, Links
-  **Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease?**
Prog Brain Res. 2004;146:279-89. Review.
PMID: 14699970 [PubMed - indexed for MEDLINE]
-  **38:** [Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL.](#) Related Articles, Links
-  **Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques.**
Am J Cardiol. 2004 Jan 1;93(1):6-9.
PMID: 14697457 [PubMed - indexed for MEDLINE]
-  **39:** [Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Mische E, Bohm M, Nickenig G.](#) Related Articles, Links
-  **Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis.**
Circulation. 2004 Jan 20;109(2):220-6. Epub 2003 Dec 22.
PMID: 14691039 [PubMed - indexed for MEDLINE]
-  **40:** [Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Sinn A.](#) Related Articles, Links
-  **Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting.**
J Am Coll Cardiol. 2003 Dec 17;42(12):2073-80.
PMID: 14680729 [PubMed - indexed for MEDLINE]
-  **41:** [Bruemmner D, Law RE.](#) Related Articles, Links
-  **Thiazolidinedione regulation of smooth muscle cell proliferation.**
Am J Med. 2003 Dec 8;115 Suppl 8A:87S-92S. Review.
PMID: 14678872 [PubMed - indexed for MEDLINE]
-  **42:** [Miller GE, Freedland KE, Carney RM, Stetler CA, Banks WA.](#) Related Articles, Links
-  **Cynical hostility, depressive symptoms, and the expression of inflammatory risk markers for coronary heart disease.**
J Behav Med. 2003 Dec;26(6):501-15.
PMID: 14677209 [PubMed - indexed for MEDLINE]
-  **43:** [Ungerstedt JS, Heimersson K, Soderstrom T, Hansson M.](#) Related Articles, Links
-  **Nicotinamide inhibits endotoxin-induced monocyte tissue factor expression.**
J Thromb Haemost. 2003 Dec;1(12):2554-60.
PMID: 14675092 [PubMed - indexed for MEDLINE]
-  **44:** [Matsuzawa Y, Shimomura I, Kihara S, Funahashi T.](#) Related Articles, Links
-  **Importance of adipocytokines in obesity-related diseases.**
Horm Res. 2003;60 Suppl 3:56-9.
PMID: 14671398 [PubMed - in process]


-  **45:** [Kolsut P, Malecki M, Zelazny P, Teresinska A, Firek B, Janik P, Religa Z.](#) [Related Articles, Links](#)

 **Gene therapy of coronary artery disease with phvegf165--early outcome.**
Kardiol Pol. 2003 Nov;59(11):373-84. English, Polish.
PMID: 14668888 [PubMed - indexed for MEDLINE]


-  **46:** [Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, Barbieri M, Paolisso G, Giugliano D.](#) [Related Articles, Links](#)


 **Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus.**
Am J Clin Nutr. 2003 Dec;78(6):1135-40.
PMID: 14668275 [PubMed - indexed for MEDLINE]


-  **47:** [Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, Stridsberg M, Venge P, Wallentin L.](#) [Related Articles, Links](#)

 **N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease.**
J Am Coll Cardiol. 2003 Dec 3;42(11):1909-16.
PMID: 14662251 [PubMed - indexed for MEDLINE]


-  **48:** [Baklanov D, Simons M.](#) [Related Articles, Links](#)

 **Arteriogenesis: lessons learned from clinical trials.**
Endothelium. 2003;10(4-5):217-23. Review.
PMID: 14660081 [PubMed - indexed for MEDLINE]


-  **49:** [Conraads VM, Bosmans JM, Schuerwegh AJ, De Clerck LS, Bridts CH, Wuyts FL, Stevens WJ, Vrints CJ.](#) [Related Articles, Links](#)


 **Association of lipoproteins with cytokines and cytokine receptors in heart failure patients. Differences between ischaemic versus idiopathic cardiomyopathy.**
Eur Heart J. 2003 Dec;24(24):2221-6.
PMID: 14659774 [PubMed - indexed for MEDLINE]


-  **50:** [Chepelenko G.V.](#) [Related Articles, Links](#)


 **[Pathogenesis of atherosclerosis in patients with lipid metabolism disturbances: hypothesis on cholesterol utilization and atheromatous plaque formation]**
Angiol Sosud Khir. 2003;9(3):20-5. Review. Russian.
PMID: 14657928 [PubMed - indexed for MEDLINE]


-  **51:** [Roguin A, Resar JR.](#) [Related Articles, Links](#)

 **Genetics and susceptibility of coronary collateral formation.**
Circulation. 2003 Nov 25;108(21):e149; author reply e149. No abstract available.
PMID: 14638531 [PubMed - indexed for MEDLINE]

-  **52:** [DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B.](#) [Related Articles, Links](#)

 **Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.**
Cancer Res. 2003 Nov 15;63(22):8051-6.
PMID: 14633738 [PubMed - indexed for MEDLINE]

-  **53:** [Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GY.](#) [Related Articles, Links](#)

 **Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease.**
Heart. 2003 Dec;89(12):1411-5.

PMID: 14617549 [PubMed - indexed for MEDLINE]

- 54: [Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Kaibuchi K, Takeshita A.](#) [Related Articles, Links](#)



Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice.

Circ Res. 2004 Jan 9;94(1):46-52. Epub 2003 Nov 13.
PMID: 14615290 [PubMed - indexed for MEDLINE]

- 55: [Grines C, Rubanyi GM, Kleiman NS, Marrott P, Watkins MW.](#) [Related Articles, Links](#)



Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease.

Am J Cardiol. 2003 Nov 7;92(9B):24N-31N. Review.
PMID: 14615023 [PubMed - indexed for MEDLINE]

- 56: [Moien-Afshari F, McManus BM, Laher I.](#) [Related Articles, Links](#)



Immunosuppression and transplant vascular disease: benefits and adverse effects.

Pharmacol Ther. 2003 Nov;100(2):141-56. Review.
PMID: 14609717 [PubMed - indexed for MEDLINE]

- 57: [Boehm M, Nabel EG.](#) [Related Articles, Links](#)



The cell cycle and cardiovascular diseases.

Prog Cell Cycle Res. 2003;5:19-30. Review.
PMID: 14593697 [PubMed - indexed for MEDLINE]

- 58: [Panatsopoulos D, Zafiropoulos A, Krambovitis E, Kochiadakis GE, Igoumenidis NE, Spandidos DA.](#) [Related Articles, Links](#)



Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression.

J Transl Med. 2003 Oct 06;1(1):6.
PMID: 14585103 [PubMed - as supplied by publisher]

- 59: [Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y.](#) [Related Articles, Links](#)



Human epicardial adipose tissue is a source of inflammatory mediators.

Circulation. 2003 Nov 18;108(20):2460-6. Epub 2003 Oct 27.
PMID: 14581396 [PubMed - indexed for MEDLINE]

- 60: [Walter RB, Fuchs D, Weiss G, Walter TR, Reinhart WH.](#) [Related Articles, Links](#)



HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease.

Clin Chem Lab Med. 2003 Oct;41(10):1314-9.
PMID: 14580158 [PubMed - indexed for MEDLINE]

- 61: [Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M, Bertazzoni G, Gazzaniga PP, Alessandri C.](#) [Related Articles, Links](#)



Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation.

J Invest Med. 2003 Sep;51(5):295-300.
PMID: 14577520 [PubMed - indexed for MEDLINE]

- 62: [Koch W, Tiroch K, von Beckerath N, Schomig A, Kastrati A.](#) [Related Articles, Links](#)



Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting.

Cytokine. 2003 Nov 21;24(4):161-71.
PMID: 14572794 [PubMed - indexed for MEDLINE]

- 63: [Juan-Babot JO, Martinez-Gonzalez J, Berrozpe M, Badimon L.](#) [Related Articles, Links](#)



[Neovascularization in human coronary arteries with lesions of different severity]

Rev Esp Cardiol. 2003 Oct;56(10):978-86. Spanish.
PMID: 14563292 [PubMed - indexed for MEDLINE]



64: [Kaul D, Kaur R, Baba I, Singh D.](#)

[Related Articles, Links](#)



Functional proteomics of receptor-Ck in the developmental stages of human atherosclerotic arterial wall.

Indian Heart J. 2003 May-Jun;55(3):252-5.
PMID: 14560935 [PubMed - indexed for MEDLINE]



65: [Aviles RJ, Annex BH, Lederman RJ.](#)

[Related Articles, Links](#)



Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).

Br J Pharmacol. 2003 Oct;140(4):637-46.
PMID: 14534147 [PubMed - in process]



66: [Cordain L, Eades MR, Eades MD.](#)

[Related Articles, Links](#)



Hyperinsulinemic diseases of civilization: more than just Syndrome X.

Comp Biochem Physiol A Mol Integr Physiol. 2003 Sep;136(1):95-112. Review.
PMID: 14527633 [PubMed - indexed for MEDLINE]



67: [Ng MK, Quinn CM, McCrohon JA, Nakhla S, Jessup W, Handelsman DJ, Celermaier DS, Death AK.](#)

[Related Articles, Links](#)



Androgens up-regulate atherosclerosis-related genes in macrophages from males but not females: molecular insights into gender differences in atherosclerosis.

J Am Coll Cardiol. 2003 Oct 1;42(7):1306-13.
PMID: 14522500 [PubMed - indexed for MEDLINE]



68: [Yamaoka-Tojo M, Tojo T, Masuda T, Machida Y, Kitano Y, Kurosawa T, Izumi T.](#)

[Related Articles, Links](#)



C-reactive protein-induced production of interleukin-18 in human endothelial cells: a mechanism of orchestrating cytokine cascade in acute coronary syndrome.

Heart Vessels. 2003 Sep;18(4):183-7.
PMID: 14520485 [PubMed - indexed for MEDLINE]



69: [Nishimura S, Zaito M, Hara M, Yokota G, Watanabe M, Ueda Y, Imayoshi M, Ishii E, Tasaki H, Hamasaki Y.](#)

[Related Articles, Links](#)



A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease.

J Pediatr. 2003 Sep;143(3):357-62.
PMID: 14517520 [PubMed - indexed for MEDLINE]



70: [Fujita M, Ikemoto M, Tanaka T, Tamaki S, Yamazato A, Sawamura T, Hasegawa K, Kihara Y, Nohara R, Sasayama S.](#)

[Related Articles, Links](#)



Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.

Angiogenesis. 1998;2(1):105-8.
PMID: 14517380 [PubMed]



71: [Blake GJ.](#)

[Related Articles, Links](#)



Inflammatory biomarkers of the patient with myocardial insufficiency.


Curr Opin Crit Care. 2003 Oct;9(5):369-74. Review.
PMID: 14508149 [PubMed - indexed for MEDLINE]




72: [Crottogini A, Meckert PC, Vera Janavel G, Lascano E, Negroni J, Del Valle H, Dulbecco E, Werba P, Cuniberti L, Martinez V, De](#)

[Related Articles, Links](#)


Lorenzi A, Telayna J, Mele A, Fernandez JL, Marangunich L, Criscuolo M, Capogrossi MC, Laguens R


-  **Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs.**
Hum Gene Ther. 2003 Sep 20;14(14):1307-18.
PMID: 14503966 [PubMed - indexed for MEDLINE]


 **73:** Girndt M, Kohler H Related Articles, Links


-  **Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk.**
Nephrol Dial Transplant. 2003 Oct;18(10):1976-9. Review. No abstract available.
PMID: 13679468 [PubMed - indexed for MEDLINE]


 **74:** Ruel M, Sellke FW Related Articles, Links


-  **Angiogenic protein therapy.**
Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review.
PMID: 12973700 [PubMed - indexed for MEDLINE]


 **75:** Buechler C, Ullrich H, Aslanidis C, Bared SM, Lingenhel A, Ritter M, Schmitz G Related Articles, Links


-  **Lipoprotein (a) downregulates lysosomal acid lipase and induces interleukin-6 in human blood monocytes.**
Biochim Biophys Acta. 2003 Sep 23;1642(1-2):25-31.
PMID: 12972290 [PubMed - indexed for MEDLINE]


 **76:** Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Li J, Laham RJ, Sellke FW Related Articles, Links


-  **Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model.**
Circulation. 2003 Sep 9;108 Suppl 1:II335-40.
PMID: 12970256 [PubMed - indexed for MEDLINE]


 **77:** Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, Janowska J, Szulc A, Jastrzebska-Maj E, Kobielusz-Gembala J Related Articles, Links


-  **Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes.**
Coron Artery Dis. 2003 Sep;14(6):431-8.
PMID: 12966263 [PubMed - indexed for MEDLINE]


 **78:** Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Tracy RP, Rubin SM, Harris TB, Pahor M Related Articles, Links










-  **Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study).**
Am J Cardiol. 2003 Sep 1;92(5):522-8.
PMID: 12943870 [PubMed - indexed for MEDLINE]

 **79:** Georges JL, Rupprecht HJ, Blankenberg S, Poirier O, Bickel C, Hafner G, Nicaud V, Meyer J, Cambien F, Tiret L, AtheroGene Group Related Articles, Links

-  **Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines.**
Am J Cardiol. 2003 Sep 1;92(5):515-21.
PMID: 12943869 [PubMed - indexed for MEDLINE]

 **80:** Bogavac-Stanojevic N, Djurovic S, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Kalimanovska-Ostic D Related Articles, Links

-  **Circulating transforming growth factor-beta1, lipoprotein(a) and cellular adhesion molecules in angiographically assessed coronary artery disease.**
Clin Chem Lab Med. 2003 Jul;41(7):893-8.
PMID: 12940514 [PubMed - indexed for MEDLINE]

-  **81:** Wei M, Kuukasjarvi P, Laurikka J, Kaukinen S, Honkonen EL, Metsanoja R, Tarkka M. [Related Articles, Links](#)
Relation of cytokines to vasodilation after coronary artery bypass grafting.
 World J Surg. 2003 Oct;27(10):1093-8. Epub 2003 Aug 21.
 PMID: 12925902 [PubMed - indexed for MEDLINE]
-  **82:** Glowinska B, Urban M. [Related Articles, Links](#)
[Selected cytokines (Il-6, Il-8, Il-10, MCP-1, TNF-alpha) in children and adolescents with atherosclerosis risk factors: obesity, hypertension, diabetes]
 Wiad Lek. 2003;56(3-4):109-16. Polish.
 PMID: 12923954 [PubMed - indexed for MEDLINE]
-  **83:** Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R. [Related Articles, Links](#)
Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.
 Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 07.
 PMID: 12907464 [PubMed - indexed for MEDLINE]
-  **84:** Watkins MW, Rubanyi GM. [Related Articles, Links](#)
Gene therapy for coronary artery disease: preclinical and initial clinical results with intracoronary administration of Ad5FGF-4.
 Ernst Schering Res Found Workshop. 2003;(43):61-78. Review. No abstract available.
 PMID: 12894451 [PubMed - indexed for MEDLINE]
-  **85:** Geraldes P, Sirois MG, Tanguay JF. [Related Articles, Links](#)
Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation.
 Circ Res. 2003 Sep 5;93(5):399-405. Epub 2003 Jul 31.
 PMID: 12893737 [PubMed - indexed for MEDLINE]
-  **86:** Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. [Related Articles, Links](#)
Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase.
 Circ Res. 2003 Aug 22;93(4):321-9. Epub 2003 Jul 24.
 PMID: 12881477 [PubMed - indexed for MEDLINE]
-  **87:** Xia H, Redman CM. [Related Articles, Links](#)
Oxysterols suppress constitutive fibrinogen expression.
 Thromb Haemost. 2003 Jul;90(1):43-51.
 PMID: 12876624 [PubMed - indexed for MEDLINE]
-  **88:** Murata S, Miniati DN, Kown MH, Koransky ML, Balsam LB, Lijkwan MA, Martens JM, Robbins RC. [Related Articles, Links](#)
Elevated cyclic adenosine monophosphate ameliorates ischemia-reperfusion injury in rat cardiac allografts.
 J Heart Lung Transplant. 2003 Jul;22(7):802-9.
 PMID: 12873549 [PubMed - indexed for MEDLINE]
-  **89:** Holm T, Damas JK, Holven K, Nordoy I, Brosstad FR, Ueland T, Wahre T, Kjekshus J, Froland SS, Eiken HG, Solum NO, Gullestad L, Nenseter M, Aukrust P. [Related Articles, Links](#)
CXC-chemokines in coronary artery disease: possible pathogenic role of interactions between oxidized low-density lipoprotein, platelets and peripheral blood mononuclear cells.
 J Thromb Haemost. 2003 Feb;1(2):257-62.
 PMID: 12871498 [PubMed - indexed for MEDLINE]

90: [Aldhahi W, Hamdy O.](#)

[Related Articles, Links](#)



Adipokines, inflammation, and the endothelium in diabetes.

Curr Diab Rep. 2003 Aug;3(4):293-8. Review.

PMID: 12866991 [PubMed - indexed for MEDLINE]

91: [Chien S.](#)

[Related Articles, Links](#)



Molecular and mechanical bases of focal lipid accumulation in arterial wall.

Prog Biophys Mol Biol. 2003 Oct;83(2):131-51.

PMID: 12865076 [PubMed - in process]

92: [Azar RR, Klayme S, Germanos M, Kassab R, Tawm S, Aboujaoude S, Naman R.](#)

[Related Articles, Links](#)



Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers.

Am J Cardiol. 2003 Jul 15;92(2):236-9. No abstract available.

PMID: 12860235 [PubMed - indexed for MEDLINE]

93: [Berg HF, Maraha B, Scheffer GJ, Peeters MF, Kluytmans JA.](#)

[Related Articles, Links](#)



Effect of clarithromycin on inflammatory markers in patients with atherosclerosis.

Clin Diagn Lab Immunol. 2003 Jul;10(4):525-8.

PMID: 12853380 [PubMed - indexed for MEDLINE]

94: [Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M.](#)

[Related Articles, Links](#)



Toward surgical angiogenesis using slow-released basic fibroblast growth factor.

Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112.

PMID: 12853053 [PubMed - indexed for MEDLINE]

95: [Smith DA, Zouridakis EG, Mariani M, Fredericks S, Cole D, Kaski JC.](#)

[Related Articles, Links](#)



Neopterin levels in patients with coronary artery disease are independent of Chlamydia pneumoniae seropositivity.

Am Heart J. 2003 Jul;146(1):69-74.

PMID: 12851610 [PubMed - indexed for MEDLINE]

96: [Hedman M, Yla-Herttuala S.](#)

[Related Articles, Links](#)



Gene therapy for the treatment of peripheral vascular disease and coronary artery disease.

Drugs Today (Barc). 2000 Sep;36(9):609-17.

PMID: 12847566 [PubMed]

97: [Heeneman S, Cleutjens JP, Faber BC, Creemers EE, van Suylen RJ, Lutgens E, Cleutjens KB, Daemen MJ.](#)

[Related Articles, Links](#)



The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis.

J Pathol. 2003 Jul;200(4):516-25. Review.

PMID: 12845619 [PubMed - indexed for MEDLINE]

98: [Giomarelli P, Scolletta S, Borrelli E, Biagioli B.](#)

[Related Articles, Links](#)













Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10.

Ann Thorac Surg. 2003 Jul;76(1):117-23.

PMID: 12842524 [PubMed - indexed for MEDLINE]

99: [Buschmann IR, Busch HJ, Mijs G, Hossmann KA.](#)


[Related Articles, Links](#)

-  **Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor.**
Circulation. 2003 Aug 5;108(5):610-5. Epub 2003 Jun 30.
PMID: 12835229 [PubMed - indexed for MEDLINE]
- ☐ **100:** [Suarez EC.](#) Related Articles, Links
-  **Plasma interleukin-6 is associated with psychological coronary risk factors: moderation by use of multivitamin supplements.**
Brain Behav Immun. 2003 Aug;17(4):296-303.
PMID: 12831832 [PubMed - indexed for MEDLINE]
- ☐ **101:** [Huang M, Pang X, Karalis K, Theoharides TC.](#) Related Articles, Links
-  **Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice.**
Cardiovasc Res. 2003 Jul 1;59(1):241-9.
PMID: 12829195 [PubMed - indexed for MEDLINE]
- ☐ **102:** [Norata GD, Pirillo A, Callegari E, Hamsten A, Catapano AL, Eriksson P.](#) Related Articles, Links
-  **Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL.**
Cardiovasc Res. 2003 Jul 1;59(1):169-80.
PMID: 12829188 [PubMed - indexed for MEDLINE]
- ☐ **103:** [Stenvinkel P, Pecoits-Filho R, Lindholm B.](#) Related Articles, Links
-  **Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem.**
J Am Soc Nephrol. 2003 Jul;14(7):1927-39. Review. No abstract available.
PMID: 12819254 [PubMed - indexed for MEDLINE]
- ☐ **104:** [Rallidis LS, Paschos G, Liakos GK, Velissaridou AH, Anastasiadis G, Zampelas A.](#) Related Articles, Links
-  **Dietary alpha-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients.**
Atherosclerosis. 2003 Apr;167(2):237-42.
PMID: 12818406 [PubMed - indexed for MEDLINE]
- ☐ **105:** [Chung NA, Makin AJ, Lip GY.](#) Related Articles, Links
-  **Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay.**
Eur J Clin Invest. 2003 Jul;33(7):529-35.
PMID: 12814387 [PubMed - indexed for MEDLINE]
- ☐ **106:** [Goetzl EJ, Graeler M, Huang MC, Shankar G.](#) Related Articles, Links
-  **Lysophospholipid growth factors and their G protein-coupled receptors in immunity, coronary artery disease, and cancer.**
ScientificWorldJournal. 2002 Feb 6;2:324-38. Review.
PMID: 12806020 [PubMed - indexed for MEDLINE]
- ☐ **107:** [Densem CG, Hutchinson IV, Yonan N, Brooks NH.](#) Related Articles, Links
-  **Influence of interleukin-10 polymorphism on the development of coronary vasculopathy following cardiac transplantation.**
Transpl Immunol. 2003 Apr-Jun;11(2):223-8.
PMID: 12799207 [PubMed - indexed for MEDLINE]
- ☐ **108:** [Brevetti G, Piscione F, Silvestro A, Galasso G, Di Donato A, Oliva G, Scopacasa F, Chiariello M.](#) Related Articles, Links
-  **Increased inflammatory status and higher prevalence of three-vessel**

coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis.

Thromb Haemost. 2003 Jun;89(6):1058-63.

PMID: 12783119 [PubMed - indexed for MEDLINE]

 **109:** [Kastrup J.](#)

[Related Articles, Links](#)



Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy?

Curr Gene Ther. 2003 Jun;3(3):197-206. Review.

PMID: 12762479 [PubMed - indexed for MEDLINE]

 **110:** [Koerselman J, van der Graaf Y, de Jaegere PP, Grobbee DE.](#)


[Related Articles, Links](#)



Coronary collaterals: an important and underexposed aspect of coronary artery disease.

Circulation. 2003 May 20;107(19):2507-11. Review. No abstract available.

PMID: 12756191 [PubMed - indexed for MEDLINE]

 **111:** [Damas JK, Wachre T, Yndestad A, Otterdal K, Hognestad A, Solum NO, Gullestad L, Frøland SS, Aukrust P.](#)


[Related Articles, Links](#)



Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets.

Circulation. 2003 Jun 3;107(21):2670-6. Epub 2003 May 12.

PMID: 12742982 [PubMed - indexed for MEDLINE]

 **112:** [Yoshioka S, Tsukamoto T, Chihara K.](#)


[Related Articles, Links](#)



[Vascular smooth muscle cells in coronary heart disease]

Nippon Rinsho. 2003 Apr;61 Suppl 4:80-5. Review. Japanese. No abstract available.

PMID: 12734957 [PubMed - indexed for MEDLINE]

 **113:** [Amann FW.](#)


[Related Articles, Links](#)



[Coronary stents]

Ther Umsch. 2003 Apr;60(4):179-82. German.

PMID: 12731426 [PubMed - indexed for MEDLINE]

 **114:** [Mazzone A, Gianetti J, Picano E, Bevilacqua S, Zucchelli G, Biagini A, Glauber M.](#)

[Related Articles, Links](#)



Correlation between inflammatory response and markers of neuronal damage in coronary revascularization with and without cardiopulmonary bypass.

Perfusion. 2003 Mar;18(1):3-8.

PMID: 12705643 [PubMed - indexed for MEDLINE]

 **115:** [Rasmussen HS, Rasmussen CS, Macko J.](#)


[Related Articles, Links](#)



VEGF gene therapy for coronary artery disease and peripheral vascular disease.

Cardiovasc Radiat Med. 2002 Apr-Jun;3(2):114-7. Review.

PMID: 12699842 [PubMed - indexed for MEDLINE]

 **116:** [Kao J, Kobashigawa J, Fishbein MC, MacLellan WR, Burdick MD, Belperio JA, Strieter RM.](#)


[Related Articles, Links](#)



Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease.

Circulation. 2003 Apr 22;107(15):1958-61. Epub 2003 Apr 14.

PMID: 12695288 [PubMed - indexed for MEDLINE]


 **117:** [Despres JP, Lemieux I, Pascot A, Almeras N, Dumont M, Nadeau A, Bergeron J, Prud'homme D.](#)

[Related Articles, Links](#)



Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):702-3. No abstract available.
PMID: 12692010 [PubMed - indexed for MEDLINE]

-  **118:** [Ananyeva N, Tjurmin A, Saenko E, Haudenschild C.](#) [Related Articles, Links](#)



Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 06.
PMID: 12692004 [PubMed - indexed for MEDLINE]

-  **119:** [Khurana R, Simons M.](#) [Related Articles, Links](#)



Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease.

Trends Cardiovasc Med. 2003 Apr;13(3):116-22. Review.
PMID: 12691676 [PubMed - indexed for MEDLINE]

-  **120:** [Abo-Auda W, Benza RL.](#) [Related Articles, Links](#)



Therapeutic angiogenesis: review of current concepts and future directions.


J Heart Lung Transplant. 2003 Apr;22(4):370-82. Review. No abstract available.
PMID: 12681415 [PubMed - indexed for MEDLINE]

-  **121:** [Hughes GC, Post MJ, Simons M, Annex BH.](#) [Related Articles, Links](#)



Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis.


J Appl Physiol. 2003 May;94(5):1689-701. Review.
PMID: 12679343 [PubMed - indexed for MEDLINE]

-  **122:** [Kwak HJ, Pae HO, Oh GS, Choi BM, Jang SI, Jung S, Chung HT.](#) [Related Articles, Links](#)



Molsidomine ameliorates experimental allergic encephalomyelitis in Lewis rats.

Immunopharmacol Immunotoxicol. 2003 Feb;25(1):41-52.
PMID: 12675198 [PubMed - indexed for MEDLINE]

-  **123:** [Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM; CAPTURE Study Investigators.](#) [Related Articles, Links](#)



Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes.

Circulation. 2003 Apr 29;107(16):2109-14. Epub 2003 Mar 31.
PMID: 12668510 [PubMed - indexed for MEDLINE]

-  **124:** [Felmeden DC, Blann AD, Lip GY.](#) [Related Articles, Links](#)



Angiogenesis: basic pathophysiology and implications for disease.


Eur Heart J. 2003 Apr;24(7):586-603. Review. No abstract available.
PMID: 12657217 [PubMed - indexed for MEDLINE]

-  **125:** [Blake GJ, Ridker PM.](#) [Related Articles, Links](#)



C-reactive protein and other inflammatory risk markers in acute coronary syndromes.



















J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):37S-42S. Review.
PMID: 12644339 [PubMed - indexed for MEDLINE]

-  **126:** [Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, Koskinen PK, Lemstrom KB.](#) [Related Articles, Links](#)




Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis.


Circulation. 2003 Mar 11;107(9):1308-14.
PMID: 12628953 [PubMed - indexed for MEDLINE]


-  **127:** [Libby P, Zhao DX.](#) [Related Articles, Links](#)
-  **Allograft arteriosclerosis and immune-driven angiogenesis.**
Circulation. 2003 Mar 11;107(9):1237-9. No abstract available.
PMID: 12628940 [PubMed - indexed for MEDLINE]
-  **128:** [Mizia-Stec K, Zahorska-Markiewicz B, Mandecki T, Janowska J, Szulc A, Jastrzebska-Maj E, Gasior Z.](#) [Related Articles, Links](#)
-  **Hyperlipidaemias and serum cytokines in patients with coronary artery disease.**
Acta Cardiol. 2003 Feb;58(1):9-15.
PMID: 12625489 [PubMed - indexed for MEDLINE]
-  **129:** [Cotton JM, Hong Y, Hawe E, Mathur A, Humphries SE, Brown AS, Martin JF, Erusalimsky JD.](#) [Related Articles, Links](#)
-  **Rise of circulating thrombopoietin following cardiothoracic surgery is potentiated in patients with coronary atherosclerosis: correlation with a preceding increase in levels of interleukin-6.**
Thromb Haemost. 2003 Mar;89(3):538-43.
PMID: 12624639 [PubMed - indexed for MEDLINE]
-  **130:** [Braun-Dullacius RC, Ziegler A, Bohle RM, Bauer E, Hein S, Tillmanns H, Haberbosch W.](#) [Related Articles, Links](#)
-  **Quantification of the cell-cycle inhibitors p27(Kip1) and p21(Cip1) in human atherectomy specimens: primary stenosis versus restenosis.**
J Lab Clin Med. 2003 Mar;141(3):179-89.
PMID: 12624599 [PubMed - indexed for MEDLINE]
-  **131:** [Kusumanto YH, Hospers GA, Mulder NH, Tio RA.](#) [Related Articles, Links](#)
-  **Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review.**
Int J Cardiovasc Intervent. 2003;5(1):27-34. Review.
PMID: 12623562 [PubMed - indexed for MEDLINE]
-  **132:** [Clejan S, Japa S, Clemetson C, Hasabnis SS, David O, Talano JV.](#) [Related Articles, Links](#)
-  **Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis.**
J Cell Mol Med. 2002 Oct-Dec;6(4):583-92.
PMID: 12611642 [PubMed - indexed for MEDLINE]
-  **133:** [Sellke FW, Ruel M.](#) [Related Articles, Links](#)
-  **Vascular growth factors and angiogenesis in cardiac surgery.**
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
PMID: 12607713 [PubMed - indexed for MEDLINE]
-  **134:** [Sihvola RK, Tikkanen JM, Krebs R, Aaltola EM, Buchdunger E, Laitinen O, Koskinen PK, Lemstrom KB.](#) [Related Articles, Links](#)
-  **Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits.**
Transplantation. 2003 Feb 15;75(3):334-9.
PMID: 12589154 [PubMed - indexed for MEDLINE]
-  **135:** [Lindmark E, Siegbahn A.](#) [Related Articles, Links](#)
-  **Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin.**
Thromb Res. 2002 Oct 1;108(1):77-84.
PMID: 12586136 [PubMed - indexed for MEDLINE]

 **136:** [Teramoto S, Yamamoto H, Ouchi Y.](#) [Related Articles](#), [Links](#)

 Increased C-reactive protein and increased plasma interleukin-6 may synergistically affect the progression of coronary atherosclerosis in obstructive sleep apnea syndrome.


Circulation. 2003 Feb 11;107(5):E40-0. No abstract available.
PMID: 12578892 [PubMed - indexed for MEDLINE]

 **137:** [Nahrendorf M, Frantz S, Hu K, von zur Muhlen C, Tomaszewski M, Scheuermann H, Kaiser R, Jazbutyte V, Beer S, Bauer W, Neubauer S, Ertl G, Allolio B, Callies F.](#) [Related Articles](#), [Links](#)

 Effect of testosterone on post-myocardial infarction remodeling and function.


Cardiovasc Res. 2003 Feb;57(2):370-8.
PMID: 12566109 [PubMed - indexed for MEDLINE]

 **138:** [Suzuki M, Inaba S, Nagai T, Tatsuno H, Kazatani Y.](#) [Related Articles](#), [Links](#)


 Relation of C-reactive protein and interleukin-6 to culprit coronary artery plaque size in patients with acute myocardial infarction.


Am J Cardiol. 2003 Feb 1;91(3):331-3. No abstract available.
PMID: 12565091 [PubMed - indexed for MEDLINE]

 **139:** [Khan TA, Sellke FW, Laham RJ.](#) [Related Articles](#), [Links](#)


 Therapeutic angiogenesis: protein-based therapy for coronary artery disease.


Expert Opin Pharmacother. 2003 Feb;4(2):219-26. Review.
PMID: 12562312 [PubMed - indexed for MEDLINE]

 **140:** [Vohnout B, Di Castelnuovo A, Trotta R, D'Orazi A, Panniteri G, Montali A, Donati MB, Arca M, Iacoviello L.](#) [Related Articles](#), [Links](#)

 Interleukin-1 gene cluster polymorphisms and risk of coronary artery disease.

Haematologica. 2003 Jan;88(1):54-60.
PMID: 12551827 [PubMed - indexed for MEDLINE]

 **141:** [Sim EK, Zhang L, Shim WS, Lim YL, Ge R.](#) [Related Articles](#), [Links](#)

 Therapeutic angiogenesis for coronary artery disease.


J Card Surg. 2002 Jul-Aug;17(4):350-4. Review.
PMID: 12546086 [PubMed - indexed for MEDLINE]

 **142:** [Kutryk MJ, Stewart DJ.](#) [Related Articles](#), [Links](#)

 Angiogenesis of the heart.


Microsc Res Tech. 2003 Feb 1;60(2):138-58. Review.
PMID: 12539168 [PubMed - indexed for MEDLINE]

 **143:** [SoRelle R.](#) [Related Articles](#), [Links](#)


 Erythropoietin--not at the Olympics but maybe for anemic heart failure patients.



















Circulation. 2003 Jan 21;107(2):e9004. No abstract available.
PMID: 12538444 [PubMed - indexed for MEDLINE]




















 **144:** [Wang XQ, Jian ZJ, Xie JC.](#) [Related Articles](#), [Links](#)

 [Changes in plasma concentration of interleukin-6 in elderly patients with coronary artery disease complicated with heart failure]

Hunan Yi Ke Da Xue Xue Bao. 2001 Jun 28;26(3):231-2. Chinese.
PMID: 12536690 [PubMed - indexed for MEDLINE]

 **145:** [Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR.](#) [Related Articles](#), [Links](#)


-  **Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes.**
Atherosclerosis. 2003 Feb;166(2):387-94.
PMID: 12535753 [PubMed - indexed for MEDLINE]
-  **146:** Martinez-Gonzalez J, Rius J, Castello A, Cases-Langhoff C, Badimon L. [Related Articles](#), [Links](#)
-  **Neuron-derived orphan receptor-1 (NOR-1) modulates vascular smooth muscle cell proliferation.**
Circ Res. 2003 Jan 10;92(1):96-103.
PMID: 12522126 [PubMed - indexed for MEDLINE]
-  **147:** Lenihan DJ, Osman A, Sriram V, Aitsebaomo J, Patterson C. [Related Articles](#), [Links](#)
-  **Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease.**
Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1507-12. Epub 2003 Jan 09.
PMID: 12521946 [PubMed - indexed for MEDLINE]
-  **148:** Stompor T, Pasowicz M, Sullowicz W, Dembinska-Kiec A, Janda K, Wojcik K, Tracz W, Zdzenicka A, Klimeczek P, Janusz-Grzybowska E. [Related Articles](#), [Links](#)
-  **An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis.**
Am J Kidney Dis. 2003 Jan;41(1):203-11.
PMID: 12500238 [PubMed - indexed for MEDLINE]
-  **149:** van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluij C; DALI-Study Group. [Related Articles](#), [Links](#)
-  **Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus.**
Atherosclerosis. 2003 Jan;166(1):129-35.
PMID: 12482559 [PubMed - indexed for MEDLINE]
-  **150:** Mehrabi MR, Huber K, Serbecic N, Wild T, Wojta J, Tamaddon F, Morgan A, Ullrich R, Dietmar Glogar H. [Related Articles](#), [Links](#)
-  **Elevated homocysteine serum level is associated with low enrichment of homocysteine in coronary arteries of patients with coronary artery disease.**
Thromb Res. 2002 Sep 1;107(5):189-96.
PMID: 12479877 [PubMed - indexed for MEDLINE]
-  **151:** Tamirisa KP, Mukherjee D. [Related Articles](#), [Links](#)
-  **Gene therapy in cardiovascular diseases.**
Curr Gene Ther. 2002 Dec;2(4):427-35. Review.
PMID: 12477254 [PubMed - indexed for MEDLINE]
-  **152:** Lee CH, Smits PC. [Related Articles](#), [Links](#)
-  **Vascular growth factors for coronary angiogenesis.**
J Interv Cardiol. 2002 Dec;15(6):511-8. Review.
PMID: 12476656 [PubMed - indexed for MEDLINE]
-  **153:** Conraads VM, Beckers P, Bosmans J, De Clerck LS, Stevens WJ, Vrints CJ, Brutsaert DL. [Related Articles](#), [Links](#)
-  **Combined endurance/resistance training reduces plasma TNF-alpha receptor levels in patients with chronic heart failure and coronary artery disease.**
Eur Heart J. 2002 Dec;23(23):1854-60.
PMID: 12445534 [PubMed - indexed for MEDLINE]
-  **154:** Rasmussen HS, Rasmussen CS, Macko J, Yonehiro G. [Related Articles](#), [Links](#)

-  **Angiogenic gene therapy strategies for the treatment of cardiovascular disease.**
Curr Opin Mol Ther. 2002 Oct;4(5):476-81. Review.
PMID: 12435049 [PubMed - indexed for MEDLINE]
-  **155:** [Sun D, Xu C, Li J, Jiao X, Chen Y.](#) [Related Articles, Links](#)
-  **[Changes of inflammatory factors in patients with coronary artery disease during perioperation]**
Zhonghua Wai Ke Za Zhi. 2002 Aug;40(8):571-3. Chinese.
PMID: 12417066 [PubMed - indexed for MEDLINE]
-  **156:** [Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, Takeshita A.](#) [Related Articles, Links](#)
-  **Antiinflammatory and antiarteriosclerotic effects of pioglitazone.**
Hypertension. 2002 Nov;40(5):687-93.
PMID: 12411463 [PubMed - indexed for MEDLINE]
-  **157:** [Bouwman JJ, Visseren FL, Bosch MC, Bouter KP, Diepersloot RJ.](#) [Related Articles, Links](#)
-  **Procoagulant and inflammatory response of virus-infected monocytes.**
Eur J Clin Invest. 2002 Oct;32(10):759-66.
PMID: 12406025 [PubMed - indexed for MEDLINE]
-  **158:** [Rosenkranz S, Knirel D, Dietrich H, Flesch M, Erdmann E, Bohm M.](#) [Related Articles, Links](#)
-  **Inhibition of the PDGF receptor by red wine flavonoids provides a molecular explanation for the "French paradox".**
FASEB J. 2002 Dec;16(14):1958-60. Epub 2002 Oct 18.
PMID: 12397093 [PubMed - indexed for MEDLINE]
-  **159:** [Grube E, Gerckens U, Buellesfeld L.](#) [Related Articles, Links](#)
-  **Drug-eluting stents: clinical experiences and perspectives.**
Minerva Cardioangiol. 2002 Oct;50(5):469-73. Review.
PMID: 12384629 [PubMed - indexed for MEDLINE]
-  **160:** [Sheiban I, Carrieri L, Catuzzo B, Destefanis P, Oliaro E, Moretti C, Trevi GP.](#) [Related Articles, Links](#)
-  **Drug-eluting stent: the emerging technique for the prevention of restenosis.**
Minerva Cardioangiol. 2002 Oct;50(5):443-53. Review.
PMID: 12384626 [PubMed - indexed for MEDLINE]
-  **161:** [Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufrils P, Chvatchko Y, Tedgui A.](#) [Related Articles, Links](#)
-  **Increased plasma concentrations of interleukin-18 in acute coronary syndromes.**
Heart. 2002 Nov;88(5):467-9.
PMID: 12381634 [PubMed - indexed for MEDLINE]
-  **162:** [Gouni-Berthold I, Sachinidis A.](#) [Related Articles, Links](#)
-  **Does the coronary risk factor low density lipoprotein alter growth and signaling in vascular smooth muscle cells?**
FASEB J. 2002 Oct;16(12):1477-87. Review.
PMID: 12374770 [PubMed - indexed for MEDLINE]
-  **163:** [Os I, Os A, Sandset PM, Bolling S, Seljeflot I, Djurovic S, Westheim A.](#) [Related Articles, Links](#)
-  **Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma**

homocysteine.

Cardiology. 2002;98(1-2):6-12.

PMID: 12373040 [PubMed - indexed for MEDLINE]


-  **164:** [Kubik L, Gajewski M, Stankiewicz W, Plocharski A, Skolimowska B, Karpinski M, Dabrowski M, Szmigielski S, Kosior J, Pecak R.](#) [Related Articles, Links](#)



[Selected inflammatory markers in patients with acute coronary syndrome]

Pol Merkuriusz Lek. 2002 Jul;13(73):32-5. Polish.

PMID: 12362502 [PubMed - indexed for MEDLINE]


-  **165:** [Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG.](#) [Related Articles, Links](#)



Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.

Mol Ther. 2002 Aug;6(2):287-97.

PMID: 12349828 [PubMed - indexed for MEDLINE]

-  **166:** [Vallely MP, Bannon PG, Hughes CF, Kritharides L.](#) [Related Articles, Links](#)



Endothelial expression of intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 is suppressed by postbypass plasma containing increased soluble intercellular adhesion molecule 1 and vascular cell adhesion molecule 1.

J Thorac Cardiovasc Surg. 2002 Oct;124(4):758-67.

PMID: 12324734 [PubMed - indexed for MEDLINE]

-  **167:** [Zeleny M, Swertfeger DK, Weisgraber KH, Hui DY.](#) [Related Articles, Links](#)



Distinct apolipoprotein E isoform preference for inhibition of smooth muscle cell migration and proliferation.

Biochemistry. 2002 Oct 1;41(39):11820-3.

PMID: 12269825 [PubMed - indexed for MEDLINE]

-  **168:** [Zeuke S, Ulmer AJ, Kusumoto S, Katus HA, Heine H.](#) [Related Articles, Links](#)



TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS.

Cardiovasc Res. 2002 Oct;56(1):126-34.

PMID: 12237173 [PubMed - indexed for MEDLINE]


-  **169:** [Zhang C, Yang J, Feng J, Jennings LK.](#) [Related Articles, Links](#)



Short-term administration of basic fibroblast growth factor enhances coronary collateral development without exacerbating atherosclerosis and balloon injury-induced vasoproliferation in atherosclerotic rabbits with acute myocardial infarction.

J Lab Clin Med. 2002 Aug;140(2):119-25.

PMID: 12228768 [PubMed - indexed for MEDLINE]


-  **170:** [Freedman SB, Vale P, Kalka C, Kearney M, Pieczek A, Symes J, Losordo D, Isner JM.](#) [Related Articles, Links](#)



Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA.

Hum Gene Ther. 2002 Sep 1;13(13):1595-603.


PMID: 12228014 [PubMed - indexed for MEDLINE]


-  **171:** [Galderisi M, Caso P, Cicala S, De Simone L, Barbieri M, Vitale G, de Divitiis O, Paolisso G.](#) [Related Articles, Links](#)




Positive association between circulating free insulin-like growth factor-1 levels and coronary flow reserve in arterial systemic hypertension.


Am J Hypertens. 2002 Sep;15(9):766-72.
PMID: 12219870 [PubMed - indexed for MEDLINE]

-  **172:** Theoharides TC, Boucher W, Spear K. [Related Articles](#), [Links](#)


 **Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients.**


Int Arch Allergy Immunol. 2002 Aug;128(4):344-50.
PMID: 12218373 [PubMed - indexed for MEDLINE]

-  **173:** Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. [Related Articles](#), [Links](#)


 **Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?**


Stroke. 2002 Sep;33(9):2187-91.
PMID: 12215585 [PubMed - indexed for MEDLINE]

-  **174:** Nauck M, Winkelmann BR, Hoffmann MM, Böhm BO, Wieland H, März W. [Related Articles](#), [Links](#)


 **The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction.**


J Mol Med. 2002 Aug;80(8):507-13. Epub 2002 Jun 21.
PMID: 12185451 [PubMed - indexed for MEDLINE]

-  **175:** Billia F, Carter K, Rao V, Gorczynski R, Feindel C, Ross HJ. [Related Articles](#), [Links](#)

 **Transforming growth factor-beta expression is significantly lower in hearts preserved with blood/insulin versus crystalloid cardioplegia.**


J Heart Lung Transplant. 2002 Aug;21(8):918-22.
PMID: 12163095 [PubMed - indexed for MEDLINE]

-  **176:** Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF. [Related Articles](#), [Links](#)


 **A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.**


Clin Pharmacol Ther. 2002 Jul;72(1):20-32.
PMID: 12152001 [PubMed - indexed for MEDLINE]

-  **177:** Tashiro H, Shimokawa H, Sadamatu K, Yamamoto K. [Related Articles](#), [Links](#)

 **Prognostic significance of plasma concentrations of transforming growth factor-beta in patients with coronary artery disease.**


Coron Artery Dis. 2002 May;13(3):139-43.
PMID: 12131016 [PubMed - indexed for MEDLINE]

-  **178:** Katinioti AA, Tousoulis D, Economou E, Stefanadis C, Trikas A, Tentolouris C, Pitsavos C, Androulakis A, Toutouzas P. [Related Articles](#), [Links](#)


 **Basic fibroblast growth factor changes in response to coronary angioplasty in patients with stable angina.**



















Int J Cardiol. 2002 Aug;84(2-3):195-9.
PMID: 12127372 [PubMed - indexed for MEDLINE]

-  **179:** Aronson D, Rayfield EJ. [Related Articles](#), [Links](#)

 **How hyperglycemia promotes atherosclerosis: molecular mechanisms.**

Cardiovasc Diabetol. 2002 Apr 08;1(1):1.
PMID: 12119059 [PubMed - as supplied by publisher]

-  **180:** Damas JK, Wachre T, Yndestad A, Ueland T, Müller F, Eiken HG, Holm AM, Halvorsen B, Frøland SS, Gullestad L, Aukrust P. [Related Articles](#), [Links](#)


-  **Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects.**
Circulation. 2002 Jul 2;106(1):36-42.
PMID: 12093767 [PubMed - indexed for MEDLINE]
-  **181:** Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ, AtheroGene Investigators. [Related Articles](#), [Links](#)
-  **Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina.**
Circulation. 2002 Jul 2;106(1):24-30.
PMID: 12093765 [PubMed - indexed for MEDLINE]
-  **182:** Ito T, Ikeda U, Shimpo M, Ohki R, Takahashi M, Yamamoto K, Shimada K. [Related Articles](#), [Links](#)
-  **HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.**
Cardiovasc Drugs Ther. 2002 Mar;16(2):121-6.
PMID: 12090904 [PubMed - indexed for MEDLINE]
-  **183:** Alber HF, Dulak J, Frick M, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F. [Related Articles](#), [Links](#)
-  **Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease.**
J Am Coll Cardiol. 2002 Jun 19;39(12):1951-5.
PMID: 12084593 [PubMed - indexed for MEDLINE]
-  **184:** Cotton JM, Mathur A, Hong Y, Brown AS, Martin JF, Erusalimsky JD. [Related Articles](#), [Links](#)
-  **Acute rise of circulating vascular endothelial growth factor-A in patients with coronary artery disease following cardiothoracic surgery.**
Eur Heart J. 2002 Jun;23(12):953-9.
PMID: 12069450 [PubMed - indexed for MEDLINE]
-  **185:** Post MJ, Laham RJ, Kuntz RE, Novicki D, Simons M. [Related Articles](#), [Links](#)
-  **The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis.**
Clin Cardiol. 2002 Jun;25(6):271-8.
PMID: 12058790 [PubMed - indexed for MEDLINE]
-  **186:** Vale PR, Isner JM, Rosenfield K. [Related Articles](#), [Links](#)
-  **Therapeutic angiogenesis in critical limb and myocardial ischemia.**
J Interv Cardiol. 2001 Oct;14(5):511-28. Review.
PMID: 12053643 [PubMed - indexed for MEDLINE]
-  **187:** Pradhan AD, Ridker PM. [Related Articles](#), [Links](#)
-  **Do atherosclerosis and type 2 diabetes share a common inflammatory basis?**
Eur Heart J. 2002 Jun;23(11):831-4. Review. No abstract available.
PMID: 12042000 [PubMed - indexed for MEDLINE]
-  **188:** Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, Stacker SA, Carnevale KA, Siemionow M, Deitcher SR, DiCorleto PE. [Related Articles](#), [Links](#)
-  **Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo.**
Blood. 2002 Jun 15;99(12):4434-42.
PMID: 12036873 [PubMed - indexed for MEDLINE]
-  **189:** Rauchhaus M, Gross M, Schulz S, Francis DP, Greiser P, Norwig A, Weidhase L, Coats AJ, Dietz R, Anker SD, Glaser C. [Related Articles](#), [Links](#)



The E-selectin SER128ARG gene polymorphism and restenosis after successful coronary angioplasty.

Int J Cardiol. 2002 Jun;83(3):249-57.

PMID: 12036529 [PubMed - indexed for MEDLINE]

 **190:** [Werner GS.](#)


[Related Articles, Links](#)



Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease.

Circulation. 2002 May 14;105(19):e175; author reply e175. No abstract available.

PMID: 12010922 [PubMed - indexed for MEDLINE]

 **191:** [Sima A, Stancu C.](#)


[Related Articles, Links](#)



Modified lipoproteins accumulate in human coronary atheroma.

J Cell Mol Med. 2002 Jan-Mar;6(1):110-1. No abstract available.

PMID: 12003674 [PubMed - indexed for MEDLINE]


 **192:** [Sindermann JR, Skaletz-Rorowski A, Bartels A, Hohage H, Plenz G, Schmidt A, Breithardt G.](#) [Related Articles, Links](#)



Paclitaxel and cyclosporine A show supra-additive antiproliferative effects on smooth muscle cells by activation of protein kinase C.

Basic Res Cardiol. 2002 Mar;97(2):125-31.

PMID: 12002259 [PubMed - indexed for MEDLINE]

 **193:** [Dudek D, Heba G, Rzeszutko L, Dubiel JS.](#)


[Related Articles, Links](#)



[Therapeutic angiogenesis for coronary artery disease. Contemporary results and perspectives]

Przegl Lek. 2001;58(11):1000-3. Review. Polish.

PMID: 11987827 [PubMed - indexed for MEDLINE]

 **194:** [Herrmann J, Best PJ, Ritman EL, Holmes DR, Lerman LO, Lerman A.](#)

[Related Articles, Links](#)



Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia.

J Am Coll Cardiol. 2002 May 1;39(9):1555-61.

PMID: 11985922 [PubMed - indexed for MEDLINE]

 **195:** [Lowe HC, Oesterle SN, Burkhoff D.](#)

[Related Articles, Links](#)



Alternatives to traditional coronary bypass surgery.

Semin Thorac Cardiovasc Surg. 2002 Jan;14(1):110-8. Review.

PMID: 11977024 [PubMed - indexed for MEDLINE]

 **196:** [Auer J, Berent R, Labetanig E, Eber B.](#)


[Related Articles, Links](#)



Serum neopterin and activity of coronary artery disease.

Heart Dis. 2001 Sep-Oct;3(5):297-301.

PMID: 11975809 [PubMed - indexed for MEDLINE]

 **197:** [Batuman O, Go D, Clark LT, Smith EL, Clements P, Feit A, Lederer D.](#)


[Related Articles, Links](#)



Relationship between cytokine levels and coronary artery disease in women.

Heart Dis. 2001 Mar-Apr;3(2):80-4.

PMID: 11975775 [PubMed - indexed for MEDLINE]

 **198:** [Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R.](#)

[Related Articles, Links](#)



Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease.

Br J Haematol. 2002 May;117(2):399-404.

PMID: 11972524 [PubMed - indexed for MEDLINE]

199: [Rosen L.S.](#)[Related Articles](#), [Links](#)**Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.**

Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44. Review.

PMID: 11965229 [PubMed - indexed for MEDLINE]

200: [Filippatos GS, Kardaras E.](#)[Related Articles](#), [Links](#)**Chemokines and other novel inflammatory markers in hypertension: what can their plasma levels tell us?**

Int J Cardiol. 2002 Apr;83(1):21-3. No abstract available.

PMID: 11959379 [PubMed - indexed for MEDLINE]

201: [Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P.](#)[Related Articles](#), [Links](#)**Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia?**

Eur J Med Res. 2002 Mar 28;7(3):93-7.

PMID: 11953278 [PubMed - indexed for MEDLINE]

202: [Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM.](#)[Related Articles](#), [Links](#)**Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase.**

Circulation. 2002 Apr 9;105(14):1656-62.

PMID: 11940543 [PubMed - indexed for MEDLINE]

203: [Chaidakov GN, Fiore M, Stankulov IS, Hristova M, Antonelli A, Manni L, Ghenev PL, Angelucci F, Aloe L.](#)[Related Articles](#), [Links](#)**NGF, BDNF, leptin, and mast cells in human coronary atherosclerosis and metabolic syndrome.**

Arch Physiol Biochem. 2001 Oct;109(4):357-60.

PMID: 11935372 [PubMed - indexed for MEDLINE]

204: [Zimmerman MA, Selzman CH, Raeburn CD, Calkins CM, Barsness K, Harken AH.](#)[Related Articles](#), [Links](#)**Clinical applications of cardiovascular angiogenesis.**

J Card Surg. 2001 Nov-Dec;16(6):490-7. Review.

PMID: 11925031 [PubMed - indexed for MEDLINE]

205: [Matsumoto S, Kishida K, Shimomura I, Maeda N, Nagaretani H, Matsuda M, Nishizawa H, Kihara S, Funahashi T, Matsuzawa Y, Yamada A, Yamashita S, Tamura S, Kawata S.](#)[Related Articles](#), [Links](#)**Increased plasma HB-EGF associated with obesity and coronary artery disease.**

Biochem Biophys Res Commun. 2002 Apr 5;292(3):781-6. Erratum in: Biochem

Biophys Res Commun 2002 Jul 12;295(2):571.


















PMID: 11922634 [PubMed - indexed for MEDLINE]

206: [Wang XL, Wang J, Rainwater DL.](#)[Related Articles](#), [Links](#)**Acute effects of insulin-like growth factor-1 and recombinant growth hormone on lipoprotein(a) levels in baboons.**


Metabolism. 2002 Apr;51(4):508-13.

PMID: 11912562 [PubMed - indexed for MEDLINE]

207: [Link A, Bohm M, Nickenig G.](#)[Related Articles](#), [Links](#)

-  [Acute coronary syndrome--better risk stratification by determination of inflammatory parameters?]
Med Klin (Munich). 2002 Feb 15;97(2):63-9. Review. German.
PMID: 11910871 [PubMed - indexed for MEDLINE]
-  **208:** [\[No authors listed\]](#) Related Articles, Links
-  FGF-4 gene therapy GENERX--Collateral Therapeutics.
BioDrugs. 2002;16(1):75-6. Review.
PMID: 11909005 [PubMed - indexed for MEDLINE]
-  **209:** [Hojo Y, Ikeda U, Takahashi M, Shimada K.](#) Related Articles, Links
-  Increased levels of monocyte-related cytokines in patients with unstable angina.
Atherosclerosis. 2002 Apr;161(2):403-8.
PMID: 11888524 [PubMed - indexed for MEDLINE]
-  **210:** [Sarkar N, Ruck A, Kaliner G, Y-Hassan S, Blomberg P, Islam KB, van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C.](#) Related Articles, Links
-  Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy.
J Intern Med. 2001 Nov;250(5):373-81.
PMID: 11887971 [PubMed - indexed for MEDLINE]
-  **211:** [De Nardin E.](#) Related Articles, Links
-  The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease.
Ann Periodontol. 2001 Dec;6(1):30-40. Review.
PMID: 11887469 [PubMed - indexed for MEDLINE]
-  **212:** [Os I, Djurovic S, Seljeflot I, Berg K.](#) Related Articles, Links
-  Transforming growth factor (TGF)-beta1 inversely related to vascular cell adhesion molecule-1 in postmenopausal women with coronary artery disease. A possible mechanism for the putative cardioprotective role of TGF-beta1?
J Intern Med. 2002 Mar;251(3):223-7.
PMID: 11886481 [PubMed - indexed for MEDLINE]
-  **213:** [Ankersmit HJ, Moser B, Roedler S, Teufel I, Zuckermann A, Roth G, Lietz K, Back C, Gerlitz S, Wolner E, Boltz-Nitulescu G.](#) Related Articles, Links
-  Death-inducing receptors and apoptotic changes in lymphocytes of patients with heart transplant vasculopathy.
Clin Exp Immunol. 2002 Jan;127(1):183-9.
PMID: 11882051 [PubMed - indexed for MEDLINE]
-  **214:** [Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA.](#) Related Articles, Links
-  Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial.
Circulation. 2002 Feb 19;105(7):788-93.
PMID: 11854116 [PubMed - indexed for MEDLINE]
-  **215:** [Sihvola RK, Pulkkinen VP, Koskinen PK, Lemstrom KB.](#) Related Articles, Links
-  Crosstalk of endothelin-1 and platelet-derived growth factor in cardiac allograft arteriosclerosis.
J Am Coll Cardiol. 2002 Feb 20;39(4):710-7.

PMID: 11849873 [PubMed - indexed for MEDLINE]


-  **216:** [Lyness JM, Moynihan JA, Williford DJ, Cox C, Caine ED.](#) [Related Articles, Links](#)



Depression, medical illness, and interleukin-1beta in older cardiac patients.

Int J Psychiatry Med. 2001;31(3):305-10.

PMID: 11841127 [PubMed - indexed for MEDLINE]


-  **217:** [Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, Sellevold OF, Espevik T, Sundan A.](#) [Related Articles, Links](#)



Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4.

Circulation. 2002 Feb 12;105(6):685-90.

PMID: 11839622 [PubMed - indexed for MEDLINE]


-  **218:** [von Schacky C, Baumann K, Angerer P.](#) [Related Articles, Links](#)



The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications.

Lipids. 2001;36 Suppl:S99-102.

PMID: 11838000 [PubMed - indexed for MEDLINE]


-  **219:** [Tateishi J, Waku S, Masutani M, Ohyanagi M, Iwasaki T.](#) [Related Articles, Links](#)



Hepatocyte growth factor as a potential predictor of the presence of atherosclerotic aorto-iliac artery disease.

Am Heart J. 2002 Feb;143(2):272-6.

PMID: 11835030 [PubMed - indexed for MEDLINE]

-  **220:** [Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY.](#) [Related Articles, Links](#)



Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes.

Clin Sci (Lond). 2002 Feb;102(2):187-94.

PMID: 11834138 [PubMed - indexed for MEDLINE]

-  **221:** [Spieker LE, Luscher TF, Noll G.](#) [Related Articles, Links](#)



Current strategies and perspectives for correcting endothelial dysfunction in atherosclerosis.

J Cardiovasc Pharmacol. 2001 Nov;38 Suppl 2:S35-41. Review.

PMID: 11811375 [PubMed - indexed for MEDLINE]


-  **222:** [Khan TA, Sellke FW, Laham RJ.](#) [Related Articles, Links](#)



Therapeutic Angiogenesis for Coronary Artery Disease.

Curr Treat Options Cardiovasc Med. 2002 Feb;4(1):65-74.

PMID: 11792229 [PubMed - as supplied by publisher]


-  **223:** [Sarkar N, Blomberg P, Wardell E, Eskandarpour M, Sylven C, Drvota V, Islam KB.](#) [Related Articles, Links](#)



Nonsurgical direct delivery of plasmid DNA into rat heart: time course, dose response, and the influence of different promoters on gene expression.

J Cardiovasc Pharmacol. 2002 Feb;39(2):215-24.

PMID: 11791007 [PubMed - indexed for MEDLINE]


-  **224:** [Seshiah PN, Kerciaques DJ, Vasudevan SS, Lopes N, Su BY, Flayahan NA, Goldschmidt-Clermont PJ.](#) [Related Articles, Links](#)



Activated monocytes induce smooth muscle cell death: role of macrophage colony-stimulating factor and cell contact.

Circulation. 2002 Jan 15;105(2):174-80.

PMID: 11790697 [PubMed - indexed for MEDLINE]


-  **225:** [Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, Liu JP, Funder JW, Sudhir K, Komesaroff PA](#) [Related Articles](#), [Links](#)



Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs.

J Clin Endocrinol Metab. 2002 Jan;87(1):176-81.

PMID: 11788644 [PubMed - indexed for MEDLINE]


-  **226:** [Stefoni S, Cianciolo G, Donati G, Dormi A, Silvestri MG, Coli L, De Pascalis A, Iannelli S](#) [Related Articles](#), [Links](#)



Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients.

Kidney Int. 2002 Jan;61(1):324-35.

PMID: 11786115 [PubMed - indexed for MEDLINE]


-  **227:** [Saadeddin SM, Habbab MA, Ferns GA](#) [Related Articles](#), [Links](#)



Markers of inflammation and coronary artery disease.

Med Sci Monit. 2002 Jan;8(1):RA5-12. Review.

PMID: 11782689 [PubMed - indexed for MEDLINE]


-  **228:** [Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C](#) [Related Articles](#), [Links](#)



Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.

Hum Gene Ther. 2002 Jan 1;13(1):65-100.

PMID: 11779413 [PubMed - indexed for MEDLINE]


-  **229:** [Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG](#) [Related Articles](#), [Links](#)



Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.

Hum Gene Ther. 2002 Jan 1;13(1):15-63.

PMID: 11779412 [PubMed - indexed for MEDLINE]


-  **230:** [Freedman SB, Isner JM](#) [Related Articles](#), [Links](#)



Therapeutic angiogenesis for coronary artery disease.

Ann Intern Med. 2002 Jan 1;136(1):54-71. Review.

PMID: 11777364 [PubMed - indexed for MEDLINE]

-  **231:** [Harig F, Hohenstein B, von der Emde J, Weyand M](#) [Related Articles](#), [Links](#)



Modulating IL-6 and IL-10 levels by pharmacologic strategies and the impact of different extracorporeal circulation parameters during cardiac surgery.

Shock. 2001;16 Suppl 1:33-8.

PMID: 11770031 [PubMed - indexed for MEDLINE]


-  **232:** [Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M](#) [Related Articles](#), [Links](#)



Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation.

Eur J Pharmacol. 2001 Dec 21;433(2-3):163-8.


PMID: 11755148 [PubMed - indexed for MEDLINE]


-  **233:** [Weiss CR, Arai AE, Bui MN, Agyeman KO, Wacławski MA, Balaban RS, Cannon RO 3rd](#) [Related Articles](#), [Links](#)





Arterial wall MRI characteristics are associated with elevated serum markers of inflammation in humans.


J Magn Reson Imaging. 2001 Dec;14(6):698-704.
PMID: 11747026 [PubMed - indexed for MEDLINE]


-  **234:** Dulak J, Jozkowicz A, Frick M, Alber HF, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F. [Related Articles, Links](#)


 **Vascular endothelial growth factor: angiogenesis, atherogenesis or both?**
J Am Coll Cardiol. 2001 Dec;38(7):2137-8. No abstract available.
PMID: 11738334 [PubMed - indexed for MEDLINE]


-  **235:** Mazzone A, Cusa C, Mazzucchelli I, Vezzoli M, Ottini E, Pacifici R, Zuccaro P, Falcone C. [Related Articles, Links](#)


 **Increased production of inflammatory cytokines in patients with silent myocardial ischemia.**
J Am Coll Cardiol. 2001 Dec;38(7):1895-901.
PMID: 11738291 [PubMed - indexed for MEDLINE]


-  **236:** Mueller XM, Tevaearai HT, Genton CY, Chaubert P, von Segesser LK. [Related Articles, Links](#)

 **Is an endocardial connection necessary for growth factor induced angiogenesis in transmyocardial laser revascularization?**
ASAIO J. 2001 Nov-Dec;47(6):662-6.
PMID: 11730207 [PubMed - indexed for MEDLINE]


-  **237:** Hebert MJ, Masse M, Vigneault N, Sirois I, Troyanov S, Madore E. [Related Articles, Links](#)


 **Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease.**
Am J Kidney Dis. 2001 Dec;38(6):1271-6.
PMID: 11728960 [PubMed - indexed for MEDLINE]


-  **238:** Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. [Related Articles, Links](#)

 **The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men.**
Eur Heart J. 2001 Dec;22(24):2243-52.
PMID: 11728144 [PubMed - indexed for MEDLINE]


-  **239:** Lamblin N, Bauters C, Helbecque N. [Related Articles, Links](#)


 **Gene polymorphisms of pro- (or anti-) inflammatory cytokines and vascular disease.**
Eur Heart J. 2001 Dec;22(24):2219-20. No abstract available.
PMID: 11728138 [PubMed - indexed for MEDLINE]


-  **240:** Huwer H, Welter C, Ozbek C, Seifert M, Straub U, Greilach P, Kalweit G, Isringhaus H. [Related Articles, Links](#)

 **Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease.**
Eur J Cardiothorac Surg. 2001 Dec;20(6):1128-34.
PMID: 11717016 [PubMed - indexed for MEDLINE]


-  **241:** Vorchheimer DA, Fuster V. [Related Articles, Links](#)

 **Inflammatory markers in coronary artery disease: let prevention douse the flames.**
JAMA. 2001 Nov 7;286(17):2154-6. No abstract available.
PMID: 11694158 [PubMed - indexed for MEDLINE]

-  **242:** Lindmark E, Diderholm E, Wallentin L, Siegbahn A. [Related Articles, Links](#)

 **Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.**


JAMA. 2001 Nov 7;286(17):2107-13.
PMID: 11694151 [PubMed - indexed for MEDLINE]

 **243:** [Ikeda U, Ito T, Shimada K.](#)

[Related Articles, Links](#)




Interleukin-6 and acute coronary syndrome.
Clin Cardiol. 2001 Nov;24(11):701-4.
PMID: 11714126 [PubMed - indexed for MEDLINE]

 **244:** [Hong HJ, Hsiao G, Cheng TH, Yen MH.](#)

[Related Articles, Links](#)




Supplementation with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats.
Hypertension. 2001 Nov;38(5):1044-8.
PMID: 11711495 [PubMed - indexed for MEDLINE]

 **245:** [Burzotta F, Iacoviello L, Di Castelnuovo A, Glicca F, Luciani N, Zamparelli R, Schiavello R, Donati MB, Maseri A, Possati G, Andreotti F.](#)

[Related Articles, Links](#)




Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization.
Am J Cardiol. 2001 Nov 15;88(10):1125-8.
PMID: 11703956 [PubMed - indexed for MEDLINE]

 **246:** [Plutzky J.](#)

[Related Articles, Links](#)




Inflammatory pathways in atherosclerosis and acute coronary syndromes.
Am J Cardiol. 2001 Oct 18;88(8A):10K-15K. Review.
PMID: 11694213 [PubMed - indexed for MEDLINE]

 **247:** [Davda J, Labhsetwar V.](#)

[Related Articles, Links](#)




An update on angiogenesis therapy.
Crit Rev Eukaryot Gene Expr. 2001;11(1-3):1-21. Review.
PMID: 11693956 [PubMed - indexed for MEDLINE]

 **248:** [Koch W, Kastrati A, Bottiger C, Mehilli J, von Beckerath N, Schomig A.](#)

[Related Articles, Links](#)




Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction.
Atherosclerosis. 2001 Nov;159(1):137-44.
PMID: 11689215 [PubMed - indexed for MEDLINE]

 **249:** [Chalidakov GN, Stankulov IS, Fiore M, Ghenev PI, Aloe L.](#)

[Related Articles, Links](#)




Nerve growth factor levels and mast cell distribution in human coronary atherosclerosis.
Atherosclerosis. 2001 Nov;159(1):57-66.
PMID: 11689207 [PubMed - indexed for MEDLINE]

 **250:** [Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Losordo DW, Hendel RC, Bonow RO, Eppler SM, Zioncheck TF, Holmgren EB, McCluskey ER.](#)

[Related Articles, Links](#)



Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.
Am Heart J. 2001 Nov;142(5):872-80.
PMID: 11685177 [PubMed - indexed for MEDLINE]


 **251:** [Berdowska A, Zwirska-Korczala K.](#)

[Related Articles, Links](#)



Neopterin measurement in clinical diagnosis.
J Clin Pharm Ther. 2001 Oct;26(5):319-29. Review.
PMID: 11679022 [PubMed - indexed for MEDLINE]

[Seiler C, Pohl T, Wustmann K, Hutter D, Nicolet PA, Windecker](#) [Related Articles, Links](#)


 **252:** [S. Eberli FR, Meier B.](#)



Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study.

Circulation. 2001 Oct 23;104(17):2012-7.

PMID: 11673338 [PubMed - indexed for MEDLINE]


 **253:** [Watanabe K, Fukuda H, Sueda S, Funada J, Kitakaze M, Sekiya M.](#) [Related Articles, Links](#)



Metabolism of hepatocyte growth factor in the heart in patients with coronary artery disease: implication for coronary arteriosclerosis.

Cardiovasc Drugs Ther. 2001 Mar;15(2):147-53.

PMID: 11669408 [PubMed - indexed for MEDLINE]

 **254:** [Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS.](#) [Related Articles, Links](#)



Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.

N Engl J Med. 2001 Oct 4;345(14):1022-9.

PMID: 11586954 [PubMed - indexed for MEDLINE]

 **255:** [Kastrup J, Jorgensen E.](#) [Related Articles, Links](#)



[Gene therapy of ischemic heart disease. Growth factors and angiogenesis/arteriogenesis]

Ugeskr Laeger. 2001 Jan 1;163(1):13-5. Danish. No abstract available.

PMID: 11586665 [PubMed - indexed for MEDLINE]

 **256:** [Choukroun G.](#) [Related Articles, Links](#)



[Prevention and treatment of type 1 diabetes]

Presse Med. 2001 Sep 1;30(24 Pt 2):21-3. French.

PMID: 11577580 [PubMed - indexed for MEDLINE]


 **257:** [Basara N.](#) [Related Articles, Links](#)



AdGVVEGF121.10 (GenVec).

Curr Opin Investig Drugs. 2001 Jun;2(6):792-5. Review.

PMID: 11572658 [PubMed - indexed for MEDLINE]


 **258:** [Sadamatsu K, Shimokawa H, Tashiro H, Yamamoto K.](#) [Related Articles, Links](#)



Long term treatment with enalapril reduces plasma concentrations of macrophage colony stimulating factor in patients with coronary artery disease.

Heart. 2001 Oct;86(4):457-8. No abstract available.

PMID: 11559692 [PubMed - indexed for MEDLINE]


 **259:** [Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, Humphries SE.](#) [Related Articles, Links](#)



Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery.

Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1458-63.

PMID: 11557672 [PubMed - indexed for MEDLINE]


 **260:** [Holm T, Berge RK, Andreassen AK, Ueland T, Kjekshus J, Simonsen S, Froland S, Gullestad L, Aukrust P.](#) [Related Articles, Links](#)



Omega-3 fatty acids enhance tumor necrosis factor-alpha levels in heart transplant recipients.

Transplantation. 2001 Aug 27;72(4):706-11.

PMID: 11544435 [PubMed - indexed for MEDLINE]


-  **261:** [Pieniazek P, Karczewska E, Stepien E, Tracz W, Konturek SJ.](#) [Related Articles](#), [Links](#)



Incidence of Chlamydia pneumoniae infection in patients with coronary artery disease subjected to angioplasty or bypass surgery.

Med Sci Monit. 2001 Sep-Oct;7(5):995-1001.

PMID: 11535948 [PubMed - indexed for MEDLINE]


-  **262:** [Momiyama Y, Hirano R, Taniguchi H, Nakamura H, Ohsuzu F.](#) [Related Articles](#), [Links](#)



Effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection.

J Am Coll Cardiol. 2001 Sep;38(3):712-7.

PMID: 11527622 [PubMed - indexed for MEDLINE]

-  **263:** [Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC.](#) [Related Articles](#), [Links](#)



Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina.

Circulation. 2001 Aug 14;104(7):746-9.

PMID: 11502695 [PubMed - indexed for MEDLINE]


-  **264:** [Setoguchi S, Mohri M, Shimokawa H, Takeshita A.](#) [Related Articles](#), [Links](#)



Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease.

J Am Coll Cardiol. 2001 Aug;38(2):493-8.

PMID: 11499743 [PubMed - indexed for MEDLINE]


-  **265:** [Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Ruten H, Fichtlscherer S, Martin H, Zeiher AM.](#) [Related Articles](#), [Links](#)



HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.

J Clin Invest. 2001 Aug;108(3):391-7.

PMID: 11489932 [PubMed - indexed for MEDLINE]

-  **266:** [Wilke NM, Zenovich AG, Jerosch-Herold M, Henry TD.](#) [Related Articles](#), [Links](#)



Cardiac Magnetic Resonance Imaging for the Assessment of Myocardial Angiogenesis.

Curr Interv Cardiol Rep. 2001 Aug;3(3):205-212.

PMID: 11485690 [PubMed - as supplied by publisher]


-  **267:** [Simons M, Post MJ.](#) [Related Articles](#), [Links](#)



Coronary Artery Disease: Vascular Endothelial Growth Factor and Fibroblast Growth Factor.

Curr Interv Cardiol Rep. 2001 Aug;3(3):185-191.

PMID: 11485687 [PubMed - as supplied by publisher]


-  **268:** [Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, Kredan MB, Lewis MJ, Goodfellow J.](#) [Related Articles](#), [Links](#)



Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide?

Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1196-202.

PMID: 11451751 [PubMed - indexed for MEDLINE]

-  **269:** [Izawa A, Suzuki Ji, Takahashi W, Amano J, Isobe M.](#) [Related Articles](#), [Links](#)



Tranilast inhibits cardiac allograft vasculopathy in association with p21 (Waf1/Cip1) expression on neointimal cells in murine cardiac transplantation model.

Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1172-8.

PMID: 11451747 [PubMed - indexed for MEDLINE]

-  **270:** [Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H.](#) [Related Articles](#), [Links](#)

[Zeicher AM, Dimmeler S.](#)



Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease.

Circ Res. 2001 Jul 6;89(1):E1-7.

PMID: 11440984 [PubMed - indexed for MEDLINE]



271: [Mukherjee D, Comella K, Bhatt DL, Roe MT, Patel V, Ellis SG.](#) [Related Articles](#), [Links](#)



Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization.

Am Heart J. 2001 Jul;142(1):72-4.

PMID: 11431659 [PubMed - indexed for MEDLINE]



272: [Aziz T, Saad RA, Burgess M, Yonan N, Hasleton P, Hutchinson IV.](#) [Related Articles](#), [Links](#)



Transforming growth factor beta and myocardial dysfunction following heart transplantation.

Eur J Cardiothorac Surg. 2001 Jul;20(1):177-86.

PMID: 11423293 [PubMed - indexed for MEDLINE]



273: [Graff J, Andries D, Elsner M, Westrup D, Bassus S, Franz N, Klinkhardt U, Harder S.](#) [Related Articles](#), [Links](#)



Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.

Br J Clin Pharmacol. 2001 Jun;51(6):577-82.

PMID: 11422017 [PubMed - indexed for MEDLINE]



274: [Blankenberg S, Rupprecht HJ, Bickel C, Espinola-Klein C, Rippin G, Hafner G, Ossendorf M, Steinhagen K, Meyer J.](#) [Related Articles](#), [Links](#)



Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease.

Circulation. 2001 Jun 19;103(24):2915-21.

PMID: 11413080 [PubMed - indexed for MEDLINE]



275: [Wei M, Kuukasjarvi P, Laurikka J, Pehkonen E, Kaukinen S, Laine S, Tarkka M.](#) [Related Articles](#), [Links](#)



Cytokine responses in patients undergoing coronary artery bypass surgery after ischemic preconditioning.

Scand Cardiovasc J. 2001 Mar;35(2):142-6.

PMID: 11405491 [PubMed - indexed for MEDLINE]



276: [Oesterle SN, Reifart N, Hauptmann E, Hayase M, Yeung AC.](#) [Related Articles](#), [Links](#)



Percutaneous in situ coronary venous arterialization: report of the first human catheter-based coronary artery bypass.

Circulation. 2001 May 29;103(21):2539-43.

PMID: 11382720 [PubMed - indexed for MEDLINE]



277: [Benjafield AV, Wang XL, Morris BJ.](#) [Related Articles](#), [Links](#)



Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease.

J Mol Med. 2001 Apr;79(2-3):109-15.

PMID: 11357933 [PubMed - indexed for MEDLINE]



278: [Hillebrands JL, Raue HP, Klatter FA, Hylkema MN, Platteel I, Hardonk-Wubben A, Nieuwenhuis P, Rozing J.](#) [Related Articles](#), [Links](#)



Intrathymic immune modulation prevents acute rejection but not the development of graft arteriosclerosis (chronic rejection).

Transplantation. 2001 Apr 15;71(7):914-24.

PMID: 11349727 [PubMed - indexed for MEDLINE]

[Walter R, Blau N, Kierat L, Schoedon G, Reinhart WH.](#)

[Related Articles](#), [Links](#)

279:



Systemic tetrahydrobiopterin (BH4) levels and coronary artery disease.
Cardiology. 2000;94(4):265-6. No abstract available.
PMID: 11326151 [PubMed - indexed for MEDLINE]

280: [Xue M, Ren S, Welch S, Shen GX.](#)

[Related Articles, Links](#)



Hirulog-like peptide reduces balloon catheter injury induced neointima formation in rat carotid artery without increase in bleeding tendency.
J Vasc Res. 2001 Mar-Apr;38(2):144-52.
PMID: 11316950 [PubMed - indexed for MEDLINE]

281: [Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA.](#) [Related Articles, Links](#)



Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease.
J Clin Pharmacol. 2001 Apr;41(4):378-85.
PMID: 11304894 [PubMed - indexed for MEDLINE]

282: [Clark KJ, Cary NR, Grace AA, Metcalfe JC.](#)

[Related Articles, Links](#)



Microsatellite mutation of type II transforming growth factor-beta receptor is rare in atherosclerotic plaques.
Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):555-9.
PMID: 11304472 [PubMed - indexed for MEDLINE]

283: [Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N.](#) [Related Articles, Links](#)



Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease.
Heart Vessels. 2000;15(3):105-11.
PMID: 11289497 [PubMed - indexed for MEDLINE]

284: [Ray S, Panja M.](#)

[Related Articles, Links](#)



Current understanding of pathogenesis of coronary artery disease and its future implications.
J Indian Med Assoc. 2000 Nov;98(11):710-1, 714, 718.
PMID: 11265801 [PubMed - indexed for MEDLINE]

285: [Brizzi MF, Formato L, Bonamini R.](#)

[Related Articles, Links](#)



The molecular mechanisms of angiogenesis: a new approach to cardiovascular diseases.
Ital Heart J. 2001 Feb;2(2):81-92. Review.
PMID: 11256548 [PubMed - indexed for MEDLINE]

286: [Morse MA.](#)

[Related Articles, Links](#)



Technology evaluation: VEGF165 gene therapy, Valentis Inc.
Curr Opin Mol Ther. 2001 Feb;3(1):97-101. Review.
PMID: 11249737 [PubMed - indexed for MEDLINE]

287: [Lee RS, Yamada K, Houser SL, Womer KL, Maloney ME, Rose HS, Sayegh MH, Madsen JC.](#) [Related Articles, Links](#)




Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy.
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3276-81.
PMID: 11248069 [PubMed - indexed for MEDLINE]

288: [Margaglione M, Bossone A, Cappucci G, Colaizzo D, Grandone E, Di Minno G.](#) [Related Articles, Links](#)



The effect of the interleukin-6 c/g-174 polymorphism and circulating interleukin-6 on fibrinogen plasma levels.


Haematologica. 2001 Feb;86(2):199-204.
PMID: 11224491 [PubMed - indexed for MEDLINE]

 **289:** Rosengart TK, Hillebrand K.

[Related Articles, Links](#)




Gene therapy for coronary artery disease.
Adv Card Surg. 2001;13:107-20. Review. No abstract available.
PMID: 11209652 [PubMed - indexed for MEDLINE]

 **290:** Mueller XM, Tevacarai HT, Genton CY, Chaubert P, von Segesser LK.

[Related Articles, Links](#)




Myocardial angiogenesis induction with bone protein derived growth factors (animal experiment).
Swiss Med Wkly. 2001 Jan 12;131(1-2):23-5.
PMID: 11205183 [PubMed - indexed for MEDLINE]

 **291:** Haroon ZA, Wannenburg T, Gupta M, Greenberg CS, Wallin R, Sane DC.

[Related Articles, Links](#)




Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: implications for plaque stability and progression.
Lab Invest. 2001 Jan;81(1):83-93.
PMID: 11204277 [PubMed - indexed for MEDLINE]

 **292:** Elghannam H, Tavackoli S, Ferlic L, Gotto AM Jr, Ballantyne CM, Marian AJ.

[Related Articles, Links](#)




A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy.
J Mol Med. 2000;78(10):562-8.
PMID: 11199329 [PubMed - indexed for MEDLINE]

 **293:** Freedman SB, Isner JM.

[Related Articles, Links](#)



Therapeutic angiogenesis for ischemic cardiovascular disease.
J Mol Cell Cardiol. 2001 Mar;33(3):379-93. Review.
PMID: 11181008 [PubMed - indexed for MEDLINE]

 **294:** Duraiaraj A, Mehra A, Singh RP, Faxon DP.

[Related Articles, Links](#)




Therapeutic angiogenesis.
Cardiol Rev. 2000 Sep-Oct;8(5):279-87. Review.
PMID: 11174906 [PubMed - indexed for MEDLINE]

 **295:** Shaw JA, Chin-Dusting JP, Kingwell BA, Dart AM.

[Related Articles, Links](#)




Diurnal variation in endothelium-dependent vasodilatation is not apparent in coronary artery disease.
Circulation. 2001 Feb 13;103(6):806-12.
PMID: 11171787 [PubMed - indexed for MEDLINE]

 **296:** Zhang S, Day I, Ye S.

[Related Articles, Links](#)



Nicotine induced changes in gene expression by human coronary artery endothelial cells.
Atherosclerosis. 2001 Feb 1;154(2):277-83.
PMID: 11166759 [PubMed - indexed for MEDLINE]

 **297:** Lambiase P, Edwards R, Bucknall CA, Marber MS.



















[Related Articles, Links](#)






















Physiologically assessed collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.
Circulation. 2001 Jan 30;103(4):E22. No abstract available.
PMID: 11157734 [PubMed - indexed for MEDLINE]


 **298:** Rutanen J, Rissanen TT, Kivela A, Vajanto I, Yla-Herttuala S.


[Related Articles, Links](#)


-  **Clinical applications of vascular gene therapy.**
Curr Cardiol Rep. 2001 Jan;3(1):29-36. Review.
PMID: 11139796 [PubMed - indexed for MEDLINE]
-  **299:** [Hutchinson IV.](#) Related Articles, Links
-  **Cardiac allograft vasculopathy--the cellular attack.**
Z Kardiol. 2000;89 Suppl 9:IX/16-20.
PMID: 11151784 [PubMed - indexed for MEDLINE]
-  **300:** [Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO.](#) Related Articles, Links
-  **Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation.**
Circulation. 2001 Jan 2;103(1):108-12.
PMID: 11136694 [PubMed - indexed for MEDLINE]
-  **301:** [Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM.](#) Related Articles, Links
-  **Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.**
Anesth Analg. 2001 Jan;92(1):19-25.
PMID: 11133594 [PubMed - indexed for MEDLINE]
-  **302:** [Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila JM, Bouchard C, Toyry J, Humphries SE.](#) Related Articles, Links
-  **Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis.**
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2657-62.
PMID: 11116068 [PubMed - indexed for MEDLINE]
-  **303:** [Ma X, Labinaz M, Goldstein J, Miller H, Keon WJ, Letarte M, O'Brien E.](#) Related Articles, Links
-  **Endoglin is overexpressed after arterial injury and is required for transforming growth factor-beta-induced inhibition of smooth muscle cell migration.**
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2546-52.
PMID: 11116051 [PubMed - indexed for MEDLINE]
-  **304:** [Wildhirt SM, Weis M, Schulze C, Conrad N, Rieder G, Enders G, Hoeppe C, von Scheidt W, Reichart B.](#) Related Articles, Links
-  **An association between microvascular endothelial dysfunction, transcatheter nitric oxide production and pro-inflammatory cytokines after heart transplantation in humans.**
Transpl Int. 2000;13 Suppl 1:S228-34.
PMID: 11112001 [PubMed - indexed for MEDLINE]
-  **305:** [Yamada DM, Topol EJ.](#) Related Articles, Links
-  **Importance of microembolization and inflammation in atherosclerotic heart disease.**
Am Heart J. 2000 Dec;140(6 Suppl):S90-102. Review.
PMID: 11100003 [PubMed - indexed for MEDLINE]
-  **306:** [Schumacher B, Hannekum A, Pecher P.](#) Related Articles, Links
-  **[Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]**
Z Kardiol. 2000;89 Suppl 7:23-30. German.
PMID: 11098556 [PubMed - indexed for MEDLINE]
-  **307:** [Kantor B, Ritman EL, Holmes Jr DR, Schwartz RS.](#) Related Articles, Links


-  **Imaging Angiogenesis with Three-Dimensional Microscopic Computed Tomography.**
Curr Interv Cardiol Rep. 2000 Aug;2(3):204-212.
PMID: 11096669 [PubMed - as supplied by publisher]
-  **308:** Gopalan R, Goldberg S. Related Articles, Links
-  **Tranilast in the Therapy of Coronary Artery Disease.**
Curr Interv Cardiol Rep. 2000 May;2(2):149-156.
PMID: 11096662 [PubMed - as supplied by publisher]
-  **309:** Zanger D, Yang BK, Ardans J, Waclawiw MA, Csako G, Wahl LM, Cannon RO 3rd. Related Articles, Links
-  **Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management.**
J Am Coll Cardiol. 2000 Nov 15;36(6):1797-802.
PMID: 11092646 [PubMed - indexed for MEDLINE]
-  **310:** Haug C, Schmid-Kotsas A, Zorn U, Bachem MG, Schuett S, Gruenert A, Rozdzinski E. Related Articles, Links
-  **Hepatocyte growth factor is upregulated by low-density lipoproteins and inhibits endothelin-1 release.**
Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H2865-71.
PMID: 11087242 [PubMed - indexed for MEDLINE]
-  **311:** Miniati DN, Hoyt EG, Feeley BT, Poston RS, Robbins RC. Related Articles, Links
-  **Ex vivo antisense oligonucleotides to proliferating cell nuclear antigen and Cdc2 kinase inhibit graft coronary artery disease.**
Circulation. 2000 Nov 7;102(19 Suppl 3):III237-42.
PMID: 11082394 [PubMed - indexed for MEDLINE]
-  **312:** Dewberry R, Holden H, Crossman D, Francis S. Related Articles, Links
-  **Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis.**
Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2394-400.
PMID: 11073843 [PubMed - indexed for MEDLINE]
-  **313:** Gruberg L, Waksman R, Sattler LF, Pichard AD, Kent KM. Related Articles, Links
-  **Novel approaches for the prevention of restenosis.**
Expert Opin Investig Drugs. 2000 Nov;9(11):2555-78. Review.
PMID: 11060820 [PubMed - indexed for MEDLINE]
-  **314:** Kaski JC. Related Articles, Links
-  **[Inflammation, infection and coronary artery disease: myths and realities. Special XXXV Conference of the National Congress of the Spanish Society of Cardiology]**
Rev Esp Cardiol. 2000 Oct;53(10):1311-7. Review. Spanish.
PMID: 11060248 [PubMed - indexed for MEDLINE]
-  **315:** Koyanagi M, Egashira K, Kitamoto S, Ni W, Shimokawa H, Takeya M, Yoshimura T, Takeshita A. Related Articles, Links
-  **Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis.**
Circulation. 2000 Oct 31;102(18):2243-8.
PMID: 11056100 [PubMed - indexed for MEDLINE]
-  **316:** Appels A, Bar FW, Bar J, Bruggeman C, de Baets M. Related Articles, Links
-  **Inflammation, depressive symptomatology, and coronary artery disease.**
Psychosom Med. 2000 Sep-Oct;62(5):601-5.


PMID: 11020087 [PubMed - indexed for MEDLINE]


-  **317:** [Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M.](#) [Related Articles, Links](#)


 **Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease.**
Circulation. 2000 Oct 3;102(14):1605-10.
PMID: 11015335 [PubMed - indexed for MEDLINE]


-  **318:** [Boyle JJ, Wilson B, Bicknell R, Harrower S, Weissberg PL, Fan TP.](#) [Related Articles, Links](#)

 **Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis.**
J Pathol. 2000 Oct;192(2):234-42.
PMID: 11004701 [PubMed - indexed for MEDLINE]


-  **319:** [Li CG, Bethell H, Wilson PB, Bhatnagar D, Walker MG, Kumar S.](#) [Related Articles, Links](#)


 **The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease.**
Atherosclerosis. 2000 Sep;152(1):249-56.
PMID: 10996361 [PubMed - indexed for MEDLINE]


-  **320:** [Ishikawa M, Akishita M, Kozaki K, Toba K, Namiki A, Yamaguchi T, Orimo H, Ouchi Y.](#) [Related Articles, Links](#)


 **Expression of parathyroid hormone-related protein in human and experimental atherosclerotic lesions: functional role in arterial intimal thickening.**
Atherosclerosis. 2000 Sep;152(1):97-105.
PMID: 10996344 [PubMed - indexed for MEDLINE]


-  **321:** [Rosen CJ, Glowacki J, Craig W.](#) [Related Articles, Links](#)


 **Sex steroids, the insulin-like growth factor regulatory system, and aging: implications for the management of older postmenopausal women.**
J Nutr Health Aging. 1998;2(1):39-44. Review.
PMID: 10995078 [PubMed - indexed for MEDLINE]


-  **322:** [Woods A, Brull DJ, Humphries SE, Montgomery HE.](#) [Related Articles, Links](#)


 **Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6.**
Eur Heart J. 2000 Oct;21(19):1574-83. Review. No abstract available.
PMID: 10988009 [PubMed - indexed for MEDLINE]

-  **323:** [August P, Leventhal B, Suthanthiran M.](#) [Related Articles, Links](#)

 **Hypertension-induced organ damage in African Americans: transforming growth factor-beta(1) excess as a mechanism for increased prevalence.**
Curr Hypertens Rep. 2000 Apr;2(2):184-91. Review.
PMID: 10981147 [PubMed - indexed for MEDLINE]

-  **324:** [Kanda T, Inoue M, Kotajima N, Fujimaki S, Hoshino Y, Kurabayashi M, Kobayashi I, Tamura J.](#) [Related Articles, Links](#)

 **Circulating interleukin-6 and interleukin-6 receptors in patients with acute and recent myocardial infarction.**
Cardiology. 2000;93(3):191-6.
PMID: 10965091 [PubMed - indexed for MEDLINE]

-  **325:** [Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, Isner JM.](#) [Related Articles, Links](#)

Left ventricular electromechanical mapping to assess efficacy of phVEGF

**(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.**

Circulation. 2000 Aug 29;102(9):965-74.

PMID: 10961959 [PubMed - indexed for MEDLINE]

326: [Bray PF.](#)

Related Articles, Links

**Platelet glycoprotein polymorphisms as risk factors for thrombosis.**

Curr Opin Hematol. 2000 Sep;7(5):284-9. Review.

PMID: 10961578 [PubMed - indexed for MEDLINE]

327: [Gabriel AS, Ahnve S, Wretling B, Martinsson A.](#)

Related Articles, Links

**IL-6 and IL-1 receptor antagonist in stable angina pectoris and relation of IL-6 to clinical findings in acute myocardial infarction.**

J Intern Med. 2000 Jul;248(1):61-6.

PMID: 10947882 [PubMed - indexed for MEDLINE]

328: [Mukherjee D, Ellis SG.](#)

Related Articles, Links

**New options for untreatable coronary artery disease: angiogenesis and laser revascularization.**

Cleve Clin J Med. 2000 Aug;67(8):577-83.

PMID: 10946453 [PubMed - indexed for MEDLINE]

329: [Hamano K, Bashuda H, Ito H, Shirasawa B, Okumura K, Esato K.](#)

Related Articles, Links

**Graft vasculopathy and tolerance: does the balance of Th cells contribute to graft vasculopathy?**

J Surg Res. 2000 Sep;93(1):28-34.

PMID: 10945940 [PubMed - indexed for MEDLINE]

330: [O'Brien T, Sinari RD.](#)

Related Articles, Links

**Gene therapy for atherosclerotic cardiovascular disease: a time for optimism and caution.**

Mayo Clin Proc. 2000 Aug;75(8):831-4. Review.

PMID: 10943238 [PubMed - indexed for MEDLINE]

331: [Reinecke H, Erren M, Schurek JO, Kropf J, Kerber S, Breithardt G, Assmann G, Cullen P.](#)

Related Articles, Links

**Transforming growth factor beta and coronary artery disease.**

Nutr Metab Cardiovasc Dis. 2000 Apr;10(2):101-2. No abstract available.

PMID: 10919175 [PubMed - indexed for MEDLINE]

332: [Bokemeyer D, Schmitz U, Kramer HJ.](#)

Related Articles, Links

**Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor.**

Kidney Int. 2000 Aug;58(2):549-58.

PMID: 10916078 [PubMed - indexed for MEDLINE]

333: [Xia H, Redman C.](#)

Related Articles, Links

**Enhanced secretion of ApoB by transfected HepG2 cells overexpressing fibrinogen.**

Biochem Biophys Res Commun. 2000 Jun 24;273(1):377-84.

PMID: 10873614 [PubMed - indexed for MEDLINE]




















334: [Testa M, De Ruvo E, Russo A, Citterio F, Serino F, Mangoni A, Capogrossi MC, Sperti G.](#)

Related Articles, Links

**Induction of interleukin-1beta and interleukin-6 gene expression in hypoperfused skeletal muscle of patients with peripheral arterial disease.**

Ital Heart J. 2000 Jan;1(1):64-7.

PMID: 10868926 [PubMed - indexed for MEDLINE]

-  **335:** [Isobe M, Suzuki J, Morishita R, Kaneda Y, Amano J.](#) [Related Articles, Links](#)
-  **Gene therapy for heart transplantation-associated coronary arteriosclerosis.**
Ann N Y Acad Sci. 2000 May;902:77-83.
PMID: 10865827 [PubMed - indexed for MEDLINE]
-  **336:** [Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyumi AA.](#) [Related Articles, Links](#)
-  **Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris.**
Am J Cardiol. 2000 Jun 15;85(12):1414-9.
PMID: 10856385 [PubMed - indexed for MEDLINE]
-  **337:** [Anderson JL, Muhlestein JB.](#) [Related Articles, Links](#)
-  **The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia).**
J Infect Dis. 2000 Jun;181 Suppl 3:S569-71.
PMID: 10839761 [PubMed - indexed for MEDLINE]
-  **338:** [Griffioen AW, Molema G.](#) [Related Articles, Links](#)
-  **Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.**
Pharmacol Rev. 2000 Jun;52(2):237-68. Review.
PMID: 10835101 [PubMed - indexed for MEDLINE]
-  **339:** [Suzuki H, Murakami M, Kondo T, Shibata M, Ezumi H, Okabayashi H, Yorozuya M, Makishima N, Hamazaki Y, Nakatani M, Namiki A, Katagiri T.](#) [Related Articles, Links](#)
-  **[Changes of serum hepatocyte growth factor in coronary artery disease]**
J Cardiol. 2000 May;35(5):319-24. Japanese.
PMID: 10834175 [PubMed - indexed for MEDLINE]
-  **340:** [Lucassen AM, de Waal RM, Verheugt FW.](#) [Related Articles, Links](#)
-  **[Therapeutic angiogenesis as a new experimental treatment for vascular disease]**
Ned Tijdschr Geneesk. 2000 Apr 1;144(14):650-5. Review. Dutch.
PMID: 10774292 [PubMed - indexed for MEDLINE]
-  **341:** [Osterziel KJ, Blum WF, Strohm O, Dietz R.](#) [Related Articles, Links](#)
-  **The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration.**
J Clin Endocrinol Metab. 2000 Apr;85(4):1533-9.
PMID: 10770193 [PubMed - indexed for MEDLINE]
-  **342:** [Ridker PM, Rifai N, Stampfer MJ, Hennekens CH.](#) [Related Articles, Links](#)
-  **Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.**
Circulation. 2000 Apr 18;101(15):1767-72.
PMID: 10769275 [PubMed - indexed for MEDLINE]
-  **343:** [Yutani C, Ishibashi-Ueda H, Suzuki T, Kojima A.](#) [Related Articles, Links](#)
-  **Histologic evidence of foreign body granulation tissue and de novo lesions in patients with coronary stent restenosis.**
Cardiology. 1999;92(3):171-7.
PMID: 10754347 [PubMed - indexed for MEDLINE]
-  **344:** [Simonini A, Moscucci M, Muller DW, Bates ER, Pagani FD.](#) [Related Articles, Links](#)

Burdick MD, Strieter RM.



IL-8 is an angiogenic factor in human coronary atherectomy tissue.

Circulation. 2000 Apr 4;101(13):1519-26.

PMID: 10747344 [PubMed - indexed for MEDLINE]

- 345: Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H. Related Articles, Links



Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability.

Circulation. 2000 Mar 28;101(12):1372-8.

PMID: 10736279 [PubMed - indexed for MEDLINE]

- 346: Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Related Articles, Links



Serum neopterin and complex stenosis morphology in patients with unstable angina.

J Am Coll Cardiol. 2000 Mar 15;35(4):956-62.

PMID: 10732894 [PubMed - indexed for MEDLINE]

- 347: Mehrabi MR, Sinzinger H, Ekmekcioglu C, Tamaddon F, Plesch K, Glogar HD, Maurer G, Stefenelli T, Lang IM. Related Articles, Links



Accumulation of oxidized LDL in human semilunar valves correlates with coronary atherosclerosis.

Cardiovasc Res. 2000 Mar;45(4):874-82.

PMID: 10728413 [PubMed - indexed for MEDLINE]

- 348: Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. Related Articles, Links



Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

Circulation. 2000 Mar 21;101(11):1311-8.

PMID: 10725292 [PubMed - indexed for MEDLINE]

- 349: Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA, Schunkert H. Related Articles, Links



Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study.

J Clin Endocrinol Metab. 2000 Mar;85(3):1340-4.

PMID: 10720088 [PubMed - indexed for MEDLINE]

- 350: Saitoh T, Kishida H, Tsukada Y, Fukuma Y, Sano J, Yasutake M, Fukuma N, Kusama Y, Hayakawa H. Related Articles, Links



Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris.

J Am Coll Cardiol. 2000 Mar 1;35(3):655-65.

PMID: 10716468 [PubMed - indexed for MEDLINE]

- 351: Ruotolo G, Bavenholm P, Brismar K, Efendic S, Ericsson CG, de Faire U, Nilsson J, Hamsten A. Related Articles, Links



Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.

J Am Coll Cardiol. 2000 Mar 1;35(3):647-54.

PMID: 10716467 [PubMed - indexed for MEDLINE]


- 352: Tabib A, Leroux C, Mornex JF, Loire R. Related Articles, Links




Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients.


Coron Artery Dis. 2000 Feb;11(1):41-6.
PMID: 10715805 [PubMed - indexed for MEDLINE]

-  **353:** [Garcia-Moll X, Cole D, Zouridakis E, Kaski JC.](#) [Related Articles, Links](#)


 **Increased serum neopterin: a marker of coronary artery disease activity in women.**


Heart. 2000 Mar;83(3):346-50.
PMID: 10677418 [PubMed - indexed for MEDLINE]

-  **354:** [Pieniazek P, Karczewska E, Duda A, Tracz W, Pasowicz M, Konturek SJ.](#) [Related Articles, Links](#)


 **Association of Helicobacter pylori infection with coronary heart disease.**


J Physiol Pharmacol. 1999 Dec;50(5):743-51.
PMID: 10695556 [PubMed - indexed for MEDLINE]

-  **355:** [Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, Unger EF.](#) [Related Articles, Links](#)


 **Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.**


Cardiovasc Res. 1999 Nov;44(2):294-302.
PMID: 10690306 [PubMed - indexed for MEDLINE]

-  **356:** [Chawla PS, Keelan MH, Kipshidze N.](#) [Related Articles, Links](#)


 **Angiogenesis for the treatment of vascular diseases.**


Int Angiol. 1999 Sep;18(3):185-92. Review.
PMID: 10688416 [PubMed - indexed for MEDLINE]

-  **357:** [Maier W, Cosentino F, Lutolf RB, Fleisch M, Seiler C, Hess OM, Meier B, Luscher TF.](#) [Related Articles, Links](#)


 **Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease.**


J Cardiovasc Pharmacol. 2000 Feb;35(2):173-8.
PMID: 10672847 [PubMed - indexed for MEDLINE]

-  **358:** [Harig F, Cesnjevar R, Mahmoud FO, von der Emde J.](#) [Related Articles, Links](#)


 **Perioperative factors influencing interleukin-10 release under cardiopulmonary bypass.**


Thorac Cardiovasc Surg. 1999 Dec;47(6):361-8.
PMID: 10670793 [PubMed - indexed for MEDLINE]

-  **359:** [Cutler CW, Shinedling EA, Nunn M, Jotwani R, Kim BO, Nares S, Iacopino AM.](#) [Related Articles, Links](#)


 **Association between periodontitis and hyperlipidemia: cause or effect?**


J Periodontol. 1999 Dec;70(12):1429-34.
PMID: 10632517 [PubMed - indexed for MEDLINE]

-  **360:** [Taher A, Ammash Z, Dabajah B, Nasrallah A, Mourad FH.](#) [Related Articles, Links](#)


 **Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review.**

Am J Hematol. 2000 Feb;63(2):90-3. Review.
PMID: 10629575 [PubMed - indexed for MEDLINE]

-  **361:** [Furukawa Y, Matsumori A, Hwang MW, Hirozane T, Ono K, Shioi T, Sasayama S.](#) [Related Articles, Links](#)

 **Cytokine gene expression during the development of graft coronary artery disease in mice.**

Jpn Circ J. 1999 Oct;63(10):775-82.
PMID: 10553920 [PubMed - indexed for MEDLINE]

-  **362:** [Furukawa Y, Becker G, Stinn JL, Shimizu K, Libby P, Mitchell](#) [Related Articles, Links](#)


RN



Interleukin-10 (IL-10) augments allograft arterial disease: paradoxical effects of IL-10 in vivo.

Am J Pathol. 1999 Dec;155(6):1929-39.

PMID: 10595923 [PubMed - indexed for MEDLINE]

 **363:** [Yamada N.](#)


[Related Articles](#), [Links](#)



[Physiopathology and therapy of acute coronary syndrome--molecular mechanism of formation and disruption of coronary atheroma]

Nippon Naika Gakkai Zasshi. 1999 Sep 10;88(9):1731-5. Review. Japanese. No abstract available.

PMID: 10581755 [PubMed - indexed for MEDLINE]

 **364:** [Hachida M.](#), [Lu H.](#), [Zhang X.](#), [Saito S.](#), [Furutani Y.](#), [Matsuoka R.](#), [Hoshi H.](#), [Koyanagi H.](#)

[Related Articles](#), [Links](#)



Inhibitory effect of triptolide on platelet derived growth factor-A and coronary arteriosclerosis after heart transplantation.

Transplant Proc. 1999 Nov;31(7):2719-23. No abstract available.

PMID: 10578264 [PubMed - indexed for MEDLINE]

 **365:** [Moussa I.](#), [Moses JW.](#)


[Related Articles](#), [Links](#)



Angiogenesis for treatment of ischemic heart disease: should we worry about progression of atherosclerosis?

Circulation. 1999 Nov 30;100(22):e109. No abstract available.

PMID: 10578010 [PubMed - indexed for MEDLINE]

 **366:** [Gullestad L.](#), [Simonsen S.](#), [Ueland T.](#), [Holm T.](#), [Aass H.](#), [Andreassen AK.](#), [Madsen S.](#), [Geiran O.](#), [Froland SS.](#), [Aukrust P.](#)

[Related Articles](#), [Links](#)



Possible role of proinflammatory cytokines in heart allograft coronary artery disease.

Am J Cardiol. 1999 Nov 1;84(9):999-1003.

PMID: 10569653 [PubMed - indexed for MEDLINE]

 **367:** [Rus H.](#), [Niculescu F.](#)


[Related Articles](#), [Links](#)



Inflammatory response in unstable angina.

Circulation. 1999 Nov 9;100(19):e98. No abstract available.

PMID: 10556236 [PubMed - indexed for MEDLINE]

 **368:** [Fleisch M.](#), [Billinger M.](#), [Eberli FR.](#), [Garachemani AR.](#), [Meier B.](#), [Seiler C.](#)


[Related Articles](#), [Links](#)



Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.

Circulation. 1999 Nov 9;100(19):1945-50.

PMID: 10556219 [PubMed - indexed for MEDLINE]

 **369:** [Meeking DR.](#), [Cummings MH.](#), [Thorne S.](#), [Donald A.](#), [Clarkson P.](#), [Crook JR.](#), [Watts GF.](#), [Shaw KM.](#)

[Related Articles](#), [Links](#)



Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria.

Diabet Med. 1999 Oct;16(10):841-7.

PMID: 10547211 [PubMed - indexed for MEDLINE]

 **370:** [Hosenpud JD.](#)



















[Related Articles](#), [Links](#)




Coronary artery disease after heart transplantation and its relation to cytomegalovirus.

Am Heart J. 1999 Nov;138(5 Pt 2):S469-72. Review.

PMID: 10539850 [PubMed - indexed for MEDLINE]

-  **371:** Kersten JR, Pagel PS, Chilian WM, Warltier DC. [Related Articles](#), [Links](#)
 **Multifactorial basis for coronary collateralization: a complex adaptive response to ischemia.**
 Cardiovasc Res. 1999 Jul;43(1):44-57. Review.
 PMID: 10536689 [PubMed - indexed for MEDLINE]
-  **372:** Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC. [Related Articles](#), [Links](#)
 **Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart.**
 Microvasc Res. 1999 Nov;58(3):238-49.
 PMID: 10527767 [PubMed - indexed for MEDLINE]
-  **373:** Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG. [Related Articles](#), [Links](#)
 **Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.**
 Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2.
 PMID: 10522716 [PubMed - indexed for MEDLINE]
-  **374:** Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, Kropf J, Kerber S, Breithardt G, Assmann G, Cullen P. [Related Articles](#), [Links](#)
 **Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries.**
 Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2355-63.
 PMID: 10521364 [PubMed - indexed for MEDLINE]
-  **375:** Ignatescu MC, Gharehbaghi-Schnell E, Hassan A, Rezaie-Majd S, Korschineck I, Schleef RR, Glogar HD, Lang IM. [Related Articles](#), [Links](#)
 **Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques: In vivo correlation of lesional microvessel density and constrictive vascular remodeling.**
 Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2340-7.
 PMID: 10521362 [PubMed - indexed for MEDLINE]
-  **376:** Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM. [Related Articles](#), [Links](#)
 **Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.**
 Ann Thorac Surg. 1999 Sep;68(3):830-6; discussion 836-7.
 PMID: 10509970 [PubMed - indexed for MEDLINE]
-  **377:** Kato K, Matsubara T, Iida K, Suzuki O, Sato Y. [Related Articles](#), [Links](#)
 **Elevated levels of pro-inflammatory cytokines in coronary artery thrombi.**
 Int J Cardiol. 1999 Aug 31;70(3):267-73.
 PMID: 10501341 [PubMed - indexed for MEDLINE]
-  **378:** Sellke FW, Simons M. [Related Articles](#), [Links](#)
 **Angiogenesis in cardiovascular disease: current status and therapeutic potential.**
 Drugs. 1999 Sep;58(3):391-6. Review.
 PMID: 10493268 [PubMed - indexed for MEDLINE]
-  **379:** Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, Hara M, Sasayama S. [Related Articles](#), [Links](#)
 **FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation.**


Circulation. 1999 Sep 21;100(12):1322-9.
PMID: 10491378 [PubMed - indexed for MEDLINE]

-  **380:** [Sato T, Yoshinouchi T, Sugimoto T, Sakamoto T, Fujieda H, Murao S, Sato H, Ohe T.](#) [Related Articles, Links](#)



Prognostic value of serum hepatocyte growth factor in patients with acute coronary syndromes.


Jpn Circ J. 1999 Aug;63(8):583-8.
PMID: 10478806 [PubMed - indexed for MEDLINE]

-  **381:** [Hachida M, Zhang X, Lu H, Hoshi H, Koyanagi H.](#) [Related Articles, Links](#)



Effects of immunosuppressants on platelet-derived growth factor-A chain mRNA expression and coronary arteriosclerosis in rat cardiac allografts.


Jpn Circ J. 1999 Apr;63(4):303-8.
PMID: 10475779 [PubMed - indexed for MEDLINE]

-  **382:** [Ishibashi T, Kijima M, Yokoyama K, Shindo J, Nagata K, Hirosaka A, Techigawara M, Abe Y, Sato E, Yamaguchi N, Watanabe N, Saito T, Machara K, Ohmoto Y, Maruyama Y.](#) [Related Articles, Links](#)



Expression of cytokine and adhesion molecule mRNA in atherectomy specimens from patients with coronary artery disease.


Jpn Circ J. 1999 Apr;63(4):249-54.
PMID: 10475771 [PubMed - indexed for MEDLINE]

-  **383:** [Spallarossa P, Rossettin P, Minuto F, Caruso D, Cordera R, Battistini M, Barreca A, Masperone MA, Brunelli C.](#) [Related Articles, Links](#)



Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease.


Am J Cardiol. 1999 Aug 15;84(4):430-3.
PMID: 10468082 [PubMed - indexed for MEDLINE]

-  **384:** [Hussain MM, Strickland DK, Bakillah A.](#) [Related Articles, Links](#)



The mammalian low-density lipoprotein receptor family.


Annu Rev Nutr. 1999;19:141-72. Review.
PMID: 10448520 [PubMed - indexed for MEDLINE]

-  **385:** [Schultz A, Lavie L, Hochberg J, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, Levy AP.](#) [Related Articles, Links](#)



Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation.

Circulation. 1999 Aug 3;100(5):547-52.
PMID: 10430770 [PubMed - indexed for MEDLINE]

-  **386:** [Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG.](#) [Related Articles, Links](#)



Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.


Circulation. 1999 Aug 3;100(5):468-74.
PMID: 10430759 [PubMed - indexed for MEDLINE]

-  **387:** [Losordo DW, Vale PR, Isner JM.](#) [Related Articles, Links](#)



Gene therapy for myocardial angiogenesis.

Am Heart J. 1999 Aug;138(2 Pt 2):S132-41. Review.
PMID: 10426872 [PubMed - indexed for MEDLINE]

-  **388:** [Casterella PJ, Teirstein PS.](#) [Related Articles, Links](#)

**Prevention of coronary restenosis.**

Cardiol Rev. 1999 Jul-Aug;7(4):219-31. Review.

PMID: 10423674 [PubMed - indexed for MEDLINE]

389: [Nogueira JB.](#)

Related Articles, Links

**[Hypertensive cardiopathy. From arterial hypertension to congestive heart failure]**

Rev Port Cardiol. 1999 Jun;18(6):635-46. Review. Portuguese.

PMID: 10422461 [PubMed - indexed for MEDLINE]

390: [Wan S, Izzat MB, Lee TW, Wan IY, Tang NL, Yim AP.](#)

Related Articles, Links

**Avoiding cardiopulmonary bypass in multivessel CABG reduces cytokine response and myocardial injury.**

Ann Thorac Surg. 1999 Jul;68(1):52-6; discussion 56-7.

PMID: 10421114 [PubMed - indexed for MEDLINE]

391: [Herity NA, Ward MR, Lo S, Yeung AC.](#)

Related Articles, Links

**Review: Clinical aspects of vascular remodeling.**

J Cardiovasc Electrophysiol. 1999 Jul;10(7):1016-24. Review.

PMID: 10413382 [PubMed - indexed for MEDLINE]

392: [Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.](#)

Related Articles, Links

**Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.**

Clin Chim Acta. 1999 May;283(1-2):171-82.

PMID: 10404741 [PubMed - indexed for MEDLINE]

393: [Yamashita N, Hoshida S, Otsu K, Asahi M, Kuzuya T, Hori M.](#)

Related Articles, Links

**Exercise provides direct biphasic cardioprotection via manganese superoxide dismutase activation.**

J Exp Med. 1999 Jun 7;189(11):1699-706.

PMID: 10359573 [PubMed - indexed for MEDLINE]

394: [Hattersley AT, Tooke JE.](#)

Related Articles, Links

**The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease.**

Lancet. 1999 May 22;353(9166):1789-92. Review.

PMID: 10348008 [PubMed - indexed for MEDLINE]

395: [Patterson C, Runge MS.](#)

Related Articles, Links

**Therapeutic angiogenesis: the new electrophysiology?**

Circulation. 1999 May 25;99(20):2614-6. Review. No abstract available.

PMID: 10338451 [PubMed - indexed for MEDLINE]

396: [Zhang X, Hachida M, Lu H, Hoshi H, Koyanagi H.](#)

Related Articles, Links

**Effect of 15-deoxyspergualine on coronary arteriosclerosis and platelet-derived growth factor-A mRNA expression in the transplanted heart.**

Transplant Proc. 1999 May;31(3):1706-9. No abstract available.

PMID: 10331045 [PubMed - indexed for MEDLINE]

397: [Kahn NN.](#)

Related Articles, Links

















**Platelet-stimulated thrombin and PDGF are normalized by insulin and Ca²⁺ channel blockers.**

Am J Physiol. 1999 May;276(5 Pt 1):E856-62.

PMID: 10329979 [PubMed - indexed for MEDLINE]

398: [Hachida M, Zhang X, Lu H, Hoshi H, Koyanagi H.](#)

Related Articles, Links

-  **Multiglycosidorum tripterygii**, a new immunosuppressant, suppresses coronary arteriosclerosis after heart transplantation.
J Heart Lung Transplant. 1999 Mar;18(3):248-54.
PMID: 10328151 [PubMed - indexed for MEDLINE]
-  **399:** McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS. [Related Articles, Links](#)
-  **Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1.**
Circulation. 1999 May 4;99(17):2317-22.
PMID: 10226099 [PubMed - indexed for MEDLINE]
-  **400:** Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Home B, Lim T. [Related Articles, Links](#)
-  **Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.**
Circulation. 1999 Mar 30;99(12):1540-7.
PMID: 10096928 [PubMed - indexed for MEDLINE]
-  **401:** Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S. [Related Articles, Links](#)
-  **Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.**
Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7.
PMID: 10082659 [PubMed - indexed for MEDLINE]
-  **402:** Fukumoto H, Naito Z, Asano G, Aramaki T. [Related Articles, Links](#)
-  **Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus.**
J Atheroscler Thromb. 1998;5(1):29-35.
PMID: 10077455 [PubMed - indexed for MEDLINE]
-  **403:** Gurfinkel EP, Scirica BM, Bozovich G, Macchia A, Manos E, Mautner B. [Related Articles, Links](#)
-  **Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction.**
Am J Cardiol. 1999 Feb 15;83(4):515-8.
PMID: 10073853 [PubMed - indexed for MEDLINE]
-  **404:** Song IS, Yang WS, Kim SB, Lee JH, Kwon TW, Park JS. [Related Articles, Links](#)
-  **Association of plasma fibrinogen concentration with vascular access failure in hemodialysis patients.**
Nephrol Dial Transplant. 1999 Jan;14(1):137-41.
PMID: 10052493 [PubMed - indexed for MEDLINE]
-  **405:** Dickson TJ, Gurudutt V, Nguyen AQ, Kumfer K, Maxted W, Brown J, Mahomed Y, Sharp T, Auffiero TX, Finberg N, March KL. [Related Articles, Links](#)
-  **Establishment of a clinically correlated human pericardial fluid bank: evaluation of intrapericardial diagnostic potential.**
Clin Cardiol. 1999 Jan;22(1 Suppl 1):I40-2.
PMID: 9929767 [PubMed - indexed for MEDLINE]
-  **406:** Hachida M, Zhang X, Lu H, Hoshi H, Furutani Y, Matsuoka R. [Related Articles, Links](#)

Koyanagi H.



Association between the degree of platelet-derived growth factor-A chain mRNA expression and coronary arteriosclerosis in the transplanted heart. *Heart Vessels*. 1998;13(1):24-9. PMID: 9923562 [PubMed - indexed for MEDLINE]

- ☐ **407:** Chen YX, Nakashima Y, Tanaka K, Shiraishi S, Nakagawa K, Sueishi K. [Related Articles](#), [Links](#)



Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries. *Arterioscler Thromb Vasc Biol*. 1999 Jan;19(1):131-9. PMID: 9888875 [PubMed - indexed for MEDLINE]

- ☐ **408:** Losordo DW, Vale PR, Symes JE, Dunnington CH, Esakof DD, Mavsky M, Ashare AB, Lathi K, Isner JM. [Related Articles](#), [Links](#)



Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. *Circulation*. 1998 Dec 22-29;98(25):2800-4. PMID: 9860779 [PubMed - indexed for MEDLINE]

- ☐ **409:** Ito H, Hamano K, Gohra H, Katoh T, Fujimura Y, Zempo N, Esato K. [Related Articles](#), [Links](#)



Coronary arteriosclerosis did not occur in the transplanted hearts of tolerance-induced rats: analysis from platelet-derived growth factor expression. *Transplant Proc*. 1998 Nov;30(7):3871-2. No abstract available. PMID: 9838694 [PubMed - indexed for MEDLINE]

- ☐ **410:** Laham RJ, Simons M, Tofukuji M, Hung D, Sellke FW. [Related Articles](#), [Links](#)



Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: insight into ischemia-induced reduction in endothelium-dependent vasodilatation. *J Thorac Cardiovasc Surg*. 1998 Dec;116(6):1022-8. PMID: 9832695 [PubMed - indexed for MEDLINE]

- ☐ **411:** Wang XL, Sim AS, Wilcken DE. [Related Articles](#), [Links](#)



A common polymorphism of the transforming growth factor-beta1 gene and coronary artery disease. *Clin Sci (Lond)*. 1998 Dec;95(6):745-6. No abstract available. PMID: 9831700 [PubMed - indexed for MEDLINE]

- ☐ **412:** Syrris P, Carter ND, Metcalfe JC, Kemp PR, Grainger DJ, Kaski JC, Crossman DC, Francis SE, Gunn J, Jeffery S, Heathcote K. [Related Articles](#), [Links](#)



Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. *Clin Sci (Lond)*. 1998 Dec;95(6):659-67. PMID: 9831690 [PubMed - indexed for MEDLINE]

- ☐ **413:** Samani NJ. [Related Articles](#), [Links](#)



Molecular genetics of coronary artery disease: measuring the phenotype. *Clin Sci (Lond)*. 1998 Dec;95(6):645-6. No abstract available. PMID: 9831687 [PubMed - indexed for MEDLINE]

- ☐ **414:** Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K. [Related Articles](#), [Links](#)

Vascular endothelial growth factor (VEGF) expression in human coronary



atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis.

Circulation. 1998 Nov 17;98(20):2108-16.

PMID: 9815864 [PubMed - indexed for MEDLINE]



415: [Urasawa K, Kitabatake A.](#)

[Related Articles, Links](#)



[Transgenic animals]

Nippon Rinsho. 1998 Oct;56(10):2521-6. Review. Japanese.

PMID: 9796313 [PubMed - indexed for MEDLINE]



416: [Iwakura A, Komeda M, Fujita M.](#)

[Related Articles, Links](#)



[Coronary stenosis and mechanisms of collateral vessel growth]

Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese.

PMID: 9796310 [PubMed - indexed for MEDLINE]



417: [Komatsu R, Ueda M.](#)

[Related Articles, Links](#)



[Plaque progression and destabilization in human coronary arteries]

Nippon Rinsho. 1998 Oct;56(10):2477-82. Review. Japanese.

PMID: 9796305 [PubMed - indexed for MEDLINE]



418: [Vogel RA, Corretti MC, Gellman J.](#)

[Related Articles, Links](#)



Cholesterol, cholesterol lowering, and endothelial function.

Prog Cardiovasc Dis. 1998 Sep-Oct;41(2):117-36. Review.

PMID: 9790413 [PubMed - indexed for MEDLINE]



419: [Goalstone ML, Natarajan R, Standley PR, Walsh MF, Leitner JW, Carel K, Scott S, Nadler J, Sowers JR, Draznin B.](#)

[Related Articles, Links](#)



Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells.

Endocrinology. 1998 Oct;139(10):4067-72.

PMID: 9751484 [PubMed - indexed for MEDLINE]



420: [Métais C, Li J, Li J, Simons M, Sellke FW.](#)

[Related Articles, Links](#)



Effects of coronary artery disease on expression and microvascular response to VEGF.

Am J Physiol. 1998 Oct;275(4 Pt 2):H1411-8.

PMID: 9746492 [PubMed - indexed for MEDLINE]



421: [Nishimura M, Ushiyama M, Nanbu A, Ohtsuka K, Yoshimura M.](#)

[Related Articles, Links](#)



[Vascular endothelium-related factors and atherosclerosis/arteriosclerosis: serum hepatocyte growth factor as a possible indicator of vascular lesions]

Rinsho Byori. 1998 Jul;46(7):671-7. Review. Japanese.

PMID: 9721534 [PubMed - indexed for MEDLINE]



422: [Yazdani S, Simon AD, Vidhun R, Gulotta C, Schwartz A, Rabbani LE.](#)

[Related Articles, Links](#)



Inflammatory profile in unstable angina versus stable angina in patients undergoing percutaneous interventions.

Am Heart J. 1998 Aug;136(2):357-61.

PMID: 9704702 [PubMed - indexed for MEDLINE]



423: [Kagan SA, Myers SI.](#)

[Related Articles, Links](#)



Mediators of restenosis.

Surg Clin North Am. 1998 Jun;78(3):481-500. Review.

PMID: 9673658 [PubMed - indexed for MEDLINE]




424: [Renme WJ.](#)

[Related Articles, Links](#)



The sympathetic nervous system and ischaemic heart disease.

Eur Heart J. 1998 Jun;19 Suppl F:F62-71. Review.
PMID: 9651738 [PubMed - indexed for MEDLINE]


-  **425:** [Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M.](#) [Related Articles, Links](#)



Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.

Ann Thorac Surg. 1998 Jun;65(6):1540-4.

PMID: 9647055 [PubMed - indexed for MEDLINE]


-  **426:** [Hachida M, Zhang XL, Lu H, Hoshi H, Koyanagi H.](#) [Related Articles, Links](#)



Inhibitory effect of Multiglycosidum tripterygii on coronary arteriosclerosis after heart transplantation.

Transplantation. 1998 Jun 15;65(11):1446-50.

PMID: 9645800 [PubMed - indexed for MEDLINE]


-  **427:** [Vanhof S, Brost B, Stille-Siegener M, Grumbach IM, Kreuzer H, Figulla HR.](#) [Related Articles, Links](#)



Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy.

Int J Cardiol. 1998 Feb 28;63(3):237-44.

PMID: 9578350 [PubMed - indexed for MEDLINE]


-  **428:** [Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, Aas H, Kjekshus J, Simonsen S, Froland SS, Gullestad L.](#) [Related Articles, Links](#)



Elevated circulating levels of C-C chemokines in patients with congestive heart failure.

Circulation. 1998 Mar 31;97(12):1136-43.

PMID: 9537339 [PubMed - indexed for MEDLINE]


-  **429:** [Molestina RE, Dean D, Miller RD, Ramirez JA, Summersgill JT.](#) [Related Articles, Links](#)



Characterization of a strain of Chlamydia pneumoniae isolated from a coronary atheroma by analysis of the omp1 gene and biological activity in human endothelial cells.

Infect Immun. 1998 Apr;66(4):1370-6.

PMID: 9529055 [PubMed - indexed for MEDLINE]

-  **430:** [Selzman CH, Whitehill TA, Shames BD, Pulido EJ, Cain BS, Harken AH, Cain BC.](#) [Related Articles, Links](#)



The biology of estrogen-mediated repair of cardiovascular injury.

Ann Thorac Surg. 1998 Mar;65(3):868-74. Review. Erratum in: Ann Thorac Surg 1998 Jul;66(1):310. Cain BC[corrected to Cain BS].

PMID: 9527242 [PubMed - indexed for MEDLINE]


-  **431:** [Focgh ML, Ramwell PW.](#) [Related Articles, Links](#)



Pharmacologic control of smooth muscle cells in allografts.

Transpl Immunol. 1997 Dec;5(4):267-75. Review. No abstract available.

PMID: 9504146 [PubMed - indexed for MEDLINE]


-  **432:** [Schwartz SM.](#) [Related Articles, Links](#)



Smooth muscle migration in vascular development and pathogenesis.

Transpl Immunol. 1997 Dec;5(4):255-60. Review. No abstract available.

PMID: 9504144 [PubMed - indexed for MEDLINE]



















-  **433:** [Pober JS, Ma W, Biedermann B, Libby P.](#) [Related Articles, Links](#)



Vascular cells have limited capacities to activate and differentiate T cells: implications for transplant vascular sclerosis.


Transpl Immunol. 1997 Dec;5(4):251-4. Review. No abstract available.

PMID: 9504143 [PubMed - indexed for MEDLINE]

-  **434:** [Eickelberg O, Roth M, Block LH.](#) [Related Articles, Links](#)
-  Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection.
Int J Cardiol. 1997 Dec 31;62 Suppl 2:S31-7. Review.
PMID: 9488193 [PubMed - indexed for MEDLINE]
-  **435:** [Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW.](#) [Related Articles, Links](#)
-  Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease.
Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):277-82. Erratum in: Arterioscler Thromb Vasc Biol 1998 Jul;18(7):1197.
PMID: 9484994 [PubMed - indexed for MEDLINE]
-  **436:** [Brilla CG, Rybinski L, Gehrke D, Rupp H.](#) [Related Articles, Links](#)
-  [Transmyocardial laser revascularization--an innovative pathophysiologic concept]
Herz. 1997 Aug;22(4):183-9. Review. German.
PMID: 9378452 [PubMed - indexed for MEDLINE]
-  **437:** [Juvonen J, Surcel HM, Satta J, Teppo AM, Bloigu A, Syrjala H, Airaksinen J, Leinonen M, Saikku P, Juvonen T.](#) [Related Articles, Links](#)
-  Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm.
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2843-7.
PMID: 9409264 [PubMed - indexed for MEDLINE]
-  **438:** [Plenz G, Koenig C, Severs NJ, Robenek H.](#) [Related Articles, Links](#)
-  Smooth muscle cells express granulocyte-macrophage colony-stimulating factor in the undiseased and atherosclerotic human coronary artery.
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2489-99.
PMID: 9409219 [PubMed - indexed for MEDLINE]
-  **439:** [Shanahan CM, Cary NR, Osbourn JK, Weissberg PL.](#) [Related Articles, Links](#)
-  Identification of osteoglycin as a component of the vascular matrix. Differential expression by vascular smooth muscle cells during neointima formation and in atherosclerotic plaques.
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2437-47.
PMID: 9409213 [PubMed - indexed for MEDLINE]
-  **440:** [Fukumoto Y, Shimokawa H, Kozai T, Kadokami T, Kuwata K, Yonemitsu Y, Kuga T, Egashira K, Sueishi K, Takeshita A.](#) [Related Articles, Links](#)
-  Vasculoprotective role of inducible nitric oxide synthase at inflammatory coronary lesions induced by chronic treatment with interleukin-1beta in pigs in vivo.
Circulation. 1997 Nov 4;96(9):3104-11.
PMID: 9386181 [PubMed - indexed for MEDLINE]
-  **441:** [Bombardini T, Picano E.](#) [Related Articles, Links](#)
-  The coronary angiogenetic effect of heparin: experimental basis and clinical evidence.
Angiology. 1997 Nov;48(11):969-76. Review.
PMID: 9373049 [PubMed - indexed for MEDLINE]
-  **442:** [Suzuki J, Isobe M, Yamazaki S, Horie S, Okubo Y, Sekiguchi M.](#) [Related Articles, Links](#)
-  Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-

associated antigen-1 in a heterotopic murine model of heart transplantation.

J Heart Lung Transplant. 1997 Nov;16(11):1141-8.
PMID: 9402514 [PubMed - indexed for MEDLINE]


-  **443:** [Nishimura M, Ushiyama M, Yoshimura M.](#)

[Related Articles, Links](#)



[Serum hepatocyte growth factor as a possible indicator of vascular lesions]

Rinsho Byori. 1997 Sep;45(9):831-6. Japanese.
PMID: 9311255 [PubMed - indexed for MEDLINE]


-  **444:** [Schumacher M, Halwachs G, Tatzber F, Fruhwald FM, Zweiker R, Watzinger N, Eber B, Wilders-Truschnig M, Esterbauer H, Klein W.](#)

[Related Articles, Links](#)



Increased neopterin in patients with chronic and acute coronary syndromes.

J Am Coll Cardiol. 1997 Sep;30(3):703-7.
PMID: 9283529 [PubMed - indexed for MEDLINE]

-  **445:** [Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA, King GL.](#)

[Related Articles, Links](#)



Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy.

Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9320-5.
PMID: 9256480 [PubMed - indexed for MEDLINE]


-  **446:** [Nagao K, Tsuchihashi K, Ura N, Nakata T, Shimamoto K.](#)

[Related Articles, Links](#)



Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease.

Can J Cardiol. 1997 Aug;13(8):747-53. Review.
PMID: 9284841 [PubMed - indexed for MEDLINE]


-  **447:** [Wang XL, Liu SX, Wilcken DE.](#)

[Related Articles, Links](#)



Circulating transforming growth factor beta 1 and coronary artery disease.

Cardiovasc Res. 1997 May;34(2):404-10.
PMID: 9205555 [PubMed - indexed for MEDLINE]


-  **448:** [Nishigaki K, Minatoguchi S, Seishima M, Asano K, Noda T, Yasuda N, Sano H, Kumada H, Takemura M, Noma A, Tanaka T, Watanabe S, Fujiwara H.](#)

[Related Articles, Links](#)



Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.

J Am Coll Cardiol. 1997 May;29(6):1214-20.
PMID: 9137215 [PubMed - indexed for MEDLINE]


-  **449:** [Hasdai D, Barak V, Leibovitz E, Herz I, Sclarovsky S, Eldar M, Scheinowitz M.](#)

[Related Articles, Links](#)



Serum basic fibroblast growth factor levels in patients with ischemic heart disease.

Int J Cardiol. 1997 Apr 18;59(2):133-8.
PMID: 9158164 [PubMed - indexed for MEDLINE]

-  **450:** [Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE.](#)

[Related Articles, Links](#)



Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)

Eur J Endocrinol. 1997 Apr;136(4):377-81.
PMID: 9150696 [PubMed - indexed for MEDLINE]

-  **451:** [Botker HE, Skjaerbaek C, Eriksen UH, Schmitz O, Orskov H.](#)

[Related Articles, Links](#)



Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X.

Am J Cardiol. 1997 Apr 1;79(7):961-3.

PMID: 9104913 [PubMed - indexed for MEDLINE]

452: [Newby AC.](#)

[Related Articles](#), [Links](#)



Molecular and cell biology of native coronary and vein-graft atherosclerosis: regulation of plaque stability and vessel-wall remodelling by growth factors and cell-extracellular matrix interactions.

Coron Artery Dis. 1997 Mar-Apr;8(3-4):213-24. Review.

PMID: 9237032 [PubMed - indexed for MEDLINE]

453: [Fukumoto Y, Shimokawa H, Ito A, Kadokami T, Yonemitsu Y, Aikawa M, Owada MK, Egashira K, Sueishi K, Nagai R, Yazaki Y, Takeshita A.](#)

[Related Articles](#), [Links](#)



Inflammatory cytokines cause coronary arteriosclerosis-like changes and alterations in the smooth-muscle phenotypes in pigs.

J Cardiovasc Pharmacol. 1997 Feb;29(2):222-31.

PMID: 9057072 [PubMed - indexed for MEDLINE]

454: [Thorne SA, Abbot SE, Stevens CR, Winyard PG, Mills PG, Blake DR.](#)

[Related Articles](#), [Links](#)



Modified low density lipoprotein and cytokines mediate monocyte adhesion to smooth muscle cells.

Atherosclerosis. 1996 Dec 20;127(2):167-76.

PMID: 9125306 [PubMed - indexed for MEDLINE]

455: [Grant MB, Wargovich TJ, Ellis EA, Tarnuzzer R, Caballero S, Estes K, Rossing M, Spierri PE, Pepine C.](#)

[Related Articles](#), [Links](#)



Expression of IGF-I, IGF-I receptor and IGF binding proteins-1, -2, -3, -4 and -5 in human atherectomy specimens.

Regul Pept. 1996 Dec 17;67(3):137-44.

PMID: 8988513 [PubMed - indexed for MEDLINE]

456: [Lou H, Kodama T, Wang YN, Katz N, Ramwell P, Foegh ML.](#)

[Related Articles](#), [Links](#)



L-arginine prevents heart transplant arteriosclerosis by modulating the vascular cell proliferative response to insulin-like growth factor-I and interleukin-6.

J Heart Lung Transplant. 1996 Dec;15(12):1248-57.

PMID: 8981210 [PubMed - indexed for MEDLINE]

457: [Nakata A, Miyagawa J, Yamashita S, Nishida M, Tamura R, Yamamori K, Nakamura T, Nozaki S, Kameda-Takemura K, Kawata S, Taniguchi N, Higashiyama S, Matsuzawa Y.](#)

[Related Articles](#), [Links](#)



Localization of heparin-binding epidermal growth factor-like growth factor in human coronary arteries. Possible roles of HB-EGF in the formation of coronary atherosclerosis.

Circulation. 1996 Dec 1;94(11):2778-86.

PMID: 8941102 [PubMed - indexed for MEDLINE]

458: [Hasper D, Hummel M, Docke WD, Kleber FX, Felix SB, Hetzer R, Volk HD.](#)

[Related Articles](#), [Links](#)



[Inflammatory mediators in patients with biventricular assist device systems]

Z Kardiol. 1996 Nov;85(11):820-7. German.

PMID: 9064944 [PubMed - indexed for MEDLINE]

459: [Newby AC, George SJ.](#)

[Related Articles](#), [Links](#)




Proliferation, migration, matrix turnover, and death of smooth muscle

cells in native coronary and vein graft atherosclerosis.

Curr Opin Cardiol. 1996 Nov;11(6):574-82. Review.

PMID: 8968671 [PubMed - indexed for MEDLINE]


-  **460:** [Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A, Arveiler D, Luc G, Ruidavets JB, Poirier O.](#) [Related Articles, Links](#)



Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study.

Hypertension. 1996 Nov;28(5):881-7.

PMID: 8901839 [PubMed - indexed for MEDLINE]


-  **461:** [Imagawa DK, Dawson S 3rd, Holt CD, Kirk PS, Kaldas FM, Shackleton CR, Seu P, Rudich SM, Kinkhabwala MM, Martin P, Goldstein LI, Murray NG, Terasaki PI, Busuttil RW.](#) [Related Articles, Links](#)



Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin.

Transplantation. 1996 Oct 15;62(7):934-42.

PMID: 8878387 [PubMed - indexed for MEDLINE]


-  **462:** [Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE.](#) [Related Articles, Links](#)



Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome.

Metabolism. 1996 Oct;45(10):1263-6.

PMID: 8843182 [PubMed - indexed for MEDLINE]


-  **463:** [Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH.](#) [Related Articles, Links](#)



Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension.

J Am Coll Cardiol. 1996 Oct;28(4):964-71.

PMID: 8837575 [PubMed - indexed for MEDLINE]


-  **464:** [Laron Z, Wang XL, Klinger B, Silbergeld A, Davidovits M, Eisenstein B, Wilcken DE.](#) [Related Articles, Links](#)



Growth hormone treatment increases circulating lipoprotein(a) in children with chronic renal failure.

J Pediatr Endocrinol Metab. 1996 Sep-Oct;9(5):533-7.

PMID: 8961129 [PubMed - indexed for MEDLINE]


-  **465:** [Ito A, Shimokawa H, Fukumoto Y, Kadokami T, Nakaike R, Takayanagi T, Egashira K, Sueishi K, Takeshita A.](#) [Related Articles, Links](#)



The role of fibroblast growth factor-2 in the vascular effects of interleukin-1 beta in porcine coronary arteries in vivo.

Cardiovasc Res. 1996 Sep;32(3):570-9.

PMID: 8881517 [PubMed - indexed for MEDLINE]


-  **466:** [Lombardi G, Colao A, Ferone D, Marzullo P, Landi ML, Longobardi S, Iervolino E, Cuocolo A, Fazio S, Merola B, Sacca L.](#) [Related Articles, Links](#)



Cardiovascular aspects in acromegaly: effects of treatment.

Metabolism. 1996 Aug;45(8 Suppl 1):57-60.

PMID: 8769383 [PubMed - indexed for MEDLINE]


-  **467:** [Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.](#) [Related Articles, Links](#)



Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

Surgery. 1996 Aug;120(2):182-8.

PMID: 8751581 [PubMed - indexed for MEDLINE]


-  **468:** [Hasdai D, Scheinowitz M, Leibovitz E, Sclarovsky S, Eldar M, Barak V.](#) [Related Articles, Links](#)



Increased serum concentrations of interleukin-1 beta in patients with coronary artery disease.

Heart. 1996 Jul;76(1):24-8.

PMID: 8774323 [PubMed - indexed for MEDLINE]


-  **469:** [Baas IO, Offerhaus JA, El-Deiry WS, Wu TC, Hutchins GM, Kasper EK, Baughman KL, Baumgartner WA, Chiou CJ, Hayward GS, Hruban RH.](#) [Related Articles, Links](#)



The WAF1-mediated p53 growth-suppressor pathway is intact in the coronary arteries of heart transplant recipients.

Hum Pathol. 1996 Apr;27(4):324-9.

PMID: 8617473 [PubMed - indexed for MEDLINE]


-  **470:** [Kanda T, Hirao Y, Oshima S, Yuasa K, Taniguchi K, Nagai R, Kobayashi I.](#) [Related Articles, Links](#)



Interleukin-8 as a sensitive marker of unstable coronary artery disease.

Am J Cardiol. 1996 Feb 1;77(4):304-7. No abstract available.

PMID: 8607415 [PubMed - indexed for MEDLINE]

-  **471:** [Spallarossa P, Brunelli C, Minuto F, Caruso D, Battistini M, Caponnetto S, Cordera R.](#) [Related Articles, Links](#)



Insulin-like growth factor-I and angiographically documented coronary artery disease.

Am J Cardiol. 1996 Jan 15;77(2):200-2.

PMID: 8546095 [PubMed - indexed for MEDLINE]

-  **472:** [Gibbons GH.](#) [Related Articles, Links](#)



The pathogenesis of graft vascular disease: implications of vascular remodeling.

J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 2):S149-58. Review. No abstract available.

PMID: 8719477 [PubMed - indexed for MEDLINE]


-  **473:** [Labarrere CA, Faulk WP.](#) [Related Articles, Links](#)



Antithrombin determinants of coronary artery disease in transplanted human hearts.

Semin Hematol. 1995 Oct;32(4 Suppl 2):61-6. Review. No abstract available.

PMID: 8821212 [PubMed - indexed for MEDLINE]


-  **474:** [Ito A, Shimokawa H, Kadokami T, Fukumoto Y, Owada MK, Shiraishi T, Nakaike R, Takayanagi T, Egashira K, Takeshita A.](#) [Related Articles, Links](#)



Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-1 beta in pigs in vivo.

J Clin Invest. 1995 Sep;96(3):1288-94.

PMID: 7657803 [PubMed - indexed for MEDLINE]


-  **475:** [Taylor AJ, Farb AA, Angello DA, Burwell LR, Virmani R.](#) [Related Articles, Links](#)






















Proliferative activity in coronary atherectomy tissue. Clinical, histopathologic, and immunohistochemical correlates.

Chest. 1995 Sep;108(3):815-20.

PMID: 7656639 [PubMed - indexed for MEDLINE]

-  **476:** [Chen CH, Nguyen HH, Weilbacher D, Luo S, Gotto AM Jr, Henry PD.](#) [Related Articles, Links](#)

Basic fibroblast growth factor reverses atherosclerotic impairment of


-  human coronary angiogenesis-like responses in vitro.
Atherosclerosis. 1995 Aug;116(2):261-8.
PMID: 7575781 [PubMed - indexed for MEDLINE]
-  **477:** Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. [Related Articles](#), [Links](#)
-  The three processes leading to post PTCA restenosis: dependence on the lesion substrate.
Thromb Haemost. 1995 Jul;74(1):552-9. Review. No abstract available.
PMID: 8578523 [PubMed - indexed for MEDLINE]
-  **478:** Clausell N, de Lima VC, Molossi S, Liu P, Turley E, Gotlieb AI, Adelman AG, Rabinovitch M. [Related Articles](#), [Links](#)
-  Expression of tumour necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy.
Br Heart J. 1995 Jun;73(6):534-9.
PMID: 7626352 [PubMed - indexed for MEDLINE]
-  **479:** Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT, Koren G, Colucci WS, Goldberg MA. [Related Articles](#), [Links](#)
-  Regulation of vascular endothelial growth factor in cardiac myocytes.
Circ Res. 1995 May;76(5):758-66.
PMID: 7728992 [PubMed - indexed for MEDLINE]
-  **480:** Vijayakumar M, Fall CH, Osmond C, Barker DJ. [Related Articles](#), [Links](#)
-  Birth weight, weight at one year, and left ventricular mass in adult life.
Br Heart J. 1995 Apr;73(4):363-7.
PMID: 7756071 [PubMed - indexed for MEDLINE]
-  **481:** Eritsland J, Seljeflot I, Arnesen H, Westvik AB, Kjerulf P. [Related Articles](#), [Links](#)
-  Effect of long-term, moderate-dose supplementation with omega-3 fatty acids on monocyte procoagulant activity and release of interleukin-6 in patients with coronary artery disease.
Thromb Res. 1995 Feb 15;77(4):337-46.
PMID: 7740525 [PubMed - indexed for MEDLINE]
-  **482:** Badimon L, Royo T, Martinez-Gonzalez J, Badimon JJ. [Related Articles](#), [Links](#)
-  [Development of coronary arteriosclerosis and its clinical complications]
Med Clin (Barc). 1995 Jan 28;104(3):105-14. Review. Spanish. No abstract available.
PMID: 7877359 [PubMed - indexed for MEDLINE]
-  **483:** Hombach V, Waltenberger J, Voisard R, Hoher M. [Related Articles](#), [Links](#)
-  [Recurrent stenosis following coronary angioplasty. Clinical, cell biological and molecular aspects]
Z Kardiol. 1995 Jan;84(1):5-21. Review. German.
PMID: 7863714 [PubMed - indexed for MEDLINE]
-  **484:** Mann JF. [Related Articles](#), [Links](#)
-  Hypertension and cardiovascular effects--long-term safety and potential long-term benefits of r-HuEPO.
Nephrol Dial Transplant. 1995;10 Suppl 2:80-4.
PMID: 7644111 [PubMed - indexed for MEDLINE]
-  **485:** Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. [Related Articles](#), [Links](#)
-  The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis.
Nat Med. 1995 Jan;1(1):74-9.
PMID: 7584958 [PubMed - indexed for MEDLINE]

 **486:** [Tada N.](#) Related Articles, Links



[LDL receptor gene analysis and phenotypic variation of familial hypercholesterolemia]

Nippon Rinsho. 1994 Dec;52(12):3228-35. Review. Japanese.
PMID: 7853715 [PubMed - indexed for MEDLINE]

 **487:** [Schulte HM, Bamberger CM, Elsen H, Herrmann G, Bamberger AM, Barth J.](#) Related Articles, Links



Systemic interleukin-1 alpha and interleukin-2 secretion in response to acute stress and to corticotropin-releasing hormone in humans.


Eur J Clin Invest. 1994 Nov;24(11):773-7.
PMID: 7890016 [PubMed - indexed for MEDLINE]

 **488:** [Dahlen GH.](#) Related Articles, Links



Indications of an autoimmune component in LP(a) associated disorders.

Eur J Immunogenet. 1994 Oct;21(5):301-12.
PMID: 9098440 [PubMed - indexed for MEDLINE]

 **489:** [Tamamoto T, Toda T, Shimajiri S, Kiyuna M, Shingaki Y, Nakashima Y, Takei H.](#) Related Articles, Links



[Expression of PDGF-A and -B in human coronary atherosclerotic lesion: immunohistochemical and in situ hybridization study]


Rinsho Byori. 1994 Sep;42(9):971-6. Japanese.
PMID: 7967123 [PubMed - indexed for MEDLINE]

 **490:** [Denko CW, Boja B, Moskowitz RW.](#) Related Articles, Links



Growth promoting peptides in osteoarthritis and diffuse idiopathic skeletal hyperostosis--insulin, insulin-like growth factor-I, growth hormone.

J Rheumatol. 1994 Sep;21(9):1725-30.
PMID: 779357 [PubMed - indexed for MEDLINE]

 **491:** [Kawai C.](#) Related Articles, Links



Pathogenesis of acute myocardial infarction. Novel regulatory systems of bioactive substances in the vessel wall.


Circulation. 1994 Aug;90(2):1033-43. Review.
PMID: 8044917 [PubMed - indexed for MEDLINE]

 **492:** [Dzau VJ.](#) Related Articles, Links



Cell biology and genetics of angiotensin in cardiovascular disease.


J Hypertens Suppl. 1994 Jul;12(4):S3-10. Review.
PMID: 7965271 [PubMed - indexed for MEDLINE]

 **493:** [Hofling B, Gonschior P, Nikol S, Bauriedel G, Welsch U, Nerlich A.](#) Related Articles, Links



[Pathophysiology and pathobiochemistry of restenosis]

Z Kardiol. 1994 May;83(5):313-8. Review. German.
PMID: 8053238 [PubMed - indexed for MEDLINE]

 **494:** [Nakayama T, Ohtsuru A, Enomoto H, Namba H, Ozeki S, Shibata Y, Yokota T, Nobuyoshi M, Ito M, Sekine I et al.](#) Related Articles, Links



Coronary atherosclerotic smooth muscle cells overexpress human parathyroid hormone-related peptides.

Biochem Biophys Res Commun. 1994 Apr 29;200(2):1028-35.
PMID: 8179578 [PubMed - indexed for MEDLINE]

 **495:** [Pfeifer PB, Collins EG.](#) Related Articles, Links



Cardiac allograft vasculopathy.

J Cardiovasc Nurs. 1994 Apr;8(3):68-86. Review.
PMID: 8207461 [PubMed - indexed for MEDLINE]

☐ **496:** [Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ.](#) [Related Articles, Links](#)



Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis?

Circulation. 1994 Apr;89(4):1511-7.

PMID: 7908609 [PubMed - indexed for MEDLINE]

☐ **497:** [Luscher TF.](#) [Related Articles, Links](#)



Endothelium in the control of vascular tone and growth: role of local mediators and mechanical forces.

Blood Press Suppl. 1994;1:18-22. Review.

PMID: 8205293 [PubMed - indexed for MEDLINE]

☐ **498:** [Bauriedel G, Kandolf R, Welsch U, Hofling B.](#) [Related Articles, Links](#)



[Mechanisms of re-stenosis after angioplasty]

Z Kardiol. 1994;83 Suppl 4:31-41. Review. German.

PMID: 7856278 [PubMed - indexed for MEDLINE]

☐ **499:** [Yang Z, Luscher TF.](#) [Related Articles, Links](#)



Basic cellular mechanisms of coronary bypass graft disease.

Eur Heart J. 1993 Nov;14 Suppl I:193-7.

PMID: 8293775 [PubMed - indexed for MEDLINE]

☐ **500:** [Wilcox JN.](#) [Related Articles, Links](#)



Molecular biology: insight into the causes and prevention of restenosis after arterial intervention.

Am J Cardiol. 1993 Oct 18;72(13):88E-95E. Review.

PMID: 8213576 [PubMed - indexed for MEDLINE]

Items 1-500 of 548

Page of 2 [Next](#)

[Display](#) [Summary](#) Show: [Sort](#) [Send to](#) [Text](#)


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search for

Limits Preview/Index History Clipboard Details

About Entrez

Show:

Text Version

☐ 1: Ann Thorac Surg. 1998 Jun;65(6):1540-4.

[Related Articles, Links](#)

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

[Full Text Article](#)

Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.

Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M.

Angiogenesis Research Center, Department of Surgery at Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
fsellke@bidmc.harvard.edu

BACKGROUND: Patients not amenable to complete myocardial revascularization by conventional methods present a difficult clinical problem. Here we present the early results and technical considerations of the administration of basic fibroblast growth factor for the induction of collateral growth using heparin-alginate slow-release devices in patients undergoing coronary artery bypass grafting. **METHODS:** Eight patients were enrolled. Patients were candidates if they had at least one graftable obstructed coronary artery and at least one major arterial distribution not amenable to revascularization, a serum creatinine level less than 3 mg/dL, ejection fraction greater than 0.20, and estimated operative mortality of less than 25%. During conventional coronary artery bypass grafting, 10 heparin-alginate devices, each containing either 1 microg or 10 microg of basic fibroblast growth factor, were implanted in the epicardial fat in multiple regions of the unvascularizable territory and also in the distal distribution of a grafted or patent artery. **RESULTS:** There was no mortality and no evidence of renal, hematologic, or hepatic toxicity during follow-up. Three months after the operation, all patients remain free of angina. Seven patients were examined with stress perfusion scans. Three patients had clear enhancement of perfusion to the unvascularized myocardium, 1 patient had a new fixed defect, and 3 had minimal overall change but had evidence of new small, fixed perfusion defects. Seven patients had improved or similar myocardial contractile function (ejection fraction at 3-month follow-up = 0.53 +/- 0.22 versus 0.47 +/- 0.14 preoperatively). One patient suffered a perioperative myocardial infarction in the area of basic fibroblast growth factor administration. **CONCLUSIONS:** This preliminary study demonstrates the safety and technical feasibility of therapeutic angiogenesis with basic fibroblast growth factor delivered by heparin-alginate slow-release devices. Further studies examining the safety, clinical efficacy, and long-term results are ongoing.

Publication Types:

- Clinical Trial

- Clinical Trial, Phase I

PMID: 9647055 [PubMed - indexed for MEDLINE]

Display	Abstract	Show:	20	Sort	Send to	Text
---------	----------	-------	----	------	---------	------

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37

Entrez PubMed



PubMed

National
Library
of Medicine
NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book
 Search PubMed for Limits Preview/Index History Clipboard Details
 Go Clear

About Entrez

Text Version

Entrez PubMed
 Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities

PubMed Services
 Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Cubby

Related Resources
 Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central

☐ 1: Am Heart J. 1999 Aug;138(2 Pt 2):S132-41.

Am Heart J

Gene therapy for myocardial angiogenesis.

Losordo DW, Vale PR, Isner JM.

St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135,
 USA.

In patients in whom antianginal medications fail to provide sufficient symptomatic relief, additional interventions such as angioplasty or bypass surgery may be required. Although both types of intervention have been shown to be effective for various types of patients, a certain group of patients may not be candidates for either intervention because of the diffuse nature of their coronary artery disease. Moreover, there are many patients in whom recurrent narrowing and/or occlusion of bypass conduits after initially successful surgery has left the patient again symptomatic with no further angioplasty or surgical option. Ischemic muscle represents a promising target for gene therapy with naked plasmid DNA. Intramuscular transfection of genes encoding angiogenic cytokines, particularly those naturally secreted by intact cells, may constitute an alternative treatment strategy for patients with extensive tissue ischemia in whom contemporary therapies (antianginal medications, angioplasty, bypass surgery) have previously failed or are not feasible. This strategy is designed to promote the development of supplemental collateral blood vessels that will constitute endogenous bypass conduits around occluded native arteries, a strategy termed "therapeutic angiogenesis." Preclinical animal studies from our laboratory have established that intramuscular gene transfer may be used to successfully accomplish therapeutic angiogenesis. More recently, phase 1 clinical studies from our institution have established that intramuscular gene transfer may be used to safely and successfully accomplish therapeutic angiogenesis in patients with critical limb ischemia. The notion that this concept could be extrapolated to the treatment of chronic myocardial ischemia was demonstrated in our laboratory by administering recombinant human vascular endothelial growth factor (VEGF) to a porcine model of chronic myocardial ischemia. Recent experiments performed in this same porcine model of myocardial ischemia have shown that direct intramyocardial gene transfer of naked plasmid DNA encoding VEGF (phVEGF(165), the identical plasmid used in our previous animal and human clinical trials) can be safely and successfully achieved through a minimally invasive chest wall incision. Finally, initial results have supported the concept that intramyocardial injection of naked plasmid DNA encoding VEGF can achieve therapeutic angiogenesis, as demonstrated by clinical improvement in patient symptoms and improved myocardial

h

cb

hg

e

e

efcg c

e e e

b

b e

b

c

perfusion shown by single-photon emission computed tomography-sestamibi imaging.

Publication Types:


- Review
- Review, Tutorial

PMID: 10426872 [PubMed - indexed for MEDLINE]

Display	Abstract	Show:	20	Sort	Send to	Text
---------	----------	-------	----	------	---------	------

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search PubMed for [] Go Clear
Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

1: Am J Cardiol. 1999 Aug 15;84(4):430-3.

[Related Articles, Links](#)

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

[Full Text Article](#)

Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease.

Spallarossa P, Rossettin P, Minuto F, Caruso D, Cordera R, Battistini M, Barreca A, Masperone MA, Brunelli C.

Department of Internal Medicine, University of Genoa, Italy.

We have examined the effects of 6 months of treatment with growth hormone (GH) (0.02 U/kg/day) in 10 patients with chronic postischemic cardiac failure. Ten patients matched for age, body mass index, functional class, and ejection fraction served as a control group. In the GH group, 1 patient died and 2 were withdrawn from the study because of arrhythmia or worsening of heart failure. In the control group, 1 patient died and 1 patient was withdrawn from the study because of progressive heart failure. Among GH patients, those with an unfavorable outcome had a greater left ventricular end-diastolic diameter (79, 82, and 88 mm) on entry to the study than patients without adverse events (range 62 to 72 mm). At the end of the study, the seven GH patients reported a feeling of well-being and had a significant increase in their exercise test duration (462 +/- 121 vs 591 +/- 105 seconds, $p < 0.05$). Low baseline insulin-like growth factor-I values were increased with GH treatment (189 +/- 52 vs 100 +/- 22 ng/ml, $p < 0.01$). GH did not change left ventricular diameters or wall thickness. A trend toward decreased serum triglyceride levels and adipose body tissue associated with an increase in high-density lipoproteins was observed in the GH group. In conclusion, our present data support previous suggestions that GH treatment exerts some beneficial effects in patients with chronic, stabilized, moderately severe heart failure, but may have deleterious effects in patients with more severe heart failure.

Publication Types:


- Clinical Trial
- Controlled Clinical Trial

PMID: 10468082 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books
 Search PubMed for coronary artery disease AND growth factor Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Text Version

Items 501-548 of 548

Previous Page 2 of 2

Entrez PubMed

Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities

PubMed Services

Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Cubby

Related Resources

Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central

☐ 501: Yang Z, Noll G, Luscher TF.

Related Articles, Links



Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor.

Circulation. 1993 Sep;88(3):832-6.

PMID: 8353912 [PubMed - indexed for MEDLINE]

☐ 502: Anderson HV, Vignale SJ, Benedict CR, Willerson JT.

Related Articles, Links



Restenosis after coronary angioplasty.

J Interv Cardiol. 1993 Sep;6(3):187-202. Review.

PMID: 10151016 [PubMed - indexed for MEDLINE]

☐ 503: Klassen KJ, Nordt TK, Schneider DJ, Sobel BE.

Related Articles, Links



Constitutive biosynthesis of plasminogen activator inhibitor type-1 (PAI-1) by cultured human aortic endothelial cells independent of insulin.

Coron Artery Dis. 1993 Aug;4(8):713-9.

PMID: 8261243 [PubMed - indexed for MEDLINE]

☐ 504: Johansson SR, Nilsson J, Hamsten A, Emanuelsson H.

Related Articles, Links



Mitogenic activity in connection with coronary angioplasty.

Eur Heart J. 1993 Jul;14(7):904-9.

PMID: 8375413 [PubMed - indexed for MEDLINE]

☐ 505: Clausell N, Molossi S, Rabinovitch M.

Related Articles, Links



Increased interleukin-1 beta and fibronectin expression are early features of the development of the postcardiac transplant coronary arteriopathy in piglets.

Am J Pathol. 1993 Jun;142(6):1772-86.

PMID: 8506947 [PubMed - indexed for MEDLINE]

☐ 506: Ko Y, Haring R, Stiebler H, Wieczorek AJ, Vetter H, Sachinidis A.

Related Articles, Links



High-density lipoprotein reduces epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells.

Atherosclerosis. 1993 Mar;99(2):253-9.

PMID: 8503952 [PubMed - indexed for MEDLINE]

☐ 507: Badimon JJ, Fuster V, Chesebro JH, Badimon L.

Related Articles, Links



Coronary atherosclerosis. A multifactorial disease.

Circulation. 1993 Mar;87(3 Suppl):II3-16. Review.

PMID: 8443920 [PubMed - indexed for MEDLINE]


☐ 508: Hase H, Imamura Y, Nakamura R, Inishi Y, Machii K, Yamaguchi T.


Related Articles, Links




Effects of rHuEPO therapy on exercise capacity in hemodialysis patients with coronary artery disease.


Jpn Circ J. 1993 Feb;57(2):131-7.
PMID: 8450597 [PubMed - indexed for MEDLINE]


-  **509:** Luscher TF, Tanner FC, Tschudi MR, Noll G. Related Articles, Links

 Endothelial dysfunction in coronary artery disease.
Annu Rev Med. 1993;44:395-418. Review.
PMID: 8476260 [PubMed - indexed for MEDLINE]


-  **510:** Lindemann A, Rumberger B. Related Articles, Links


 Vascular complications in patients treated with granulocyte colony-stimulating factor (G-CSF)
Eur J Cancer. 1993;29A(16):2338-9. No abstract available.
PMID: 8110510 [PubMed - indexed for MEDLINE]


-  **511:** Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. Related Articles, Links

 A cascade model for restenosis. A special case of atherosclerosis progression.
Circulation. 1992 Dec;86(6 Suppl):III47-52. Review.
PMID: 1424051 [PubMed - indexed for MEDLINE]


-  **512:** Fuster V, Badimon JJ, Badimon L. Related Articles, Links


 Clinical-pathological correlations of coronary disease progression and regression.
Circulation. 1992 Dec;86(6 Suppl):III1-11. Review.
PMID: 1424042 [PubMed - indexed for MEDLINE]


-  **513:** Nilsson J, Volk-Jovinge S, Svensson J, Landou C, De Faire U, Hamsten A. Related Articles, Links


 Association between high levels of growth factors in plasma and progression of coronary atherosclerosis.
J Intern Med. 1992 Nov;232(5):397-404.
PMID: 1453123 [PubMed - indexed for MEDLINE]


-  **514:** Yla-Herttuala S. Related Articles, Links

 Gene expression in atherosclerotic lesions.
Herz. 1992 Oct;17(5):270-6. Review.
PMID: 1473813 [PubMed - indexed for MEDLINE]


-  **515:** Bauriedel G, Heidemann P, Klingel K, Windstetter U, Hofling B, Kandolf R. Related Articles, Links


 [In situ detection of EGF receptor mRNA in arteriosclerotic lesions in man: implications for the proliferative activity of smooth muscle cells]
Z Kardiol. 1992 Oct;81(10):519-24. German. Erratum in: Z Kardiol 1992 Dec;81(12):712.
PMID: 1441690 [PubMed - indexed for MEDLINE]

-  **516:** Schumacher M, Eber B, Tatzber F, Kaufmann P, Esterbauer H, Klein W. Related Articles, Links

 Neopterin levels in patients with coronary artery disease.
Atherosclerosis. 1992 May;94(1):87-8. No abstract available.
PMID: 1632862 [PubMed - indexed for MEDLINE]

-  **517:** Gordon D. Related Articles, Links

 Growth factors and cell proliferation in human transplant arteriosclerosis.
J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 2):S7. No abstract available.
PMID: 1623005 [PubMed - indexed for MEDLINE]

-  **518:** Wiedermann CJ, Niedermühlbichler M, Braunsteiner H, Wiedermann CJ. Related Articles, Links

**Priming of polymorphonuclear neutrophils by atrial natriuretic peptide in vitro.**

J Clin Invest. 1992 May;89(5):1580-6.

PMID: 1314851 [PubMed - indexed for MEDLINE]

**519:** [Ganguly NK, Nalini K, Wahi S, Dhawan V, Meenakshi S, Chakravarti RN.](#)[Related Articles, Links](#)**Free radicals in myocardial injury: experimental and clinical studies.**

Mol Cell Biochem. 1992 Apr;111(1-2):71-6.

PMID: 1588945 [PubMed - indexed for MEDLINE]

**520:** [Sasayama S, Fujita M.](#)[Related Articles, Links](#)**Recent insights into coronary collateral circulation.**

Circulation. 1992 Mar;85(3):1197-204. Review.

PMID: 1371432 [PubMed - indexed for MEDLINE]

**521:** [Watanabe Y, Fuse K, Naruse Y, Kobayashi T, Konishi H, Shibata Y.](#)[Related Articles, Links](#)**[Autologous blood transfusion with erythropoietin in heart surgery in an anemic patient]**

Nippon Kyobu Geka Gakkai Zasshi. 1992 Feb;40(2):282-5. Japanese.

PMID: 1593170 [PubMed - indexed for MEDLINE]

**522:** [Juliard JM, Himbert D, Steg PG.](#)[Related Articles, Links](#)**[Can coronary "restenosis" after percutaneous angioplasty be prevented?]**

Presse Med. 1992 Feb 1;21(4):149-52. Review. French. No abstract available.

PMID: 1532070 [PubMed - indexed for MEDLINE]

**523:** [Shaddy RE, Hansen JC, Cowley CG.](#)[Related Articles, Links](#)**Effects of T cells on platelet-derived growth factor-like protein secretion from endothelial cells.**

J Heart Lung Transplant. 1992 Jan-Feb;11(1 Pt 1):48-56; discussion 57.

PMID: 1540612 [PubMed - indexed for MEDLINE]

**524:** [Heidemann P, Hofling B, Heimerl J, Emberger C, Meyer G, Kandolf R, Bauriedel G.](#)[Related Articles, Links](#)**[Proliferative response of smooth muscle cells from human arteriosclerosis lesions to PDGF, bFGF and EGF]**

Vasa Suppl. 1992;35:137-9. German. No abstract available.

PMID: 1481019 [PubMed - indexed for MEDLINE]

**525:** [Wizemann V, Kaufmann J, Kramer W.](#)[Related Articles, Links](#)**Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease.**

Nephron. 1992;62(2):161-5.

PMID: 1436308 [PubMed - indexed for MEDLINE]

**526:** [Paul M, Ganten D.](#)[Related Articles, Links](#)**The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system.**

J Cardiovasc Pharmacol. 1992;19 Suppl 5:S51-8. Review.

PMID: 1381795 [PubMed - indexed for MEDLINE]

**527:** [Luscher TF.](#)[Related Articles, Links](#)**[Thrombocyte-vascular wall interaction and coronary heart disease]**

Schweiz Med Wochenschr. 1991 Dec 28;121(51-52):1913-22. Review. German.

PMID: 1763300 [PubMed - indexed for MEDLINE]

**528:** [Cercek B, Sharifi B, Barath P, Bailey L, Forrester JS.](#)[Related Articles, Links](#)

**Growth factors in pathogenesis of coronary arterial restenosis.**

Am J Cardiol. 1991 Nov 4;68(12):24C-33C. Review.
PMID: 1951099 [PubMed - indexed for MEDLINE]

529: [Rosendorff C.](#)

[Related Articles, Links](#)

**Reversal of structural changes in hypertensive arteries--a major prospect for the future.**

S Afr Med J. 1991 Sep 21;Suppl:4-6. Review.
PMID: 1925814 [PubMed - indexed for MEDLINE]

530: [Arbustini E, Grasso M, Diegoli M, Pucci A, Bramerio M, Ardisino D, Angoli L, de Servi S, Bramucci E, Mussini A, et al.](#)

[Related Articles, Links](#)

**Coronary atherosclerotic plaques with and without thrombus in ischemic heart syndromes: a morphologic, immunohistochemical, and biochemical study.**

Am J Cardiol. 1991 Sep 3;68(7):36B-50B.
PMID: 1892066 [PubMed - indexed for MEDLINE]

531: [Hermans WR, Rensing BJ, Strauss BH, Serruys PW.](#)

[Related Articles, Links](#)

**Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet".**

Am Heart J. 1991 Jul;122(1 Pt 1):171-87. Review. No abstract available.
PMID: 2063736 [PubMed - indexed for MEDLINE]

532: [Wilcox JN.](#)

[Related Articles, Links](#)

**Thrombin and other potential mechanisms underlying restenosis.**

Circulation. 1991 Jul;84(1):432-5. No abstract available.
PMID: 2060116 [PubMed - indexed for MEDLINE]

533: [Stout RW.](#)

[Related Articles, Links](#)

**Insulin as a mitogenic factor: role in the pathogenesis of cardiovascular disease.**

Am J Med. 1991 Feb 21;90(2A):62S-65S.
PMID: 1994720 [PubMed - indexed for MEDLINE]

534: [Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL.](#)

[Related Articles, Links](#)

**Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis.**

J Biol Chem. 1991 Feb 5;266(4):2459-65.
PMID: 1824942 [PubMed - indexed for MEDLINE]

535: [DeFeudis FV.](#)

[Related Articles, Links](#)

**Coronary atherosclerosis: current therapeutic approaches and future trends.**

Life Sci. 1991;49(10):689-705. Review.
PMID: 1875779 [PubMed - indexed for MEDLINE]

536: [Kragel AH, Travis WD, Feinberg L, Pittaluga S, Striker LM, Roberts WC, Lotze MT, Yang JJ, Rosenberg SA.](#)

[Related Articles, Links](#)

**Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients.**






















Hum Pathol. 1990 May;21(5):493-502.
PMID: 2338330 [PubMed - indexed for MEDLINE]

537: [Mustard JF, Packham MA, Kinlough-Rathbone RL.](#)

[Related Articles, Links](#)

**Platelets, blood flow, and the vessel wall.**

Circulation. 1990 Jan;81(1 Suppl):I24-7; discussion I40-1. Review.
PMID: 2403865 [PubMed - indexed for MEDLINE]

-  **538:** [Popma JJ, Topol EJ.](#) [Related Articles, Links](#)
-  **Factors influencing restenosis after coronary angioplasty.**
Am J Med. 1990 Jan;88(1N):16N-24N. Review.
PMID: 2195881 [PubMed - indexed for MEDLINE]
-  **539:** [Sueishi K, Yasunaga C, Castellanos E, Kumamoto M, Tanaka K.](#) [Related Articles, Links](#)
-  **Sustained arterial injury and progression of atherosclerosis.**
Ann N Y Acad Sci. 1990;598:223-31. Review.
PMID: 1701074 [PubMed - indexed for MEDLINE]
-  **540:** [Ouchi Y, Orimo H.](#) [Related Articles, Links](#)
-  **The role of calcium antagonists in the treatment of atherosclerosis and hypertension.**
J Cardiovasc Pharmacol. 1990;16 Suppl 2:S1-4. Review.
PMID: 1369701 [PubMed - indexed for MEDLINE]
-  **541:** [Libby P.](#) [Related Articles, Links](#)
-  **The functions of blood vessel wall cells in atherogenesis and coronary artery disease.**
Arq Bras Cardiol. 1989 Aug;53(2):71-4. Review. No abstract available.
PMID: 2696454 [PubMed - indexed for MEDLINE]
-  **542:** [Nora R, Abrams JS, Tait NS, Hiponia DJ, Silverman HJ.](#) [Related Articles, Links](#)
-  **Myocardial toxic effects during recombinant interleukin-2 therapy.**
J Natl Cancer Inst. 1989 Jan 4;81(1):59-63.
PMID: 2783257 [PubMed - indexed for MEDLINE]
-  **543:** [Friedman EA.](#) [Related Articles, Links](#)
-  **Renal failure in diabetes: a substantive problem in provision of health care.**
Verh K Acad Geneeskd Belg. 1989;51(2):81-149; discussion 149-51. Review.
PMID: 2678807 [PubMed - indexed for MEDLINE]
-  **544:** [Nardoni A, Di Piazza V, Moretti V, Copetti R, Cruciatti A.](#) [Related Articles, Links](#)
-  **[Clinicopathogenetic correlations of copper and zinc and atherosclerotic myocardiopathy]**
Minerva Cardioangiol. 1987 Sep;35(9):451-5. Italian. No abstract available.
PMID: 3500428 [PubMed - indexed for MEDLINE]
-  **545:** [Nilsson J, Svensson J, Hamsten A, de Faire U.](#) [Related Articles, Links](#)
-  **Increased platelet-derived mitogenic activity in plasma of young patients with coronary atherosclerosis.**
Atherosclerosis. 1986 Sep;61(3):237-43.
PMID: 2429675 [PubMed - indexed for MEDLINE]
-  **546:** [Kottke BA.](#) [Related Articles, Links](#)
-  **Lipid markers for atherosclerosis.**
Am J Cardiol. 1986 Feb 12;57(5):11C-17C. Review.
PMID: 3080862 [PubMed - indexed for MEDLINE]
-  **547:** [Fuster V, Griggs TR.](#) [Related Articles, Links](#)
-  **Porcine von Willebrand disease: implications for the pathophysiology of atherosclerosis and thrombosis.**
Prog Hemost Thromb. 1986;8:159-83. Review.
PMID: 3550894 [PubMed - indexed for MEDLINE]
-  **548:** [Stuart J.](#) [Related Articles, Links](#)

**Rheological importance of acute-phase reactants.**

Nouv Rev Fr Hematol. 1986;28(1):33-6.

PMID: 2423964 [PubMed - indexed for MEDLINE]

Items 501-548 of 548


Previous

Page 2 of 2

Display	Summary	Show: 500	Sort	Send to	Text
---------	---------	-----------	------	---------	------

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for CPK-MB AND coronary artery disease Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Text Version

Items 1-12 of 12

One page.

Entrez PubMed

Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities

PubMed Services

Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Cubby

Related Resources

Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central

1: [Sala MF, Barcena JP, Rota JJ, Roca JV, Lopez CA, Puigdevall JM, Soldevilla JG, de Luna AB](#) Related Articles, Links

Sustained ventricular tachycardia as a marker of inadequate myocardial perfusion during the acute phase of myocardial infarction.
 Clin Cardiol. 2002 Jul;25(7):328-34.
 PMID: 12109866 [PubMed - indexed for MEDLINE]

2: [Chauhan S, Wasir HS, Bhan A, Rao BH, Saxena N, Venugopal P](#) Related Articles, Links

Adenosine for cardioplegic induction: a comparison with St Thomas solution.
 J Cardiothorac Vasc Anesth. 2000 Feb;14(1):21-4.
 PMID: 10698387 [PubMed - indexed for MEDLINE]

3: [Trehan N, Mishra M, Bapna R, Mishra A, Maheshwari P, Karlekar A](#) Related Articles, Links

Transmyocardial laser revascularisation combined with coronary artery bypass grafting without cardiopulmonary bypass.
 Eur J Cardiothorac Surg. 1997 Aug;12(2):276-84.
 PMID: 9288519 [PubMed - indexed for MEDLINE]

4: [Kondo K, Minohara S, Sawada Y, Irie H, Okamoto K, Kinugasa S, Nakao M, Sasaki S](#) Related Articles, Links

Indications and problems of coronary artery bypass grafting without cardiopulmonary bypass.
 Surg Today. 1997;27(3):202-6.
 PMID: 9068098 [PubMed - indexed for MEDLINE]

5: [Aggarwal SP, Thukral R, Wander GS, Kapoor DK](#) Related Articles, Links

Evaluation of serum lipid profile and cardiac enzyme changes in cerebrovascular accidents.
 J Indian Med Assoc. 1995 Sep;93(9):331-2.
 PMID: 8648151 [PubMed - indexed for MEDLINE]

6: [Kanno M, Kurihara H, Satoh H, Hamawaki M, Honda M](#) Related Articles, Links


[Coronary artery spasm after mitral valve replacement: a case report]
 Kyobu Geka. 1994 Apr;47(4):315-8. Japanese.
 PMID: 8152181 [PubMed - indexed for MEDLINE]


7: [Moizumi Y, Ohsaka K, Akasaka J, Kondoh S, Shimizu M, Imai Y, Kumagai T, Uchiyama T, Abe Y, Suzuki I](#) Related Articles, Links

[Advantages of combined antegrade/retrograde GIK cardioplegia for coronary artery bypass surgery]
 Nippon Kyobu Geka Gakkai Zasshi. 1994 Feb;42(2):198-205. Japanese.
 PMID: 8138686 [PubMed - indexed for MEDLINE]


8: [Ladowski JS, Sullivan M, Schatzlein MH, Peterson AC, Underhill DJ, Scheeringa RH](#) Related Articles, Links


Cardiac isoenzymes following heart transplantation.

 Chest. 1992 Nov;102(5):1520-1.
PMID: 1424875 [PubMed - indexed for MEDLINE]


 **9:** [McLean RF, Devitt JH, Dubbin J, McLellan BA.](#)


[Related Articles, Links](#)

 Incidence of abnormal RNA studies and dysrhythmias in patients with blunt chest trauma.
J Trauma. 1991 Jul;31(7):968-70.
PMID: 2072436 [PubMed - indexed for MEDLINE]


 **10:** [Campbell JB, Baker J, Morris DM.](#)


[Related Articles, Links](#)

 Cardiac complications of aneurysm repair.
South Med J. 1989 Apr;82(4):458-61.
PMID: 2705072 [PubMed - indexed for MEDLINE]


 **11:** [Roberts AJ, Faro RS, Williams LA, Cohen JA, Knauf DK, Alexander JA.](#)

[Related Articles, Links](#)

 Relative efficacy of left ventricular venting and venous drainage techniques commonly used during coronary artery bypass graft surgery.
Ann Thorac Surg. 1983 Oct;36(4):444-52.
PMID: 6605127 [PubMed - indexed for MEDLINE]

 **12:** [Mirhoseini M, Fisher JC, Cayton M.](#)

[Related Articles, Links](#)

 Myocardial revascularization by laser: a clinical report.
Lasers Surg Med. 1983;3(3):241-5.
PMID: 6608040 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** **Sort** **Send to** **Text**


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for [] Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

1: Cardiovasc Res. 1999 Nov;44(2):294-302.

Related Articles, Links

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

ADENOVIRAL-MEDIATED
 FULL-TEXT ARTICLE


Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.

Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, Unger EF.

Experimental Physiology and Pharmacology Section, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA. dlazarou@welch.jhu.edu

OBJECTIVE: Angiogenic peptides like VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor) have entered clinical trials for coronary artery disease. Attempts are being made to devise clinically relevant means of delivery and to effect site-specific delivery of these peptides to the cardiac tissue, in order to limit systemic side-effects. We characterized the response of the pericardium to delivery of a replication-deficient adenovirus carrying the cDNA for AdCMV.VEGF165, and assessed the effect of pericardial VEGF165 on myocardial collateral development in a canine model of progressive coronary occlusion. **METHODS:** Ameroid constrictors were placed on the proximal left circumflex coronary artery of mongrel dogs. Ten days later, 6×10^9 pfu AdCMV.VEGF165 ($n = 9$), AdRSV.beta-gal ($n = 9$), or saline ($n = 7$) were injected through an indwelling pericardial catheter. Transfection efficiency was assessed by X-gal staining. Pericardial and serum VEGF levels were measured serially by ELISA. Maximal myocardial collateral perfusion was quantified with radiolabeled or fluorescent microspheres 28 days after treatment. **RESULTS:** In AdRSV.beta-gal-treated dogs, there was extensive beta-gal staining in the pericardium and epicardium, with minimal beta-gal staining in the mid-myocardium and endocardium. Pericardial delivery of AdCMV.VEGF165 resulted in sustained (8-14 day) pericardial transgene expression, with VEGF levels peaking 3 days after infection (> 200 ng/ml) and decreasing thereafter. There was no detectable increase in serum VEGF levels. Maximal collateral perfusion, a principal correlate of collateral development and angiogenesis, was equivalent in all groups. **CONCLUSION:** Adenoviral-mediated gene transfer is capable of inducing sustained VEGF165 expression in the pericardium; however, locally targeted pericardial VEGF delivery failed to improve myocardial collateral perfusion in this model.

PMID: 10690306 [PubMed - indexed for MEDLINE]



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book
 Search PubMed for [] Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

1: Am J Cardiol. 1991 Nov 4;68(12):24C-33C.

Related Articles, Links

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Growth factors in pathogenesis of coronary arterial restenosis.

Cercek B, Sharifi B, Barath P, Bailey L, Forrester JS.

Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California 90048.

Restenosis occurs in 25% to 55% of patients within 6 months of successful angioplasty. The major histologic component of the restenotic lesion is intimal hyperplasia, which is almost certainly driven by growth factors. After vascular injury, smooth muscle cells proliferate, reaching a maximum rate at day 2. Smooth muscle cell proliferation diminishes as the vessel surface is re-endothelialized at about day 7, and by week 4 the smooth muscle cell mitotic rate returns to baseline of less than 1% per day. The events of the histologic evolution of arterial injury can be used to create a hypothetical paradigm for the role of growth factors in restenosis. Restenosis might logically be prevented by an inhibitory intervention at any of the various steps in the healing process.

Publication Types:

- Review
- Review, Academic

PMID: 1951099 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM FMC Journals Books
Search PubMed for [] Go Clear
Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

1: J Thorac Cardiovasc Surg. 1976 Jun;71(6):884-90.

[Related Articles, Links](#)

Entrez PubMed

[Overview](#)

[Help](#) | [FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

CPK-MB isoenzyme: use in diagnosis of acute myocardial infarction in the early postoperative period.

Pyle RB, Blomberg DJ, Burke MD, Lindsay WG, Nicoloff DM.

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

The diagnosis of acute myocardial infarction (AMI) in the early postoperative period may be quite difficult in certain patients. Electrocardiograms fail to be diagnostic of AMI in as many as one third of patients with myocardial injury found at autopsy. Enzyme patterns commonly used to diagnose AMI in patients admitted to coronary care units are obscured by muscle injury, medications, cardioversion, surgical manipulation, and blood transfusion. The MB isoenzyme of creatinine phosphokinase (CPK) has been described as a specific indicator of myocardial injury. Therefore the CPK-MB isoenzyme level was evaluated as a potential aid in the diagnosis of AMI in the early postoperative period. Thirty patients undergoing cardiac surgery and 7 patients undergoing thoracic surgery not involving the heart were studied. CPK-MB isoenzyme was present in the serum in 10 of 30 patients after cardiac surgery but in none of 7 patients after thoracic surgery. The presence of CPK-MB isoenzyme was found to be a valuable adjunctive indicator in the diagnosis of AMI in the early postoperative period.

Related Resources

[Order Documents](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

PMID: 1271838 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for [] Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

1: Circulation. 1976 Jun;53(6):965-9.

Related Articles, Links

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Diagnosis of acute myocardial infarction in a community hospital: significance of CPK-MB determination.

Roark SF, Wagner GS, Izlar HL Jr, Roe CR.

Twice-daily CPK-MB determinations were performed but not made available to the physicians of 179 consecutive patients with precordial pain admitted to a community hospital to evaluate the diagnostic importance of this isoenzyme. Physician decision was based upon history and once-daily ECG and total enzymes (CPK, SGOT, LDH). Following hospital discharge, each patient's clinical record was reviewed to determine the physician diagnostic decision. The patients were subdivided into three groups. The first group consisted of 46 patients with diagnostic QRS changes and elevated total enzymes. All 46 had physician diagnosis of acute myocardial infarction and CPK-MB was present in 44 (96%). The second group included 55 patients with nondiagnostic QRS but elevated total enzymes. Physician diagnosis was acute myocardial infarction in 28 (51%) but 16 (57%) of these had no CPK-MB. The third group contained 50 patients with nondiagnostic QRS and normal enzyme levels. Six (12%) had physician diagnosis of acute myocardial infarction but none had CPK-MB. Thus, absence of CPK-MB failed to confirm physician diagnosis of acute myocardial infarction when based upon history and total enzymes in the absence of QRS changes in 22 of 34 (65%) patients.

PMID: 1269133 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for [] Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Cancer Chemother Pharmacol. 1980;4(2):95-101.

[Related Articles, Links](#)

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Evaluation of antitumor drug side effects in small animals.

Bradner WT, Schurig JE, Huftalen JB, Doyle GJ.

This is an initial report on the development of screening tests for side effects of antitumor drugs, with small amounts of compound and short time intervals. These tests are based on acute dosing of mice and various blood or serum measurements: (a) total white blood cell count for leukopenia; (b) BUN for kidney toxicity; (c) SGPT for liver toxicity; and (d) creatine phosphokinase MB isozyme (CPK-MB) for cardiotoxicity. A correlation with the toxicity observed in other species is developed by establishing the effect of a prototype compound for each toxicity and tests of one or more compounds expected to lack such toxicity. On the basis of the limited number of compounds studied all four tests, although varying in sensitivity, seem to correlate with the results of tests in other species and with known effects in man. Final validation of these acute tests, especially the CPK-MB, will require both further study of histopathologic effects and correlation with results from clinical trials of an extended list of agents.

PMID: 7389061 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text




[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



EntrezPubMedNucleotideProteinGenomeStructureOMIMPMCJournalsBooks

SearchPubMedforGoClear

LimitsPreview/IndexHistoryClipboardDetails

About Entrez

DisplayAbstractShow:20SortSend toText

Text Version

☐ 1: Clin Cancer Res. 1995 Oct;1(10):1145-52.

Related Articles, Links

Entrez PubMed

OverviewHelp | FAQTutorialNew/NoteworthyE-Utilities

PubMed Services

Journals DatabaseMeSH DatabaseSingle Citation MatcherBatch Citation MatcherClinical QueriesLinkOutCubby

Related Resources




Order DocumentsNLM GatewayTOXNETConsumer HealthClinical AlertsClinicalTrials.govPubMed Central

Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.

Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L.

Texas Tech University Health Sciences Center, Lubbock, Texas 79430, USA.

Interleukin (IL) 2 plays an important role in enhancing the immune response, whereas IL-4 has pluripotent activities which include affecting immune function. Preclinical data suggest that the combination might have enhanced immunomodulatory activity. In this Phase I trial in patients with advanced solid tumors, both IL-2 and IL-4 were given by separate s.c. injections simultaneously daily, 5 days in a row, Monday through Friday, for 3 consecutive weeks, followed by a 1-week break from treatment. Cycles could be repeated. The dose of IL-2 was kept constant at 9 x 10(6) IU/m2/injection while the dose of IL-4 was escalated beginning at 100 microgram/m2/injection and increasing by 100-microgram/m2 increments to a planned level of 400 microgram/m2/injection. Sixteen patients were entered in this study, with one patient being ineligible because of the presence of brain metastases. Of the 15 eligible patients, there were 14 males and 1 female, with a median age of 54 (range, 38-67) years and initial performance status of 0 in 5 patients and 1 in 10 patients. Patients were treated at levels of up to 300 microgram/m2/injection of IL-4 before the study was closed due to withdrawal of the drug by the manufacturer. The most commonly observed toxicities were fatigue, fever and chills, local reaction, nausea/vomiting and anorexia, headache and nasal stuffiness, and coughing, sometimes with the production of clear white sputum, more common in smokers. Duodenal ulcers occurred in one patient and one patient had grade 4 cardiac toxicity consisting of an asymptomatic minimal elevation of the creatinine phosphokinase MB isoenzyme (CPK-MB). Grade 3 hyponatremia occurred in two patients, and elevated liver function tests and creatinine occurred but were not dose limiting. Eosinophilia of unknown significance occurred in all patients. There were statistically significant elevations in absolute numbers of most T-cell subsets examined, without changes in circulating B cells. No antibodies to the IL-4 were found after one cycle. One patient with renal cell carcinoma showed a significant decrease in tumor burden after one cycle of treatment. Because of the IL-4 withdrawal, the maximum tolerated dose for this combination of drugs given by the route and schedule used here was not determined and will require additional testing. Subcutaneous IL-2 and IL-4 given simultaneously show important immunomodulatory and antitumor effects and should be tested further in cancer patients.



EntrezPubMedNucleotideProteinGenomeStructureOMIMPMCJournalsBooks

SearchPubMedforGoClear

LimitsPreview/IndexHistoryClipboardDetails

About Entrez

DisplayAbstractShow:20SortSend toText

Text Version

☐ 1: J Invasive Cardiol. 1996;8 Suppl C:3C-9C.

Related Articles, Links

- Entrez PubMed
- Overview
- Help | FAQ
- Tutorial
- New/Noteworthy
- E-Utilities
- PubMed Services
- Journals Database
- MeSH Database
- Single Citation Matcher
- Batch Citation Matcher
- Clinical Queries
- LinkOut
- Cubby
- Related Resources
- Order Documents
- NLM Gateway
- TOXNET
- Consumer Health
- Clinical Alerts
- ClinicalTrials.gov
- PubMed Central


Frequency and Prognostic Importance of Creatine Phosphokinase Myocardial Isoforms after Successful Balloon and New Device Coronary Angioplasty.

Lansky AJ, Popma JJ, Mintz GS, Bucher TA, Kent KM, Pichard AD, Satler LF, Leon MB.

Director, Angiographic Core Laboratory, 110 Irving Street, N.W., Suite 4B-1, Washington, D.C., 20010, USA.

The frequency and prognostic importance of subclinical myocardial necrosis after new device coronary intervention is not known. To identify the frequency of CPK-MB release after balloon and single new device angioplasty in native coronary arteries, we reviewed the course of 810 patients who underwent successful single lesion, native vessel angioplasty using balloon angioplasty (N=174), Gianturco-Roubin stent placement for suboptimal angioplasty results (N=31), Palmaz-Schatz stent deployment (N=320), directional coronary atherectomy (N=102), or rotational atherectomy (N=183). All patients had serial measurements of CPK-MB isoenzymes 6 and 18Eth24 hours after coronary intervention; absolute CPK-MB levels were determined by radioimmunoassay (normal assay < 4 ng/ml). CPK-MB isoenzymes were > 2 times normal (> 8 ng/dl) in 15.6% of procedures, > 3 times normal ((3) 12 ng/ml) in 11.5% of procedures, > 4 times normal ((3) 16 ng/ml) in 8.6% of procedures, and > 5 times normal ((3) 20 ng/ml) in 7.7% of procedures. CPK-MB elevation > 2 times normal was more common in those undergoing directional atherectomy (20.8%) and Gianturco-Roubin stent placement (34.4%) than in those undergoing balloon angioplasty (11.7%). No significant differences were noted in patients undergoing rotational atherectomy (13.2%) or Palmaz-Schatz stent placement (15.6%) than in those undergoing balloon angioplasty. CPK-MB > 5 times normal occurred after 7.7% of procedures, but did not vary significantly among the devices used in this study. We conclude that CPK-MB elevations > 2 times normal are highest in patients undergoing directional coronary atherectomy and ObailoutO use of the Gianturco-Roubin stent. No significant differences in CPK-MB elevation were seen in patients undergoing balloon angioplasty, Palmaz-Schatz stent deployment, or rotational atherectomy. Identification of the prognostic importance of these CPK-MB elevations is currently under study.

PMID: 10785773 [PubMed - as supplied by publisher]



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Book
 Search PubMed for Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Cardiovasc Res. 1996 Sep;32(3):570-9.

Related Articles, Links

FULL-TEXT ARTICLE


The role of fibroblast growth factor-2 in the vascular effects of interleukin-1 beta in porcine coronary arteries in vivo.

Ito A, Shimokawa H, Fukumoto Y, Kadokami T, Nakaike R, Takayanagi T, Egashira K, Sueishi K, Takeshita A.

Research Institute of Angiocardiology and Cardiovascular Clinic, Kyushu University School of Medicine, Fukuoka, Japan.

OBJECTIVE: We recently demonstrated that chronic treatment with interleukin-1 beta (IL-1 beta), a major inflammatory cytokine found in atherosclerotic lesions, induces coronary arteriosclerotic changes and vasospastic responses to serotonin and histamine in pigs in vivo and that those responses are partially mediated by platelet-derived growth factor (PDGF). This study was designed to examine, first, whether the effects of IL-1 beta are also partially mediated by fibroblast growth factor-2 (FGF-2), which is another important growth factor in atherosclerotic lesions, and, secondly, whether chronic treatment with FGF-2 per se also induces histological and functional changes in porcine coronary arteries in vivo. **METHODS:** Porcine coronary arteries were aseptically wrapped with cotton mesh absorbing IL-1 beta with or without neutralizing antibody to FGF-2. In a separate series of experiments porcine coronary arteries were chronically treated with FGF-2 itself in the same manner. Coronary vascular responses in vivo and histological changes were examined 2 weeks after the operation. **RESULTS:** Coronary vasospastic responses to serotonin and histamine and neointimal formation were induced at the site of the coronary artery where IL-1 beta was chronically and locally applied. These responses were significantly suppressed by co-treatment with a neutralizing antibody to FGF-2 but not by that with non-immune IgG. Immunostaining revealed the presence of FGF-2 in the endothelial cells, the thickened intima and the media at the IL-1 beta-treated site. Furthermore, chronic treatment with FGF-2 also induced coronary vasospastic responses to serotonin and histamine and neointimal formation. **CONCLUSIONS:** These results suggest that the vascular effects of IL-1 beta may also be mediated by FGF-2 in our swine model and that chronic treatment with FGF-2 also causes coronary arteriosclerotic changes and vasospastic responses in vivo.

PMID: 8881517 [PubMed - indexed for MEDLINE]



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search **PubMed** for **CPK-MB** **Go** **Clear**
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display **Summary** Show: **500** **Sort** **Send to** **Text**
 Items 1-303 of 303 One page.

☐ 1: [Ushijima K, Oka Y, Weinberg P, Kitahata H, Yellin EL, Goldiner PL](#) Related Articles, Links

Hemodynamic effects of high-frequency jet ventilation in dogs with acute right coronary arterial ligation and pulmonary arterial banding.
 J Anesth. 1990 Jul 1;4(3):232-41.
 PMID: 15235979 [PubMed - in process]

☐ 2: [Karmakar S, Das T, Ghosh A, Dasgupta SC, Biswas AK, Gomes A](#) Related Articles, Links

Isolation and partial structural evaluation of a cardiotoxic factor from Indian common murrel (*Channa striatus* L.) skin extract.
 Indian J Exp Biol. 2004 Mar;42(3):271-8.
 PMID: 15233296 [PubMed - indexed for MEDLINE]

☐ 3: [Stammers AH, Mills N, Kmiecik SA, Petterson CM, Liu JL, Nichols JD, Kohtz RJ, Zheng H, Hock IM](#) Related Articles, Links

The effect of electrolyte imbalance on weaning from cardiopulmonary bypass: an experimental study.
 J Extra Corpor Technol. 2003 Dec;35(4):322-5.
 PMID: 14979424 [PubMed - indexed for MEDLINE]

☐ 4: [Ajani AE, Waksman R, Sharma AK, Lew R, Pinnow E, Canos DA, Cheneau E, Castagna M, Cha DH, Leborgne L, Satler LF, Pichard AD, Kent KM, Lindsay J](#) Related Articles, Links

Usefulness of periprocedural creatinine phosphokinase-MB release to predict adverse outcomes after intracoronary radiation therapy for in-stent restenosis.
 Am J Cardiol. 2004 Feb 1;93(3):313-7.
 PMID: 14759380 [PubMed - indexed for MEDLINE]

☐ 5: [Weisel RD, Lipton IH, Lyall RN, Baird RJ](#) Related Articles, Links


Cardiac metabolism and performance following cold potassium cardioplegia.
 Circulation. 1978 Sep;58(3 Pt 2):1217-26.
 PMID: 14740705 [PubMed - indexed for MEDLINE]


☐ 6: [Jones JW, Richman BW, Baldwin JC, Losanoff JE](#) Related Articles, Links


Noninvasive characterization of myocardium after transmyocardial laser revascularization.
 J Cardiovasc Surg (Torino). 2003 Dec;44(6):681-4.
 PMID: 14735027 [PubMed - indexed for MEDLINE]


☐ 7: [Kamohara K, Yoshikai M, Yunoki J, Fumoto H, Itoh T, Murayama J, Hamada M](#) Related Articles, Links


[Emergency coronary artery bypass grafting for acute coronary syndrome with preoperative intraaortic balloon pumping; comparative surgical outcome and long-term results]
 Kyobu Geka. 2003 Dec;56(13):1075-81; discussion 1081-4. Japanese.
 PMID: 14672015 [PubMed - indexed for MEDLINE]


 **8:** [Papadopoulos CE, Karvounis HI, Gourasas IT, Parharidis GE, Louridas GE](#). Related Articles, Links
Evidence of ischemic preconditioning in patients experiencing first non-ST-segment elevation myocardial infarction (NSTEMI).
Int J Cardiol. 2003 Dec;92(2-3):209-17.
PMID: 14659855 [PubMed - indexed for MEDLINE]


 **9:** [Rahimi AR, Marzano PM 3rd, Richard CM](#). Related Articles, Links
Evaluation of lactate and C-reactive protein in the assessment of acute myocardial infarction.
South Med J. 2003 Nov;96(11):1107-12.
PMID: 14632359 [PubMed - indexed for MEDLINE]


 **10:** [Takigawa T, Tokioka H, Chikai T, Fukushima T, Ishizu T, Kosogabe Y](#). Related Articles, Links
[A case of undiagnosed "takotsubo" cardiomyopathy during anesthesia]
Masui. 2003 Oct;52(10):1104-6. Japanese.
PMID: 14598678 [PubMed - indexed for MEDLINE]


 **11:** [Blum A, Safori G, Hous N, Lupovitch S](#). Related Articles, Links
The prognostic value of high-sensitive C-reactive protein and cardiac troponin T in young and middle-aged patients with chest pain without ECG changes.
Eur J Intern Med. 2003 Aug;14(5):310-314.
PMID: 13678756 [PubMed - as supplied by publisher]


 **12:** [Sposato B, Mariotta S, Ricci A, Lucantoni G, Schmid G](#). Related Articles, Links
[Legionnaire's pneumonia with rhabdomyolysis and acute renal failure. A case report]
Recenti Prog Med. 2003 Sep;94(9):391-4. Italian.
PMID: 12942801 [PubMed - indexed for MEDLINE]


















 **13:** [Ibanez JJ, Sobrado R, Rivero M, Olite JM, Idoate I, Berrozpe I, Arina E, Metola L, Sesma J](#). Related Articles, Links
[Use of troponin-I, CPK-MB and myoglobin in the diagnosis of myocardial infarct and processes of muscular necrosis of non-cardiac origin]
An Sist Sanit Navar. 2001 Jan-Apr;24(1):15-23. Spanish.
PMID: 12876598 [PubMed]

 **14:** [Bhaskar I, Rao SB](#). Related Articles, Links
New, simple and cheap alternative to troponin test for diagnosis of acute myocardial infarction.
Indian J Exp Biol. 2002 May;40(5):628-30.
PMID: 12622217 [PubMed - indexed for MEDLINE]

 **15:** [Gandra SM, Rivetti LA](#). Related Articles, Links
Experimental evidence of regional myocardial ischemia during beating heart coronary bypass: prevention with temporary intraluminal shunts.
Heart Surg Forum. 2002;6(1):10-8.
PMID: 12611726 [PubMed - indexed for MEDLINE]

 **16:** [Doue T, Ito K, Yuba T, Tanabe T, Adachi Y, Katoh S, Azuma A, Sugihara H, Nakagawa M](#). Related Articles, Links
[A case of "Takotsubo" cardiomyopathy observed with myocardial scintigraphy from the acute phase]
Kaku Igaku. 2002 Nov;39(4):511-8. Japanese.
PMID: 12607239 [PubMed - indexed for MEDLINE]

 **17:** [Kong QF, Song SZ, Xie XY](#). Related Articles, Links

-  [Clinical study on therapeutic effects of treatment according to syndrome differentiation of traditional Chinese medicine combined with captopril on severe viral myocarditis complicated heart failure]
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001 Jul;21(7):513-5. Chinese.
PMID: 12575396 [PubMed - indexed for MEDLINE]
-  **18:** [Meki AR, Mohamed ZM, Mohey El-deen HM.](#) [Related Articles, Links](#)
-  Significance of assessment of serum cardiac troponin I and interleukin-8 in scorpion envenomed children.
Toxicon. 2003 Feb;41(2):129-37.
PMID: 12565731 [PubMed - indexed for MEDLINE]
-  **19:** [Pimenov LT, Dudarev MV, Eshunakov SV.](#) [Related Articles, Links](#)
-  [Clinicofunctional characteristics of the heart in hemorrhagic fever with renal syndrome]
Klin Med (Mosk). 2002;80(10):28-31. Russian.
PMID: 12471834 [PubMed - indexed for MEDLINE]
-  **20:** [Louagie Y, Jamart J, Broka S, Collard E, Scavee V, Gonzalez M.](#) [Related Articles, Links](#)
-  Off-pump coronary artery bypass grafting: a case-matched comparison of hemodynamic outcome.
Eur J Cardiothorac Surg. 2002 Oct;22(4):552-8.
PMID: 12297171 [PubMed - indexed for MEDLINE]
-  **21:** [Fernandez Portales J, Garcia Robles JA, Jimenez Candil J, Perez David E, Rey Blas JR, Perez De Isla L, Diaz Castro O, Almendral J.](#) [Related Articles, Links](#)
-  [Utility of the serum biochemical markers CPK, CPK MB mass, myoglobin, and cardiac troponin T in a chest pain unit. Which marker determinations should be requested and when?]
Rev Esp Cardiol. 2002 Sep;55(9):913-20. Spanish.
PMID: 12236920 [PubMed - indexed for MEDLINE]
-  **22:** [Sala MF, Barcena JP, Rota JJ, Roca JV, Lopez CA, Puigdevall JM, Soldevilla JG, de Luna AB.](#) [Related Articles, Links](#)
-  Sustained ventricular tachycardia as a marker of inadequate myocardial perfusion during the acute phase of myocardial infarction.
Clin Cardiol. 2002 Jul;25(7):328-34.
PMID: 12109866 [PubMed - indexed for MEDLINE]
-  **23:** [Meki AR, El-Deen ZM, El-Deen HM.](#) [Related Articles, Links](#)
-  Myocardial injury in scorpion envenomed children: significance of assessment of serum troponin I and interleukin-8.
Neuro Endocrinol Lett. 2002 Apr;23(2):133-40.
PMID: 12011799 [PubMed - indexed for MEDLINE]
-  **24:** [Ji H, Liu Q, Jiang H.](#) [Related Articles, Links](#)
-  [Clinical observation on therapeutic effect of xinyikang oral liquid in treating 92 patients of viral myocarditis]
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Jan;20(1):22-4. Chinese.
PMID: 11783329 [PubMed - indexed for MEDLINE]
-  **25:** [Li L, Sun Z, Zhao H.](#) [Related Articles, Links](#)
-  [Cardiac protective effects of tetramethylpyrazine in patients performed open-heart operation with cardiopulmonary bypass]
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Jan;20(1):13-4. Chinese.
PMID: 11783326 [PubMed - indexed for MEDLINE]
- [Clermont G, Vergely C, Jazayeri S, Lahet JJ, Goudeau JJ, Lecour](#) [Related Articles, Links](#)

26: [S. David M, Rochette L, Girard C.](#)



Systemic free radical activation is a major event involved in myocardial oxidative stress related to cardiopulmonary bypass.

Anesthesiology. 2002 Jan;96(1):80-7.

PMID: 11753006 [PubMed - indexed for MEDLINE]

27: [Stys T, Lawson WE, Liuzzo JP, Hanif B, Bragg L, Cohn PF.](#)

[Related Articles, Links](#)



Direct coronary stenting without balloon or device pretreatment: acute success and long-term results.

Catheter Cardiovasc Interv. 2001 Oct;54(2):158-63.

PMID: 11590675 [PubMed - indexed for MEDLINE]

28: [Morandi P, Ruffini PA, Benvenuto GM, La Vecchia L, Mezzena G, Raimondi R.](#)

[Related Articles, Links](#)



Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide.

Bone Marrow Transplant. 2001 Aug;28(3):277-82.

PMID: 11535996 [PubMed - indexed for MEDLINE]

29: [Briassoulis G, Narlioglou M, Zavras N, Hatzis T.](#)

[Related Articles, Links](#)



Myocardial injury in meningococcus-induced purpura fulminans in children.

Intensive Care Med. 2001 Jun;27(6):1073-82.

PMID: 11497141 [PubMed - indexed for MEDLINE]

30: [Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB.](#)

[Related Articles, Links](#)



Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients.

Circulation. 2001 Aug 7;104(6):642-7.

PMID: 11489768 [PubMed - indexed for MEDLINE]

31: [Del Rio-Navarro BE, Sienna-Monge JJ, Alvarez-Amador M, Reyes-Ruiz N, Arevalo-Salas A, Berber A.](#)

[Related Articles, Links](#)



Serum potassium levels, CPK-MB and ECG in children suffering asthma treated with beclomethasone or beclomethasone-salmeterol.

Allergol Immunopathol (Madr). 2001 Jan-Feb;29(1):16-21.

PMID: 11449530 [PubMed - indexed for MEDLINE]

32: [Angus DC, Wax RS.](#)

[Related Articles, Links](#)



Epidemiology of sepsis: an update.

Crit Care Med. 2001 Jul;29(7 Suppl):S109-16. Review.

PMID: 11445744 [PubMed - indexed for MEDLINE]

33: [Matsumiya G, Ohtake S, Sawa Y, Takahashi T, Nishimura M, Kagizaki K, Katsura T, Matsue H, Matsuda H.](#)

[Related Articles, Links](#)



[Is routine application of off-pump coronary artery bypass grafting warranted?]

Kyobu Geka. 2001 Apr;54(4):315-20. Japanese.

PMID: 11296423 [PubMed - indexed for MEDLINE]

34: [Ulus AT, Aksoyek A, Katircioglu SF, Gokce P, Koc B.](#)

[Related Articles, Links](#)



Preservation of myocardial functions by pentoxifylline cardioplegia during and after cardiopulmonary bypass.

Panminerva Med. 2000 Dec;42(4):253-6.

PMID: 11294087 [PubMed - indexed for MEDLINE]

35: [Yano K, Yoshino H, Taniuchi M, Kachi E, Shimizu H, Watanuki](#)

[Related Articles, Links](#)

A. Ishikawa K.



Myocardial bridging of the left anterior descending coronary artery in acute inferior wall myocardial infarction.

Clin Cardiol. 2001 Mar;24(3):202-8.

PMID: 11288965 [PubMed - indexed for MEDLINE]

☐ **36:** Zalenski RJ, Grzybowski M, Ross MA, Blaustein N, Bock B.

[Related Articles](#), [Links](#)



ECG scores for a triage of patients with acute myocardial infarction transported by the emergency medical system.

J Electrocardiol. 2000;33 Suppl:245-9.

PMID: 11265729 [PubMed - indexed for MEDLINE]

☐ **37:** Nagy KK, Krosner SM, Roberts RR, Joseph KT, Smith RF, Barrett J.

[Related Articles](#), [Links](#)



Determining which patients require evaluation for blunt cardiac injury following blunt chest trauma.

World J Surg. 2001 Jan;25(1):108-11.

PMID: 11213149 [PubMed - indexed for MEDLINE]

☐ **38:** Ranjit MS.

[Related Articles](#), [Links](#)



Cardiac abnormalities in birth asphyxia.

Indian J Pediatr. 2000 Mar;67(3 Suppl):S26-9. Review.

PMID: 11129917 [PubMed - indexed for MEDLINE]

☐ **39:** Hashimoto K, Onoguchi K, Sasaki T, Hachiya T, Takakura H, Oshiumi M, Takenuchi S.

[Related Articles](#), [Links](#)



[Combined use of ante- and retrograde cardioplegia: limited efficacy in elective coronary artery bypass]

Kyobu Geka. 2000 Dec;53(13):1105-9. Japanese.

PMID: 11127556 [PubMed - indexed for MEDLINE]

☐ **40:** Ananthanarayan C, Castro C, McKee N, Sakotic G.

[Related Articles](#), [Links](#)



Compartment syndrome following intravenous regional anesthesia.

Can J Anaesth. 2000 Nov;47(11):1094-8.

PMID: 11097539 [PubMed - indexed for MEDLINE]

☐ **41:** Tapia-Rombo CA, Carpio-Hernandez JC, Salazar-Acuna AH, Alvarez-Vazquez E, Mendoza-Zanella RM, Perez-Olea V, Rosas-Fernandez C.

[Related Articles](#), [Links](#)



Detection of transitory myocardial ischemia secondary to perinatal asphyxia.

Arch Med Res. 2000 Jul-Aug;31(4):377-83.

PMID: 11068079 [PubMed - indexed for MEDLINE]

☐ **42:** Ranjit MS.

[Related Articles](#), [Links](#)



Cardiac abnormalities in birth asphyxia.

Indian J Pediatr. 2000 Jul;67(7):529-32.

PMID: 10957839 [PubMed - indexed for MEDLINE]

☐ **43:** Cassin M, Nicolosi GL.

[Related Articles](#), [Links](#)



[The usefulness of CPK-MB and troponin I in the management of chest pain in first aid]

Ital Heart J. 2000 May;1(5 Suppl):705-7. Italian. No abstract available.

PMID: 10834139 [PubMed - indexed for MEDLINE]

☐ **44:** Lansky AJ, Popma JJ, Mintz GS, Bucher TA, Kent KM, Pichard AD, Satler LF, Leon MB.

[Related Articles](#), [Links](#)



Frequency and Prognostic Importance of Creatine Phosphokinase Myocardial Isoforms after Successful Balloon and New Device Coronary

Angioplasty.

J Invasive Cardiol. 1996;8 Suppl C:3C-9C.

PMID: 10785773 [PubMed - as supplied by publisher]

- 45: [Gunaydin B, Cakici I, Soncul H, Kalaycioglu S, Cevik C, Sancak B, Kanzik I, Karadenizli Y.](#) [Related Articles, Links](#)



Does remote organ ischaemia trigger cardiac preconditioning during coronary artery surgery?

Pharmacol Res. 2000 Apr;41(4):493-6.

PMID: 10704275 [PubMed - indexed for MEDLINE]

- 46: [Chauhan S, Wasir HS, Bhan A, Rao BH, Saxena N, Venugopal P.](#) [Related Articles, Links](#)



Adenosine for cardioplegic induction: a comparison with St Thomas solution.

J Cardiothorac Vasc Anesth. 2000 Feb;14(1):21-4.

PMID: 10698387 [PubMed - indexed for MEDLINE]

- 47: [Shirasawa B, Hamano K, Kawamura T, Gobra H, Katoh T, Fujimura Y, Zempo N, Esato K.](#) [Related Articles, Links](#)



[Dose the serum brain natriuretic peptide (BNP) level after open heart surgery reflect myocardial protection?]

Kyobu Geka. 2000 Feb;53(2):123-6. Japanese.

PMID: 10667022 [PubMed - indexed for MEDLINE]

- 48: [Maini CL, Tofani A, Sciuto R, Ferraironi A, Festa A, Rea S.](#) [Related Articles, Links](#)



Myocardial 123I-MIBG kinetics in acutely hypothyroid patients with differentiated thyroid carcinoma.

Nucl Med Commun. 1999 Aug;20(8):719-26.

PMID: 10451880 [PubMed - indexed for MEDLINE]

- 49: [Stringham JC, Love RB, Welter D, Canver CC, Mentzer RM Jr.](#) [Related Articles, Links](#)



Does University of Wisconsin solution harm the transplanted heart?

J Heart Lung Transplant. 1999 Jun;18(6):587-96.

PMID: 10395357 [PubMed - indexed for MEDLINE]

- 50: [Aboyans V, Lacroix P, Virot P, Tapie P, Cassat C, Rambaud G, Laskar M, Bensaid J.](#) [Related Articles, Links](#)



Sleep apnoea syndrome and the extent of atherosclerotic lesions in middle-aged men with myocardial infarction.

Int Angiol. 1999 Mar;18(1):70-3.

PMID: 10392484 [PubMed - indexed for MEDLINE]

- 51: [Butte MJ, Nguyen BX, Hutchison TJ, Wiggins JW, Ziegler JW.](#) [Related Articles, Links](#)



Pediatric myocardial infarction after racemic epinephrine administration.

Pediatrics. 1999 Jul;104(1):e9.

PMID: 10390295 [PubMed - indexed for MEDLINE]

- 52: [Hughes GC, Landolfo KP, Lowe JE, Coleman RB, Donovan CL.](#) [Related Articles, Links](#)



Diagnosis, incidence, and clinical significance of early postoperative ischemia after transmyocardial laser revascularization.

Am Heart J. 1999 Jun;137(6):1163-8.

PMID: 10347346 [PubMed - indexed for MEDLINE]

- 53: [Pompilio G, Antona C, Cannata A, Lotto A, Alamanni F, Gelpi G, Tartara P, Biglioli P.](#) [Related Articles, Links](#)



[Coronary surgery without extracorporeal circulation: the short-term results in high-risk patients]

G Ital Cardiol. 1999 Mar;29(3):246-54. Italian.

PMID: 10231669 [PubMed - indexed for MEDLINE]

 **54:** [Czajkowski V, Marechal P, Soyeur D, Kulbertus H.](#) [Related Articles, Links](#)



[Clinical case of the month. Inaugural myocardial infarction from a congenital coronary-cardiac fistula]


Rev Med Liege. 1999 Jan;54(1):12-6. Review. French.
PMID: 10081304 [PubMed - indexed for MEDLINE]

 **55:** [Di Salvo C, Louca LL, Pattichis K, Hooper J, Walesby RK.](#) [Related Articles, Links](#)



Does activated neutrophil depletion on bypass by leukocyte filtration reduce myocardial damage? A preliminary report.


J Cardiovasc Surg (Torino). 1996 Dec;37(6 Suppl 1):93-100.
PMID: 10064358 [PubMed - indexed for MEDLINE]

 **56:** [Asano H, Kyo S, Ogiwara M, Tsunemoto M, Yokote Y, Omoto R, Koike K, Kobayashi T, Kobayashi J, Taketazu M.](#) [Related Articles, Links](#)



[Single-dose and high-volume Bretschneider cardioplegic solution for congenital heart surgery]


Kyobu Geka. 1999 Jan;52(1):82-6. Japanese.
PMID: 10024809 [PubMed - indexed for MEDLINE]

 **57:** [Katircioglu SF, Ulus AT, Iscan Z, Yamak B, Saritas Z, Birincioglu L.](#) [Related Articles, Links](#)



Preservation of myocardial metabolism in acute coronary artery occlusions with retrograde coronary sinus perfusion and iloprost.


Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):169-74.
PMID: 9844988 [PubMed - indexed for MEDLINE]

 **58:** [Badary OA, Al-Shabanah OA, Al-Gharably NM, Elmazar MM.](#) [Related Articles, Links](#)



Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice.


Anticancer Drugs. 1998 Oct;9(9):809-15.
PMID: 9840728 [PubMed - indexed for MEDLINE]

 **59:** [Le Conte P, Hulot de Collart G, Chevalier JC, Yatim D, Touze MD, Garrec F, Baron D.](#) [Related Articles, Links](#)



[Diagnostic difficulties of myocardial infarct in an admissions and emergency service: influence of age]

Presse Med. 1998 Oct 24;27(32):1613-6. French.
PMID: 9819598 [PubMed - indexed for MEDLINE]

 **60:** [Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L.](#) [Related Articles, Links](#)



Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.


Clin Cancer Res. 1995 Oct;1(10):1145-52.
PMID: 9815906 [PubMed - indexed for MEDLINE]

 **61:** [Uno Y, Horikoshi S, Emoto H, Miyamoto H, Suzuki H.](#) [Related Articles, Links](#)



[Clinical advantages and myocardial protection of normothermal CPB--comparison with hypothermal CPB]


Jpn J Thorac Cardiovasc Surg. 1998 Aug;46(8):671-6. Japanese.
PMID: 9785862 [PubMed - indexed for MEDLINE]



















 **62:** [Stephanopoulos DE, Monge R, Schell KH, Wyckoff P, Peterson BM.](#) [Related Articles, Links](#)





Continuous intravenous terbutaline for pediatric status asthmaticus.


Crit Care Med. 1998 Oct;26(10):1744-8.
PMID: 9781734 [PubMed - indexed for MEDLINE]


 **63:** [Gozal Y, Drenger B, Robertson JE, Davis RF.](#) [Related Articles, Links](#)


-  **ST segment changes following retinal surgery.**
J Clin Anesth. 1998 Jun;10(4):297-301.
PMID: 9667345 [PubMed - indexed for MEDLINE]
-  **64:** [Takamasu T, Yanagawa S, Kurihara K.](#) [Related Articles, Links](#)
-  **[Isoproterenol continuous nebulization for childhood status asthmaticus. I. Efficacy and side effects of high-dose method]**
Arerugi. 1998 May;47(5):504-10. Japanese.
PMID: 9656572 [PubMed - indexed for MEDLINE]
-  **65:** [Suzuki I, Ogoshi N, Chiba M, Komatsu T, Moizumi Y.](#) [Related Articles, Links](#)
-  **Clinical evaluation of a leucocyte-depleting blood cardioplegia filter (BC1B) for elective open-heart surgery.**
Perfusion. 1998 May;13(3):205-10.
PMID: 9638718 [PubMed - indexed for MEDLINE]
-  **66:** [Bessho R, Tanaka S.](#) [Related Articles, Links](#)
-  **Measurement of the upper limit of vulnerability during defibrillator implantation can substitute defibrillation threshold measurement.**
Int J Artif Organs. 1998 Mar;21(3):151-60.
PMID: 9622114 [PubMed - indexed for MEDLINE]
-  **67:** [Ishikura Y, Odagiri S, Shimazu A, Tokunaga H, Shimokawaji M, Yoshimatsu H.](#) [Related Articles, Links](#)
-  **[Evaluation of myocardial protection with DBcAMP in crystalloid cardioplegic solutions]**
Rinsho Kyobu Geka. 1989 Dec;9(6):559-63. Japanese.
PMID: 9308660 [PubMed - indexed for MEDLINE]
-  **68:** [Inui K, Kobayashi M, Orita H, Shimanuki T, Kohno M, Fukasawa M, Abe K, Kuraoka S, Washio M.](#) [Related Articles, Links](#)
-  **[Effect of magnesium containing cardioplegic solution on the cases of extended aortic cross clamping]**
Rinsho Kyobu Geka. 1989 Oct;9(5):468-71. Japanese.
PMID: 9301958 [PubMed - indexed for MEDLINE]
-  **69:** [Kuki S, Matsuda H, Sawa Y, Ohtani M, Sasako Y, Ohtake S, Takami H, Kuratani T, Nakano S, Kawashima Y, et al.](#) [Related Articles, Links](#)
-  **[Experimental and clinical assessment of myocardial protective effect of a prostacyclin analogue (OP 41483)]**
Rinsho Kyobu Geka. 1989 Apr;9(2):180-3. Japanese.
PMID: 9301917 [PubMed - indexed for MEDLINE]
-  **70:** [Kuraoka S, Orita H, Shimanuki T, Kohno M, Fukasawa M, Inui K, Washio M.](#) [Related Articles, Links](#)
-  **[Comparison of cold blood cardioplegia and cold crystalloid cardioplegia with or without magnesium]**
Rinsho Kyobu Geka. 1989 Apr;9(2):173-5. Japanese.
PMID: 9301915 [PubMed - indexed for MEDLINE]
-  **71:** [Fulda GJ, Giberson F, Hailstone D, Law A, Stillabower M.](#) [Related Articles, Links](#)
-  **An evaluation of serum troponin T and signal-averaged electrocardiography in predicting electrocardiographic abnormalities after blunt chest trauma.**
J Trauma. 1997 Aug;43(2):304-10; discussion 310-2.
PMID: 9291377 [PubMed - indexed for MEDLINE]
-  **72:** [Trehan N, Mishra M, Bapna R, Mishra A, Maheshwari P, Karlekar A.](#) [Related Articles, Links](#)


 **Transmyocardial laser revascularisation combined with coronary artery bypass grafting without cardiopulmonary bypass.**
Eur J Cardiothorac Surg. 1997 Aug;12(2):276-84.
PMID: 9288519 [PubMed - indexed for MEDLINE]


 **73:** Hayashi S, Sasaki M, Kawamoto J. Related Articles, Links


 **[Urgent coronary artery bypass surgery by only arterial graft for acute myocardial infarction]**
Nippon Kyobu Geka Gakkai Zasshi. 1997 Jul;45(7):935-9. Japanese.
PMID: 9256627 [PubMed - indexed for MEDLINE]


 **74:** Garre L, Alvarez A, Rubio M, Pellegrini A, Caridi M, Berardi A, Lazzaro C, Blanco P, Menchem C, Diaz M. Related Articles, Links


 **Use of cardiac troponin T rapid assay in the diagnosis of a myocardial injury secondary to electrical cardioversion.**
Clin Cardiol. 1997 Jul;20(7):619-21.
PMID: 9220177 [PubMed - indexed for MEDLINE]


 **75:** Chiu WC, D'Amelio LF, Hammond JS. Related Articles, Links


 **Sternal fractures in blunt chest trauma: a practical algorithm for management.**
Am J Emerg Med. 1997 May;15(3):252-5.
PMID: 9148979 [PubMed - indexed for MEDLINE]


 **76:** Bouchart F, Bessou JP, Tabley A, Hecketsweiler B, Mouton-Schleifer D, Redonnet M, Arrignon J, Soyier R. Related Articles, Links


 **[What myocardial protection to select for isolated aortic valve replacement? A clinical prospective study of 3 cases of cardioplegia]**
Arch Mal Coeur Vaiss. 1997 Mar;90(3):345-51. French.
PMID: 9232072 [PubMed - indexed for MEDLINE]


 **77:** Dwivedi SK, Kumar R, Saran RK, Narain VS, Bansal S, Puri VK, Hasan M. Related Articles, Links


 **Improvement in contractility of infarct zone after dobutamine infusion predicts good (TIMI II or III) flow in infarct related artery.**
Indian Heart J. 1997 Mar-Apr;49(2):147-51.
PMID: 9231544 [PubMed - indexed for MEDLINE]


 **78:** Kondo K, Minohara S, Sawada Y, Irie H, Okamoto K, Kinugasa S, Nakao M, Sasaki S. Related Articles, Links


 **Indications and problems of coronary artery bypass grafting without cardiopulmonary bypass.**
Surg Today. 1997;27(3):202-6.
PMID: 9068098 [PubMed - indexed for MEDLINE]










 **79:** Aronson S, Savage R, Fernandez A, Klein A, Young C, Toledano A, Lee BK, Karp RB, Lytle B, Loop F. Related Articles, Links

 **Assessing myocardial perfusion with Alburnex during coronary artery bypass surgery: technical considerations and safety of aortic root injections.**
J Cardiothorac Vasc Anesth. 1996 Oct;10(6):713-8.
PMID: 8910149 [PubMed - indexed for MEDLINE]


 **80:** Bastecky J, Palicka V, Vavrova J, Ettlerova E, Wasyliwova V. Related Articles, Links

 **[Changes in troponin T levels in patients with acute myocardial infarct treated with fibrinolysis]**
Vnitr Lek. 1996 Aug;42(8):519-23. Czech.
PMID: 8967018 [PubMed - indexed for MEDLINE]

 **81:** Irie H, Kitamura N, Ko T, Kimura S, Kumano H, Syuntou K, Noji S, Yamaguchi A. Related Articles, Links

-  [Pit fall of aprotinin administration during open heart surgery]
Nippon Kyobu Geka Gakkai Zasshi. 1996 Aug;44(8):1119-23. Japanese.
PMID: 8828369 [PubMed - indexed for MEDLINE]
-  **82:** [Baumgartner F](#), [Brundage B](#), [Bleiweis M](#), [Lee J](#), [Ferrario T](#), [Georgiou D](#), [Milliken J](#). Related Articles, Links
Feasibility of ultrafast computed tomography in the early evaluation of coronary bypass patency.
Am J Card Imaging. 1996 Jul;10(3):170-4.
PMID: 8914703 [PubMed - indexed for MEDLINE]
-  **83:** [Trehan N](#), [Mishra M](#), [Kohli VM](#), [Mishra A](#), [Jangid DR](#), [Bapna R](#). Related Articles, Links
Transmyocardial laser revascularisation as an adjunct to CABG.
Indian Heart J. 1996 Jul-Aug;48(4):381-8.
PMID: 8908826 [PubMed - indexed for MEDLINE]
-  **84:** [Mathieu P](#), [Villemot JP](#), [Stoltz JF](#), [Scheck F](#), [Garnier LF](#). Related Articles, Links
[Antiaggregant effect and tolerance of calcium carbasalate administrated immediately after aorto-coronary bypass. Results of a double-blind versus placebo study]
Pathol Biol (Paris). 1996 Jun;44(6):571-80. French.
PMID: 8977914 [PubMed - indexed for MEDLINE]
-  **85:** [Miyamoto Y](#), [Takahashi T](#), [Kadoba K](#), [Taniguchi K](#), [Imagawa H](#), [Sawa Y](#), [Masai T](#), [Matsuda H](#). Related Articles, Links
[Coronary artery bypass grafting under bradycardia induced by ultra-short acting beta blocker]
Nippon Kyobu Geka Gakkai Zasshi. 1996 Jun;44(6):801-5. Japanese.
PMID: 8753090 [PubMed - indexed for MEDLINE]
-  **86:** [Maenza RL](#), [Seaberg D](#), [D'Amico F](#). Related Articles, Links
A meta-analysis of blunt cardiac trauma: ending myocardial confusion.
Am J Emerg Med. 1996 May;14(3):237-41.
PMID: 8639191 [PubMed - indexed for MEDLINE]
-  **87:** [Ohuchi H](#), [Nagata N](#), [Okabe H](#), [Koseni K](#), [Itoh K](#). Related Articles, Links
[Anomalous origin of the left coronary artery from the pulmonary artery coronary revascularization under normothermic coronary perfusion in an infant]
Nippon Kyobu Geka Gakkai Zasshi. 1996 Feb;44(2):216-9. Japanese.
PMID: 8717274 [PubMed - indexed for MEDLINE]
-  **88:** [Craig VL](#), [Bigos D](#), [Brilli RJ](#). Related Articles, Links
Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus.
Pediatr Emerg Care. 1996 Feb;12(1):1-5.
PMID: 8677169 [PubMed - indexed for MEDLINE]
-  **89:** [Obadia JF](#), [Ben Baouali A](#), [Maupoil V](#), [Rochette L](#). Related Articles, Links
Crystalloid versus cold blood cardioplegia in patients operated on for myocardial revascularisation.
J Cardiovasc Surg (Torino). 1996 Feb;37(1):45-51.
PMID: 8606207 [PubMed - indexed for MEDLINE]
- **90:** [Obadia JF](#), [Ben Baouali A](#), [Maupoil V](#), [Rochette L](#). Related Articles, Links
[A study of the 30 minutes following reperfusion after crystalloid and cold blood cardioplegia by enzymatic and metabolic analysis of coronary blood flow]


Ann Chir. 1996;50(5):390-6. French.
PMID: 8761109 [PubMed - indexed for MEDLINE]

 **91:** Dowd MD, Krug S.

[Related Articles](#), [Links](#)




Pediatric blunt cardiac injury: epidemiology, clinical features, and diagnosis. Pediatric Emergency Medicine Collaborative Research Committee: Working Group on Blunt Cardiac Injury.
J Trauma. 1996 Jan;40(1):61-7.
PMID: 8577001 [PubMed - indexed for MEDLINE]

 **92:** Hoshino J, Arai H, Fukusato T, Nakamura T, Nushiro N, Sato K, Sakamaki T, Murata K.

[Related Articles](#), [Links](#)




Creatine phosphokinase-linked immunoglobulin associated with hypokalemic myopathy.
Intern Med. 1995 Dec;34(12):1210-4.
PMID: 8929653 [PubMed - indexed for MEDLINE]

 **93:** Zou HJ, Ding Y, Huang KL, Xu ML, Tang GF, Wu MH, Wang SY.

[Related Articles](#), [Links](#)




Effects of lead on systolic and diastolic cardiac functions.
Biomed Environ Sci. 1995 Dec;8(4):281-8.
PMID: 8719169 [PubMed - indexed for MEDLINE]

 **94:** Aggarwal SP, Thukral R, Wander GS, Kapoor DK.

[Related Articles](#), [Links](#)




Evaluation of serum lipid profile and cardiac enzyme changes in cerebrovascular accidents.
J Indian Med Assoc. 1995 Sep;93(9):331-2.
PMID: 8648151 [PubMed - indexed for MEDLINE]

 **95:** Lucia P, Caiola S, Coppola A, Maroccia E, Belli M, Colliardo A, Borelli LG, De Martinis C, Buongiorno A.

[Related Articles](#), [Links](#)




[The physiopathological role and prognostic value of the vasoactive intestinal peptide in acute myocardial infarct]
Cardiologia. 1995 Aug;40(8):579-84. Italian.
PMID: 8536284 [PubMed - indexed for MEDLINE]

 **96:** Berton G, Citro T, Cordiano R, Palmieri R, De Toni R, Cucchini F, Palatini P.

[Related Articles](#), [Links](#)




[Urinary albumin excretion increases during an acute myocardial infarct especially in patients who develop heart failure]
G Ital Cardiol. 1995 Aug;25(8):999-1009. Italian.
PMID: 7498633 [PubMed - indexed for MEDLINE]

 **97:** Amano H, Okuda M, Furuhashi K, Utsunomiya H, Nakai Y, Munezaki M.

[Related Articles](#), [Links](#)




[Clinical evaluation of prophylactic nitroglycerin infusion during coronary artery bypass grafting]
Masui. 1995 Apr;44(4):594-6. Japanese.
PMID: 7776530 [PubMed - indexed for MEDLINE]

 **98:** Moler FW, Johnson CE, Van Laanen C, Palmisano JM, Nasr SZ, Akingbola O.

[Related Articles](#), [Links](#)



Continuous versus intermittent nebulized terbutaline: plasma levels and effects.
Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):602-6.
PMID: 7881645 [PubMed - indexed for MEDLINE]


 **99:** Lu W, Chen Y, Liu L.


[Related Articles](#), [Links](#)





[The injury of heart of rats sustaining delayed fluid resuscitation after burn shock]


Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi. 1995 Mar;11(2):112-4. Chinese.
PMID: 7648496 [PubMed - indexed for MEDLINE]


 **100:** [Movahed A, Nair KG, Ashavaid TF, Kumar P.](#) [Related Articles, Links](#)


 Evidence for free-radical mediated injury during coronary artery bypass surgery.
Indian Heart J. 1995 Mar-Apr;47(2):107-11.
PMID: 7590833 [PubMed - indexed for MEDLINE]


 **101:** [Anderson WA, Berrizbeitia LD, Ilkowski DA, Cha R, Gu J, Fernandez J, Laub GW, Adkins MS, Chen C, McGrath LB.](#) [Related Articles, Links](#)


 Normothermic retrograde cardioplegia is effective in patients with left ventricular hypertrophy. A prospective and randomized study.
J Cardiovasc Surg (Torino). 1995 Feb;36(1):17-24.
PMID: 7721921 [PubMed - indexed for MEDLINE]


 **102:** [Spaggiari I, Cavoza C, Fesani F, D'Amico E, Menozzi E, Sciaraffia M.](#) [Related Articles, Links](#)


 [Myocardial protection during extracorporeal circulation. Preliminary results with different techniques]
Acta Biomed Ateneo Parmense. 1995;66(5):203-7. Italian.
PMID: 8928583 [PubMed - indexed for MEDLINE]


 **103:** [Efthimiadis A, Cheiridou M, Lefkos N, Doumalas A, Arampatzis P, Tsapas G.](#) [Related Articles, Links](#)


 The predictive value of troponin T in patients who underwent an extracardiac surgery operation.
Acta Cardiol. 1995;50(4):309-13.
PMID: 8540272 [PubMed - indexed for MEDLINE]


 **104:** [Imai Y, Watanabe N, Hashimoto J, Nishiyama A, Sakuma H, Sekino H, Omata K, Abe K.](#) [Related Articles, Links](#)


 Muscle cramps and elevated serum creatine phosphokinase levels induced by beta-adrenoceptor blockers.
Eur J Clin Pharmacol. 1995;48(1):29-34.
PMID: 7621844 [PubMed - indexed for MEDLINE]


 **105:** [Sousa RC, Garcia-Fernandez MA, Moreno M, Quero F, Torrecilla E, San Roman D, Delcan JL.](#) [Related Articles, Links](#)


 [Value of transesophageal echocardiography in the assessment of blunt chest trauma: correlation with electrocardiogram, heart enzymes, and transthoracic echocardiogram]
Rev Port Cardiol. 1994 Nov;13(11):833-43, 807-8. Portuguese.
PMID: 7848654 [PubMed - indexed for MEDLINE]

 **106:** [Dingchao H, Zhidian Q, Liye H, Xiaodong F.](#) [Related Articles, Links](#)




















 The protective effects of high-dose ascorbic acid on myocardium against reperfusion injury during and after cardiopulmonary bypass.
Thorac Cardiovasc Surg. 1994 Oct;42(5):276-8.
PMID: 7863489 [PubMed - indexed for MEDLINE]





















 **107:** [Yamaguchi A, Kitamura N, Kimura S, Irie H, Ko T, Shuntoh K.](#) [Related Articles, Links](#)











 [The efficacy of both antegrade and retrograde cardioplegia in coronary artery bypass surgery]
Nippon Kyobu Geka Gakkai Zasshi. 1994 Oct;42(10):1916-24. Japanese.
PMID: 7798709 [PubMed - indexed for MEDLINE]











 **108:** [Marques N, Sanchez de la Pena S, Mushiya T, Yasmineh WG, Cornelissen G, Halberg F.](#) [Related Articles, Links](#)




















Ultradian-infradian variation of cardiac creatine phosphokinase (CPK)

-  activity in male Holtzman rats.
Chronobiologia. 1994 Jul-Dec;21(3-4):241-50.
PMID: 7729240 [PubMed - indexed for MEDLINE]
-  **109:** [Kanno M, Kurihara H, Satoh H, Hamawaki M, Honda M.](#) [Related Articles, Links](#)
-  [Coronary artery spasm after mitral valve replacement: a case report]
Kyobu Geka. 1994 Apr;47(4):315-8. Japanese.
PMID: 8152181 [PubMed - indexed for MEDLINE]
-  **110:** [Moizumi Y, Ohsaka K, Akasaka J, Kondoh S, Shimizu M, Imai Y, Kunagai T, Uchiyama T, Abe Y, Suzuki I.](#) [Related Articles, Links](#)
-  [Advantages of combined antegrade/retrograde GIK cardioplegia for coronary artery bypass surgery]
Nippon Kyobu Geka Gakkai Zasshi. 1994 Feb;42(2):198-205. Japanese.
PMID: 8138686 [PubMed - indexed for MEDLINE]
-  **111:** [Nishimaki H, Kobayashi A.](#) [Related Articles, Links](#)
-  [Phase analysis of gated blood pool scintigraphy in traumatic myocardial contusion]
Nippon Igaku Hoshasen Gakkai Zasshi. 1994 Jan 25;54(1):55-66. Japanese.
PMID: 8121771 [PubMed - indexed for MEDLINE]
-  **112:** [Deramoudt V, Lecloirec J, Moisan A, Bourguet P, Reymann JM, Malledant Y.](#) [Related Articles, Links](#)
-  [Role of isotopic imaging in intensive care]
Ann Fr Anesth Reanim. 1994;13(3):360-72. Review. French.
PMID: 7992943 [PubMed - indexed for MEDLINE]
-  **113:** [Efthymiadis A, Lefkos N, Liatsis I, Bountonas G, Styliadis IG, Aroditis K, Tsapas G.](#) [Related Articles, Links](#)
-  The diagnostic value of the determination of troponin T in the diagnosis of unstable angina.
Acta Cardiol. 1994;49(5):419-24.
PMID: 7839760 [PubMed - indexed for MEDLINE]
-  **114:** [Yamamoto N, Hisamochi K, Morimoto T, Nakayama Y, Senoo Y, Teramoto S.](#) [Related Articles, Links](#)
-  [Comparison between antegrade and retrograde cardioplegia with warm blood]
Nippon Kyobu Geka Gakkai Zasshi. 1993 Dec;41(12):2311-8. Japanese.
PMID: 8288919 [PubMed - indexed for MEDLINE]
-  **115:** [Kerr LD, Spiera H.](#) [Related Articles, Links](#)
-  Myocarditis as a complication in scleroderma patients with myositis.
Clin Cardiol. 1993 Dec;16(12):895-9.
PMID: 8168276 [PubMed - indexed for MEDLINE]
-  **116:** [Minutiello L.](#) [Related Articles, Links](#)
-  [The enzymatic and electrocardiographic changes falsely indicative of an acute myocardial infarct during hypothyroidism]
Minerva Cardioangiol. 1993 Dec;41(12):597-602. Italian.
PMID: 8139781 [PubMed - indexed for MEDLINE]
-  **117:** [Demirtas M, Dagsali S, Tarcan S, Sungu U.](#) [Related Articles, Links](#)
-  Is continuous normothermic blood cardioplegia really a practical way of myocardial preservation? Comparison with intermittent cold crystalloid cardioplegia.
Thorac Cardiovasc Surg. 1993 Oct;41(5):284-9.
PMID: 8303696 [PubMed - indexed for MEDLINE]

-  **118:** [Frank R, Tonet J, Gallais Y, Lazraq S, Fellat R, Fontaine G.](#) [Related Articles](#), [Links](#)
 [Treatment of ventricular tachycardia by endocardial fulguration. Apropos of 86 cases]
 Arch Mal Coeur Vaiss. 1993 Sep;86(9):1317-24. Review. French.
 PMID: 8129548 [PubMed - indexed for MEDLINE]
-  **119:** [Yip AS, Chow WH, Fu KH, Cheung KL, Li JP, Lee JS.](#) [Related Articles](#), [Links](#)
 Effect of percutaneous balloon mitral valvuloplasty on serum creatinine phosphokinase MB-isoenzyme levels.
 Cathet Cardiovasc Diagn. 1993 Jul;29(3):179-82.
 PMID: 8402839 [PubMed - indexed for MEDLINE]
-  **120:** [Yamaguchi A, Kitamura N, Kawashima M, Miki T, Tamura H.](#) [Related Articles](#), [Links](#)
 [Clinical preeminence of single aortic cross-clamping for proximal anastomoses in coronary artery bypass surgery]
 Nippon Kyobu Geka Gakkai Zasshi. 1993 Jul;41(7):1194-8. Japanese.
 PMID: 8376888 [PubMed - indexed for MEDLINE]
-  **121:** [Yamamoto N.](#) [Related Articles](#), [Links](#)
 [A comaprative study of continuous warm blood cardioplegia]
 Nippon Kyobu Geka Gakkai Zasshi. 1993 Jul;41(7):1154-62. Japanese.
 PMID: 8376885 [PubMed - indexed for MEDLINE]
-  **122:** [Bhave CG, Gadre KC, Gharpure BS.](#) [Related Articles](#), [Links](#)
 Myoglobinuria following the use of succinylcholine.
 J Postgrad Med. 1993 Jul-Sep;39(3):157-9.
 PMID: 8051650 [PubMed - indexed for MEDLINE]
-  **123:** [Fourestie V, Douceron H, Brugieres P, Ancelle T, Lejone JL, Gherardi RK.](#) [Related Articles](#), [Links](#)
 Neurotrichinosis. A cerebrovascular disease associated with myocardial injury and hypereosinophilia.
 Brain. 1993 Jun;116 (Pt 3):603-16.
 PMID: 8513394 [PubMed - indexed for MEDLINE]
-  **124:** [Takemura T.](#) [Related Articles](#), [Links](#)
 [A clinical trial of recombinant human superoxide dismutase for myocardial protection]
 Nippon Kyobu Geka Gakkai Zasshi. 1993 Feb;41(2):247-53. Japanese.
 PMID: 8473790 [PubMed - indexed for MEDLINE]
-  **125:** [Shimoda Y, Kimura O, Miyate Y, Takata R, Terui K, Saito H, Wakusawa R.](#) [Related Articles](#), [Links](#)
 [Coronary artery spasm under general and epidural anesthesia]
 Masui. 1993 Feb;42(2):284-7. Japanese.
 PMID: 8437365 [PubMed - indexed for MEDLINE]
-  **126:** [Dziewiecki J, Trusz-Gluza M, Wnuk-Wojnar A, Jaklik A, Czerwinski C, Filipecki A, Szydlo K, Ciemniowski Z, Giec L.](#) [Related Articles](#), [Links](#)
 [Intravenous ablation of the atrio-ventricular junction in patients with supraventricular tachyarrhythmias]
 Kardiol Pol. 1993 Jan;38(1):5-11; discussion 12-3. Polish.
 PMID: 8230978 [PubMed - indexed for MEDLINE]
-  **127:** [Ladowski JS, Sullivan M, Schatzlein MH, Peterson AC, Underhill DJ, Scheeringa RH.](#) [Related Articles](#), [Links](#)
 Cardiac isoenzymes following heart transplantation.
 Chest. 1992 Nov;102(5):1520-1.
 PMID: 1424875 [PubMed - indexed for MEDLINE]

- ☐ **128:** [Raga X, Vilanova MA, Bardaji A, Pastor MR, Richart C.](#) [Related Articles, Links](#)
 [Macrocreatine kinase, a cause of MB isoenzyme levels falsely elevated]
 Arch Mal Coeur Vaiss. 1992 Nov;85(11):1601-3. French.
 PMID: 1300958 [PubMed - indexed for MEDLINE]
- ☐ **129:** [Contini GA, Astorri E, Gavaruzzi G, Campodonico R, Albertini D, Reverberi C, Antonelli AM, Fesani F.](#) [Related Articles, Links](#)
 [Assessment of perioperative myocardial damage based on circulating heavy chain myosin fragments]
 Cardiologia. 1992 Nov;37(11):797-800. Italian.
 PMID: 1298552 [PubMed - indexed for MEDLINE]
- ☐ **130:** [Attenhofer C, Vuilliminet A, Richter M, Kaufmann U, Metzger U, Bertel O.](#) [Related Articles, Links](#)
 [Heart contusions: pathological findings and clinical course]
 Schweiz Med Wochenschr. 1992 Oct 24;122(43):1593-9. German.
 PMID: 1439679 [PubMed - indexed for MEDLINE]
- ☐ **131:** [Bhunia BC, Basu K, Batabyal SK, Khatwa SP, Sanyal S, Banerjee S, Basu A, Sanyal S.](#) [Related Articles, Links](#)
 Myocardial changes in neonates dying of asphyxia neonatorum.
 Indian J Pathol Microbiol. 1992 Oct;35(4):308-18.
 PMID: 1344220 [PubMed - indexed for MEDLINE]
- ☐ **132:** [Varani E, Pirazzini L, Casanova R, Patroncini A, Maresta A.](#) [Related Articles, Links](#)
 [Management and prognosis of acute myocardial infarct in advanced age: comparison of the cardiac intensive care unit and the cardiology ward]
 G Ital Cardiol. 1992 Sep;22(9):1069-75. Italian.
 PMID: 1291424 [PubMed - indexed for MEDLINE]
- ☐ **133:** [Isbikura Y, Odagiri S, Shimazu A, Hirao D, Watanabe H, Hatooka S, Hamada M.](#) [Related Articles, Links](#)
 [Clinical evaluation of myocardial protection by oxygenated crystalloid cardioplegic solutions with DBcAMP]
 Nippon Geka Gakkai Zasshi. 1992 Jun;93(6):632-8. Japanese.
 PMID: 1321329 [PubMed - indexed for MEDLINE]
- ☐ **134:** [Yasu T, Nonogi H, Oshima S, Daikoku S, Haze K.](#) [Related Articles, Links](#)
 [A case of unstable angina pectoris associated with an active phase of polymyositis]
 Kokyu To Junkan. 1992 May;40(5):491-4. Japanese.
 PMID: 1589649 [PubMed - indexed for MEDLINE]
- ☐ **135:** [Gokgoz L, Soncul H, Sinci V, Karasu C, Kaptanoglu M, Yener A, Ersoz A.](#) [Related Articles, Links](#)
 Dipyridamole induced myocardial recovery after global ischemia.
 Gen Pharmacol. 1992 May;23(3):435-7.
 PMID: 1511853 [PubMed - indexed for MEDLINE]
- ☐ **136:** [Antunes MJ, Bernardo JE, Oliveira JM, Fernandes LE, Andrade CM.](#) [Related Articles, Links](#)
 Coronary artery bypass surgery with intermittent aortic cross-clamping.
 Eur J Cardiothorac Surg. 1992;6(4):189-93; discussion 193-4.
 PMID: 1586493 [PubMed - indexed for MEDLINE]
- ☐ **137:** [Amato M, Aegerter E, Reiber W, Schneider H.](#) [Related Articles, Links](#)
 Creatine phosphokinase isoenzyme activity in umbilical artery, umbilical vein and capillary blood of newborn infants at term.
 Arch Gynecol Obstet. 1992;251(4):171-4.
 PMID: 1503508 [PubMed - indexed for MEDLINE]

-  **138:** [Ohyanagi H, Saitoh Y, Uchida T, Watanabe M, Yamanouchi K, Yokoyama K, Mitsuno T](#). [Related Articles, Links](#)
[Extended use of Fluosol emulsion in acute myocardial ischemia treatment.](#)
 Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):941-9.
 PMID: 1391538 [PubMed - indexed for MEDLINE]
-  **139:** [Maguire JF, O'Rourke PP, Colan SD, Geha RS, Crone R](#). [Related Articles, Links](#)
[Cardiotoxicity during treatment of severe childhood asthma.](#)
 Pediatrics. 1991 Dec;88(6):1180-6.
 PMID: 1956735 [PubMed - indexed for MEDLINE]
-  **140:** [Bernardo JE, Antunes M, Andrade C, Fernandes LE, Ferrao JM](#). [Related Articles, Links](#)
[\[Aortocoronary bypass. Intermittent clamping of the aorta versus cardioplegia\]](#)
 Rev Port Cardiol. 1991 Nov;10(11):811-5. Portuguese.
 PMID: 1686181 [PubMed - indexed for MEDLINE]
-  **141:** [Tsukube T, Yamaguchi M, Hosokawa Y, Ohashi H, Imai M, Oshima Y, Obo H, Nishikawa Y, Maeda H, Tachibana H](#). [Related Articles, Links](#)
[\[Results of open heart surgery in neonates--comparison between profound hypothermia with circulatory arrest and deep hypothermic bypass\]](#)
 Nippon Kyobu Geka Gakkai Zasshi. 1991 Oct;39(10):1831-8. Japanese.
 PMID: 1960423 [PubMed - indexed for MEDLINE]
-  **142:** [Gustafson DL, Swanson JD, Pritsos CA](#). [Related Articles, Links](#)
[Role of xanthine oxidase in the potentiation of doxorubicin-induced cardiotoxicity by mitomycin C.](#)
 Cancer Commun. 1991 Sep;3(9):299-304.
 PMID: 1911046 [PubMed - indexed for MEDLINE]
-  **143:** [McLean RF, Devitt JH, Dubbin J, McLellan BA](#). [Related Articles, Links](#)
[Incidence of abnormal RNA studies and dysrhythmias in patients with blunt chest trauma.](#)
 J Trauma. 1991 Jul;31(7):968-70.
 PMID: 2072436 [PubMed - indexed for MEDLINE]
-  **144:** [Gunnar WP, Martin M, Smith RF, Mangano R, Resnick DJ, Lopez V, Barrett JA](#). [Related Articles, Links](#)
[The utility of cardiac evaluation in the hemodynamically stable patient with suspected myocardial contusion.](#)
 Am Surg. 1991 Jun;57(6):373-7.
 PMID: 2048849 [PubMed - indexed for MEDLINE]
-  **145:** [Fabian TC, Cicala RS, Croce MA, Westbrook LL, Coleman PA, Minard G, Kudsk KA](#). [Related Articles, Links](#)
[A prospective evaluation of myocardial contusion: correlation of significant arrhythmias and cardiac output with CPK-MB measurements.](#)
 J Trauma. 1991 May;31(5):653-9; discussion 659-60.
 PMID: 2030512 [PubMed - indexed for MEDLINE]
-  **146:** [Matsumura H, Iwai F, Ichikizaki K](#). [Related Articles, Links](#)
[\[Ischemic myocardial disorder in acute phase subarachnoid hemorrhage: clinical study of 52 patients\]](#)
 No Shinkei Geka. 1991 Apr;19(4):349-57. Japanese.
 PMID: 2046849 [PubMed - indexed for MEDLINE]
-  **147:** [Nomura F, Matsuda H, Nakano S, Ohtani M, Takami H, Hirose H, Kawashima Y](#). [Related Articles, Links](#)
[Enhancement of cardiac prostacyclin release during reperfusion after](#)

-  **diltiazem supplemented potassium cardioplegia.**
J Cardiovasc Surg (Torino). 1991 Jan-Feb;32(1):26-30.
PMID: 2010447 [PubMed - indexed for MEDLINE]
-  **148:** [Chung F, Seyone C, Rakowski H.](#) Related Articles, Links
 **Transoesophageal echocardiogram may fail to diagnose perioperative myocardial infarction.**
Can J Anaesth. 1991 Jan;38(1):98-101.
PMID: 1989746 [PubMed - indexed for MEDLINE]
-  **149:** [Asaji T, Murakami E, Takekoshi N.](#) Related Articles, Links
 **[Evaluation of healing process in myocardial infarction by the time course of serum myosin light chain I: the effects of early reperfusion]**
J Cardiol. 1991;21(3):579-87. Japanese.
PMID: 1843508 [PubMed - indexed for MEDLINE]
-  **150:** [Schlienger JL, Sapin R, Capgras T, Gasser F, Monassier JP, Hauer B, Arnold P.](#) Related Articles, Links
 **[Evaluation of thyroid function after myocardial infarction]**
Ann Endocrinol (Paris). 1991;52(4):283-8. French.
PMID: 1818532 [PubMed - indexed for MEDLINE]
-  **151:** [Makarovskii VV.](#) Related Articles, Links
 **[Correlations of laboratory and instrumental method parameters in the diagnosis of acute ischemic lesion of the myocardium]**
Kardiologiia. 1990 Oct;30(10):35-9. Russian.
PMID: 2290268 [PubMed - indexed for MEDLINE]
-  **152:** [Golikov AP, Riabinin VA, Zholudev AA, Luk'ianov MM, Avilova OA.](#) Related Articles, Links
 **[Effectiveness of synthetic opioid peptide dalargin in acute myocardial infarction]**
Kardiologiia. 1990 Sep;30(9):24-7. Russian.
PMID: 2273732 [PubMed - indexed for MEDLINE]
-  **153:** [Wada S, Nagaoka S, Yoshiike Y, Chiba J.](#) Related Articles, Links
 **[A case of polymyositis associated with unusual CPK isoenzyme pattern and myocardial imaging]**
Ryumachi. 1990 Aug;30(4):264-71. Japanese.
PMID: 2287967 [PubMed - indexed for MEDLINE]
-  **154:** [Lu FM.](#) Related Articles, Links
 **[Carrier detection and gene analysis in a Duchenne muscular dystrophy family]**
Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1990 Aug;23(4):231-3, 255. Chinese.
PMID: 1979269 [PubMed - indexed for MEDLINE]
-  **155:** [Avital B, Port S, Gal R, McKinnie J, Tchou P, Jazayeri M, Troup P, Akhtar M.](#) Related Articles, Links
 **Automatic implantable cardioverter/defibrillator discharges and acute myocardial injury.**
Circulation. 1990 May;81(5):1482-7.
PMID: 2158864 [PubMed - indexed for MEDLINE]
-  **156:** [Hamada M, Shigematsu Y, Fujiwara Y, Sumimoto T, Hiwada K, Kokubu T.](#) Related Articles, Links
 **Persistent elevation of cardiac enzymes in a patient with hypertrophic cardiomyopathy--with special reference to electrocardiographic, echocardiographic and 201-thallium myocardial scintigraphic findings.**

Jpn Circ J. 1990 Apr;54(4):354-60.
PMID: 2398616 [PubMed - indexed for MEDLINE]

- 157: [Hamano K, Mori F, Miyamoto M, Tsuboi H, Fujimura Y, Noda H, Matsumoto N, Nishida K, Esato K.](#) [Related Articles, Links](#)



[Significance of measuring Cu, Zn-superoxide dismutase (SOD) levels in open heart surgery]

Nippon Kyobu Geka Gakkai Zasshi. 1990 Mar;38(3):412-5. Japanese.
PMID: 2348122 [PubMed - indexed for MEDLINE]

- 158: [Koike R.](#) [Related Articles, Links](#)



[The protective effect of diltiazem, a calcium channel blocker on myocardial ischemia during open heart surgery--an analysis of electrolyte changes in myocardial cells]

Nippon Kyobu Geka Gakkai Zasshi. 1990 Mar;38(3):358-69. Japanese.
PMID: 2348117 [PubMed - indexed for MEDLINE]

- 159: [Ozaki S, Sugiura Y, Ozeki Y, Okuda E, Yoshizu H, Shima S, Tanaka S, Suzuki M.](#) [Related Articles, Links](#)



[Cardiac arrest episodes by cardiomyopathy following total pancreatectomy, a case report]

Kokyu To Junkan. 1990 Mar;38(3):265-8. Japanese.
PMID: 2330460 [PubMed - indexed for MEDLINE]

- 160: [Colantonio D, Pasqualetti P, Casale R, Bucci V, Natali G.](#) [Related Articles, Links](#)



[Differentiated circadian chrono-risk of acute myocardial infarct]

Cardiologia. 1990 Mar;35(3):243-52. Italian.
PMID: 2245425 [PubMed - indexed for MEDLINE]

- 161: [Kinoshita Y, Okamoto K, Yahata K, Yoshioka T, Sugimoto T, Kawaguchi N, Onishi S.](#) [Related Articles, Links](#)



Clinical and pathological changes of the heart in brain death maintained with vasopressin and epinephrine.

Pathol Res Pract. 1990 Feb;186(1):173-9.
PMID: 2315211 [PubMed - indexed for MEDLINE]

- 162: [Li CC.](#) [Related Articles, Links](#)



[Changes of creatine phosphokinase and malondialdehyde in the serum and clinical use of large doses of vitamin C following open heart surgery]

Zhonghua Wai Ke Za Zhi. 1990 Jan;28(1):16-7, 60-1. Chinese.
PMID: 2364809 [PubMed - indexed for MEDLINE]

- 163: [Bonchek LI, Burlingame MW, Vazales BE, Ferdinand NJ.](#) [Related Articles, Links](#)



Coronary bypass with substrate-enhanced cardioplegia versus non-cardioplegic technique for early revascularization in acute infarction.

Eur J Cardiothorac Surg. 1990;4(3):124-9.
PMID: 2334551 [PubMed - indexed for MEDLINE]

- 164: [Aronson DC, Heymans HS, la Riviere AV, Naeff MS.](#) [Related Articles, Links](#)



Nontransmural myocardial infarction as a complication of untreated cystic fibrosis.

J Pediatr Gastroenterol Nutr. 1990 Jan;10(1):126-30.
PMID: 2324873 [PubMed - indexed for MEDLINE]

- 165: [Baxter BT, Moore EE, Moore FA, McCroskey BL, Ammons LA.](#) [Related Articles, Links](#)



A plea for sensible management of myocardial contusion.

Am J Surg. 1989 Dec;158(6):557-61; discussion 561-2.
PMID: 2589589 [PubMed - indexed for MEDLINE]


 **166:** [Cheng DC, Chung F, Burns RJ, Houston PL, Feindel CM.](#) [Related Articles](#), [Links](#)



Postoperative myocardial infarction documented by technetium pyrophosphate scan using single-photon emission computed tomography: significance of intraoperative myocardial ischemia and hemodynamic control.

Anesthesiology. 1989 Dec;71(6):818-26.

PMID: 2556063 [PubMed - indexed for MEDLINE]


 **167:** [Gohra H, Kaneda Y, Furukawa S, Oda T, Miyamoto M, Mori F, Esato K.](#) [Related Articles](#), [Links](#)



[The effect of pulsatile perfusion on aortocoronary bypass grafting]

Kyobu Geka. 1989 Nov;42(12):974-9; discussion 979-81. Japanese.

PMID: 2593408 [PubMed - indexed for MEDLINE]


 **168:** [Tamura T, Yokoyama K, Sato H, Kato K, Taneda M, Hayashi A, Jounokoshi H, Ueda Y, Kawana Y, Araki Y.](#) [Related Articles](#), [Links](#)



[Coronary artery spasm under thoracic epidural anesthesia]

Masui. 1989 Oct;38(10):1369-77. Japanese.

PMID: 2585706 [PubMed - indexed for MEDLINE]

 **169:** [Lovreglio V, Bartucci G, Simini P, Leuce U.](#) [Related Articles](#), [Links](#)



[Cardiac enzymes in acute cerebrovascular diseases: their behavior in relation to ECG]

Minerva Med. 1989 Sep;80(9):1003-10. Italian.

PMID: 2812474 [PubMed - indexed for MEDLINE]

 **170:** [Hadi HA, Albazzaz SJ.](#) [Related Articles](#), [Links](#)



Cardiac isoenzymes and electrocardiographic changes during ritodrine tocolysis.

Am J Obstet Gynecol. 1989 Aug;161(2):318-21.

PMID: 2764051 [PubMed - indexed for MEDLINE]


 **171:** [Helling TS, Duke P, Beggs CW, Crouse LJ.](#) [Related Articles](#), [Links](#)



A prospective evaluation of 68 patients suffering blunt chest trauma for evidence of cardiac injury.

J Trauma. 1989 Jul;29(7):961-5; discussion 965-6.

PMID: 2746707 [PubMed - indexed for MEDLINE]


 **172:** [Kohata T, Ono Y, Yoshibayashi M, Fukushima H, Yamada O, Kamiya T, Nishimura T, Takamiya M, Yutani C.](#) [Related Articles](#), [Links](#)



[Gallium-67 imaging in patients with myocarditis in childhood and youth]

J Cardiol. 1989 Jun;19(2):445-53. Japanese.

PMID: 2636626 [PubMed - indexed for MEDLINE]


 **173:** [Fernandez-Quero Bonilla L, Jardon Contreras E, Lajara Montell A, Manzanos Luna A.](#) [Related Articles](#), [Links](#)



[A controversial entity: myocardial contusion in 51 patients with thoracic trauma]

Rev Esp Anesthesiol Reanim. 1989 May-Jun;36(3):145-8. Spanish.

PMID: 2762608 [PubMed - indexed for MEDLINE]


 **174:** [Rubin RB, Neugarten J.](#) [Related Articles](#), [Links](#)




Cocaine-induced rhabdomyolysis masquerading as myocardial ischemia.


Am J Med. 1989 May;86(5):551-3.


PMID: 2712062 [PubMed - indexed for MEDLINE]


 **175:** [Ramondo A, Isabella G, Fracasso A, Sorbara C, Razzolini R, Maddalena F, Mazzucco A, Corbara F, Chioin R.](#) [Related Articles](#), [Links](#)


[Results of emergency aortocoronary bypass in complicated coronary


 angioplasty]
G Ital Cardiol. 1989 May;19(5):379-84. Italian.
PMID: 2527774 [PubMed - indexed for MEDLINE]


 **176:** Cortadellas J, Figueras J, Curos A, Cinca J, Moya A, Angel J, Salas A, Roma F. [Related Articles, Links](#)


 [Intravenous streptokinase in acute myocardial infarction. Reduction of early in-hospital mortality]
Rev Esp Cardiol. 1989 Apr;42(4):254-61. Spanish.
PMID: 2781119 [PubMed - indexed for MEDLINE]


 **177:** Dazai Y, Katoh I, Sueda S, Katoh T, Yoshida R, Fujii M, Kazatani S. [Related Articles, Links](#)


 [Report of a case of lung cancer with metastasis to the myocardium which showed electrocardiographic findings similar to acute myocardial infarction and intramyocardial mass on echocardiography]
Kokyu To Junkan. 1989 Apr;37(4):461-5. Japanese.
PMID: 2740646 [PubMed - indexed for MEDLINE]


 **178:** Campbell JB, Baker J, Morris DM. [Related Articles, Links](#)


 Cardiac complications of aneurysm repair.
South Med J. 1989 Apr;82(4):458-61.
PMID: 2705072 [PubMed - indexed for MEDLINE]


 **179:** Desai RN, Joshi SV, Vaidya P, Magotra RA, Parulkar GB. [Related Articles, Links](#)


 Blood cardioplegia--a comparative clinical and laboratory study.
Indian Heart J. 1989 Mar-Apr;41(2):134-6.
PMID: 2787289 [PubMed - indexed for MEDLINE]


 **180:** Bianchi L, Bertocchi C, Felci U, Ferrario G, Giani P, Mariani L, Medolago G, Sarti E. [Related Articles, Links](#)


 [Cardiomyopathy due to adriamycin: the possibility of its prevention. Monitoring by noninvasive technics]
Minerva Med. 1989 Mar;80(3):215-26. Italian.
PMID: 2717043 [PubMed - indexed for MEDLINE]


 **181:** Yonenaga K, Yasui H, Kado H, Andou H, Nakano E, Fukumura F, Nishimura Y, Zaitzu M, Shin T, Morimoto A. [Related Articles, Links](#)


 [Retrograde coronary sinus perfusion of cardioplegic solution in Jatene operation in neonates and infants]
Nippon Kyobu Geka Gakkai Zasshi. 1989 Feb;37(2):274-80. Japanese.
PMID: 2768906 [PubMed - indexed for MEDLINE]


 **182:** O'Connor JP, Ramsay JG, Wynands JE, Ralley FE, Casey WF, Smith CE, Robbins GR, Bilodeau J, Sami MH. [Related Articles, Links](#)


 The incidence of myocardial ischemia during anesthesia for coronary artery bypass surgery in patients receiving pancuronium or vecuronium.
Anesthesiology. 1989 Feb;70(2):230-6.
PMID: 2563317 [PubMed - indexed for MEDLINE]

 **183:** Tondeur M, Haentjens M, Piepsz A, Ham HR. [Related Articles, Links](#)

 Muscular injury in a child diagnosed by 99mTc-MDP bone scan.
Eur J Nucl Med. 1989;15(6):328-9.
PMID: 2767083 [PubMed - indexed for MEDLINE]

 **184:** Burke GL, Edlavitch SA, Crow RS. [Related Articles, Links](#)

 The effects of diagnostic criteria on trends in coronary heart disease morbidity: the Minnesota Heart Survey.
J Clin Epidemiol. 1989;42(1):17-24.
PMID: 2643674 [PubMed - indexed for MEDLINE]

-  **185:** Tabatabai M, Segal R, Amidi M, Stremple JF, Caines M, Kirimli B [Related Articles](#), [Links](#)



Serum creatine phosphokinase, lactic dehydrogenase, and their isoenzymes in the perioperative period.

J Clin Anesth. 1989;1(4):277-83.

PMID: 2627401 [PubMed - indexed for MEDLINE]


-  **186:** Magnani B, Melandri G [Related Articles](#), [Links](#)



The role of infarct size in early and late mortality.

J Cardiovasc Pharmacol. 1989;14 Suppl 9:S25-8.

PMID: 2483228 [PubMed - indexed for MEDLINE]

-  **187:** Vinogradov AV, Aloeov RS, Zhuravleva IA, Kharlap GV, Glazunov AS [Related Articles](#), [Links](#)



[Possibilities of electrocardiography in the evaluation of necrotization process in posterior myocardial infarction]

Kardiologiya. 1988 Nov;28(11):58-61. Russian.

PMID: 3230778 [PubMed - indexed for MEDLINE]

-  **188:** Lindenbaum GA, Carroll SF, Block EF, Kapusnick RA [Related Articles](#), [Links](#)



Value of creatine phosphokinase isoenzyme determinations in the diagnosis of myocardial contusion.

Ann Emerg Med. 1988 Sep;17(9):885-9.

PMID: 3415059 [PubMed - indexed for MEDLINE]

-  **189:** Bluzhas IN, Gribauskenė RA, Gribauskas PS, Rastianene DM [Related Articles](#), [Links](#)



[Atypical creatine phosphokinase isoenzyme fraction in the diagnosis of acute myocardial infarction]

Kardiologiya. 1988 Sep;28(9):46-8. Russian.

PMID: 3236643 [PubMed - indexed for MEDLINE]


-  **190:** Gibler WB, Blanton J [Related Articles](#), [Links](#)



Early identification of patients with acute myocardial infarction.

Compr Ther. 1988 Aug;14(8):41-4.

PMID: 3168429 [PubMed - indexed for MEDLINE]

-  **191:** Rizk SL, Roseman DL, Bonomi P, Sky-Peck H, Clark J, Lee I, Gould VE [Related Articles](#), [Links](#)



Elevated creatine phosphokinase MB in a patient with neuroendocrine carcinoma of the colon--evidence for a tumor marker. Report of a case.

Dis Colon Rectum. 1988 Apr;31(4):318-22.

PMID: 3359901 [PubMed - indexed for MEDLINE]


-  **192:** Keller KD, Shatney CH [Related Articles](#), [Links](#)



Creatine phosphokinase-MB assays in patients with suspected myocardial contusion: diagnostic test or test of diagnosis?

J Trauma. 1988 Jan;28(1):58-63.

PMID: 3339664 [PubMed - indexed for MEDLINE]

-  **193:** Fabian TC, Mangiante EC, Patterson CR, Payne LW, Isaacson ML [Related Articles](#), [Links](#)



Myocardial contusion in blunt trauma: clinical characteristics, means of diagnosis, and implications for patient management.

J Trauma. 1988 Jan;28(1):50-7.

PMID: 3339663 [PubMed - indexed for MEDLINE]

-  **194:** Gerrish SP, Goiti JJ, Hunsley JE [Related Articles](#), [Links](#)



A comparison of blood, crystalloid and oxygenated crystalloid

cardioplegia solutions on myoglobin and creatine kinase release following cardiac surgery.

Eur J Cardiothorac Surg. 1988;2(6):438-41.

PMID: 3272252 [PubMed - indexed for MEDLINE]

- 195: [Tellez DW, Hardin WD Jr, Takahashi M, Miller J, Galvis AG, Mahour GH.](#) [Related Articles, Links](#)



Blunt cardiac injury in children.

J Pediatr Surg. 1987 Dec;22(12):1123-8.

PMID: 3440897 [PubMed - indexed for MEDLINE]

- 196: [Czarnecki A, Hinck A.](#) [Related Articles, Links](#)



Protective effect of inosine against adrenaline toxicity in rats.

Pol J Pharmacol Pharm. 1987 Nov-Dec;39(6):675-82.

PMID: 3503988 [PubMed - indexed for MEDLINE]

- 197: [Pauletto P, Piccolo D, Scannapieco G, Paolini R, Caroli M, Corbara F, Cuman G, Chioin R, Casiglia E, Maddalena F, et al.](#) [Related Articles, Links](#)



[Changes in plasma levels of myoglobin, CPK and CPK-MB in patients subjected to percutaneous coronary angioplasty]

Cardiologia. 1987 Oct;32(10):1125-9. Italian. No abstract available.

PMID: 2961442 [PubMed - indexed for MEDLINE]

- 198: [Gibler WB, Gibler CD, Weinshenker E, Abbottsmith C, Hedges JR, Barsan WG, Sperling M, Chen IW, Embry S, Kereiakes D.](#) [Related Articles, Links](#)



Myoglobin as an early indicator of acute myocardial infarction.

Ann Emerg Med. 1987 Aug;16(8):851-6.

PMID: 3619163 [PubMed - indexed for MEDLINE]

- 199: [Livatino L, Schiatti R, Guidi L, Ignesti C.](#) [Related Articles, Links](#)



[Evaluation of isoenzymes of creatine kinase and lactate dehydrogenase in cases of suspected acute myocardial infarct]

Quad Sclavo Diagn. 1987 Mar;23(1):92-9. Italian.

PMID: 3441595 [PubMed - indexed for MEDLINE]

- 200: [Maguire JF, Geha RS, Umetsu DT.](#) [Related Articles, Links](#)



Myocardial specific creatine phosphokinase isoenzyme elevation in children with asthma treated with intravenous isoproterenol.

J Allergy Clin Immunol. 1986 Oct;78(4 Pt 1):631-6.

PMID: 3771954 [PubMed - indexed for MEDLINE]

- 201: [Glinz W.](#) [Related Articles, Links](#)



Problems caused by the unstable thoracic wall and by cardiac injury due to blunt injury.

Injury. 1986 Sep;17(5):322-6.

PMID: 3770934 [PubMed - indexed for MEDLINE]

- 202: [Flancbaum L, Wright J, Siegel JH.](#) [Related Articles, Links](#)



Emergency surgery in patients with post-traumatic myocardial contusion.

J Trauma. 1986 Sep;26(9):795-803.

PMID: 3746954 [PubMed - indexed for MEDLINE]

- 203: [Czarnecki A.](#) [Related Articles, Links](#)





















Protective effect of inosine on adrenaline-induced myocardial necrosis.

Pharmacol Res Commun. 1986 May;18(5):459-69.

PMID: 3737656 [PubMed - indexed for MEDLINE]

- 204: [Marchionni N, Moschi G, Lombardi A, Tozzi P, Salani B, Di Bari M, Ferrucci L, Paoletti M.](#) [Related Articles, Links](#)

-  **Prediction of left ventricular function in acute anterior myocardial infarction by serum creatine kinase activity and precordial ECG mapping.**
Clin Cardiol. 1986 May;9(5):187-90.
PMID: 3708944 [PubMed - indexed for MEDLINE]
-  **205:** Lash AD, Wittman AL, Quismorio FP Jr. [Related Articles, Links](#)
-  **Myocarditis in mixed connective tissue disease: clinical and pathologic study of three cases and review of the literature.**
Semin Arthritis Rheum. 1986 May;15(4):288-96.
PMID: 2940685 [PubMed - indexed for MEDLINE]
-  **206:** Hammond J, Ward CG. [Related Articles, Links](#)
-  **Myocardial damage and electrical injuries: significance of early elevation of CPK-MB isoenzymes.**
South Med J. 1986 Apr;79(4):414-6.
PMID: 3704697 [PubMed - indexed for MEDLINE]
-  **207:** Moran SV, Chuaqui B, Irarrazaval MJ, Thomsen P, Navarro M, Urzua J, Maturana G. [Related Articles, Links](#)
-  **Ultrastructural myocardial preservation during coronary artery surgery: a controlled, prospective, randomized study in humans.**
Ann Thorac Surg. 1986 Jan;41(1):79-84.
PMID: 3510594 [PubMed - indexed for MEDLINE]
-  **208:** Helias J, Daumy F, Nicolas F, Nicolas G. [Related Articles, Links](#)
-  **[Myocardial contusions. Contribution of scintigraphy using thallium-201. A prospective series]**
Arch Mal Coeur Vaiss. 1986 Jan;79(1):69-74. French.
PMID: 3085612 [PubMed - indexed for MEDLINE]
-  **209:** George BS, Myler RK, Stertz SH, Clark DA, Cote G, Shaw RE, Fishman-Rosen J, Murphy M. [Related Articles, Links](#)
-  **Balloon angioplasty of coronary bifurcation lesions: the kissing balloon technique.**
Cathet Cardiovasc Diagn. 1986;12(2):124-38.
PMID: 2939962 [PubMed - indexed for MEDLINE]
-  **210:** Matsuda H, Maeda S, Hirose H, Nakano S, Shirakura R, Kaneko M, Kadoba K, Kawashima Y. [Related Articles, Links](#)
-  **Optimum dose of cold potassium cardioplegia for patients with chronic aortic valve disease: determination by left ventricular mass.**
Ann Thorac Surg. 1986 Jan;41(1):22-6.
PMID: 2935091 [PubMed - indexed for MEDLINE]
-  **211:** Sugiura M, Yozawa Y, Kubo O, Kitamura K, Kimata S, Hagiwara H, Joshita H. [Related Articles, Links](#)
-  **[Myocardial damage (myocytolysis) caused by subarachnoid hemorrhage]**
No To Shinkei. 1985 Dec;37(12):1155-61. Japanese.
PMID: 4091985 [PubMed - indexed for MEDLINE]
-  **212:** Kitamura S, Nishii T, Kawachi K, Koh Y, Morita R, Kim K, Oyama C. [Related Articles, Links](#)
-  **[Evaluation of the effectiveness and safety in the use of cold-diltiazem-potassium cardioplegia in coronary artery bypass surgery: a first clinical trial]**
Nippon Geka Gakkai Zasshi. 1985 Sep;86(9):1199-202. Japanese.
PMID: 3911052 [PubMed - indexed for MEDLINE]
-  **213:** Tokioka M, Miura H, Masaoka Y, Nishizaki S, Mikouchi H, Nishizaki Y, Murakami M. [Related Articles, Links](#)



[Transient appearance of asynergy on the echocardiogram and electrocardiographic changes simulating acute myocardial infarction following non-cardiac surgery]

J Cardiogr. 1985 Sep;15(3):639-53. Japanese.

PMID: 3837059 [PubMed - indexed for MEDLINE]

214: [Dewar ML, Rosengarten MD, Blundell PE, Chiu RC.](#)

[Related Articles, Links](#)



Perioperative Holter monitoring and computer analysis of dysrhythmias in cardiac surgery.

Chest. 1985 May;87(5):593-7.

PMID: 3872775 [PubMed - indexed for MEDLINE]

215: [Possati F, Calafiore AM, Luciani N, Falcone F, Scesi M.](#)

[Related Articles, Links](#)



[Variations in CPK-MB during extracorporeal circulation]

Minerva Cardioangiol. 1985 Mar;33(3):123-6. Italian. No abstract available.

PMID: 4010978 [PubMed - indexed for MEDLINE]

216: [Hines GL, Wehbe U, Mele V.](#)

[Related Articles, Links](#)



Papaverine hydrochloride as an adjunct to asanguinous cardioplegia, is it beneficial?

J Cardiovasc Surg (Torino). 1985 Mar-Apr;26(2):196-9.

PMID: 3872304 [PubMed - indexed for MEDLINE]

217: [Rasmussen LH, Madsen HN, Ladefoged SD.](#)

[Related Articles, Links](#)



Creatine phosphokinase MB and lactate dehydrogenase isoenzyme 1 in polymyositis.

Scand J Rheumatol. 1985;14(4):427-30.

PMID: 4081664 [PubMed - indexed for MEDLINE]

218: [Gianrossi R, Marruzzo M, Torrielli A, Azzolini A, Nizzo MC, Montemanni M, Mottola G.](#)

[Related Articles, Links](#)



Left ventricular thrombus and myocardial infarction.

Acta Cardiol. 1985;40(6):599-612.

PMID: 3879418 [PubMed - indexed for MEDLINE]

219: [Georgiades C, Cokkinos DV, Kalofoutis A, Miras C.](#)

[Related Articles, Links](#)



Deoxycytidylate deaminase in the diagnosis of acute myocardial infarction.

Acta Cardiol. 1985;40(2):247-54.

PMID: 3873159 [PubMed - indexed for MEDLINE]

220: [Burlina A, Rizzotti P, Plebani M, Cocco C, Vassanelli C, Menegatti G.](#)

[Related Articles, Links](#)



CPK and CPK-MB in the early diagnosis of acute myocardial infarction and prediction of infarcted area.

Clin Biochem. 1984 Dec;17(6):356-61.

PMID: 6518651 [PubMed - indexed for MEDLINE]

221: [Doust-Blazy P, Delay M, Douste-Blazy MY, Fauvel M, Marco J, Bernadet P.](#)

[Related Articles, Links](#)



[Systemic fibrinolytic treatment in the acute phase of myocardial infarction. Effects on coronary repermeation and left ventricular function]

Arch Mal Coeur Vaiss. 1984 Nov;77(12):1322-8. French.

PMID: 6439157 [PubMed - indexed for MEDLINE]

222: [Graeber GM, Cafferty PJ, Wolf RE, Harmon JW.](#)


[Related Articles, Links](#)



An analysis of creatine phosphokinase in the mucosa and the muscularis of the gastrointestinal tract.

J Surg Res. 1984 Nov;37(5):376-82.

PMID: 6333551 [PubMed - indexed for MEDLINE]

-  **223:** [Fenner JE, Knopp R, Lee B, dos Santos PA, Wessel RJ, Dang CV, Parks SN.](#) [Related Articles, Links](#)



The use of gated radionuclide angiography in the diagnosis of cardiac contusion.

Ann Emerg Med. 1984 Sep;13(9 Pt 1):688-94.
PMID: 6087698 [PubMed - indexed for MEDLINE]

-  **224:** [Ngalikpima V, Stalpaert G.](#) [Related Articles, Links](#)



Quantification of creatine phosphokinase and its isoenzyme MB, serum glutamic oxaloacetic transaminase and lactic dehydrogenase from different sources during aortic valve replacement procedure.

Acta Chir Belg. 1984 Jul-Aug;84(4):244-8.
PMID: 6485684 [PubMed - indexed for MEDLINE]

-  **225:** [Maresta A, Melandri G, Leghissa R, Magnani B.](#) [Related Articles, Links](#)



[Extension of necrosis in the acute phase of myocardial infarct. Clinical picture and prognosis]


G Ital Cardiol. 1983 Dec;13(12):388-92. Italian.
PMID: 6671496 [PubMed - indexed for MEDLINE]

-  **226:** [Mashiko K.](#) [Related Articles, Links](#)



[Clinical and pathophysiological study of myocardial contusion]

Nippon Geka Gakkai Zasshi. 1983 Nov;84(11):1138-48. Japanese.
PMID: 6674773 [PubMed - indexed for MEDLINE]

-  **227:** [Radu I, Costache L, Gherasim L, Cinteza M, Trutia E, Pirvu V.](#) [Related Articles, Links](#)



The diagnostic value of myoglobin in the acute myocardial infarction in comparison with GOT and CPK-MB.


Arch Roum Pathol Exp Microbiol. 1983 Oct-Dec;42(4):327-36. No abstract available.
PMID: 6678576 [PubMed - indexed for MEDLINE]

-  **228:** [Perez Navero J, Calvo C, Malo P, Ruiz A, Ruza F.](#) [Related Articles, Links](#)



[Myocardial infarction and myocardial ischemia in newborn children and infants, not secondary to an abnormal coronary]

An Esp Pediatr. 1983 Oct;19(4):255-62. Spanish.
PMID: 6660644 [PubMed - indexed for MEDLINE]

-  **229:** [Roberts AJ, Faro RS, Williams LA, Cohen JA, Knauf DK, Alexander JA.](#) [Related Articles, Links](#)



Relative efficacy of left ventricular venting and venous drainage techniques commonly used during coronary artery bypass graft surgery.


Ann Thorac Surg. 1983 Oct;36(4):444-52.
PMID: 6605127 [PubMed - indexed for MEDLINE]

-  **230:** [Hirayama T.](#) [Related Articles, Links](#)



[Change in isoenzyme CPK-MB following open heart surgery in children and adults--with reference to the evaluation of cardioplegic effect]





















Nippon Kyobu Geka Gakkai Zasshi. 1983 Jun;31(6):915-24. Japanese. No abstract available.
PMID: 6619599 [PubMed - indexed for MEDLINE]


-  **231:** [Foresti V, Mana O, Natale L, Gamba G, Arpesani A.](#) [Related Articles, Links](#)



[Dissecting aneurysm of the thoracic aorta with paraplegic onset. Diagnosis using computerized tomography]


Minerva Med. 1983 May 31;74(22-23):1365-8. Italian.
PMID: 6856148 [PubMed - indexed for MEDLINE]

-  **232:** Hicks GL, Arnold W, DeWall RA. [Related Articles, Links](#)
 **Fluorocarbon cardioplegia and myocardial protection.**
 Ann Thorac Surg. 1983 May;35(5):500-3.
 PMID: 6847286 [PubMed - indexed for MEDLINE]
-  **233:** Kumar SA, Puri VK, Mittal VK, Cortez J. [Related Articles, Links](#)
 **Myocardial contusion following nonfatal blunt chest trauma.**
 J Trauma. 1983 Apr;23(4):327-31.
 PMID: 6302297 [PubMed - indexed for MEDLINE]
-  **234:** Titov VN, Krauze EG, Filippov IK, Rabich G, Filippova VA. [Related Articles, Links](#)
 **[Glycogen phosphorylase activity in acute myocardial infarction]**
 Kardiologiia. 1983 Mar;23(3):51-5. Russian.
 PMID: 6855063 [PubMed - indexed for MEDLINE]
-  **235:** Grenadier E, Keidar S, Kahana L, Alpan G, Marmur A, Palant A. [Related Articles, Links](#)
 **The roles of serum myoglobin, total CPK, and CK-MB isoenzyme in the acute phase of myocardial infarction.**
 Am Heart J. 1983 Mar;105(3):408-16.
 PMID: 6829403 [PubMed - indexed for MEDLINE]
-  **236:** Takimoto M, Matsuoka S, Hirohata T, Suzuki Y, Enomoto K, Ohta H, Okada N. [Related Articles, Links](#)
 **Myocardial protection during cardiac ischemia by coronary perfusion with cold lactated Ringer's solution plus mannitol.**
 Jpn Heart J. 1983 Mar;24(2):199-213.
 PMID: 6406721 [PubMed - indexed for MEDLINE]
-  **237:** Kakihana M, Shino A, Nagaoka A. [Related Articles, Links](#)
 **Cardiovascular responses to cerebral ischemia following bilateral carotid artery occlusion in SHRSP, SHRSP and WKY rats.**
 Jpn J Pharmacol. 1983 Feb;33(1):17-26.
 PMID: 6876514 [PubMed - indexed for MEDLINE]
-  **238:** Yazaki Y, Nagai R, Yamaoki K, Ueda S. [Related Articles, Links](#)
 **Myocardial infarct size from serum cardiac myosin light chain. Clinical and experimental studies.**
 Adv Myocardiol. 1983;4:489-95.
 PMID: 6856976 [PubMed - indexed for MEDLINE]
-  **239:** Mirhoseini M, Fisher JC, Cayton M. [Related Articles, Links](#)
 **Myocardial revascularization by laser: a clinical report.**
 Lasers Surg Med. 1983;3(3):241-5.
 PMID: 6608040 [PubMed - indexed for MEDLINE]
-  **240:** Gualandi G, Facchin L, Anastasio R, Raho L, Peroni L, Caturelli G. [Related Articles, Links](#)
 **[Possible myocardial damage caused by electric countershock: analysis of CPK MB isoenzyme variations]**
 Cardiologia. 1982 Dec;27(12):1177-85. Italian. No abstract available.
 PMID: 6927476 [PubMed - indexed for MEDLINE]
-  **241:** Gualandi G, Facchin L, Anastasio R, Raho L, Peroni L, Caturelli G. [Related Articles, Links](#)
 **[Possible myocardium damage caused by D.C. shock: analysis of changes in the CPK MB isoenzyme]**
 Cardiologia. 1982 Dec;27(12):1177-85. Italian. No abstract available.
 PMID: 6892403 [PubMed - indexed for MEDLINE]

-  **242:** [Kano H, Kokuryu H, Ushikubi F, Uchino H, Imai M.](#) [Related Articles, Links](#)




[Case of polymyositis with unique creatine phosphokinase (CPK) isoenzyme patterns: appearance of marked CPK-MB and macro CPK]
Nippon Naika Gakkai Zasshi. 1982 Oct 10;71(10):1451-4. Japanese. No abstract available.
PMID: 7166667 [PubMed - indexed for MEDLINE]

-  **243:** [Rodriguez A, Shatney C.](#) [Related Articles, Links](#)



The value of technetium99m pyrophosphate scanning in the diagnosis of myocardial contusion.
Am Surg. 1982 Sep;48(9):472-4.
PMID: 6289712 [PubMed - indexed for MEDLINE]

-  **244:** [Potkin RT, Werner JA, Trobaugh GB, Chestnut CH 3rd, Carrico CJ, Hallstrom A, Cobb LA.](#) [Related Articles, Links](#)




Evaluation of noninvasive tests of cardiac damage in suspected cardiac contusion.
Circulation. 1982 Sep;66(3):627-31.
PMID: 6284407 [PubMed - indexed for MEDLINE]

-  **245:** [Pick RA, Glover MU, Vieweg WV.](#) [Related Articles, Links](#)




Myocardial infarction in a young woman with isolated coronary arteritis.
Chest. 1982 Sep;82(3):378-80.
PMID: 6125346 [PubMed - indexed for MEDLINE]

-  **246:** [Torres-Mirabal P, Gruenberg JC, Brown RS, Obeid FN.](#) [Related Articles, Links](#)



Spectrum of myocardial contusion.
Am Surg. 1982 Aug;48(8):383-92.
PMID: 7114607 [PubMed - indexed for MEDLINE]

-  **247:** [Henderson BM, Dougherty WJ, James VC, Tilley LP, Noble JF.](#) [Related Articles, Links](#)



Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations.
Cancer Treat Rep. 1982 May;66(5):1139-43.
PMID: 7083216 [PubMed - indexed for MEDLINE]

-  **248:** [Molina JE, Gani KS, Voss DM.](#) [Related Articles, Links](#)



Pressurized rapid cardioplegia versus administration of exogenous substrate and topical hypothermia.
Ann Thorac Surg. 1982 May;33(5):434-44.
PMID: 7044326 [PubMed - indexed for MEDLINE]

-  **249:** [Singh AK, Farrugia R, Teplitz C, Karlson E.](#) [Related Articles, Links](#)




Electrolyte versus blood cardioplegia: randomized clinical and myocardial ultrastructural study.
Ann Thorac Surg. 1982 Mar;33(3):218-27.
PMID: 6978687 [PubMed - indexed for MEDLINE]

-  **250:** [Negroni JA, Lascano EC, Depaoli JR.](#) [Related Articles, Links](#)




Sensitivity of enzymatic release due to ischemia in the isolated rat heart.
Acta Physiol Lat Am. 1982;32(4):303-11.
PMID: 7186746 [PubMed - indexed for MEDLINE]

-  **251:** [Torres-Mirabal P, Gruenberg JC, Talbert JG, Brown RS.](#) [Related Articles, Links](#)



Ventricular function in myocardial contusion: a preliminary study.
Crit Care Med. 1982 Jan;10(1):19-24.
PMID: 7056050 [PubMed - indexed for MEDLINE]

 **252:** [Iwasaki T.](#)

[Related Articles](#), [Links](#)



[Studies on myocardial infarct size and the release of myocardial enzymes in experimental infarction: correlation of infarct size and released myocardial enzymes after coronary artery ligation and reperfusion with special reference to CPK-MB]

Jpn Circ J. 1981 Dec;45 Suppl 3:477-82. Japanese. No abstract available.
PMID: 7310986 [PubMed - indexed for MEDLINE]


 **253:** [Ward RE, Woo J, Pace P.](#)

[Related Articles](#), [Links](#)



Increased release of beta thromboglobulin during acute myocardial infarction.

Cardiovasc Dis. 1981 Sep;8(3):372-378.
PMID: 15216194 [PubMed - as supplied by publisher]


 **254:** [Graeber GM, Reardon MJ, Fleming AW, Head HD, Zajtchuk R, Brott WH, Foster JH.](#)

[Related Articles](#), [Links](#)



An analysis of the isoenzymes of creatine phosphokinase and lactic dehydrogenase in the esophagus.

Ann Thorac Surg. 1981 Sep;32(3):230-4.
PMID: 7283514 [PubMed - indexed for MEDLINE]


 **255:** [Graeber GM, Cafferty PJ, Reardon MJ, Curley CP, Ackerman NB, Harmon JW.](#)

[Related Articles](#), [Links](#)



Changes in serum total creatine phosphokinase (CPK) and its isoenzymes caused by experimental ligation of the superior mesenteric artery.

Ann Surg. 1981 Apr;193(4):499-505.
PMID: 7212812 [PubMed - indexed for MEDLINE]


 **256:** [Soffer O, Fellner SK, Rush RL.](#)

[Related Articles](#), [Links](#)



Creatine phosphokinase in long-term dialysis patients.

Arch Intern Med. 1981 Feb;141(2):181-8.
PMID: 7458513 [PubMed - indexed for MEDLINE]

 **257:** [Besson C, Rocheongar P, Beauverger Y, Dassonville J, Aubree M, Catheline M.](#)

[Related Articles](#), [Links](#)



[Study of the valuations of serum muscular enzymes and myoglobin after maximal exercise test and during the next 24 hours (author's transl)]

Eur J Appl Physiol Occup Physiol. 1981;47(1):47-56. French.
PMID: 7197623 [PubMed - indexed for MEDLINE]


 **258:** [Michelson WB.](#)

[Related Articles](#), [Links](#)



CPK-MB isoenzyme determinations: diagnostic and prognostic value in evaluation of blunt chest trauma.

Ann Emerg Med. 1980 Nov;9(11):562-7.
PMID: 7436065 [PubMed - indexed for MEDLINE]


 **259:** [Graeber GM, Snyder RJ, Zajtchuk R, Brott WH.](#)

[Related Articles](#), [Links](#)



A comparison of serum isoenzyme levels of creatine phosphokinase and lactic dehydrogenase in patients undergoing thoracic operations and patients admitted to a coronary care unit.

Ann Thorac Surg. 1980 Oct;30(4):364-9.
PMID: 7425715 [PubMed - indexed for MEDLINE]

 **260:** [Mikaeloff P, Amouroux C, Boivin J, Guidollet J, Vial C, El Kirat M.](#)


[Related Articles](#), [Links](#)



[Myocardial metabolism during coronary perfusion at 10 degrees C with or without cardioplegia associated with potassium]


Arch Mal Coeur Vaiss. 1980 Sep;73(9):1075-85. French.

PMID: 6776926 [PubMed - indexed for MEDLINE]

-  **261:** [Maklari E, Dekany P, Keltai M, Gabor G.](#) [Related Articles, Links](#)

**[Determination of free CPK and CPK/MB isoenzyme in myocardial infarct]**

Orv Hetil. 1980 Feb 24;121(8):441-5. Hungarian. No abstract available.
PMID: 7383681 [PubMed - indexed for MEDLINE]

-  **262:** [Ofir D, Morag A.](#) [Related Articles, Links](#)


**[Isoenzyme CPK-MB in myocardial infarction]**

Harefuah. 1980 Feb 1;98(3):129-32. Hebrew. No abstract available.
PMID: 7429355 [PubMed - indexed for MEDLINE]

-  **263:** [Suzuki T, Kashimura S, Umetsu K.](#) [Related Articles, Links](#)


**Creatine phosphokinase and malate dehydrogenase isozymes in heart muscle of sudden death cases.**

Tohoku J Exp Med. 1980 Feb;130(2):175-82.
PMID: 7385226 [PubMed - indexed for MEDLINE]

-  **264:** [Bradner WT, Schurig JE, Huftalen JB, Doyle GJ.](#) [Related Articles, Links](#)

**Evaluation of antitumor drug side effects in small animals.**

Cancer Chemother Pharmacol. 1980;4(2):95-101.
PMID: 7389061 [PubMed - indexed for MEDLINE]

-  **265:** [Bauman DJ.](#) [Related Articles, Links](#)

**Creatine phosphokinase isoenzymes and the diagnosis of myocardial infarction.**

Postgrad Med. 1980 Jan;67(1):103-6, 109-12, 115-6.
PMID: 7350557 [PubMed - indexed for MEDLINE]

-  **266:** [Cosic V.](#) [Related Articles, Links](#)

**[Improvements in the diagnosis of acute myocardial infarct. Diagnostic values of CPK-MB isoenzymes]**

Vojnosanit Pregl. 1979 Nov-Dec;36(6):464-6. Serbian. No abstract available.
PMID: 538893 [PubMed - indexed for MEDLINE]

-  **267:** [Lin CS, Shih MC.](#) [Related Articles, Links](#)


**Reappraisal of enzyme diagnosis in acute myocardial infarction--with special reference to CPK-MB isoenzyme.**

Taiwan Yi Xue Hui Za Zhi. 1979 Sep;78(9):789-94. No abstract available.
PMID: 292754 [PubMed - indexed for MEDLINE]

-  **268:** [Reynolds M, Jones JW.](#) [Related Articles, Links](#)

**CPK-MB isoenzyme determinations in blunt chest trauma.**

JACEP. 1979 Aug;8(8):304-6.
PMID: 459188 [PubMed - indexed for MEDLINE]

-  **269:** [Marmor A, Grenadir E, Keidar S, Edward S, Palant A.](#) [Related Articles, Links](#)


**The MB fraction of creatine phosphokinase. An indicator of myocardial involvement in acute pericarditis.**

Arch Intern Med. 1979 Jul;139(7):819-20.
PMID: 454073 [PubMed - indexed for MEDLINE]

-  **270:** [Oda T, Hamamoto K, Morinaga H.](#) [Related Articles, Links](#)

**Clinical aspects of nonrheumatic myocarditis in children.**

Jpn Circ J. 1979 May;43(5):433-40.
PMID: 470104 [PubMed - indexed for MEDLINE]


 **271:** [Val-Mejias J, Lee WK, Weisse AB, Regan TJ.](#) [Related Articles, Links](#)



Left ventricular performance during and after sickle cell crisis.

Am Heart J. 1979 May;97(5):585-91.

PMID: 433733 [PubMed - indexed for MEDLINE]

 **272:** [Wakabayashi A, Nishi T, Mihranian M, Ito Y, Guilmette JE, Connolly JE.](#) [Related Articles, Links](#)



Experimental evaluation of hypothermic intermittent coronary perfusion.

J Thorac Cardiovasc Surg. 1979 May;77(5):641-6.

PMID: 431097 [PubMed - indexed for MEDLINE]

 **273:** [Witherspoon LR, Shuler SE, Garcia MM, Zollinger LA.](#) [Related Articles, Links](#)



Assessment of serum myoglobin as a marker for acute myocardial infarction.

J Nucl Med. 1979 Feb;20(2):115-9.

PMID: 430183 [PubMed - indexed for MEDLINE]

 **274:** [Sordahl LA.](#) [Related Articles, Links](#)



Role of mitochondria in heart cell function.

Tex Rep Biol Med. 1979;39:5-18.

PMID: 553325 [PubMed - indexed for MEDLINE]

 **275:** [Mercado TL, Garbus J.](#) [Related Articles, Links](#)



Creatine phosphokinase isoenzymes and Trypanosoma cruzi infections.

Comp Biochem Physiol B. 1979;64(1):11-5.

PMID: 45531 [PubMed - indexed for MEDLINE]


 **276:** [Maggs PR.](#) [Related Articles, Links](#)



CPK MB elevations in hypothermia.

Am Heart J. 1978 Nov;96(5):703. No abstract available.

PMID: 263405 [PubMed - indexed for MEDLINE]

 **277:** [D'Souza JP, Sine HE, Horvitz RA, Kubasik NP, Brody BB, Barold SS.](#) [Related Articles, Links](#)



The significance of the MB isoenzyme in patients with acute cardiovascular disease with a normal or borderline total CPK activity.

Clin Biochem. 1978 Oct;11(5):204-9.

PMID: 729162 [PubMed - indexed for MEDLINE]

 **278:** [Harwood SJ, Catrou PG, Cole GW.](#) [Related Articles, Links](#)



Creatine phosphokinase isoenzyme fractions in the serum of a patient struck by lightning.

Arch Intern Med. 1978 Apr;138(4):645-6.

PMID: 637650 [PubMed - indexed for MEDLINE]

 **279:** [Fiolet JW, Willebrands AF, Lie KI, Ter Welle HF, Durrer D.](#) [Related Articles, Links](#)



[The isoenzyme creatine phosphokinase-MB (CPK-MB) as an aid in the diagnosis of acute heart infarct]

Ned Tijdschr Geneesk. 1978 Mar 25;122(12):393-8. Dutch. No abstract available.

PMID: 643093 [PubMed - indexed for MEDLINE]


 **280:** [Carlson CJ, Emilson B, Rapaport E.](#) [Related Articles, Links](#)





















Creatine phosphokinase MB isoenzyme in hypothermia: case reports and experimental studies.

Am Heart J. 1978 Mar;95(3):352-8.

PMID: 622978 [PubMed - indexed for MEDLINE]

 **281:** [Delva E, Maille JG, Solymoss BC, Chabot M, Grondin CM, Bourassa MG.](#) [Related Articles, Links](#)

-  **Evaluation of myocardial damage during coronary artery grafting with serial determinations of serum CPK MB isoenzyme.**
J Thorac Cardiovasc Surg. 1978 Mar;75(3):467-75.
PMID: 305508 [PubMed - indexed for MEDLINE]
-  **282:** [Guzy PM.](#) Related Articles, Links
-  **Creatine phosphokinase-MB (CPK-MB) and the diagnosis of myocardial infarction.**
West J Med. 1977 Dec;127(6):455-60. Review. No abstract available.
PMID: 339548 [PubMed - indexed for MEDLINE]
-  **283:** [Wirz P, Blum J, Brunner HH.](#) Related Articles, Links
-  **[Effect of droperidol on the creatine phosphokinase activity in acute myocardial infarct]**
Schweiz Med Wochenschr. 1977 Nov 5;107(44):1595-6. German.
PMID: 918632 [PubMed - indexed for MEDLINE]
-  **284:** [Codd JE, Sullivan RG, Weins RD, Barner HB, Kaiser GC, Willman VL.](#) Related Articles, Links
-  **Myocardial injury following myocardial revascularization. Detection by isoenzyme analysis.**
Circulation. 1977 Sep;56(3 Suppl):II49-53.
PMID: 884827 [PubMed - indexed for MEDLINE]
-  **285:** [Atzeni E, Dessalvi F, Binaghi F, Corti D, Pitzus F.](#) Related Articles, Links
-  **[The specificity of the CPK MB enzyme kinetic test for the diagnosis of acute myocardial infarction (author's transl)]**
G Ital Cardiol. 1977 Aug;7(8):770-5. Italian.
PMID: 913934 [PubMed - indexed for MEDLINE]
-  **286:** [Klausner SC, Botvinick EH, Shames D, Ulliyot DJ, Fishman NH, Roe BB, Ebert PA, Chatterjee K, Parmley WW.](#) Related Articles, Links
-  **The application of radionuclide infarct scintigraphy to diagnose perioperative myocardial infarction following revascularization.**
Circulation. 1977 Aug;56(2):173-81.
PMID: 872307 [PubMed - indexed for MEDLINE]
-  **287:** [Dinovo EC, McIntosh ME, Lynn JK.](#) Related Articles, Links
-  **Erroneously low creatine kinase activity measurements with use of the Calbiochem CPK-MB kit with the Beckman TR Enzyme Analyzer.**
Clin Chem. 1977 Jul;23(7):1362-3. No abstract available.
PMID: 872391 [PubMed - indexed for MEDLINE]
-  **288:** [Lell WA, Walker DR, Blackstone EH, Kouchoukos NT, Allarde R, Roe CR.](#) Related Articles, Links
-  **Evaluation of myocardial damage in patients undergoing coronary-artery bypass procedures with halothane-N2O anesthesia and ajuvants.**
Anesth Analg. 1977 Jul-Aug;56(4):556-63.
PMID: 301724 [PubMed - indexed for MEDLINE]
-  **289:** [Yasminch WG, Pyle RB, Cohn JN, Nicoloff DM, Hanson NQ, Steele BW.](#) Related Articles, Links
-  **Serial serum creatine phosphokinase MB isoenzyme activity after myocardial infarction. Studies in the baboon and man.**
Circulation. 1977 May;55(5):733-7.
PMID: 403031 [PubMed - indexed for MEDLINE]
-  **290:** [Baker J, Wagner GS, Greenfield JC Jr.](#) Related Articles, Links

The management of acute coronary insufficiency.



Dis Mon. 1977 May;23(8):1-39. Review.
PMID: 324738 [PubMed - indexed for MEDLINE]

291: [Roe CR.](#)

[Related Articles, Links](#)



Diagnosis of myocardial infarction by serum isoenzyme analysis.
Ann Clin Lab Sci. 1977 May-Jun;7(3):201-9. Review.
PMID: 324344 [PubMed - indexed for MEDLINE]

292:

[Willerson JT, Stone MJ, Ting R, Mukherjee A, Gomez-Sanchez CE, Lewis P, Hersh LB.](#)

[Related Articles, Links](#)



Radioimmunoassay of creatine kinase-B isoenzyme in human sera: results in patients with acute myocardial infarction.
Proc Natl Acad Sci U S A. 1977 Apr;74(4):1711-5.
PMID: 266211 [PubMed - indexed for MEDLINE]

293:

[Roe CR, Cobb FR, Starmer CF.](#)

[Related Articles, Links](#)



The relationship between enzymatic and histologic estimates of the extent of myocardial infarction in conscious dogs with permanent coronary occlusion.
Circulation. 1977 Mar;55(3):438-49.
PMID: 837480 [PubMed - indexed for MEDLINE]

294:

[Warren SG, Wagner GS, Bethea CF, Roe CR, Oldham HN, Kong Y.](#)

[Related Articles, Links](#)



Diagnostic and prognostic significance of electrocardiographic and CPK isoenzyme changes following coronary bypass surgery: correlation with findings at one year.
Am Heart J. 1977 Feb;93(2):189-96.
PMID: 299973 [PubMed - indexed for MEDLINE]

295:

[Cipressi F, Nardini M, Zennaro R, Mattioli G.](#)

[Related Articles, Links](#)



[CPK-MB enzyme changes in coronary disease patients given various types of algogenic treatment]
Boll Soc Ital Cardiol. 1977;22(10):1875-6. Italian. No abstract available.
PMID: 753320 [PubMed - indexed for MEDLINE]

296:

[Atzeni E, Meleddu GE, Bande A, Binaghi F, Corti D, Sanna A, Pitzus F.](#)

[Related Articles, Links](#)



[Evaluation of the theoretical size of the area of acute myocardial infarct by observation of the CPK and CPK-MB enzyme flow curves (preliminary experiments)]
Boll Soc Ital Cardiol. 1977;22(8):1359-68. Italian. No abstract available.
PMID: 618270 [PubMed - indexed for MEDLINE]

297:

[Noble J, Garcia-Pascual B, Fathi M, Rosenbusch CA.](#)

[Related Articles, Links](#)



[Diagnosis of myocardial infarct by means of a quick determination of the MB fraction of serum creatinephosphokinase]
Schweiz Med Wochenschr. 1976 Dec 18;106(51):1867-70. French.
PMID: 1013716 [PubMed - indexed for MEDLINE]

298:

[Lederer WH, Gerstbrein HL, McClintock WC.](#)

[Related Articles, Links](#)



A column chromatographic method for the combined analysis of creatine kinase-MB (CPK-MB) and lactate dehydrogenase 1,2 (LDH 1,2) isoenzymes.
Am J Clin Pathol. 1976 Aug;66(2):425-31.
PMID: 949040 [PubMed - indexed for MEDLINE]

299:

[Roark SF, Wagner GS, Izlar HL Jr, Roe CR.](#)

[Related Articles, Links](#)



Diagnosis of acute myocardial infarction in a community hospital: significance of CPK-MB determination.
Circulation. 1976 Jun;53(6):965-9.
PMID: 1269133 [PubMed - indexed for MEDLINE]

☐ **300:** [Pyle RB, Blomberg DJ, Burke MD, Lindsay WG, Nicoloff DM.](#) [Related Articles, Links](#)



CPK-MB isoenzyme: use in diagnosis of acute myocardial infarction in the early postoperative period.
J Thorac Cardiovasc Surg. 1976 Jun;71(6):884-90.
PMID: 1271838 [PubMed - indexed for MEDLINE]

☐ **301:** [Jarmakani JM, Limbird L, Graham TC, Marks RA.](#) [Related Articles, Links](#)



Effect of reperfusion on myocardial infarct, and the accuracy of estimating infarct size from serum creatine phosphokinase in the dog.
Cardiovasc Res. 1976 Mar;10(2):245-53.
PMID: 938992 [PubMed - indexed for MEDLINE]

☐ **302:** [Wong R, Swallen TO.](#) [Related Articles, Links](#)



Cellulose acetate electrophoresis of creatine phosphokinase isoenzymes in the diagnosis of myocardial infarction.
Am J Clin Pathol. 1975 Aug;64(2):209-16.
PMID: 1155383 [PubMed - indexed for MEDLINE]

☐ **303:** [Tonkin AM, Lester RM, Guthrow CE, Roe CR, Hackel DB, Wagner GS.](#) [Related Articles, Links](#)



Persistence of MB isoenzyme of creatine phosphokinase in the serum after minor iatrogenic cardiac trauma. Absence of postmortem evidence of myocardial infarction.
Circulation. 1975 Apr;51(4):627.
PMID: 1116253 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** **Sort** **Send to** **Text**


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jun 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for [] [Go] [Clear]

Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

- Entrez PubMed
- Overview
- Help | FAQ
- Tutorial
- New/Noteworthy
- E-Utilities

- PubMed Services
- Journals Database
- MeSH Database
- Single Citation Matcher
- Batch Citation Matcher
- Clinical Queries
- LinkOut
- Cubby

- Related Resources
- Order Documents
- NLM Gateway
- TOXNET
- Consumer Health
- Clinical Alerts
- ClinicalTrials.gov
- PubMed Central

1: J Am Coll Cardiol. 2000 Mar 1;35(3):647-54. [Related Articles, Links](#)

NEW YORK SCIENTIFIC
FULL-TEXT ARTICLE


Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.


Ruotolo G, Bavenholm P, Brismar K, Efendic S, Ericsson CG, de Faire U, Nilsson J, Hamsten A.

Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Hospital, Sweden.


OBJECTIVES: We investigated whether the effect of bezafibrate on progression of coronary atherosclerosis in the BEzafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) was related to insulin-like growth factor (IGF)-I and glucose-insulin homeostasis. **BACKGROUND:** BECAIT, the first double-blind, placebo-controlled, randomized, serial angiographic trial of a fibrate compound, demonstrated that progression of focal coronary atherosclerosis in young patients after infarction could be retarded by bezafibrate treatment. **METHODS:** The treatment effects on serum concentrations of IGF-I and insulin-like growth factor binding protein (IGFBP)-1, as well as on basal and postload glucose and insulin levels, were examined, and on-trial determinations were related to the angiographic outcome measurements. **RESULTS:** Bezafibrate treatment resulted in a significant reduction of serum IGF-I levels, both at two and five years, and on-trial serum IGF-I levels were directly related to changes in both minimal lumen diameter ($r = 0.25$, $p < 0.05$) and mean segment diameter ($r = 0.29$, $p < 0.05$). In contrast, none of the available indexes of insulin resistance (homeostasis model assessment estimate, basal and postload plasma insulin concentrations and serum IGFBP-1 levels) were related to the angiographic changes, nor were they significantly affected by bezafibrate treatment. Multiple stepwise regression analysis showed that the relation between on-trial serum IGF-I level and coronary artery disease (CAD) progression was independent of baseline angiographic score, age, body mass index, serum lipoprotein and plasma fibrinogen concentrations and measures of glucose-insulin homeostasis. **CONCLUSIONS:** IGF-I could be implicated in the progression of premature CAD, and a reduction of serum IGF-I concentration could account partly for the effect of bezafibrate on progression of focal coronary atherosclerosis.

- Publication Types:
- Clinical Trial





National Library of Medicine



EntrezPubMedNucleotideProteinGenomeStructureOMIMPMCJournalsBooks

SearchPubMedforGoClear

LimitsPreview/IndexHistoryClipboardDetails

About Entrez

Display

Abstract

Show: 20

Sort

Send to

Text

Text Version

☐ 1: Am J Cardiol. 1999 Aug 15;84(4):430-3.

Related Articles, Links

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

Full Text Article

Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease.

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Spallarossa P, Rossettin P, Minuto F, Caruso D, Cordera R, Battistini M, Barreca A, Masperone MA, Brunelli C.

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Department of Internal Medicine, University of Genoa, Italy.

We have examined the effects of 6 months of treatment with growth hormone (GH) (0.02 U/kg/day) in 10 patients with chronic postischemic cardiac failure. Ten patients matched for age, body mass index, functional class, and ejection fraction served as a control group. In the GH group, 1 patient died and 2 were withdrawn from the study because of arrhythmia or worsening of heart failure. In the control group, 1 patient died and 1 patient was withdrawn from the study because of progressive heart failure. Among GH patients, those with an unfavorable outcome had a greater left ventricular end-diastolic diameter (79, 82, and 88 mm) on entry to the study than patients without adverse events (range 62 to 72 mm). At the end of the study, the seven GH patients reported a feeling of well-being and had a significant increase in their exercise test duration (462 +/- 121 vs 591 +/- 105 seconds, $p < 0.05$). Low baseline insulin-like growth factor-I values were increased with GH treatment (189 +/- 52 vs 100 +/- 22 ng/ml, $p < 0.01$). GH did not change left ventricular diameters or wall thickness. A trend toward decreased serum triglyceride levels and adipose body tissue associated with an increase in high-density lipoproteins was observed in the GH group. In conclusion, our present data support previous suggestions that GH treatment exerts some beneficial effects in patients with chronic, stabilized, moderately severe heart failure, but may have deleterious effects in patients with more severe heart failure.

- Publication Types:
- Clinical Trial
 - Controlled Clinical Trial

PMID: 10468082 [PubMed - indexed for MEDLINE]

Display


Abstract

Show: 20

Sort

Send to

Text



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for FGF-1 AND coronary artery disease Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Text Version

Items 1-7 of 7

One page.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.](#)

[Related Articles, Links](#)



Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.

Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 07.

PMID: 12907464 [PubMed - indexed for MEDLINE]

☐ 2: [Ananyeva N, Tjurmin A, Saenko E, Haudenschild C.](#)

[Related Articles, Links](#)



Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 06.

PMID: 12692004 [PubMed - indexed for MEDLINE]

☐ 3: [Selike FW, Ruel M.](#)

[Related Articles, Links](#)



Vascular growth factors and angiogenesis in cardiac surgery.

Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.

PMID: 12607713 [PubMed - indexed for MEDLINE]

☐ 4: [Schumacher B, Hannekum A, Pecher P.](#)

[Related Articles, Links](#)



[Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]

Z Kardiol. 2000;89 Suppl 7:23-30. German.

PMID: 11098556 [PubMed - indexed for MEDLINE]

☐ 5: [Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC.](#)

[Related Articles, Links](#)



Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart.

Microvasc Res. 1999 Nov;58(3):238-49.

PMID: 10527767 [PubMed - indexed for MEDLINE]

☐ 6: [Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.](#)

[Related Articles, Links](#)



Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.

Clin Chim Acta. 1999 May;283(1-2):171-82.

PMID: 10404741 [PubMed - indexed for MEDLINE]

☐ 7: [Selike FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.](#)

[Related Articles, Links](#)



Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.


Surgery. 1996 Aug;120(2):182-8.

PMID: 8751581 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for [] Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Surgery. 1996 Aug;120(2):182-8.

[Related Articles, Links](#)

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central


Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.

Department of Surgery, Beth Israel Hospital, Boston, MA 02215, USA.

BACKGROUND: The effect of periadventitial administration of acidic fibroblast growth factor (FGF) on coronary microvascular reactivity and blood flow was examined in the collateral-dependent and normally perfused myocardium. **METHODS:** Ameroid constrictors were placed on the proximal left circumflex (LCx) coronary artery in 14 pigs. In seven pigs acidic FGF (10 micrograms) was administered into the perivascular space of the proximal LCx artery by using an ethylene vinyl acetate copolymer slow release device. After 7 to 9 weeks coronary arterial microvessels (70 to 150 microns) were studied in a pressurized (40 mm Hg) no-flow state with video microscopy. **RESULTS:** Relaxation mediated by beta-adrenoceptors and induced by isoproterenol ($p < 0.05$), and endothelium-dependent relaxation induced by adenosine 5' diphosphate (ADP) ($p < 0.05$) of isolated microvessels from the collateral-dependent LCx region were markedly reduced compared with the respective responses of vessels from the normally perfused left anterior descending (LAD) artery region. Relaxation induced by the adenylate cyclase activator forskolin and the guanylate cyclase activator sodium nitroprusside were unaltered. Chronic treatment with acidic FGF normalized responses to isoproterenol ($p < 0.001$ versus nontreated LCx) and ADP ($p < 0.001$ versus nontreated LCx) in the collateral-dependent LCx region, whereas responses to forskolin and sodium nitroprusside were not changed. Blood flow in the collateral-dependent LCx region (0.49 ± 0.24 ml/min/gm) was less than that in the normally perfused LAD region (0.80 ± 0.24 ml/min/gm, $p < 0.05$). Treatment with acidic FGF improved perfusion in the LCx region (0.80 ± 0.06 ml/min/gm, $p < 0.05$) but did not significantly affect blood flow in the LAD territory (0.89 ± 0.09 ml/min/gm). **CONCLUSIONS:** The periadventitial delivery of acidic FGF normalizes vasomotor regulation by beta-adrenergic and endothelium-dependent mechanisms and improves myocardial perfusion to the collateral-dependent myocardium. This may have implications regarding the treatment of patients with severe coronary artery disease who are not amenable to conventional methods of revascularization.

PMID: 8751581 [PubMed - indexed for MEDLINE]



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for [] Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Microvasc Res. 1999 Nov;58(3):238-49.

Related Articles, Links

ADENOVIRUS-MEDIATED
 FULL-TEXT ARTICLE

Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart.

Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC.


Laboratory of Cardiovascular Science, National Institutes of Health, Baltimore, Maryland 21224, USA.

Most patients with severe coronary artery disease have normal baseline myocardial blood flow. Therefore, interventions aimed at inducing therapeutic angiogenesis in these patients should cause new blood vessel growth in the heart in the absence of chronic ischemia. It was examined whether adenovirus-mediated gene transfer of recombinant, secreted acidic fibroblast growth factor (sp+aFGF(1-154)), next to a major epicardial artery, may induce neovascularization and reduce the risk region for myocardial infarction upon coronary ligation near the injection site. Fifteen days prior to coronary artery occlusion, rabbits were treated with intramyocardial injections of AdCMV.sp+aFGF(1-154), the control vector AdCMV.NLSbetagal (1 x 10⁹) plaque-forming units, or saline. Messenger RNA transcripts for aFGF(1-154) were present up to 12 days after injection in the tissues exposed to AdCMV.aFGF(1-154). Following coronary artery occlusion rabbits treated with AdCMV.sp+aFGF(1-154) showed a 50% reduction of the risk region for myocardial infarction (P < 0.01 vs control). Histologic analysis showed a twofold increase in length density of intramural coronary arterioles (P < 0.01 vs control) and a 17% increase in length density of the capillary network (P < 0.001) in the myocardium exposed to AdCMV.sp+aFGF(1-154). Thus, gene therapy with AdCMV.sp+aFGF(1-154) can induce angiogenesis in the absence of chronic ischemia. The newly formed collateral blood vessels provide an anatomical basis for the reduction in the risk region for myocardial infarction upon subsequent occlusion of the coronary artery in proximity of the site where angiogenesis was induced. Copyright 1999 Academic Press.

PMID: 10527767 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk
 NCBI | NLM | NIH



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search PubMed for **aFGF AND coronary artery disease** Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 500 Sort Send to Text

Items 1-7 of 7 One page.

1: [Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.](#)

[Related Articles, Links](#)



Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.

Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 07.

PMID: 12907464 [PubMed - indexed for MEDLINE]

2: [Ananyeva N, Tjurmin A, Saenko E, Haudenschild C.](#)

[Related Articles, Links](#)



Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 06.

PMID: 12692004 [PubMed - indexed for MEDLINE]

3: [Selike FW, Ruel M.](#)

[Related Articles, Links](#)



Vascular growth factors and angiogenesis in cardiac surgery.

Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.

PMID: 12607713 [PubMed - indexed for MEDLINE]

4: [Schumacher B, Hannekum A, Pecher F.](#)

[Related Articles, Links](#)



[Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]

Z Kardiol. 2000;89 Suppl 7:23-30. German.

PMID: 11098556 [PubMed - indexed for MEDLINE]

5: [Safi H Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC.](#)

[Related Articles, Links](#)



Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart.

Microvasc Res. 1999 Nov;58(3):238-49.

PMID: 10527767 [PubMed - indexed for MEDLINE]

6: [Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.](#)

[Related Articles, Links](#)



Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.

Clin Chim Acta. 1999 May;283(1-2):171-82.

PMID: 10404741 [PubMed - indexed for MEDLINE]

7: [Selike FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.](#)

[Related Articles, Links](#)



Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.


Surgery. 1996 Aug;120(2):182-8.

PMID: 8751581 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search PubMed for acidic FGF AND coronary artery disease Go Clear
Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 500 Sort Send to Text
Items 1-2 of 2 One page.

☐ 1: [Ananyeva N, Tjurmin A, Saenko E, Haudenschild C.](#)

[Related Articles, Links](#)



Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 06.

PMID: 12692004 [PubMed - indexed for MEDLINE]

☐ 2: [Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M.](#)

[Related Articles, Links](#)



Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

Surgery. 1996 Aug;120(2):182-8.

PMID: 8751581 [PubMed - indexed for MEDLINE]


[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for FGF-2 AND coronary artery disease Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 500 Sort Send to Text
 Items 1-36 of 36 One page.

- ☐ 1: [van Royen N, Voskuil M, Hoefler I, Jost M, de Graaf S, Hedwig F, Andert JP, Wormhoudt TA, Hua J, Hartmann S, Bode C, Buschmann I, Schaper W, van der Neut R, Piek JJ, Pals ST.](#) Related Articles, Links

CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization.
 Circulation. 2004 Apr 6;109(13):1647-52. Epub 2004 Mar 15.
 PMID: 15023889 [PubMed - indexed for MEDLINE]

- ☐ 2: [Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tamok A, Gielen S, Emmrich F, Schuler G, Hambrecht R.](#) Related Articles, Links

Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.
 Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.
 PMID: 14988094 [PubMed - indexed for MEDLINE]

- ☐ 3: [Biswas SS, Hughes GC, Scarborough JE, Domkowski PW, Diodato L, Smith ML, Landolfo C, Lowe JE, Annex BH, Landolfo KP.](#) Related Articles, Links

Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study.
 J Thorac Cardiovasc Surg. 2004 Jan;127(1):34-43.
 PMID: 14752410 [PubMed - indexed for MEDLINE]

- ☐ 4: [Aviles RJ, Annex BH, Lederman RJ.](#) Related Articles, Links

Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).
 Br J Pharmacol. 2003 Oct;140(4):637-46.
 PMID: 14534147 [PubMed - in process]

- ☐ 5: [Ruel M, Sellke FW.](#) Related Articles, Links

Angiogenic protein therapy.
 Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review.
 PMID: 12973700 [PubMed - indexed for MEDLINE]


















- ☐ 6: [Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Li J, Laham RJ, Sellke FW.](#) Related Articles, Links

Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model.
 Circulation. 2003 Sep 9;108 Suppl 1:II335-40.
 PMID: 12970256 [PubMed - indexed for MEDLINE]

- ☐ 7: [Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.](#) Related Articles, Links

Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.
 Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 07.
 PMID: 12907464 [PubMed - indexed for MEDLINE]

- ☐ 8: [Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M.](#) Related Articles, Links

-  **Toward surgical angiogenesis using slow-released basic fibroblast growth factor.**
Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112.
PMID: 12853053 [PubMed - indexed for MEDLINE]
-  **9:** [Sellke FW, Ruel M.](#) Related Articles, Links
-  **Vascular growth factors and angiogenesis in cardiac surgery.**
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
PMID: 12607713 [PubMed - indexed for MEDLINE]
-  **10:** [Zhang C, Yang J, Feng J, Jennings LK.](#) Related Articles, Links
-  **Short-term administration of basic fibroblast growth factor enhances coronary collateral development without exacerbating atherosclerosis and balloon injury-induced vasoproliferation in atherosclerotic rabbits with acute myocardial infarction.**
J Lab Clin Med. 2002 Aug;140(2):119-25.
PMID: 12228768 [PubMed - indexed for MEDLINE]
-  **11:** [Katinoti AA, Tousoulis D, Economou E, Stefanadis C, Trikas A, Tentolouris C, Pitsavos C, Androulakis A, Toutouzas P.](#) Related Articles, Links
-  **Basic fibroblast growth factor changes in response to coronary angioplasty in patients with stable angina.**
Int J Cardiol. 2002 Aug;84(2-3):195-9.
PMID: 12127372 [PubMed - indexed for MEDLINE]
-  **12:** [Post MJ, Laham RJ, Kuntz RE, Novicki D, Simons M.](#) Related Articles, Links
-  **The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis.**
Clin Cardiol. 2002 Jun;25(6):271-8.
PMID: 12058790 [PubMed - indexed for MEDLINE]
-  **13:** [Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Mucla A, Castro JM, Fernandez-Ayerdi A, Cuevas P.](#) Related Articles, Links
-  **Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia?**
Eur J Med Res. 2002 Mar 28;7(3):93-7.
PMID: 11953278 [PubMed - indexed for MEDLINE]
-  **14:** [Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA.](#) Related Articles, Links
-  **Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial.**
Circulation. 2002 Feb 19;105(7):788-93.
PMID: 11854116 [PubMed - indexed for MEDLINE]
-  **15:** [Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA.](#) Related Articles, Links
-  **Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease.**
J Clin Pharmacol. 2001 Apr;41(4):378-85.
PMID: 11304894 [PubMed - indexed for MEDLINE]
-  **16:** [Rosengart TK, Hillebrand K.](#) Related Articles, Links
-  **Gene therapy for coronary artery disease.**
Adv Card Surg. 2001;13:107-20. Review. No abstract available.
PMID: 11209652 [PubMed - indexed for MEDLINE]

-  **17:** [Lambiase P, Edwards R, Bucknall CA, Marber MS.](#) [Related Articles, Links](#)



Physiologically assessed collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.


Circulation. 2001 Jan 30;103(4):E22. No abstract available.
PMID: 11157734 [PubMed - indexed for MEDLINE]

-  **18:** [Schumacher B, Hannekem A, Pecher P.](#) [Related Articles, Links](#)



[Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]


Z Kardiol. 2000;89 Suppl 7:23-30. German.
PMID: 11098556 [PubMed - indexed for MEDLINE]

-  **19:** [Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M.](#) [Related Articles, Links](#)



Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease.


Circulation. 2000 Oct 3;102(14):1605-10.
PMID: 11015335 [PubMed - indexed for MEDLINE]

-  **20:** [Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyumi AA.](#) [Related Articles, Links](#)



Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris.


Am J Cardiol. 2000 Jun 15;85(12):1414-9.
PMID: 10856385 [PubMed - indexed for MEDLINE]

-  **21:** [Lucassen AM, de Waal RM, Verheugt FW.](#) [Related Articles, Links](#)



[Therapeutic angiogenesis as a new experimental treatment for vascular disease]


Ned Tijdschr Geneesk. 2000 Apr 1;144(14):650-5. Review. Dutch.
PMID: 10774292 [PubMed - indexed for MEDLINE]

-  **22:** [Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA.](#) [Related Articles, Links](#)



Expression and function of PPARgamma in rat and human vascular smooth muscle cells.


Circulation. 2000 Mar 21;101(11):1311-8.
PMID: 10725292 [PubMed - indexed for MEDLINE]

-  **23:** [Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C.](#) [Related Articles, Links](#)



Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.


Circulation. 1999 Nov 9;100(19):1945-50.
PMID: 10556219 [PubMed - indexed for MEDLINE]

-  **24:** [Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.](#) [Related Articles, Links](#)



Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.

Clin Chim Acta. 1999 May;283(1-2):171-82.
PMID: 10404741 [PubMed - indexed for MEDLINE]


-  **25:** [Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S.](#) [Related Articles, Links](#)




Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.

Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7.

PMID: 10082659 [PubMed - indexed for MEDLINE]


-  **26:** [Laham RJ, Simons M, Tofukuji M, Hung D, Sellke FW.](#) [Related Articles, Links](#)

 Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: insight into ischemia-induced reduction in endothelium-dependent vasodilatation.

J Thorac Cardiovasc Surg. 1998 Dec;116(6):1022-8.


PMID: 9832695 [PubMed - indexed for MEDLINE]


-  **27:** [Iwakura A, Komeda M, Fujita M.](#) [Related Articles, Links](#)

 [Coronary stenosis and mechanisms of collateral vessel growth]

Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese.


PMID: 9796310 [PubMed - indexed for MEDLINE]


-  **28:** [Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M.](#) [Related Articles, Links](#)

 Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.

Ann Thorac Surg. 1998 Jun;65(6):1540-4.


PMID: 9647055 [PubMed - indexed for MEDLINE]


-  **29:** [Hasdai D, Barak V, Leibovitz E, Herz I, Sclarovsky S, Eldar M, Scheinowitz M.](#) [Related Articles, Links](#)

 Serum basic fibroblast growth factor levels in patients with ischemic heart disease.

Int J Cardiol. 1997 Apr 18;59(2):133-8.

PMID: 9158164 [PubMed - indexed for MEDLINE]


-  **30:** [Ito A, Shimokawa H, Fukumoto Y, Kadokami T, Nakaie R, Takayanagi T, Egashira K, Sueishi K, Takeshita A.](#) [Related Articles, Links](#)

 The role of fibroblast growth factor-2 in the vascular effects of interleukin-1 beta in porcine coronary arteries in vivo.

Cardiovasc Res. 1996 Sep;32(3):570-9.


PMID: 8881517 [PubMed - indexed for MEDLINE]


-  **31:** [Taylor AJ, Farb AA, Angello DA, Burwell LR, Virmani R.](#) [Related Articles, Links](#)

 Proliferative activity in coronary atherectomy tissue. Clinical, histopathologic, and immunohistochemical correlates.

Chest. 1995 Sep;108(3):815-20.

PMID: 7656639 [PubMed - indexed for MEDLINE]


-  **32:** [Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ.](#) [Related Articles, Links](#)

 Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis?

Circulation. 1994 Apr;89(4):1511-7.

PMID: 7908609 [PubMed - indexed for MEDLINE]


-  **33:** [Wilcox JN.](#) [Related Articles, Links](#)

 Molecular biology: insight into the causes and prevention of restenosis after arterial intervention.

Am J Cardiol. 1993 Oct 18;72(13):88E-95E. Review.

PMID: 8213576 [PubMed - indexed for MEDLINE]

-  **34:** [Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK.](#) [Related Articles, Links](#)

 A cascade model for restenosis. A special case of atherosclerosis progression.

Circulation. 1992 Dec;86(6 Suppl):III47-52. Review.

PMID: 1424051 [PubMed - indexed for MEDLINE]

☐ **35:** [Gordon D.](#)

[Related Articles, Links](#)



Growth factors and cell proliferation in human transplant arteriosclerosis.

J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 2):S7. No abstract available.

PMID: 1623005 [PubMed - indexed for MEDLINE]

☐ **36:** [Heidemann P.](#), [Hofling B.](#), [Heimerl J.](#), [Emberger C.](#), [Meyer G.](#),
[Kandolf R.](#), [Bauriedel G.](#)

[Related Articles, Links](#)



[Proliferative response of smooth muscle cells from human arteriosclerosis lesions to PDGF, bFGF and EGF]

Vasa Suppl. 1992;35:137-9. German. No abstract available.

PMID: 1481019 [PubMed - indexed for MEDLINE]

Display	Summary	Show: 500	Sort	Send to	Text
---------	---------	-----------	------	---------	------


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Fri 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

Limits Preview/Index History Clipboard Details

About Entrez

Show:

Text Version

☐ 1: J Thorac Cardiovasc Surg. 1998 Dec;116(6):1022-8.

Related Articles, Links

Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: insight into ischemia-induced reduction in endothelium-dependent vasodilatation.

Laham RJ, Simons M, Tofukuji M, Hung D, Sellke FW.

Cardiovascular Angiogenesis Center of the Department of Medicine and Surgery, Harvard Medical School and Beth Research Division, Chiron Corporation, Emeryville, CA, USA.

OBJECTIVES: The present study was designed to study the effects of a single intrapericardial injection of basic fibroblast growth factor on myocardial vascular resistance and endothelium-dependent microvascular dilatation in a porcine model of chronic myocardial ischemia and to investigate the mechanism of ischemia-induced impairment of endothelium-dependent vasodilatation. **METHODS:** Yorkshire pigs underwent ameroid constrictor placement on the left circumflex coronary artery. At 3 weeks, animals were randomized to a single intrapericardial injection of saline solution (n = 10), 30 micrograms basic fibroblast growth factor (n = 10), or 2 mg basic fibroblast growth factor (n = 10). Myocardial vascular resistance in the normal (left anterior descending) and ischemic collateral-dependent (left circumflex artery) territories (using colored microspheres) and microvascular reactivity to adenosine diphosphate and sodium nitroprusside were measured before treatment and 4 weeks after treatment. The expression of inducible and endothelial nitric oxide synthase was determined in normal and ischemic myocardium by means of reverse transcriptase-polymerase chain reaction and Western analysis, and the effect of nitric oxide on endothelium-dependent vasodilatation was determined. **RESULTS:** Compared with results in the control group, treatment with basic fibroblast growth factor resulted in significant improvement in left circumflex artery resistance and endothelium-dependent vasodilatation, reflecting increased collaterals. Myocardial ischemia was associated with increased expression of inducible nitric oxide synthase with no change in endothelial nitric oxide synthase. However, the nitric oxide donor sodium nitroprusside did not affect endothelium-dependent vasodilatation to adenosine diphosphate. **CONCLUSIONS:** A single intrapericardial bolus of basic fibroblast growth factor may be a useful therapeutic strategy for the treatment of myocardial ischemia in patients with coronary artery disease. Although chronic myocardial ischemia is associated with increased expression of inducible nitric oxide synthase, it does not appear to be the cause of altered endothelial function.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway


TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for bFGF AND coronary artery disease Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Text Version

Items 1-42 of 42

One page.

Entrez PubMed

Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities

PubMed Services

Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Caddy

Related Resources

Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central

- ☐ 1: [van Royen N, Voskuil M, Hoefer I, Jost M, de Graaf S, Hedwig F, Andert JP, Wormhoudt TA, Hua J, Hartmann S, Bode C, Buschmann I, Schaper W, van der Neut R, Piek JJ, Pals ST.](#) Related Articles, Links



CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization.
 Circulation. 2004 Apr 6;109(13):1647-52. Epub 2004 Mar 15.
 PMID: 15023889 [PubMed - indexed for MEDLINE]

- ☐ 2: [Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R.](#) Related Articles, Links



Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.
 Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.
 PMID: 14988094 [PubMed - indexed for MEDLINE]

- ☐ 3: [Biswas SS, Hughes GC, Scarborough JE, Domkowski PW, Diodato L, Smith ML, Landolfo C, Lowe JE, Annex BH, Landolfo KP.](#) Related Articles, Links



Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study.
 J Thorac Cardiovasc Surg. 2004 Jan;127(1):34-43.
 PMID: 14752410 [PubMed - indexed for MEDLINE]

- ☐ 4: [Panoutsopoulos D, Zafiropoulos A, Krambovitis E, Kochiadakis GE, Igoumenidis NE, Spandidos DA.](#) Related Articles, Links



Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression.
 J Transl Med. 2003 Oct 06;1(1):6.
 PMID: 14585103 [PubMed - as supplied by publisher]

- ☐ 5: [Fujita M, Ikemoto M, Tanaka T, Tamaki S, Yamazato A, Sawamura T, Hasegawa K, Kihara Y, Nohara R, Sasayama S.](#) Related Articles, Links



Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.
 Angiogenesis. 1998;2(1):105-8.
 PMID: 14517380 [PubMed]

- ☐ 6: [Ruel M, Sellke FW.](#) Related Articles, Links




















Angiogenic protein therapy.
 Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review.
 PMID: 12973700 [PubMed - indexed for MEDLINE]

- ☐ 7: [Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Li J, Laham RJ, Sellke FW.](#) Related Articles, Links



Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model.
 Circulation. 2003 Sep 9;108 Suppl 1:II335-40.
 PMID: 12970256 [PubMed - indexed for MEDLINE]


- ☐ 8: [Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R.](#) Related Articles, Links

-  **Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.**
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 07.
PMID: 12907464 [PubMed - indexed for MEDLINE]
-  **9: Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M.** [Related Articles, Links](#)
-  **Toward surgical angiogenesis using slow-released basic fibroblast growth factor.**
Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112.
PMID: 12853053 [PubMed - indexed for MEDLINE]
-  **10: Sellke FW, Ruel M.** [Related Articles, Links](#)
-  **Vascular growth factors and angiogenesis in cardiac surgery.**
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
PMID: 12607713 [PubMed - indexed for MEDLINE]
-  **11: Stompor T, Pasowicz M, Sullowicz W, Dembinska-Kiec A, Janda K, Wojcik K, Tracz W, Zdzienicka A, Klimeczek P, Janusz-Grzybowska E.** [Related Articles, Links](#)
-  **An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis.**
Am J Kidney Dis. 2003 Jan;41(1):203-11.
PMID: 12500238 [PubMed - indexed for MEDLINE]
-  **12: Zhang C, Yang J, Feng J, Jennings LK.** [Related Articles, Links](#)
-  **Short-term administration of basic fibroblast growth factor enhances coronary collateral development without exacerbating atherosclerosis and balloon injury-induced vasoproliferation in atherosclerotic rabbits with acute myocardial infarction.**
J Lab Clin Med. 2002 Aug;140(2):119-25.
PMID: 12228768 [PubMed - indexed for MEDLINE]
-  **13: Katinioti AA, Tousoulis D, Economou E, Stefanadis C, Trikas A, Tentolouris C, Pitsavos C, Androulakis A, Toutouzas P.** [Related Articles, Links](#)
-  **Basic fibroblast growth factor changes in response to coronary angioplasty in patients with stable angina.**
Int J Cardiol. 2002 Aug;84(2-3):195-9.
PMID: 12127372 [PubMed - indexed for MEDLINE]
-  **14: Post MJ, Laham RJ, Kuntz RE, Novicki D, Simons M.** [Related Articles, Links](#)
-  **The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis.**
Clin Cardiol. 2002 Jun;25(6):271-8.
PMID: 12058790 [PubMed - indexed for MEDLINE]
-  **15: Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P.** [Related Articles, Links](#)
-  **Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia?**
Eur J Med Res. 2002 Mar 28;7(3):93-7.
PMID: 11953278 [PubMed - indexed for MEDLINE]
-  **16: Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA.** [Related Articles, Links](#)
-  **Pharmacological treatment of coronary artery disease with recombinant**

fibroblast growth factor-2: double-blind, randomized, controlled clinical trial.

Circulation. 2002 Feb 19;105(7):788-93.

PMID: 11854116 [PubMed - indexed for MEDLINE]


-  **17:** [Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA.](#) Related Articles, Links



Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease.

J Clin Pharmacol. 2001 Apr;41(4):378-85.

PMID: 11304894 [PubMed - indexed for MEDLINE]

-  **18:** [Rosengart TK, Hillebrand K.](#)


Related Articles, Links



Gene therapy for coronary artery disease.

Adv Card Surg. 2001;13:107-20. Review. No abstract available.

PMID: 11209652 [PubMed - indexed for MEDLINE]

-  **19:** [Lambiase P, Edwards R, Bucknall CA, Marber MS.](#)


Related Articles, Links



Physiologically assessed collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.

Circulation. 2001 Jan 30;103(4):E22. No abstract available.

PMID: 11157734 [PubMed - indexed for MEDLINE]

-  **20:** [Schumacher B, Hannekum A, Pecher P.](#)


Related Articles, Links



[Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]

Z Kardiol. 2000;89 Suppl 7:23-30. German.

PMID: 11098556 [PubMed - indexed for MEDLINE]

-  **21:** [Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M.](#)


Related Articles, Links



Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease.

Circulation. 2000 Oct 3;102(14):1605-10.

PMID: 11015335 [PubMed - indexed for MEDLINE]

-  **22:** [Unger EE, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyum AA.](#)


Related Articles, Links



Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris.

Am J Cardiol. 2000 Jun 15;85(12):1414-9.

PMID: 10856385 [PubMed - indexed for MEDLINE]

-  **23:** [Lucassen AM, de Waal RM, Verheugt FW.](#)


Related Articles, Links



[Therapeutic angiogenesis as a new experimental treatment for vascular disease]

Ned Tijdschr Geneesk. 2000 Apr 1;144(14):650-5. Review. Dutch.

PMID: 10774292 [PubMed - indexed for MEDLINE]

-  **24:** [Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Derner L, Fishbein MC, Meehan WP, Hsueh WA.](#)


Related Articles, Links













Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

Circulation. 2000 Mar 21;101(11):1311-8.

PMID: 10725292 [PubMed - indexed for MEDLINE]

-  **25:** [Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, Unger EF.](#)

Related Articles, Links

-  **Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.**
Cardiovasc Res. 1999 Nov;44(2):294-302.
PMID: 10690306 [PubMed - indexed for MEDLINE]
-  **26:** Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C. [Related Articles, Links](#)
Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.
Circulation. 1999 Nov 9;100(19):1945-50.
PMID: 10556219 [PubMed - indexed for MEDLINE]
-  **27:** Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M. [Related Articles, Links](#)
Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.
Clin Chim Acta. 1999 May;283(1-2):171-82.
PMID: 10404741 [PubMed - indexed for MEDLINE]
-  **28:** Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S. [Related Articles, Links](#)
Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.
Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7.
PMID: 10082659 [PubMed - indexed for MEDLINE]
-  **29:** Laham RJ, Simons M, Tofukuji M, Hung D, Selike FW. [Related Articles, Links](#)
Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: insight into ischemia-induced reduction in endothelium-dependent vasodilatation.
J Thorac Cardiovasc Surg. 1998 Dec;116(6):1022-8.
PMID: 9832695 [PubMed - indexed for MEDLINE]
-  **30:** Iwakura A, Komeda M, Fujita M. [Related Articles, Links](#)
[Coronary stenosis and mechanisms of collateral vessel growth]
Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese.
PMID: 9796310 [PubMed - indexed for MEDLINE]
-  **31:** Selike FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. [Related Articles, Links](#)
Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.
Ann Thorac Surg. 1998 Jun;65(6):1540-4.
PMID: 9647055 [PubMed - indexed for MEDLINE]
-  **32:** Hasdai D, Barak V, Leibovitz E, Herz I, Sclarovsky S, Eldar M, Scheinowitz M. [Related Articles, Links](#)
Serum basic fibroblast growth factor levels in patients with ischemic heart disease.
Int J Cardiol. 1997 Apr 18;59(2):133-8.
PMID: 9158164 [PubMed - indexed for MEDLINE]
-  **33:** Ito A, Shinokawa H, Fukumoto Y, Kadokami T, Nakaike R, Takayanagi T, Egashira K, Sueishi K, Takeshita A. [Related Articles, Links](#)
The role of fibroblast growth factor-2 in the vascular effects of interleukin-1 beta in porcine coronary arteries in vivo.
Cardiovasc Res. 1996 Sep;32(3):570-9.
PMID: 8881517 [PubMed - indexed for MEDLINE]
-  **34:** Taylor AJ, Farb AA, Angello DA, Burwell LR, Virmani R. [Related Articles, Links](#)



Proliferative activity in coronary atherectomy tissue. Clinical, histopathologic, and immunohistochemical correlates.

Chest. 1995 Sep;108(3):815-20.

PMID: 7656639 [PubMed - indexed for MEDLINE]



35: [Chen CH](#), [Nguyen HH](#), [Weilbaecher D](#), [Luo S](#), [Gotto AM Jr](#), [Henry PD](#).

[Related Articles](#), [Links](#)



Basic fibroblast growth factor reverses atherosclerotic impairment of human coronary angiogenesis-like responses in vitro.

Atherosclerosis. 1995 Aug;116(2):261-8.

PMID: 7575781 [PubMed - indexed for MEDLINE]



36: [Hombach V](#), [Waltenberger J](#), [Voisard R](#), [Hoher M](#).

[Related Articles](#), [Links](#)



[Recurrent stenosis following coronary angioplasty. Clinical, cell biological and molecular aspects]

Z Kardiol. 1995 Jan;84(1):5-21. Review. German.

PMID: 7863714 [PubMed - indexed for MEDLINE]



37: [Grant MB](#), [Wargovich TJ](#), [Ellis EA](#), [Caballero S](#), [Mansour M](#), [Pepine CJ](#).

[Related Articles](#), [Links](#)



Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis?

Circulation. 1994 Apr;89(4):1511-7.

PMID: 7908609 [PubMed - indexed for MEDLINE]



38: [Wilcox JN](#).

[Related Articles](#), [Links](#)



Molecular biology: insight into the causes and prevention of restenosis after arterial intervention.

Am J Cardiol. 1993 Oct 18;72(13):88E-95E. Review.

PMID: 8213576 [PubMed - indexed for MEDLINE]



39: [Libby P](#), [Schwartz D](#), [Brogi E](#), [Tanaka H](#), [Clinton SK](#).

[Related Articles](#), [Links](#)



A cascade model for restenosis. A special case of atherosclerosis progression.

Circulation. 1992 Dec;86(6 Suppl):III47-52. Review.

PMID: 1424051 [PubMed - indexed for MEDLINE]



40: [Gordon D](#).

[Related Articles](#), [Links](#)



Growth factors and cell proliferation in human transplant arteriosclerosis.

J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 2):S7. No abstract available.

PMID: 1623005 [PubMed - indexed for MEDLINE]



41: [Heidemann P](#), [Hofling B](#), [Heimerl J](#), [Emberger C](#), [Meyer G](#), [Kandolf R](#), [Bauriedel G](#).

[Related Articles](#), [Links](#)



[Proliferative response of smooth muscle cells from human arteriosclerosis lesions to PDGF, bFGF and EGF]

Vasa Suppl. 1992;35:137-9. German. No abstract available.

PMID: 1481019 [PubMed - indexed for MEDLINE]



42: [DeFeudis FV](#).

[Related Articles](#), [Links](#)




Coronary atherosclerosis: current therapeutic approaches and future trends.

Life Sci. 1991;49(10):689-705. Review.

PMID: 1875779 [PubMed - indexed for MEDLINE]

Display Show:

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search PubMed for [] Go Clear
Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

1: Life Sci. 1991;49(10):689-705.

Related Articles, Links

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services

Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources

Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Coronary atherosclerosis: current therapeutic approaches and future trends.

DeFeudis FV.

Institute for BioScience, Grafton, MA 01519.

Invasive cardiovascular procedures, such as percutaneous transluminal coronary angioplasty (PTCA) and aorto-coronary bypass surgery (ACBS), that are currently employed in treating the coronary stenosis or occlusion caused by atherosclerosis represent a major therapeutic advance for managing coronary heart disease (CHD). However, the cellular proliferative response and associated intimal hyperplasia that can follow the damage to blood vessels that occurs with these procedures leads to late complications which cannot be effectively controlled by presently available drugs. Hence, a new approach is required for managing these complications, termed "restenosis" (in the case of PTCA) or "stenosis" (in the case of ACBS). Existing drug therapy is reviewed and some new approaches to this problem are provided herein. Further studies of growth factors and other substances that influence the cellular proliferative response that follows injury to the blood vessel wall could lead to the development of effective therapy. Inhibition of intimal hyperplasia and/or acceleration of endothelial cell re-growth provide a basis for such new approaches. Platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF), as well as endothelium-derived relaxing factor(s) (EDRF) and calcitonin gene-related peptide (CGRP) are among the substances discussed. Modification of certain currently available drugs (e.g. Ca(2+)-antagonists) could also be of value in meeting this therapeutic demand.


Publication Types:

- Review
- Review, Academic

PMID: 1875779 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk
NCBI | NLM | NIH



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for basic FGF AND coronary artery disease Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 500 Sort Send to Text
 Items 1-4 of 4 One page.

☐ 1: [Aviles RJ, Annex BH, Lederman RJ.](#)

[Related Articles, Links](#)



Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).

Br J Pharmacol. 2003 Oct;140(4):637-46.

PMID: 14534147 [PubMed - in process]

☐ 2: [Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M.](#)

[Related Articles, Links](#)



Toward surgical angiogenesis using slow-released basic fibroblast growth factor.

Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112.

PMID: 12853053 [PubMed - indexed for MEDLINE]

☐ 3: [Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P.](#)

[Related Articles, Links](#)



Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia?

Eur J Med Res. 2002 Mar 28;7(3):93-7.

PMID: 11953278 [PubMed - indexed for MEDLINE]

☐ 4: [Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ.](#)

[Related Articles, Links](#)



Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis?

Circulation. 1994 Apr;89(4):1511-7.

PMID: 7908609 [PubMed - indexed for MEDLINE]


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Fri 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for VEGF AND coronary artery disease Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Text Version

Items 1-94 of 94

One page.

Entrez PubMed

Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities

PubMed Services

Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Caddy

Related Resources

Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central

- ☐ 1: [Depre C, Kim SJ, John AS, Hong Huang Y, Rimoldi OE, Pepper JR, Dreyfus GD, Gaussin V, Pennell DJ, Vatner DE, Camici PG, Vatner SE.](#) Related Articles, Links



Program of Cell Survival Underlying Human and Experimental Hibernating Myocardium.

Circ Res. 2004 Jul 8 [Epub ahead of print]

PMID: 15242971 [PubMed - as supplied by publisher]

- ☐ 2: [Nakajima K, Tabata S, Yamashita T, Kusuhara M, Arakawa K, Ohmori R, Yonemura A, Higashi K, Ayaori M, Nakamura H, Ohsuzu F.](#) Related Articles, Links



Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease.

Clin Cardiol. 2004 May;27(5):281-6.

PMID: 15188944 [PubMed - in process]

- ☐ 3: [Lemstrom KB, Nykanen AI, Tikkanen JM, Krebs R, Sibvola RK, Kallio EA, Olivier R, Koskinen PK.](#) Related Articles, Links



Role of angiogenic growth factors in transplant coronary artery disease.

Ann Med. 2004;36(3):184-93.

PMID: 15181974 [PubMed - in process]

- ☐ 4: [Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y, March KL.](#) Related Articles, Links



Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease.

J Am Coll Cardiol. 2004 Apr 21;43(8):1383-7.

PMID: 15093871 [PubMed - indexed for MEDLINE]

- ☐ 5: [Gouni-Berthold I, Sachinidis A.](#) Related Articles, Links



Molecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseases.

Curr Pharm Des. 2004;10(11):1261-71. Review.

PMID: 15078140 [PubMed - indexed for MEDLINE]

- ☐ 6: [Perrin LA, June JE, Rosebury W, Robertson A, Kovesdi I, Bruder JT, Kessler PD, Keiser JA, Gordon D.](#) Related Articles, Links



Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).

Gene Ther. 2004 Mar;11(6):512-21.

PMID: 14999223 [PubMed - indexed for MEDLINE]

- ☐ 7: [Syed IS, Sanborn TA, Rosengart TK.](#) Related Articles, Links





Therapeutic angiogenesis: a biologic bypass.

Cardiology. 2004;101(1-3):131-43. Review.


PMID: 14988635 [PubMed - indexed for MEDLINE]


- ☐ 8: [Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R.](#) Related Articles, Links

-  **Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.**
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.
PMID: 14988094 [PubMed - indexed for MEDLINE]


 **9: Chong AY, Caine GJ, Lip GY.**


[Related Articles](#), [Links](#)

-  **Angiopoietin/tie-2 as mediators of angiogenesis: a role in congestive heart failure?**
Eur J Clin Invest. 2004 Jan;34(1):9-13.
PMID: 14984432 [PubMed - indexed for MEDLINE]


 **10: Schalch P, Rahman GF, Patejunas G, Goldschmidt RA, Carbray J, Retuerto MA, Kim D, Esser K, Crystal RG, Rosengart TK.**


[Related Articles](#), [Links](#)

-  **Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state.**
J Thorac Cardiovasc Surg. 2004 Feb;127(2):535-40.
PMID: 14762365 [PubMed - indexed for MEDLINE]


 **11: Symes JF.**


[Related Articles](#), [Links](#)

-  **Gene therapy for ischemic heart disease: therapeutic potential.**
Am J Cardiovasc Drugs. 2001;1(3):159-66. Review.
PMID: 14728030 [PubMed - indexed for MEDLINE]


 **12: Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, Nickenig G.**


[Related Articles](#), [Links](#)

-  **Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis.**
Circulation. 2004 Jan 20;109(2):220-6. Epub 2003 Dec 22.
PMID: 14691039 [PubMed - indexed for MEDLINE]


 **13: Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Simm A.**


[Related Articles](#), [Links](#)

-  **Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting.**
J Am Coll Cardiol. 2003 Dec 17;42(12):2073-80.
PMID: 14680729 [PubMed - indexed for MEDLINE]


 **14: Kolsut P, Malecki M, Zelazny P, Teresinska A, Firek B, Janik P, Religa Z.**


[Related Articles](#), [Links](#)

-  **Gene therapy of coronary artery disease with phvegf165--early outcome.**
Kardiol Pol. 2003 Nov;59(11):373-84. English, Polish.
PMID: 14668888 [PubMed - indexed for MEDLINE]


 **15: Baklanov D, Simons M.**


[Related Articles](#), [Links](#)

-  **Arteriogenesis: lessons learned from clinical trials.**
Endothelium. 2003;10(4-5):217-23. Review.
PMID: 14660081 [PubMed - indexed for MEDLINE]


 **16: Roguin A, Resar JR.**










[Related Articles](#), [Links](#)






















-  **Genetics and susceptibility of coronary collateral formation.**
Circulation. 2003 Nov 25;108(21):e149; author reply e149. No abstract available.
PMID: 14638531 [PubMed - indexed for MEDLINE]


 **17: Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GY.**


[Related Articles](#), [Links](#)


-  **Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease.**
Heart. 2003 Dec;89(12):1411-5.
PMID: 14617549 [PubMed - indexed for MEDLINE]


-  **18:** [Panoutsopoulos D, Zafiropoulos A, Krambovitis E, Kochiadakis GE, Igoumenidis NE, Spandidos DA.](#) [Related Articles, Links](#)
Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression.
 J Transl Med. 2003 Oct 06;1(1):6.
 PMID: 14585103 [PubMed - as supplied by publisher]
-  **19:** [Juan-Babot JO, Martinez-Gonzalez J, Berrozpe M, Badimon L.](#) [Related Articles, Links](#)
[Neovascularization in human coronary arteries with lesions of different severity]
 Rev Esp Cardiol. 2003 Oct;56(10):978-86. Spanish.
 PMID: 14563292 [PubMed - indexed for MEDLINE]
-  **20:** [Nishimura S, Zaitzu M, Hara M, Yokota G, Watanabe M, Ueda Y, Imayoshi M, Ishii E, Tasaki H, Hamasaki Y.](#) [Related Articles, Links](#)
A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease.
 J Pediatr. 2003 Sep;143(3):357-62.
 PMID: 14517520 [PubMed - indexed for MEDLINE]
-  **21:** [Fujita M, Ikemoto M, Tanaka T, Tamaki S, Yamazato A, Sawamura T, Hasegawa K, Kihara Y, Nohara R, Sasayama S.](#) [Related Articles, Links](#)
Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.
 Angiogenesis. 1998;2(1):105-8.
 PMID: 14517380 [PubMed]
-  **22:** [Crottogini A, Meckert PC, Vera Janavel G, Lascano E, Negroni J, Del Valle H, Dulbecco E, Werba P, Cuniberti L, Martinez V, De Lorenzi A, Telayna J, Mele A, Fernandez JL, Marangunic L, Criscuolo M, Capogrossi MC, Laguens R.](#) [Related Articles, Links](#)
Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs.
 Hum Gene Ther. 2003 Sep 20;14(14):1307-18.
 PMID: 14503966 [PubMed - indexed for MEDLINE]
-  **23:** [Ruel M, Sellke FW.](#) [Related Articles, Links](#)
Angiogenic protein therapy.
 Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review.
 PMID: 12973700 [PubMed - indexed for MEDLINE]
-  **24:** [Hedman M, Yla-Herttuala S.](#) [Related Articles, Links](#)
Gene therapy for the treatment of peripheral vascular disease and coronary artery disease.
 Drugs Today (Barc). 2000 Sep;36(9):609-17.
 PMID: 12847566 [PubMed]
-  **25:** [Chung NA, Makin AJ, Lip GY.](#) [Related Articles, Links](#)
Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay.
 Eur J Clin Invest. 2003 Jul;33(7):529-35.
 PMID: 12814387 [PubMed - indexed for MEDLINE]
-  **26:** [Kastrup J.](#) [Related Articles, Links](#)
Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy?
 Curr Gene Ther. 2003 Jun;3(3):197-206. Review.
 PMID: 12762479 [PubMed - indexed for MEDLINE]


-  **27:** [Rasmussen HS, Rasmussen CS, Macko J.](#) [Related Articles, Links](#)
 **VEGF gene therapy for coronary artery disease and peripheral vascular disease.**
 Cardiovasc Radiat Med. 2002 Apr-Jun;3(2):114-7. Review.
 PMID: 12699842 [PubMed - indexed for MEDLINE]
-  **28:** [Kusumanto YH, Hospers GA, Mulder NH, Tio RA.](#) [Related Articles, Links](#)
 **Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review.**
 Int J Cardiovasc Intervent. 2003;5(1):27-34. Review.
 PMID: 12623562 [PubMed - indexed for MEDLINE]
-  **29:** [Sellke FW, Ruel M.](#) [Related Articles, Links](#)
 **Vascular growth factors and angiogenesis in cardiac surgery.**
 Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
 PMID: 12607713 [PubMed - indexed for MEDLINE]
-  **30:** [Khan TA, Sellke FW, Laham RJ.](#) [Related Articles, Links](#)
 **Therapeutic angiogenesis: protein-based therapy for coronary artery disease.**
 Expert Opin Pharmacother. 2003 Feb;4(2):219-26. Review.
 PMID: 12562312 [PubMed - indexed for MEDLINE]
-  **31:** [Sim EK, Zhang L, Shim WS, Lim YL, Ge R.](#) [Related Articles, Links](#)
 **Therapeutic angiogenesis for coronary artery disease.**
 J Card Surg. 2002 Jul-Aug;17(4):350-4. Review.
 PMID: 12546086 [PubMed - indexed for MEDLINE]
-  **32:** [Kutryk MJ, Stewart DJ.](#) [Related Articles, Links](#)
 **Angiogenesis of the heart.**
 Microsc Res Tech. 2003 Feb 1;60(2):138-58. Review.
 PMID: 12539168 [PubMed - indexed for MEDLINE]
-  **33:** [Lenihan DJ, Osman A, Sriram V, Aitsebaomo J, Patterson C.](#) [Related Articles, Links](#)
 **Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease.**
 Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1507-12. Epub 2003 Jan 09.
 PMID: 12521946 [PubMed - indexed for MEDLINE]
-  **34:** [Lee CH, Smits PC.](#) [Related Articles, Links](#)
 **Vascular growth factors for coronary angiogenesis.**
 J Interv Cardiol. 2002 Dec;15(6):511-8. Review.
 PMID: 12476656 [PubMed - indexed for MEDLINE]
-  **35:** [Rasmussen HS, Rasmussen CS, Macko J, Yonehiro G.](#) [Related Articles, Links](#)
 **Angiogenic gene therapy strategies for the treatment of cardiovascular disease.**
 Curr Opin Mol Ther. 2002 Oct;4(5):476-81. Review.
 PMID: 12435049 [PubMed - indexed for MEDLINE]
-  **36:** [Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG.](#) [Related Articles, Links](#)
 **Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.**
 Mol Ther. 2002 Aug;6(2):287-97.
 PMID: 12349828 [PubMed - indexed for MEDLINE]
-  **37:** [Freedman SB, Vale P, Kalka C, Kearney M, Pieczek A, Symes J, Losordo D, Isner JM.](#) [Related Articles, Links](#)


 Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA. Hum Gene Ther. 2002 Sep 1;13(13):1595-603. PMID: 12228014 [PubMed - indexed for MEDLINE]


 **38:** Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. Related Articles, Links


 Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke. 2002 Sep;33(9):2187-91. PMID: 12215585 [PubMed - indexed for MEDLINE]


 **39:** Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF. Related Articles, Links

 A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther. 2002 Jul;72(1):20-32. PMID: 12152001 [PubMed - indexed for MEDLINE]


 **40:** Alber HF, Dulak J, Frick M, Dichtl W, Schwarzbacher SP, Pachinger O, Weidinger F. Related Articles, Links


 Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol. 2002 Jun 19;39(12):1951-5. PMID: 12084593 [PubMed - indexed for MEDLINE]


 **41:** Cotton JM, Mathur A, Hong Y, Brown AS, Martin JF, Erusalimsky JD. Related Articles, Links


 Acute rise of circulating vascular endothelial growth factor-A in patients with coronary artery disease following cardiothoracic surgery. Eur Heart J. 2002 Jun;23(12):953-9. PMID: 12069450 [PubMed - indexed for MEDLINE]


 **42:** Vale PR, Isner JM, Rosenfield K. Related Articles, Links

 Therapeutic angiogenesis in critical limb and myocardial ischemia. J Interv Cardiol. 2001 Oct;14(5):511-28. Review. PMID: 12053643 [PubMed - indexed for MEDLINE]


 **43:** Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, Stacker SA, Carnevale KA, Siemionow M, Deitcher SR, DiCorleto PE. Related Articles, Links

 Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood. 2002 Jun 15;99(12):4434-42. PMID: 12036873 [PubMed - indexed for MEDLINE]


















 **44:** Herrmann J, Best PJ, Ritman EL, Holmes DR, Lerman LO, Lerman A. Related Articles, Links

 Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Am Coll Cardiol. 2002 May 1;39(9):1555-61. PMID: 11985922 [PubMed - indexed for MEDLINE]





















 **45:** Rosen LS. Related Articles, Links

 Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44. Review. PMID: 11965229 [PubMed - indexed for MEDLINE]

Zimmerman MA, Selzman CH, Raeburn CD, Calkins CM.

-  **46:** [Barsness K, Harken AH.](#) [Related Articles, Links](#)
-  **Clinical applications of cardiovascular angiogenesis.**
J Card Surg. 2001 Nov-Dec;16(6):490-7. Review.
PMID: 11925031 [PubMed - indexed for MEDLINE]
-  **47:** [Sarkar N, Ruck A, Kallner G, Y-Hassan S, Blomberg P, Islam KB, van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C.](#) [Related Articles, Links](#)
-  **Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy.**
J Intern Med. 2001 Nov;250(5):373-81.
PMID: 11887971 [PubMed - indexed for MEDLINE]
-  **48:** [Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY.](#) [Related Articles, Links](#)
-  **Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes.**
Clin Sci (Lond). 2002 Feb;102(2):187-94.
PMID: 11834138 [PubMed - indexed for MEDLINE]
-  **49:** [Sarkar N, Blomberg P, Wardell E, Eskandarpour M, Sylven C, Drvota V, Islam KB.](#) [Related Articles, Links](#)
-  **Nonsurgical direct delivery of plasmid DNA into rat heart: time course, dose response, and the influence of different promoters on gene expression.**
J Cardiovasc Pharmacol. 2002 Feb;39(2):215-24.
PMID: 11791007 [PubMed - indexed for MEDLINE]
-  **50:** [Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C.](#) [Related Articles, Links](#)
-  **Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.**
Hum Gene Ther. 2002 Jan 1;13(1):65-100.
PMID: 11779413 [PubMed - indexed for MEDLINE]
-  **51:** [Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG.](#) [Related Articles, Links](#)
-  **Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.**
Hum Gene Ther. 2002 Jan 1;13(1):15-63.
PMID: 11779412 [PubMed - indexed for MEDLINE]
-  **52:** [Freedman SB, Isner JM.](#) [Related Articles, Links](#)
-  **Therapeutic angiogenesis for coronary artery disease.**
Ann Intern Med. 2002 Jan 1;136(1):54-71. Review.
PMID: 11777364 [PubMed - indexed for MEDLINE]
-  **53:** [Dulak J, Jozkowicz A, Frick M, Alber HF, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F.](#) [Related Articles, Links](#)
-  **Vascular endothelial growth factor: angiogenesis, atherogenesis or both?**
J Am Coll Cardiol. 2001 Dec;38(7):2137-8. No abstract available.
PMID: 11738334 [PubMed - indexed for MEDLINE]
-  **54:** [Huwer H, Welter C, Ozbek C, Seifert M, Straub U, Greilach P, Kalweit G, Isringhaus H.](#) [Related Articles, Links](#)

Simultaneous surgical revascularization and angiogenic gene therapy in

-  diffuse coronary artery disease.
Eur J Cardiothorac Surg. 2001 Dec;20(6):1128-34.
PMID: 11717016 [PubMed - indexed for MEDLINE]
-  **55:** [Davda J, Labhasetwar V.](#) Related Articles, Links
-  An update on angiogenesis therapy.
Crit Rev Eukaryot Gene Expr. 2001;11(1-3):1-21. Review.
PMID: 11693956 [PubMed - indexed for MEDLINE]
-  **56:** [Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Losordo DW, Hendel RC, Bonow RO, Eppler SM, Zioncheck TF, Holmgren EB, McCluskey ER.](#) Related Articles, Links
-  Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.
Am Heart J. 2001 Nov;142(5):872-80.
PMID: 11685177 [PubMed - indexed for MEDLINE]
-  **57:** [Choukroun G.](#) Related Articles, Links
-  [Prevention and treatment of type 1 diabetes]
Presse Med. 2001 Sep 1;30(24 Pt 2):21-3. French.
PMID: 11577580 [PubMed - indexed for MEDLINE]
-  **58:** [Basara N.](#) Related Articles, Links
-  AdGVVEGF121.10 (GenVec).
Curr Opin Investig Drugs. 2001 Jun;2(6):792-5. Review.
PMID: 11572658 [PubMed - indexed for MEDLINE]
-  **59:** [Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM.](#) Related Articles, Links
-  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.
J Clin Invest. 2001 Aug;108(3):391-7.
PMID: 11489932 [PubMed - indexed for MEDLINE]
-  **60:** [Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N.](#) Related Articles, Links
-  Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease.
Heart Vessels. 2000;15(3):105-11.
PMID: 11289497 [PubMed - indexed for MEDLINE]
-  **61:** [Ray S, Panja M.](#) Related Articles, Links
-  Current understanding of pathogenesis of coronary artery disease and its future implications.
J Indian Med Assoc. 2000 Nov;98(11):710-1, 714, 718.
PMID: 11265801 [PubMed - indexed for MEDLINE]
-  **62:** [Brizzi MF, Formato L, Bonamini R.](#) Related Articles, Links
-  The molecular mechanisms of angiogenesis: a new approach to cardiovascular diseases.
Ital Heart J. 2001 Feb;2(2):81-92. Review.
PMID: 11256548 [PubMed - indexed for MEDLINE]
-  **63:** [Morse MA.](#) Related Articles, Links
-  Technology evaluation: VEGF165 gene therapy, Valentis Inc.
Curr Opin Mol Ther. 2001 Feb;3(1):97-101. Review.
PMID: 11249737 [PubMed - indexed for MEDLINE]
-  **64:** [Rosengart TK, Hillebrand K.](#) Related Articles, Links

**Gene therapy for coronary artery disease.**

Adv Card Surg. 2001;13:107-20. Review. No abstract available.
PMID: 11209652 [PubMed - indexed for MEDLINE]

65: [Freedman SB, Isner JM.](#)

[Related Articles, Links](#)

**Therapeutic angiogenesis for ischemic cardiovascular disease.**

J Mol Cell Cardiol. 2001 Mar;33(3):379-93. Review.
PMID: 11181008 [PubMed - indexed for MEDLINE]

66: [Durairaj A, Mehra A, Singh RP, Faxon DP.](#)

[Related Articles, Links](#)

**Therapeutic angiogenesis.**

Cardiol Rev. 2000 Sep-Oct;8(5):279-87. Review.
PMID: 11174906 [PubMed - indexed for MEDLINE]

67: [Rutanen J, Rissanen TT, Kivela A, Vajanto I, Yla-Herttuala S.](#)

[Related Articles, Links](#)

**Clinical applications of vascular gene therapy.**

Curr Cardiol Rep. 2001 Jan;3(1):29-36. Review.
PMID: 11139796 [PubMed - indexed for MEDLINE]

68: [Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM.](#)

[Related Articles, Links](#)

**Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.**

Anesth Analg. 2001 Jan;92(1):19-25.
PMID: 11133594 [PubMed - indexed for MEDLINE]

69: [Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, Isner JM.](#)

[Related Articles, Links](#)

**Left ventricular electromechanical mapping to assess efficacy of phVEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.**

Circulation. 2000 Aug 29;102(9):965-74.
PMID: 10961959 [PubMed - indexed for MEDLINE]

70: [Mukherjee D, Ellis SG.](#)

[Related Articles, Links](#)

**New options for untreatable coronary artery disease: angiogenesis and laser revascularization.**

Cleve Clin J Med. 2000 Aug;67(8):577-83.
PMID: 10946453 [PubMed - indexed for MEDLINE]

71: [O'Brien T, Simari RD.](#)

[Related Articles, Links](#)

**Gene therapy for atherosclerotic cardiovascular disease: a time for optimism and caution.**

Mayo Clin Proc. 2000 Aug;75(8):831-4. Review.
PMID: 10943238 [PubMed - indexed for MEDLINE]

72: [Lucassen AM, de Waal RM, Verheugt FW.](#)

[Related Articles, Links](#)

**[Therapeutic angiogenesis as a new experimental treatment for vascular disease]**


Ned Tijdschr Geneesk. 2000 Apr 1;144(14):650-5. Review. Dutch.
PMID: 10774292 [PubMed - indexed for MEDLINE]


73: [Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, Unger EF.](#)

[Related Articles, Links](#)


**Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.**


Cardiovasc Res. 1999 Nov;44(2):294-302.
PMID: 10690306 [PubMed - indexed for MEDLINE]


 **74:** [Chawla PS, Keelan MH, Kipshidze N.](#) Related Articles, Links


 **Angiogenesis for the treatment of vascular diseases.**
Int Angiol. 1999 Sep;18(3):185-92. Review.
PMID: 10688416 [PubMed - indexed for MEDLINE]


 **75:** [Moussa I, Moses JW.](#) Related Articles, Links


 **Angiogenesis for treatment of ischemic heart disease: should we worry about progression of atherosclerosis?**
Circulation. 1999 Nov 30;100(22):e109. No abstract available.
PMID: 10578010 [PubMed - indexed for MEDLINE]


 **76:** [Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C.](#) Related Articles, Links


 **Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.**
Circulation. 1999 Nov 9;100(19):1945-50.
PMID: 10556219 [PubMed - indexed for MEDLINE]


 **77:** [Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG.](#) Related Articles, Links


 **Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.**
Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2.
PMID: 10522716 [PubMed - indexed for MEDLINE]


 **78:** [Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mavskiy M, Isner JM.](#) Related Articles, Links

 **Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.**
Ann Thorac Surg. 1999 Sep;68(3):830-6; discussion 836-7.
PMID: 10509970 [PubMed - indexed for MEDLINE]


 **79:** [Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, Levy AP.](#) Related Articles, Links


 **Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation.**
Circulation. 1999 Aug 3;100(5):547-52.
PMID: 10430770 [PubMed - indexed for MEDLINE]


 **80:** [Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG.](#) Related Articles, Links

 **Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.**
Circulation. 1999 Aug 3;100(5):468-74.
PMID: 10430759 [PubMed - indexed for MEDLINE]

 **81:** [Losordo DW, Vale PR, Isner JM.](#) Related Articles, Links


 **Gene therapy for myocardial angiogenesis.**
Am Heart J. 1999 Aug;138(2 Pt 2):S132-41. Review.
PMID: 10426872 [PubMed - indexed for MEDLINE]


 **82:** [Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M.](#) Related Articles, Links


 **Development of enzyme-linked immunosorbent assay for acidic fibroblast**


growth factor and its clinical application.
 Clin Chim Acta. 1999 May;283(1-2):171-82.
 PMID: 10404741 [PubMed - indexed for MEDLINE]


 **83:** [Patterson C, Runge MS.](#) Related Articles, Links


 **Therapeutic angiogenesis: the new electrophysiology?**
 Circulation. 1999 May 25;99(20):2614-6. Review. No abstract available.
 PMID: 10338451 [PubMed - indexed for MEDLINE]


 **84:** [Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S.](#) Related Articles, Links


 **Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.**
 Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7.
 PMID: 10082659 [PubMed - indexed for MEDLINE]


 **85:** [Chen YX, Nakashima Y, Tanaka K, Shiraishi S, Nakagawa K, Sueishi K.](#) Related Articles, Links

 **Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries.**
 Arterioscler Thromb Vasc Biol. 1999 Jan;19(1):131-9.
 PMID: 9888875 [PubMed - indexed for MEDLINE]


 **86:** [Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM.](#) Related Articles, Links

 **Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.**
 Circulation. 1998 Dec 22-29;98(25):2800-4.
 PMID: 9860779 [PubMed - indexed for MEDLINE]


 **87:** [Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K.](#) Related Articles, Links


 **Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis.**
 Circulation. 1998 Nov 17;98(20):2108-16.
 PMID: 9815864 [PubMed - indexed for MEDLINE]


 **88:** [Iwakura A, Komeda M, Fujita M.](#) Related Articles, Links


 **[Coronary stenosis and mechanisms of collateral vessel growth]**
 Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese.
 PMID: 9796310 [PubMed - indexed for MEDLINE]

 **89:** [Komatsu R, Ueda M.](#) Related Articles, Links

 **[Plaque progression and destabilization in human coronary arteries]**
 Nippon Rinsho. 1998 Oct;56(10):2477-82. Review. Japanese.
 PMID: 9796305 [PubMed - indexed for MEDLINE]

 **90:** [Goalstone ML, Natarajan R, Standley PR, Walsh MF, Leitner JW, Carel K, Scott S, Nadler J, Sowers JR, Draznin B.](#) Related Articles, Links

 **Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells.**
 Endocrinology. 1998 Oct;139(10):4067-72.
 PMID: 9751484 [PubMed - indexed for MEDLINE]

 **91:** [Métais C, Li J, Li J, Simons M, Sellke FW.](#) Related Articles, Links



Effects of coronary artery disease on expression and microvascular response to VEGF.

Am J Physiol. 1998 Oct;275(4 Pt 2):H1411-8.

PMID: 9746492 [PubMed - indexed for MEDLINE]



92: [Brilla CG, Rybinski L, Gehrke D, Rupp H.](#)

[Related Articles, Links](#)



[Transmyocardial laser revascularization--an innovative pathophysiologic concept]

Herz. 1997 Aug;22(4):183-9. Review. German.

PMID: 9378452 [PubMed - indexed for MEDLINE]



93: [Labarrere CA, Faulk WP.](#)

[Related Articles, Links](#)



Antithrombin determinants of coronary artery disease in transplanted human hearts.

Semin Hematol. 1995 Oct;32(4 Suppl 2):61-6. Review. No abstract available.

PMID: 8821212 [PubMed - indexed for MEDLINE]



94: [Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT, Koren G, Colucci WS, Goldberg MA.](#)

[Related Articles, Links](#)



Regulation of vascular endothelial growth factor in cardiac myocytes.

Circ Res. 1995 May;76(5):758-66.

PMID: 7728992 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** Sort **Send to** **Text**


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for [] Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

Entrez PubMed

Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities

PubMed Services

Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Caddy

Related Resources

Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central

1: Am J Physiol. 1998 Oct;275(4 Pt 2):H1411-8.

Related Articles, Links

Am J Physiology

Effects of coronary artery disease on expression and microvascular response to VEGF.

Metais C, Li J, Li J, Simons M, Sellke FW.

Division of Cardiothoracic Surgery, Department of Surgery, Department of Medicine of Beth Israel-Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.

The effects of coronary artery disease (CAD) on human coronary microvascular responses to vascular endothelial growth factor (VEGF) and the alterations of the myocardial expressions of VEGF and its flk-1 and flt-1 receptors were examined in 48 patients. Microvascular studies were performed in vitro with video microscopy. The expressions of VEGF and its receptors were examined using Northern analysis of total mRNA, and the expressions of constitutive nitric oxide synthase (cNOS) and inducible nitric oxide synthase (iNOS) were examined by RT-PCR. VEGF and hepatocyte growth factor (HGF) caused potent relaxations of microvessels. These responses were reduced in the presence of NG-nitro-L-arginine and the tyrosine kinase inhibitor genistein or in microvessels from patients with CAD. Relaxations to substance P and sodium nitroprusside were similar in both groups. The substance P response was abolished in the presence of NG-nitro-L-arginine. The expression of VEGF and its receptors and the expression of cNOS and iNOS were not altered in patients with CAD. In conclusion, VEGF and HGF elicit the release of nitric oxide through activation of tyrosine kinase receptors. CAD is associated with reduced vascular responses to both VEGF and HGF; this is not likely due to a reduced expression of VEGF or flt-1 or flk-1 receptors and not due to a generalized endothelium dysfunction despite the presence of mild hypercholesterolemia in these patients with CAD. These findings may have important implications regarding the efficacy of endogenous and exogenous VEGF in patients with risk factor for CAD.


PMID: 9746492 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for [] Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Circulation. 1998 Dec 22-29;98(25):2800-4.

Related Articles, Links

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

FREE full text article at
circ.ahajournals.org

Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.

Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM.

Departments of Medicine, Biomedical Research, Surgery, and Anesthesiology, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Mass 02135, USA.

BACKGROUND: We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of vascular endothelial growth factor (VEGF) as sole therapy for patients with symptomatic myocardial ischemia. **METHODS AND RESULTS:** VEGF gene transfer (GTx) was performed in 5 patients (all male, ages 53 to 71) who had failed conventional therapy; these men had angina (determined by angiographically documented coronary artery disease). Naked plasmid DNA encoding VEGF (phVEGF165) was injected directly into the ischemic myocardium via a mini left anterior thoracotomy. Injections caused no changes in heart rate (pre-GTx=75 \pm 15/min versus post-GTx=80 \pm 16/min, P=NS), systolic BP (114 \pm 7 versus 118 \pm 7 mm Hg, P=NS), or diastolic BP (57 \pm 2 versus 59 \pm 2 mm Hg, P=NS). Ventricular arrhythmias were limited to single unifocal premature beats at the moment of injection. Serial ECGs showed no evidence of new myocardial infarction in any patient. Intraoperative blood loss was 0 to 50 cm³, and total chest tube drainage was 110 to 395 cm³. Postoperative cardiac output fell transiently but increased within 24 hours (preanesthesia=4.8 \pm 0.4 versus postanesthesia=4.1 \pm 0.3 versus 24 hours postoperative=6.3 \pm 0.8, P=0.02). Time to extubation after closure was 18.4 \pm 1.4 minutes; average postoperative hospital stay was 3.8 days. All patients had significant reduction in angina (nitroglycerin [NTG] use=53.9 \pm 10.0/wk pre-GTx versus 9.8 \pm 6.9/wk post-GTx, P<0.03). Postoperative left ventricular ejection fraction (LVEF) was either unchanged (n=3) or improved (n=2, mean increase in LVEF=5%). Objective evidence of reduced ischemia was documented using dobutamine single photon emission computed tomography (SPECT)-sestamibi imaging in all patients. Coronary angiography showed improved Rentrop score in 5 of 5 patients. **CONCLUSIONS:** This initial experience with naked gene transfer as sole therapy for myocardial ischemia suggests that direct myocardial injection of naked plasmid DNA, via a minimally invasive chest wall incision, is safe and

may lead to reduced symptoms and improved myocardial perfusion in selected patients with chronic myocardial ischemia.

Publication Types:


- Case Reports
- Clinical Trial
- Clinical Trial, Phase I

PMID: 9860779 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
Department of Health & Human Services
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search PubMed for [] Go Clear
Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

☐ 1: Circulation. 1999 May 25;99(20):2614-6.

[Related Articles, Links](#)

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

Comment on:

- [Circulation. 1999 May 25;99\(20\):2682-7.](#)

FREE full text article at
circ.ahajournals.org

Therapeutic angiogenesis: the new electrophysiology?

Patterson C, Runge MS.

Publication Types:

- Comment
- Editorial
- Review
- Review, Tutorial

PMID: 10338451 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jul 27 2004 06:47:37



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search PubMed for [] Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services


Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources

Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2.

Related Articles, Links



Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.

Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG.


Department of Cardiothoracic Surgery, Weill Medical College of Cornell University-New York Presbyterian Hospital, New York City 10021, USA.

OBJECTIVE: To summarize the 6-month follow-up of a cohort of patients with clinically significant coronary artery disease who received direct myocardial injection of an E1-E3- adenovirus (Ad) gene transfer vector (Ad (GV)VEGF121.10) expressing the human vascular endothelial growth factor (VEGF) 121 cDNA to induce therapeutic angiogenesis. **BACKGROUND:** Therapeutic angiogenesis describes a novel approach to the treatment of vascular occlusive disease that uses the administration of growth factors known to induce neovascularization of ischemic tissues. **METHODS:** Direct myocardial injection of Ad(GV)VEGF121.10 into an area of reversible ischemia was carried out in 21 patients as an adjunct to conventional coronary artery bypass grafting (group A, n = 15) or as sole therapy using a minithoracotomy (group B, n = 6). **RESULTS:** No evidence of systemic or cardiac-related adverse events related to vector administration was observed up to 6 months after therapy. Trends toward improvement in angina class and exercise treadmill testing at 6-month follow-up in the sole therapy group suggest the effects of this therapy are persistent for > or =6 months. **CONCLUSIONS:** This study suggests that direct myocardial administration of Ad(GV)VEGF121.10 appears to be well tolerated in patients with clinically significant coronary artery disease. Initiation of phase II evaluation of this therapy appears warranted.

Publication Types:

- Clinical Trial
- Clinical Trial, Phase I

PMID: 10522716 [PubMed - indexed for MEDLINE]



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books
 Search PubMed for Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2.

Related Articles, Links



Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.

Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG.

Department of Cardiothoracic Surgery, Weill Medical College of Cornell University-New York Presbyterian Hospital, New York City 10021, USA.

OBJECTIVE: To summarize the 6-month follow-up of a cohort of patients with clinically significant coronary artery disease who received direct myocardial injection of an E1-E3- adenovirus (Ad) gene transfer vector (Ad (GV)VEGF121.10) expressing the human vascular endothelial growth factor (VEGF) 121 cDNA to induce therapeutic angiogenesis. **BACKGROUND:** Therapeutic angiogenesis describes a novel approach to the treatment of vascular occlusive disease that uses the administration of growth factors known to induce neovascularization of ischemic tissues. **METHODS:** Direct myocardial injection of Ad(GV)VEGF121.10 into an area of reversible ischemia was carried out in 21 patients as an adjunct to conventional coronary artery bypass grafting (group A, n = 15) or as sole therapy using a minithoracotomy (group B, n = 6). **RESULTS:** No evidence of systemic or cardiac-related adverse events related to vector administration was observed up to 6 months after therapy. Trends toward improvement in angina class and exercise treadmill testing at 6-month follow-up in the sole therapy group suggest the effects of this therapy are persistent for > or =6 months. **CONCLUSIONS:** This study suggests that direct myocardial administration of Ad(GV)VEGF121.10 appears to be well tolerated in patients with clinically significant coronary artery disease. Initiation of phase II evaluation of this therapy appears warranted.

Publication Types:

- Clinical Trial
- Clinical Trial, Phase I

PMID: 10522716 [PubMed - indexed for MEDLINE]

Untitled

4378347
4296100
6759386
6475796
5661122
5610134
6440934
6124433
5932540
6235713
6475796
5824644

US20030109420
US20040116349
US20040023863
US20020058612
US20020156001
US20040143103
US20030181379

GB2090528B

514/2

424/9.1

530/300, 324, 399

Untitled

+ W02000013710
5057494
5358959
~~5665382~~
5710175
5750351
x 5773209
5773231
~~5785965~~
5807884
5811449
fxx 5846959
~~5925375~~
5955624
6040157

CPK-MB
4338396

Welcome to STN International! Enter x:x
* * * * * Welcome to STN International * * * * *
* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:05:23 ON 13 AUG 2004

=> file BIOSCIENCE

FILE 'ADISCTI' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 13:05:33 ON 13 AUG 2004

FILE 'AQUALINE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 13:05:33 ON 13 AUG 2004

FILE 'CAPLUS' ENTERED AT 13:05:33 ON 13 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 13:05:33 ON 13 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 13:05:33 ON 13 AUG 2004

FILE 'CROPU' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 13:05:33 ON 13 AUG 2004

FILE 'FOMAD' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 13:05:33 ON 13 AUG 2004

FILE 'HEALSAFE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetic Chemists

FILE 'LIFESCI' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'NIOSTIC' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 13:05:33 ON 13 AUG 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 13:05:33 ON 13 AUG 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 13:05:33 ON 13 AUG 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 13:05:33 ON 13 AUG 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 13:05:33 ON 13 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:05:33 ON 13 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 13:05:33 ON 13 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

```

=> S coronary artery disease
14 FILES SEARCHED...
25 FILES SEARCHED...
43 FILES SEARCHED...
55 FILES SEARCHED...
L1      291193 CORONARY ARTERY DISEASE

=> S growth factor OR FGF-1 OR aFGF OR acidic FGF OR FGF-2 OR bFGF OR basic FGF
12 FILES SEARCHED...
16 FILES SEARCHED...
25 FILES SEARCHED...
33 FILES SEARCHED...
46 FILES SEARCHED...
52 FILES SEARCHED...
63 FILES SEARCHED...
69 FILES SEARCHED...
L2      1757190 GROWTH FACTOR OR FGF-1 OR AFGF OR ACIDIC FGF OR FGF-2 OR BFGF
        OR BASIC FGF OR VEGF

=> S L1 AND L2
46 FILES SEARCHED...
L3      6283 L1 AND L2

=> DUP REM L3
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY 23% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY 45% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY 67% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY 83% COMPLETE FOR L3
PROCESSING COMPLETED FOR L3
L4      4731 DUP REM L3 (1552 DUPLICATES REMOVED)

=> S nasal OR inhalation OR inhale
42 FILES SEARCHED...
L5      811503 NASAL OR INHALATION OR INHALE

=> S L4 AND L5
29 FILES SEARCHED...
61 FILES SEARCHED...
64 FILES SEARCHED...
L6      1011 L4 AND L5

=> DUP REM L6
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L6
L7      1011 DUP REM L6 (0 DUPLICATES REMOVED)

=> S L7 AND PY<=2000
'2000' NOT A VALID FIELD CODE
6 FILES SEARCHED...
8 FILES SEARCHED...
12 FILES SEARCHED...
16 FILES SEARCHED...
20 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
24 FILES SEARCHED...
32 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
43 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
47 FILES SEARCHED...
52 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
60 FILES SEARCHED...
63 FILES SEARCHED...
64 FILES SEARCHED...

```

=> D L8 1-98

L8 ANSWER 1 OF 98 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
 AN 1641161 PHARMAML
 TI Genentech Starts Trials Of Recombinant ***VEGF***
 SO Marketletter April 3, 1998
 DT Newsletter
 WC 750

L8 ANSWER 2 OF 98 PHIN COPYRIGHT 2004 PJB on STN

AN 97:13715 PHIN
 DN S00546366
 DED 3 Jul 1997
 TI Genentech earnings down, sales flat
 SO Scrip (***1997***) No. 2253 p12
 DT Newsletter
 FS FULL

L8 ANSWER 3 OF 98 PHIN COPYRIGHT 2004 PJB on STN

AN 95:11703 PHIN
 DN S00450122
 DED 29 Jun 1995
 TI Bristol-Myers Squibb Company Profile (1995)
 SO Scrip-Online-plus (***1995***)
 DT Newsletter
 FS FULL

L8 ANSWER 4 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2000:713716 PROMT
 TITLE: CHIRON PAYING \$700M IN CASH FOR PATHOGENESIS
 ACQUISITION. (Brief Article)
 AUTHOR(S): Osborne, Randall
 SOURCE: BIO WORLD Today, (***15 Aug 2000***) Vol. 11, No. 157.
 PUBLISHER: American Health Consultants, Inc.
 DOCUMENT TYPE: Newsletter
 LANGUAGE: English
 WORD COUNT: 620
 FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L8 ANSWER 5 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2000:169616 PROMT
 TITLE: Muted progress.
 AUTHOR(S): Truelove, Christiane
 SOURCE: Med Ad News, (***Sept 1999***) Vol. 18, No. 9, pp. 172.
 ISSN: 1067-733X.
 PUBLISHER: Engel Publishing Partners
 DOCUMENT TYPE: Newsletter
 LANGUAGE: English
 WORD COUNT: 2537
 FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L8 ANSWER 6 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2000:169609 PROMT
 TITLE: Gene genies.
 AUTHOR(S): Truelove, Christiane
 SOURCE: Med Ad News, (***Sept 1999***) Vol. 18, No. 9, pp. 122.
 ISSN: 1067-733X.
 PUBLISHER: Engel Publishing Partners
 DOCUMENT TYPE: Newsletter
 LANGUAGE: English
 WORD COUNT: 2599
 FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L8 ANSWER 7 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2000:40040 PROMT
 TITLE: /FIRST AND FINAL ADD -- NYTU059B -- Pfizer Inc/.
 SOURCE: PR Newswire, (***18 Jan 2000***) pp. 3285.

DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 5191
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L8 ANSWER 8 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:802479 PROMT
TITLE: Novartis Group.
AUTHOR(S): Krajnak, Mark
SOURCE: Med Ad News, (***Sept 1997***) Vol. 16, No. 9, pp. 130.
ISSN: 0745-0907.
PUBLISHER: Engel Publishing Partners
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 6433
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L8 ANSWER 9 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:162782 PROMT
TITLE: Megabios and GeneMedicine Complete Merger.
SOURCE: PR Newswire, (***19 Mar 1999***) pp. 8437.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 636
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L8 ANSWER 10 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:175708 PROMT
TITLE: DEVELOPMENTS IN BIOTECHNOLOGY :GeneMedicine-Cationic Lipid
Gene Delivery System In Two Phase II Gene Therapy
Angioplasty Clinical Trials
SOURCE: BioAccess, (***1 Apr 1998***) pp. N/A.
ISSN: 1356-3432.
LANGUAGE: English
WORD COUNT: 712
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L8 ANSWER 11 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:173353 PROMT
TITLE: Genentech Starts Trials Of Recombinant ***VEGF***
SOURCE: Marketletter, (***13 Apr 1998***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 756
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L8 ANSWER 12 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:143219 PROMT
TITLE: GENEMEDICINE Proprietary Cationic Lipid Gene Delivery
System Is Employed in Two Phase II Gene Therapy Angioplasty
Clinical Trials.
SOURCE: Business Wire, (***19 Mar 1998***) pp. 3190068.
LANGUAGE: English
WORD COUNT: 900
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L8 ANSWER 13 OF 98 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:41293 PROMT
TITLE: Genentech's Year-End Results Show Growth Plan on Track:
Earnings Increase Nine Percent on Revenues Exceeding \$1
Billion.
SOURCE: Business Wire, (***22 Jan 1998***) pp. 01220134.
LANGUAGE: English
WORD COUNT: 2029
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L8 ANSWER 14 OF 98 USPATFULL on STN
AN 2003:228145 USPATFULL

management
IN Ajami, Alfred M., Brookline, MA, United States
PA Xanthus Life Sciences, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6610270 B1 20030826
WO 2000000636 20000106 <--
AI US 2000-719956 20001218 (9)
WO 1999-US14725 19990629
RLI Continuation-in-part of Ser. No. US 1998-107965, filed on 30 Jun 1998, now patented, Pat. No. US 6284219, issued on 4 Sep 2001
DT Utility
FS GRANTED
LN.CNT 3873
INCL INCLM: 424/009.200
INCLS: 424/001.810; 424/001.110; 435/004.000
NCL NCLM: 424/009.200
NCLS: 424/001.110; 424/001.810; 435/004.000
IC [7]
ICM: A61K049-00
EXF 424/1.11; 424/1.53; 424/1.65; 424/1.81; 424/9.2; 424/9.1; 435/4; 435/183; 435/188; 435/814; 250/472.1; 600/9
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 98 USPATFULL on STN
AN 2002:209740 USPATFULL
TI Transgenic models of inflammatory disease
IN Duff, Gordon W., Sheffield, UNITED KINGDOM
Nicklin, Martin, Sheffield, UNITED KINGDOM
PA Interleukin Genetics Inc., Waltham, MA, United States (U.S. corporation)
PI US 6437216 B1 20020820
WO 9925857 19990527 <--
AI US 2001-647826 20010312 (9)
WO 1998-US24287 19981113
20010312 PCT 371 date
PRAI GB 1997-23835 19971113
DT Utility
FS GRANTED
LN.CNT 3230
INCL INCLM: 800/021.000
INCLS: 800/018.000; 800/003.000; 435/320.100; 435/325.000; 536/023.100
NCL NCLM: 800/021.000
NCLS: 435/320.100; 435/325.000; 536/023.100; 800/003.000; 800/018.000
IC [7]
ICM: C12N015-00
EXF 800/3; 800/8; 800/21; 800/18; 435/320.1; 435/325; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 98 USPATFULL on STN
AN 2002:160701 USPATFULL
TI Benzimidazole derivatives for the treatment of viral infections
IN Tidwell, Jeffrey H., Raleigh, NC, United States
Chamberlain, Stanley D., Research Triangle Park, NC, United States
Freeman, George A., Research Triangle Park, NC, United States
Chan, Joseph H., Research Triangle Park, NC, United States
Koszalka, George W., Research Triangle Park, NC, United States
Townsend, Leroy B., Ann Arbor, MI, United States
Drach, John C., Ann Arbor, MI, United States
PA The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)
Glaxo Wellcome Inc., Research Triangle Park, NC, United States (U.S. corporation)
PI US 6413938 B1 20020702
WO 9835977 19980820 <--
AI US 1999-367260 19990825 (9)
WO 1998-GB448 19980213
19990825 PCT 371 date
PRAI GB 1997-3134 19970214
US 1997-37992P 19970213 (60)
DT Utility
FS GRANTED
LN.CNT 3484
INCL INCLM: 514/043.000
INCLS: 514/394.000; 514/934.000; 536/024.100; 536/028.900; 548/304.700
NCL NCLM: 514/043.000
NCLS: 514/394.000; 514/934.000; 536/024.100; 536/028.900; 548/304.700

ICM: A61K031-70
ICS: A61K031-415; C07H019-04; C07D235-04
EXF 514/43; 514/934; 514/394; 536/28.9; 536/24; 548/304.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 98 USPATFULL on STN
AN 2000:164487 USPATFULL
TI Polypeptide composition for oral administration
IN Grass, George M., Mountain View, CA, United States
Sweetana, Stephanie A., Indianapolis, IN, United States
PA G. D. Searle & Co., Skokie, IL, United States (U.S. corporation)
PI US 6156731 20001205 <--
AI US 1995-567501 19951205 (8)
RLI Continuation of Ser. No. US 1989-350067, filed on 10 May 1989, now
abandoned
DT Utility
FS Granted
LN.CNT 1014
INCL INCLM: 514/015.000
INCLS: 514/002.000; 514/014.000; 514/013.000; 514/016.000; 514/012.000;
530/300.000; 530/311.000; 530/313.000; 530/324.000; 530/326.000;
530/327.000; 530/328.000; 424/464.000; 424/185.100
NCL NCLM: 514/015.000
NCLS: 424/185.100; 424/464.000; 514/002.000; 514/012.000; 514/013.000;
514/014.000; 514/016.000; 530/300.000; 530/311.000; 530/313.000;
530/324.000; 530/326.000; 530/327.000; 530/328.000
IC [7]
ICM: A61K038-00
ICS: A61K039-00; C07K005-00; C07K007-00
EXF 514/2; 514/3; 514/12; 514/13; 514/14; 514/15; 514/16; 530/300; 530/311;
530/313; 530/324; 530/326; 530/327; 530/328; 424/464; 424/185.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 98 USPATFULL on STN
AN 2000:153882 USPATFULL
TI Compounds and methods for the inhibition of the expression of VCAM-1
IN Somers, Patricia K., Atlanta, GA, United States
PA AtheroGenics, Inc., Alpharetta, GA, United States (U.S. corporation)
PI US 6147250 20001114 <--
AI US 1998-79213 19980514 (9)
PRAI US 1997-47020P 19970514 (60)
DT Utility
FS Granted
LN.CNT 3089
INCL INCLM: 560/130.000
INCLS: 560/138.000; 514/548.000
NCL NCLM: 560/130.000
NCLS: 560/138.000
IC [7]
ICM: C07C069-00
ICS: A01N037-02
EXF 560/130; 560/138; 514/548
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 98 USPATFULL on STN
AN 2000:153824 USPATFULL
TI Tub interactor (TI) polypeptides and uses therefor
IN Gimeno, Carlos J., Wellesley, MA, United States
Errada, Patrick R., Cambridge, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 6147192 20001114 <--
AI US 1999-252329 19990218 (9)
RLI Division of Ser. No. US 1997-897340, filed on 21 Jul 1997, now patented,
Pat. No. US 5955306 which is a continuation-in-part of Ser. No. US
1996-715032, filed on 17 Sep 1996, now abandoned
DT Utility
FS Granted
LN.CNT 3795
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K014-00
EXF 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 98 USPATFULL ON STN
AN 2000:145865 USPATFULL
TI Targeted contrast agents for diagnostic and therapeutic use
IN Unger, Evan C., Tucson, AZ, United States
Fritz, Thomas A., Tucson, AZ, United States
Gertz, Edward W., Paradise Valley, AZ, United States
PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6139819 20001031 <--
AI US 1997-932273 19970917 (8)
RLI Continuation-in-part of Ser. No. US 1996-660032, filed on 6 Jun 1996,
now abandoned which is a continuation-in-part of Ser. No. US
1996-640464, filed on 1 May 1996, now abandoned which is a
continuation-in-part of Ser. No. US 1995-497684, filed on 7 Jun 1995,
now abandoned And a continuation-in-part of Ser. No. US 1996-666129,
filed on 19 Jun 1996, now patented, Pat. No. US 6033645
DT Utility
FS Granted
LN.CNT 7523
INCL INCLM: 424/009.520
INCLS: 424/009.510; 424/450.000
NCL NCLM: 424/009.520
NCLS: 424/009.510; 424/450.000
IC [7]
ICM: A61B008-00
ICS: A61K009-127
EXF 424/9.52; 424/9.51; 424/9.5; 424/450; 424/812; 600/441; 600/458;
264/4.1; 427/2.14; 427/213.3; 428/402.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 98 USPATFULL ON STN
AN 2000:138360 USPATFULL
TI Hydroxyl-containing bicyclic compounds
IN Underiner, Gail E., Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6133274 20001017 <--
AI US 1996-756703 19961126 (8)
RLI Continuation of Ser. No. US 1993-153256, filed on 16 Nov 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1992-976353,
filed on 16 Nov 1992, now patented, Pat. No. US 5473070
DT Utility
FS Granted
LN.CNT 1646
INCL INCLM: 514/263.000
INCLS: 544/267.000
NCL NCLM: 514/263.360
NCLS: 544/267.000
IC [7]
ICM: C07D473-04
ICS: A61K031-52
EXF 544/267; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 98 USPATFULL ON STN
AN 2000:137814 USPATFULL
TI Allelic polygene diagnosis of reward deficiency syndrome and treatment
IN Blum, Kenneth, San Antonio, TX, United States
PA City of Hope National Medical Center, Duarte, CA, United States (U.S.
corporation)
The University of Texas System AMD Board of Regents, Austin, TX, United
States (U.S. corporation)
PI US 6132724 20001017 <--
AI US 1998-69886 19980429 (9)
DT Utility
FS Granted
LN.CNT 20845
INCL INCLM: 424/195.100
INCLS: 514/188.000; 514/561.000
NCL NCLM: 424/725.000
NCLS: 514/188.000; 514/561.000
IC [7]
ICM: A61K035-78
EXF 514/188; 514/561; 424/195.1

L8 ANSWER 23 OF 98 USPATFULL on STN
 AN 2000:128465 USPATFULL
 TI Compositions and methods for treatment and diagnosis of cardiovascular disease
 IN Falb, Dean A., Wellesley, MA, United States
 Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
 PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
 Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
 PI US 6124433 20000926 <--
 AI US 1997-944496 19971006 (8)
 RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented, Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
 DT Utility
 FS Granted
 LN.CNT 5924
 INCL INCLM: 530/350.000
 INCLS: 530/324.000; 530/326.000; 536/023.100; 536/023.500; 435/069.100; 435/320.100; 435/325.000
 NCL NCLM: 530/350.000
 NCLS: 435/069.100; 435/320.100; 435/325.000; 530/324.000; 530/326.000; 536/023.100; 536/023.500
 IC [7]
 ICM: C07K016-00
 ICS: C12N015-00
 EXF 536/23.1; 536/24.1; 536/24.3; 536/23.5; 435/6; 435/69.1; 435/7.1; 435/172.3; 435/320.1; 435/325; 935/32; 935/52; 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 24 OF 98 USPATFULL on STN
 AN 2000:125096 USPATFULL
 TI Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
 IN Somers, Patricia K., Atlanta, GA, United States
 PA AtheroGenics, Inc., Alpharetta, GA, United States (U.S. corporation)
 PI US 6121319 20000919 <--
 AI US 1998-78935 19980514 (9)
 PRAI US 1997-47020P 19970514 (60)
 DT Utility
 FS Granted
 LN.CNT 992
 INCL INCLM: 514/548.000
 INCLS: 514/712.000; 514/824.000; 514/825.000; 514/826.000; 514/855.000
 NCL NCLM: 514/548.000
 NCLS: 514/712.000; 514/824.000; 514/825.000; 514/826.000; 514/855.000
 IC [7]
 ICM: A01N037-02
 ICS: A61K031-10; A61K031-225
 EXF 514/548; 514/712; 514/824; 514/855; 514/826; 514/825
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 25 OF 98 USPATFULL on STN
 AN 2000:121539 USPATFULL
 TI Methods for regulating transcription factors
 IN Qabar, Maher N., Redmond, WA, United States
 McMillan, Michael K., Bellevue, WA, United States
 Kahn, Michael S., Kirkland, WA, United States
 Tulinsky, John E., Seattle, WA, United States
 Ogbu, Cyprian O., Bellevue, WA, United States
 Mathew, Jessymol, Bellevue, WA, United States
 PA Molecumetics Ltd., Bellevue, WA, United States (U.S. corporation)
 PI US 6117896 20000912 <--
 AI US 1998-22934 19980212 (9)
 RLI Continuation-in-part of Ser. No. US 1997-797915, filed on 10 Feb 1997, now abandoned And a continuation-in-part of Ser. No. US 692420
 PRAI US 1997-47067P 19970519 (60)
 DT Utility
 FS Granted
 LN.CNT 4501
 INCL INCLM: 514/384.000
 INCLS: 514/248.000; 530/323.000; 530/332.000; 548/263.400
 NCL NCLM: 514/384.000

IC [7]
 ICM: A61K031-41
 ICS: C07K005-00; C07K007-00; C07K016-00; C07D249-12
 EXF 514/248; 514/384; 530/332; 530/323; 548/263.4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 98 USPATFULL on STN
 AN 2000:105913 USPATFULL
 TI Amine substituted compounds
 IN Klein, J. Peter, Vashon, WA, United States
 Underiner, Gail E., Brier, WA, United States
 Kumar, Anil M., Seattle, WA, United States
 Ridgers, Lance H., Bothell, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 6103730 20000815 <--
 AI US 1995-486264 19950607 (8)
 RLI Continuation of Ser. No. US 1994-217051, filed on 24 Mar 1994, now
 abandoned
 DT Utility
 FS Granted
 LN.CNT 1702
 INCL INCLM: 514/263.000
 INCLS: 514/265.000; 544/268.000; 544/269.000; 544/270.000; 544/271.000;
 544/272.000
 NCL NCLM: 514/263.200
 NCLS: 514/151.000; 514/210.210; 514/263.210; 514/263.220; 514/263.230;
 514/263.240; 514/263.350; 544/268.000; 544/269.000; 544/270.000;
 544/271.000; 544/272.000

IC [7]
 ICM: A61K031-522
 ICS: C07D473-10
 EXF 544/268; 544/269; 544/220; 544/271; 544/272; 514/263; 514/265
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 98 USPATFULL on STN
 AN 2000:102304 USPATFULL
 TI Therapeutic compounds containing xanthinyl
 IN Klein, J. Peter, Vashon, WA, United States
 Leigh, Alistair J., Brier, WA, United States
 Underiner, Gail E., Brier, WA, United States
 Kumar, Anil M., Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 6100271 20000808 <--
 AI US 1995-483871 19950607 (8)
 RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 1986
 INCL INCLM: 514/263.000
 INCLS: 514/265.000; 544/268.000; 544/269.000; 544/271.000
 NCL NCLM: 514/263.200
 NCLS: 514/210.210; 514/234.200; 514/263.220; 514/263.230; 514/263.240;
 514/263.350; 544/268.000; 544/269.000; 544/271.000

IC [7]
 ICM: A61K031-522
 ICS: C07D473-10
 EXF 544/271; 544/268; 544/269; 514/263; 514/265
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 98 USPATFULL on STN
 AN 2000:95042 USPATFULL
 TI Therapeutic methods employing disulfide derivatives of dithiocarbamates
 and compositions useful therefor
 IN Lai, Ching-San, Encinitas, CA, United States
 Vassilev, Vassil, San Diego, CA, United States
 PA Medinox Inc., San Diego, CA, United States (U.S. corporation)
 PI US 6093743 20000725 <--
 AI US 1998-103639 19980623 (9)
 DT Utility
 FS Granted
 LN.CNT 2691
 INCL INCLM: 514/599.000
 INCLS: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000;
 514/866.000; 514/909.000; 514/912.000

NCLS: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000;
514/866.000; 514/909.000; 514/912.000

IC [7]
ICM: A61K031-16
ICS: A61K031-095; A61K031-105
EXF 514/599; 514/706; 514/707; 514/851; 514/861; 514/863; 514/866; 514/909;
514/912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 29 OF 98 USPATFULL on STN
AN 2000:91763 USPATFULL
TI SV-40 derived DNA constructs comprising exogenous DNA sequences
IN Oppenheim, Ariella, Jerusalem, Israel
Dalyot, Nava, Jerusalem, Israel
Ben-Nun-Shaul, Orly, Jerusalem, Israel
Rund, Deborah, Jerusalem, Israel
Sandalon, Ziv, Jerusalem, Israel
Chajek-Shaul, Toba, Jerusalem, Israel
Metzger, Shulamit, Jerusalem, Israel
PA Yisum Research Development Company of the Hebrew University of
Jerusalem, Jerusalem, Israel (non-U.S. corporation)
Hadasit Medical Research Services and Development Company Limited,
Jerusalem, Israel (non-U.S. corporation)
PI US 6090608 20000718 <--
WO 9530762 19951116 <--
AI US 1997-737047 19970115 (8)
WO 1995-US5595 19950504
19970115 PCT 371 date
19970115 PCT 102(e) date
PRAI IL 1994-109558 19940504
DT Utility
FS Granted
LN.CNT 1838
INCL INCLM: 435/235.100
INCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.500
NCL NCLM: 435/235.100
NCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.500
IC [7]
ICM: C12N007-01
ICS: C12N015-86; C12N005-10
EXF 536/23.1; 536/23.5; 435/320.1; 435/235.1; 435/325; 514/44; 424/93.1;
424/93.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 30 OF 98 USPATFULL on STN
AN 2000:57545 USPATFULL
TI Human transferases
IN Lal, Preeti, Santa Clara, CA, United States
Bandman, Olga, Mountain View, CA, United States
Hillman, Jennifer L., Mountain View, CA, United States
Guegler, Karl J., Menlo Park, CA, United States
Gorgone, Gina A., Boulder Creek, CA, United States
Corley, Neil C., Mountain View, CA, United States
Patterson, Chandra, Mountain View, CA, United States
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
corporation)
PI US 6060250 20000509 <--
AI US 1998-109204 19980630 (9)
DT Utility
FS Granted
LN.CNT 3615
INCL INCLM: 435/006.000
INCLS: 435/193.000; 435/252.300; 435/325.000; 435/320.100; 536/023.100;
536/023.200
NCL NCLM: 435/006.000
NCLS: 435/193.000; 435/252.300; 435/320.100; 435/325.000; 536/023.100;
536/023.200
IC [7]
ICM: C12N015-54
ICS: C12N009-10; C12Q001-68
EXF 536/23.1; 536/23.2; 435/6; 435/193; 435/252.3; 435/325; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 31 OF 98 USPATFULL on STN
AN 2000:40874 USPATFULL

LN Lai, Preeti, Santa Clara, CA, United States
 Yue, Henry, Sunnyvale, CA, United States
 Corley, Neil C., Mountain View, CA, United States
 PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 6046029 20000404 <--
 AI US 1997-977001 19971124 (8)
 DT Utility
 FS Granted
 LN.CNT 2270
 INCL INCLM: 435/069.100
 INCLS: 435/070.100; 435/183.000; 435/320.100; 435/325.000; 435/252.300; 435/419.000; 435/254.200; 530/350.000; 536/023.310; 536/023.500
 NCL NCLM: 435/069.100
 NCLS: 435/070.100; 435/183.000; 435/252.300; 435/254.200; 435/320.100; 435/325.000; 435/419.000; 530/350.000; 536/023.500; 536/024.310
 IC [7]
 ICM: C12P021-06
 ICS: C12P021-04; C07H021-04; C07K001-00
 EXF 536/23.5; 536/24.31; 435/320.1; 435/325; 435/252.3; 435/419; 435/254.2; 435/69.1; 435/70.1; 435/183; 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 32 OF 98 USPATFULL on STN
 AN 2000:37806 USPATFULL
 TI Methods for using therapeutic compounds containing xanthinyl
 IN Klein, J. Peter, Vashon, WA, United States
 Leigh, Alistair J., Brier, WA, United States
 Underiner, Gail E., Brier, WA, United States
 Kumar, Anil M., Seattle, WA, United States
 Rice, Glenn C., Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 6043250 20000328 <--
 AI US 1995-472296 19950607 (8)
 RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994, now abandoned
 DT Utility
 FS Granted
 LN.CNT 2052
 INCL INCLM: 514/263.000
 NCL NCLM: 514/234.200
 NCLS: 514/210.210; 514/263.200; 514/263.220; 514/263.230; 514/263.350
 IC [7]
 ICM: A61K003-52
 EXF 514/263

L8 ANSWER 33 OF 98 USPATFULL on STN
 AN 2000:34403 USPATFULL
 TI Vascular endothelial ***growth*** ***factor*** 2
 IN Hu, Jing-Shan, Sunnyvale, CA, United States
 Rosen, Craig A., Laytonsville, MD, United States
 Cao, Liang, South Horizons, Hong Kong
 PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
 PI US 6040157 20000321 <--
 AI US 1998-42105 19980313 (9)
 RLI Continuation-in-part of Ser. No. US 1997-999811, filed on 24 Dec 1997, now patented, Pat. No. US 5932540 which is a continuation-in-part of Ser. No. US 1997-824996, filed on 27 Mar 1997 And a continuation-in-part of Ser. No. US 1995-465968, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-207550, filed on 8 Mar 1994
 DT Utility
 FS Granted
 LN.CNT 5292
 INCL INCLM: 435/069.400
 INCLS: 435/007.100; 435/325.000; 435/243.000; 435/320.100; 536/023.510; 530/399.000
 NCL NCLM: 435/069.400
 NCLS: 435/007.100; 435/243.000; 435/320.100; 435/325.000; 530/399.000; 536/023.510
 IC [7]
 ICM: C12N015-18
 ICS: C12N015-63; C12N001-21; C12N005-00
 EXF 435/69.4; 435/320.1; 435/325; 435/243; 536/23.51; 530/399
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 34 OF 98 USPATFULL on STN
 AN 2000:31222 USPATFULL
 TI MTBX protein and nucleic acid molecules and uses therefor
 IN Khodadoust, Mehran, Chestnut Hill, MA, United States
 PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 6037148 20000314 <--
 AI US 1998-188811 19981109 (9)
 RLI Continuation-in-part of Ser. No. US 1998-163116, filed on 29 Sep 1998
 PRAI US 1998-89467P 19980616 (60)
 DT Utility
 FS Granted
 LN.CNT 4497
 INCL INCLM: 435/069.100
 INCLS: 435/320.100; 435/325.000; 435/252.300; 536/023.100
 NCL NCLM: 435/069.100
 NCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.100
 IC [7]
 ICM: C12P021-06
 ICS: C12N015-00; C07H017-00
 EXF 435/69.1; 435/320.1; 435/325; 435/252.3; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 35 OF 98 USPATFULL on STN
 AN 2000:24752 USPATFULL
 TI MTbx protein and nucleic acid molecules and uses therefor
 IN Khodadoust, Mehran, Chestnut Hill, MA, United States
 PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 6031078 20000229 <--
 AI US 1998-189760 19981110 (9)
 RLI Continuation-in-part of Ser. No. US 1998-163116, filed on 29 Sep 1998
 And a continuation-in-part of Ser. No. US 1998-188811, filed on 9 Nov 1998
 PRAI US 1998-89467P 19980616 (60)
 DT Utility
 FS Granted
 LN.CNT 4457
 INCL INCLM: 530/350.000
 INCLS: 530/300.000
 NCL NCLM: 530/350.000
 NCLS: 530/300.000
 IC [7]
 ICM: C07K014-00
 EXF 530/350; 530/300
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 36 OF 98 USPATFULL on STN
 AN 2000:15642 USPATFULL
 TI Use of hyaluronic acid and forms to prevent arterial restenosis
 IN Falk, Rudolf Edgar, Toronto, Canada
 Asculai, Samuel Simon, Toronto, Canada
 Turley, Eva Anne, Winnipeg, Canada
 PA Hyal Pharmaceutical Corporation, Mississauga, Canada (non-U.S. corporation)
 PI US 6022866 20000208 <--
 WO 9407505 19940414 <--
 AI US 1995-403766 19950324 (8)
 WO 1993-CA388 19930922
 19950324 PCT 371 date
 19950324 PCT 102(e) date
 RLI Continuation-in-part of Ser. No. US 1994-285764, filed on 3 Aug 1994, now patented, Pat. No. US 5614506, issued on 25 Mar 1997 which is a continuation-in-part of Ser. No. US 1992-952095, filed on 28 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-675908, filed on 3 Jul 1991 And Ser. No. US 1992-838675, filed on 21 Feb 1992, now patented, Pat. No. US 5639738, issued on 17 Jun 1997
 PRAI CA 1992-2079205 19920925
 DT Utility
 FS Granted
 LN.CNT 1554
 INCL INCLM: 514/054.000
 INCLS: 514/023.000; 514/025.000; 514/028.000; 514/032.000; 514/042.000; 514/056.000; 514/060.000; 514/062.000; 536/055.000
 NCL NCLM: 514/054.000

514/056.000; 514/060.000; 514/062.000; 536/055.000

IC [6]
ICM: A61K031-70
EXF 424/180; 514/23; 514/25; 514/28; 514/32; 514/33; 514/42; 514/54; 514/56;
514/60; 514/62; 536/55
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 37 OF 98 USPATFULL on STN
AN 2000:12926 USPATFULL
TI Compositions and methods for the treatment and diagnosis of
cardiovascular disease using rchd523 as a target
IN Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S.
corporation)
PI US 6020463 20000201 <--
AI US 1997-944423 19971006 (8)
RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented,
Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US
1995-485573, filed on 7 Jun 1995, now patented, Pat. No. US 5968770
which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10
Feb 1995
DT Utility
FS Granted
LN.CNT 5972
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100
IC [6]
ICM: C07K016-00
ICS: C12N015-00
EXF 435/320.1; 435/325; 435/69.1; 435/6; 536/23.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 38 OF 98 USPATFULL on STN
AN 2000:12800 USPATFULL
TI Electronegative-substituted long chain xanthine compounds
IN Leigh, Alistair J., Brier, WA, United States
Michnick, John, Seattle, WA, United States
Kumar, Anil M., Seattle, WA, United States
Klein, J. Peter, Vashon, WA, United States
Underiner, Gail, Malvern, PA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6020337 20000201 <--
AI US 1997-950810 19970916 (8)
RLI Continuation-in-part of Ser. No. US 1993-42946, filed on 5 Apr 1993, now
patented, Pat. No. US 5670506 And a continuation-in-part of Ser. No. US
1997-910579, filed on 26 Jul 1997
DT Utility
FS Granted
LN.CNT 1376
INCL INCLM: 514/258.000
INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
NCL NCLM: 514/263.340
NCLS: 514/210.210; 514/263.360; 544/267.000; 544/272.000; 544/277.000
IC [6]
ICM: A61K031-52
ICS: C07D473-00
EXF 514/258; 544/267; 544/272; 544/277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 39 OF 98 USPATFULL on STN
AN 2000:10014 USPATFULL
TI Compositions and methods for the treatment and diagnosis of
cardiovascular disease using rchd528 as a target
IN Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Millenium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S.
corporation)
PI US 6018025 20000125 <--

RL1 Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented,
Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US
1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser.
No. US 1995-386844, filed on 10 Feb 1995

DT Utility
FS Granted

LN.CNT 6133

INCL INCLM: 530/350.000
INCLS: 530/324.000; 530/326.000; 536/023.100; 536/023.500; 435/069.100;
435/320.100; 435/325.000

NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/324.000; 530/326.000;
536/023.100; 536/023.500

IC [6]
ICM: C07K016-00
ICS: C12N015-00

EXF 536/23.1; 536/24.1; 536/24.3; 536/23.5; 435/6; 435/810; 435/69.1;
435/7.1; 435/172.3; 435/320.1; 435/325; 436/501; 436/63; 935/32; 935/52;
935/77; 530/350; 530/325; 530/326

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 40 OF 98 USPATFULL on STN

AN 2000:4941 USPATFULL

TI ***VEGF*** .sub.145 expression vectors

IN Neufeld, Gera, Haifa, Israel
Keshet, Eli, Kiryat Yam, Israel
Vlodavsky, Israel, Mevaseret Zion, Israel
Poltorak, Zoya, Jerusalem, Israel

PA Technion Research & Development Co. Ltd., Haifa, Israel (non-U.S.
corporation)

PI US 6013780 20000111 <--

AI US 1997-784551 19970121 (8)

PRAI US 1996-25537P 19960906 (60)

DT Utility
FS Granted

LN.CNT 2158

INCL INCLM: 536/023.100
INCLS: 435/320.100

NCL NCLM: 536/023.100
NCLS: 435/320.100

IC [6]
ICM: C07H021-04
ICS: C12N015-11; C12N015-63

EXF 514/44; 435/172.3; 435/320.1; 536/23.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 41 OF 98 USPATFULL on STN

AN 1999:166794 USPATFULL

TI Human S1-5 ECMP-like protein

IN Yue, Henry, Sunnyvale, CA, United States
Guegler, Karl J., Menlo Park, CA, United States
Shah, Purvi, Sunnyvale, CA, United States

PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.
corporation)

PI US 6004753 19991221 <--

AI US 1997-980514 19971201 (8)

DT Utility
FS Granted

LN.CNT 2285

INCL INCLM: 435/006.000
INCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.100

NCL NCLM: 435/006.000
NCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.100

IC [6]
ICM: C12Q001-68
ICS: C12N015-00; C12N005-00; C07H021-02

EXF 536/23.1; 435/69.1; 435/320.1; 435/325; 435/455; 435/6

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 42 OF 98 USPATFULL on STN

AN 1999:151198 USPATFULL

TI Use of hyaluronic acid and forms to prevent arterial restenosis

IN Falk, Rudolf Edgar, Toronto, Canada
Ascualli, Samuel Simon, Toronto, Canada
Turley, Eva Anne, Winnipeg, Canada

corporation)
PI US 5990095 19991123 <--
AI US 1995-448503 19950726 (8)
WO 1994-CA188 19940325
19950726 PCT 371 date
19950726 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1991-675908, filed on 3 Jul 1991 And
a continuation-in-part of Ser. No. US 1992-838674, filed on 21 Feb 1992,
now abandoned Ser. No. Ser. No. US 1992-838675, filed on 21 Feb 1992,
now patented, Pat. No. US 5639738 Ser. No. Ser. No. US 1992-952095,
filed on 28 Sep 1992, now abandoned And Ser. No. US 1993-125398, filed
on 23 Sep 1993, now patented, Pat. No. US 5834444
DT Utility
FS Granted
LN.CNT 1906
INCL INCLM: 514/054.000
NCL NCLM: 514/054.000
IC [6]
ICM: A61K031-70
EXF 536/55.1; 536/55.2; 514/54
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 43 OF 98 USPATFULL on STN
AN 1999:151195 USPATFULL
TI GATA-6 transcription factor: compositions and methods
IN Walsh, Kenneth, Carlisle, MA, United States
PA St. Elizabeth's Medical Center, Boston, MA, United States (U.S.
corporation)

PI US 5990092 19991123 <--
AI US 1997-927394 19970827 (8)
DT Utility
FS Granted
LN.CNT 2449
INCL INCLM: 514/044.000
INCLS: 435/320.100; 536/023.500
NCL NCLM: 514/044.000
NCLS: 435/320.100; 536/023.500
IC [6]
ICM: A61K048-00
ICS: C12N015-12; C12N015-85
EXF 435/320.1; 435/375; 435/377; 514/44; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 44 OF 98 USPATFULL on STN
AN 1999:150906 USPATFULL
TI Method for treating a subject suffering from a condition associated with
an extracellular zinc sphingomyelinase
IN Tabas, Ira, New City, NY, United States
Schissel, Scott L., Teaneck, NJ, United States
Williams, Kevin Jon, Wynnewood, PA, United States
PA The Trustees of Columbia University in the City of New York, New York,
NY, United States (U.S. corporation)
Thomas Jefferson University, Philadelphia, PA, United States (U.S.
corporation)

PI US 5989803 19991123 <--
AI US 1997-937234 19970908 (8)
DT Utility
FS Granted
LN.CNT 3580
INCL INCLM: 435/004.000
INCLS: 424/094.100; 424/094.600; 435/007.100; 435/007.210; 435/008.000;
435/018.000
NCL NCLM: 435/004.000
NCLS: 424/094.100; 424/094.600; 435/007.100; 435/007.210; 435/008.000;
435/018.000
IC [6]
ICM: C12Q001-00
ICS: C12Q001-66; C12Q001-34
EXF 424/94.1; 424/94.6; 435/4; 435/7.1; 435/18; 435/7.72; 435/8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 45 OF 98 USPATFULL on STN
AN 1999:117455 USPATFULL
TI Compositions and methods for treating erectile dysfunction
IN Kifor, Imre, Methuen, MA, United States

PA The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)
PI US 5958884 19990928 <--
AI US 1998-47594 19980325 (9)
PRAI US 1997-41875P 19970411 (60)
DT Utility
FS Granted
LN.CNT 692
INCL INCLM: 514/016.000
INCLS: 514/048.000; 514/381.000; 514/396.000; 514/397.000; 514/400.000
NCL NCLM: 514/016.000
NCLS: 514/048.000; 514/381.000; 514/396.000; 514/397.000; 514/400.000
IC [6]
ICM: A61K031-41
ICS: A61K031-70; A61K038-08
EXF 514/16; 514/48; 514/381; 514/396; 514/397; 514/400; 530/316; 548/252; 548/253; 548/312.7; 548/323.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 46 OF 98 USPATFULL on STN
AN 1999:113909 USPATFULL
TI Growth stimulating factors
IN Nudelman, Edward, Seattle, WA, United States
Hakomori, Sen-Itiroh, Mercer Island, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5955624 19990921 <--
AI US 1995-473901 19950607 (8)
RLI Continuation of Ser. No. US 1994-285153, filed on 3 Aug 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1036
INCL INCLM: 554/227.000
INCLS: 514/546.000; 514/547.000; 514/549.000; 514/552.000; 514/715.000; 514/722.000; 514/723.000
NCL NCLM: 554/227.000
IC [6]
ICM: C07C057-00
EXF 554/227; 514/546; 514/547; 514/549; 514/552; 514/715; 514/722; 514/723
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 47 OF 98 USPATFULL on STN
AN 1999:113869 USPATFULL
TI Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
IN Dittlow, Charles C., Fremont, CA, United States
Chen, Francis W., San Francisco, CA, United States
Calenoff, Emanuel, Chicago, IL, United States
PA Charter Ventures, Palo Alto, CA, United States (U.S. corporation)
PI US 5955584 19990921 <--
AI US 1993-53451 19930426 (8)
RLI Continuation-in-part of Ser. No. US 1992-828860, filed on 31 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-388129, filed on 31 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-67995, filed on 29 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-67993, filed on 29 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1987-67986, filed on 29 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-876741, filed on 20 Jun 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-871811, filed on 6 Jun 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-846401, filed on 31 Mar 1986, now abandoned
DT Utility
FS Granted
LN.CNT 14947
INCL INCLM: 530/388.200
INCLS: 530/391.100; 530/391.300; 436/543.000; 435/011.000; 522/544.000
NCL NCLM: 530/388.200
NCLS: 435/011.000; 436/543.000; 530/391.100; 530/391.300
IC [6]
ICM: C07K016-18
ICS: C12P021-08
EXF 530/388.2; 530/389.5; 530/391.1; 530/391.3; 530/359; 424/133.1; 424/141.1; 424/152.1; 424/172.1; 424/178.1; 424/184.1; 435/11; 436/543;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 48 OF 98 USPATFULL on STN
AN 1999:113594 USPATFULL
TI Genes encoding proteins that interact with the tub protein
IN Gimeno, Carlos J., Wellesley, MA, United States
Errada, Patrick R., Cambridge, MA, United States
PA Millenium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5955306 19990921 <--
AI US 1997-897340 19970721 (8)
RLI Continuation-in-part of Ser. No. US 1996-715032, filed on 17 Sep 1996, now abandoned
DT Utility
FS Granted
LN.CNT 4240
INCL INCLM: 435/069.100
INCLS: 435/071.100; 435/320.100; 435/325.000; 435/252.300; 435/254.110; 536/023.500; 536/024.300; 536/024.310
NCL NCLM: 435/069.100
NCLS: 435/071.100; 435/252.300; 435/254.110; 435/320.100; 435/325.000; 536/023.500; 536/024.300; 536/024.310
IC [6]
ICM: C12N015-12
ICS: C12P021-00; C07K014-435; C07K014-47
EXF 536/23.5; 536/24.3; 536/24.31; 435/320.1; 435/325; 435/252.3; 435/69.1; 435/71.1; 435/254.11

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 49 OF 98 USPATFULL on STN
AN 1999:113557 USPATFULL
TI Methods of screening foods for nutraceuticals
IN Ghai, Geetha, Murray Hill, NJ, United States
Boyd, Charles, New Brunswick, NJ, United States
Csizsar, Katalin, New Brunswick, NJ, United States
Ho, Chi-Tang, East Brunswick, NJ, United States
Rosen, Robert T., Pottersville, NJ, United States
PA Rutgers, The State University of New Jersey, New Brunswick, NJ, United States (U.S. corporation)
PI US 5955269 19990921 <--
AI US 1996-670826 19960620 (8)
DT Utility
FS Granted
LN.CNT 2189
INCL INCLM: 435/006.000
INCLS: 435/091.200; 435/004.000; 426/478.000
NCL NCLM: 435/006.000
NCLS: 426/478.000; 435/004.000; 435/091.200
IC [6]
ICM: C12Q001-68
ICS: C12P019-34; A23L001-00
EXF 435/91.1; 435/91.2; 435/91.51; 435/6; 435/7.1; 435/4; 426/478

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 50 OF 98 USPATFULL on STN
AN 1999:92656 USPATFULL
TI Compositions and methods for modulating growth of a tissue in a mammal
IN Weisz, Paul B., State College, PA, United States
PA Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5935940 19990810 <--
AI US 1997-906500 19970805 (8)
RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned, said Ser. No. US 900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809
DT Utility
FS Granted
LN.CNT 1497
INCL INCLM: 514/058.000

NCL NCLM: 514/058.000
NCLS: 514/021.000; 530/810.000; 530/812.000; 530/813.000
IC [6]
ICM: A61K031-715
ICS: A61K038-00
EXF 514/58; 514/21; 530/810; 530/812; 530/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 51 OF 98 USPATFULL on STN
AN 1999:81567 USPATFULL
TI Therapeutic use of multilamellar liposomal prostaglandin formulations
IN Lenk, Robert P., The Woodland, TX, United States
Tomsho, Michelle L., Levittown, PA, United States
Suddith, Robert L., Wilmington, NC, United States
Klimchak, Robert J., Flemington, NJ, United States
Janoff, Andrew S., Yardley, PA, United States
Minchey, Sharma R., Monmouth Junction, NJ, United States
Ostro, Marc J., Pennington, NJ, United States
PA The Liposome Company, Inc., Princeton, NJ, United States (U.S. corporation)
PI US 5925375 19990720 <--
AI US 1994-333770 19941103 (8)
RLI Continuation-in-part of Ser. No. US 1993-152852, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-821648, filed on 16 Jan 1992, now patented, Pat. No. US 5262168 which is a continuation of Ser. No. US 1988-195228, filed on 18 May 1988, now patented, Pat. No. US 5082664 which is a continuation-in-part of Ser. No. US 1987-53305, filed on 2 May 1987, now abandoned, said Ser. No. US 152852 which is a continuation-in-part of Ser. No. US 1993-147898, filed on 4 Nov 1993, now abandoned which is a continuation of Ser. No. US 1992-876200, filed on 30 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-697314, filed on 7 May 1991, now abandoned
DT Utility
FS Granted
LN.CNT 1206
INCL INCLM: 424/450.000
INCLS: 514/573.000
NCL NCLM: 424/450.000
NCLS: 514/573.000
IC [6]
ICM: A61K009-127
ICS: A61K009-133
EXF 424/450; 514/573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 52 OF 98 USPATFULL on STN
AN 1999:75518 USPATFULL
TI Polynucleotides encoding cytokine inducible regulatory protein
IN Hillman, Jennifer L., Mountain View, CA, United States
Guegler, Karl J., Menlo Park, CA, United States
Corley, Neil C., Mountain View, CA, United States
Shah, Purvi, Sunnyvale, CA, United States
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5919661 19990706 <--
AI US 1997-918206 19970825 (8)
DT Utility
FS Granted
LN.CNT 2184
INCL INCLM: 435/069.100
INCLS: 435/071.200; 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.500; 536/024.310; 530/350.000; 514/044.000
NCL NCLM: 435/069.100
NCLS: 435/071.200; 435/252.300; 435/320.100; 435/325.000; 435/471.000; 514/044.000; 530/350.000; 536/023.500; 536/024.310
IC [6]
ICM: C12N015-12
ICS: C12N015-63; C07K014-47
EXF 536/23.1; 536/23.5; 536/24.3; 536/24.31; 435/69.1; 435/71.1; 435/71.2; 435/172.3; 435/325; 435/252.3; 435/320.1; 435/471; 530/350; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 53 OF 98 USPATFULL on STN
AN 1999:72602 USPATFULL

uses therefore
 IN Lai, Ching-San, Encinitas, CA, United States
 PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
 PI US 5916910 19990629 <--
 AI US 1997-869158 19970604 (8)
 DT Utility
 FS Granted
 LN.CNT 1842
 INCL INCLM: 514/423.000
 INCLS: 514/514.000; 548/564.000; 548/573.000; 558/235.000
 NCL NCLM: 514/423.000
 NCLS: 514/514.000; 548/564.000; 548/573.000; 558/235.000
 IC [6]
 ICM: C07D207-04
 ICS: C07D207-30; A61K031-27; A61K031-40
 EXF 514/514; 514/423; 548/565; 548/573; 558/235
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 54 OF 98 USPATFULL on STN
 AN 1999:56471 USPATFULL
 TI Methods of modulating tissue growth and regeneration
 IN Herrmann, Howard C., Bryn Mawr, PA, United States
 Barnathan, Elliot, Havertown, PA, United States
 Weisz, Paul B., State College, PA, United States
 PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
 PI US 5902799 19990511 <--
 AI US 1997-906501 19970805 (8)
 RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned, said Ser. No. US 900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809
 DT Utility
 FS Granted
 LN.CNT 1703
 INCL INCLM: 514/058.000
 INCLS: 514/021.000; 530/810.000; 530/813.000; 530/817.000
 NCL NCLM: 514/058.000
 NCLS: 514/021.000; 530/810.000; 530/813.000; 530/817.000
 IC [6]
 ICM: A61K031-715
 ICS: A61K031-735
 EXF 514/58; 514/21; 514/56; 530/810; 530/812; 530/813; 530/817
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 55 OF 98 USPATFULL on STN
 AN 1999:40428 USPATFULL
 TI Substituted amino alkyl compounds
 IN Klein, J. Peter, Vashon Island, WA, United States
 Underiner, Gail E., Brier, WA, United States
 Leigh, Alistair J., Brier, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5889011 19990330 <--
 AI US 1997-884037 19970627 (8)
 RLI Continuation of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9 Nov 1992, now patented, Pat. No. US 5340813
 DT Utility
 FS Granted
 LN.CNT 1351
 INCL INCLM: 514/263.000
 INCLS: 514/261.000; 544/267.000; 544/264.000; 544/265.000
 NCL NCLM: 514/263.350
 NCLS: 544/264.000; 544/265.000; 544/267.000
 IC [6]
 ICM: C07D473-00
 ICS: A61K031-52
 EXF 544/257; 544/267; 544/263; 544/285; 544/287; 514/263; 514/261
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1999:34025 USPATFULL
TI Compositions and methods for treating and preventing pathologies
including cancer
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. government)
PI US 5883124 19990316 <--
AI US 1995-484615 19950607 (8)
RLI Division of Ser. No. US 1994-207521, filed on 7 Mar 1994 which is a
continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993
which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21
Oct 1991, now abandoned
DT Utility
FS Granted
LN.CNT 7729
INCL INCLM: 514/538.000
INCLS: 514/557.000; 514/563.000; 514/567.000; 514/568.000; 514/570.000;
514/725.000
NCL NCLM: 514/538.000
NCLS: 514/557.000; 514/563.000; 514/567.000; 514/568.000; 514/570.000;
514/725.000
IC [6]
ICM: A01N037-12
ICS: A01N037-44; A61K031-24
EXF 514/538; 514/557; 514/563; 514/567; 514/568; 514/570; 514/725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 57 OF 98 USPATFULL on STN
AN 1999:33831 USPATFULL
TI Compositions and method for the treatment and diagnosis of
cardiovascular disease using rchd502 as a target
IN Falb, Dean A., Wellesley, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 5882925 19990316 <--
AI US 1996-599654 19960209 (8)
RLI Continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995
which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10
Feb 1995
DT Utility
FS Granted
LN.CNT 5758
INCL INCLM: 435/325.000
INCLS: 536/023.100; 536/024.100; 536/024.300; 435/006.000; 435/069.100;
435/320.100; 435/455.000
NCL NCLM: 435/325.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/455.000; 536/023.100;
536/024.100; 536/024.300
IC [6]
ICM: C12N015-12
EXF 536/23.1; 536/24.1; 536/24.3; 435/6; 435/69.1; 435/325; 435/320.1;
435/455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 58 OF 98 USPATFULL on STN
AN 1999:24638 USPATFULL
TI Compositions and methods for modulating growth of a tissue in a mammal
IN Herrmann, Howard C., Bryn Mawr, PA, United States
Barnathan, Elliot, Havertown, PA, United States
Weisz, Paul B., State College, PA, United States
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United
States (U.S. corporation)
PI US 5874419 19990223 <--
AI US 1997-905612 19970804 (8)
RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented,
Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592,
filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser.
No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a
continuation-in-part of Ser. No. US 1991-691168, filed on 24 Apr 1991,
now abandoned which is a continuation of Ser. No. US 1989-397559, filed
on 23 Aug 1989, now abandoned, said Ser. No. US 20 -900592 which is a
continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990,
now patented, Pat. No. US 5183809, issued on 2 Feb 1993
DT Utility
FS Granted

INCL INCLM: 514/058.000
INCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 514/769.000;
424/652.000; 424/682.000; 424/617.000; 536/103.000
NCL NCLM: 514/058.000
NCLS: 424/617.000; 424/652.000; 424/682.000; 514/021.000; 514/023.000;
514/054.000; 514/060.000; 514/769.000; 536/103.000
IC [6]
ICM: A61K031-735
ICS: A61K047-02; C08B037-16
EXF 514/21; 514/23; 514/54; 514/58; 514/60; 514/769; 536/103; 424/652;
424/682; 424/617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 59 OF 98 USPATFULL on STN
AN 1999:7227 USPATFULL
TI Methods for identifying compounds that modulate mammalian tub protein
activity
IN Kleyne, Patrick W., Cambridge, MA, United States
Moore, Karen J., Maynard, MA, United States
Kapeller, Rosana, Chestnut Hill, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 5861239 19990119 <--
AI US 1997-922267 19970902 (8)
RLI Continuation-in-part of Ser. No. US 1997-829553, filed on 28 Mar 1997,
now patented, Pat. No. US 5817762 which is a division of Ser. No. US
1996-631200, filed on 12 Apr 1996, now patented, Pat. No. US 5646040,
issued on 8 Jul 1997
PRAI US 1995-604P 19950630 (60)
US 1995-1273P 19950720 (60)
US 1995-1444P 19950726 (60)
US 1995-2759P 19950824 (60)
US 1995-4424P 19950928 (60)
US 1996-15396P 19960409 (60)
DT Utility
FS Granted
LN.CNT 4705
INCL INCLM: 435/004.000
NCL NCLM: 435/004.000
IC [6]
ICM: C12Q001-00
ICS: C12Q001-02
EXF 435/4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 60 OF 98 USPATFULL on STN
AN 1999:4647 USPATFULL
TI Fas ligand compositions for treatment of proliferative disorders
IN Walsh, Kenneth, Carlisle, MA, United States
PA St. Elizabeth's Medical Center, Boston, MA, United States (U.S.
corporation)
PI US 5858990 19990112 <--
AI US 1997-810453 19970304 (8)
DT Utility
FS Granted
LN.CNT 3038
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/172.100; 435/320.100; 435/069.100; 435/375.000;
435/377.000
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/375.000; 435/377.000
IC [6]
ICM: A61K048-00
ICS: C12N015-11
EXF 435/6; 435/172.1; 435/172.3; 435/320.1; 435/325; 435/69.1; 435/31.1;
435/375; 435/377; 536/23.1; 536/23.5; 514/2; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 61 OF 98 USPATFULL on STN
AN 1998:159986 USPATFULL
TI Phenylacetate and derivatives alone or in combination with other
compounds against neoplastic conditions and other disorders
IN Samid, Dvorit, Rockville, MD, United States
PA The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. government)

WO 9510271 19950420 <--
AI US 1996-633833 19960410 (8)
WO 1994-US11492 19941012
19960410 PCT 371 date
19960410 PCT 102(e) date

RLI Continuation of Ser. No. US 1994-207521, filed on 7 Mar 1994, now patented, Pat. No. US 5605930 And Ser. No. US 1993-135661, filed on 12 Oct 1993, now patented, Pat. No. US 5635532, each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991, now abandoned

DT Utility
FS Granted
LN.CNT 5051

INCL INCLM: 514/510.000
INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000; 514/567.000

NCL NCLM: 514/510.000
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000; 514/567.000

IC [6]
ICM: A01N037-12
ICS: A01N037-44; A61K031-195; A61K031-24

EXF 514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 62 OF 98 USPATFULL on STN
AN 1998:157185 USPATFULL
TI Compositions and methods for the treatment and diagnosis of cardiovascular using RCHD528 as a target
IN Falb, Dean A., Massachusetts, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

PI US 5849578 19981215 <--
AI US 1996-616844 19960315 (8)

RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996 which is a continuation-in-part of Ser. No. US 1995-458873, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995

DT Utility
FS Granted
LN.CNT 5753

INCL INCLM: 435/325.000
INCLS: 536/023.100; 536/024.100; 536/024.300; 435/006.000; 435/069.100; 435/320.100; 435/455.000

NCL NCLM: 435/325.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/455.000; 536/023.100; 536/024.100; 536/024.300

IC [6]
ICM: C12N015-12

EXF 536/23.1; 536/24.1; 536/24.3; 435/6; 435/69.1; 435/7.1; 435/325; 435/320.1; 435/455; 436/201; 436/63; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 63 OF 98 USPATFULL on STN
AN 1998:154266 USPATFULL
TI Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
IN Medford, Russell M., Atlanta, GA, United States
Alexander, R. Wayne, Atlanta, GA, United States
Parthasarathy, Sampath, Atlanta, GA, United States
Khan, Bobby V., Dunwoody, GA, United States
PA Emory University, Atlanta, GA, United States (U.S. corporation)

PI US 5846959 19981208 <--
AI US 1995-471537 19950606 (8)

RLI Continuation of Ser. No. US 1994-317399, filed on 4 Oct 1994 which is a continuation-in-part of Ser. No. US 1994-240858, filed on 10 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-969934, filed on 30 Oct 1992, now patented, Pat. No. US 5380747

DT Utility
FS Granted
LN.CNT 2167

INCL INCLM: 514/165.000
INCLS: 424/009.100; 424/009.200; 424/006.000; 424/007.200; 424/007.210; 424/007.240; 424/007.940; 424/007.950; 436/071.000; 436/086.000; 436/129.000; 436/172.000; 436/503.000; 436/504.000; 436/548.000;

NCL NCLM: 514/457.000; 514/478.000; 514/479.000
 NCLS: 514/165.000
 424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.210;
 435/007.240; 435/007.940; 435/007.950; 436/071.000; 436/086.000;
 436/129.000; 436/172.000; 436/503.000; 436/504.000; 436/548.000;
 514/018.000; 514/171.000; 514/211.070; 514/423.000; 514/457.000;
 514/478.000; 514/479.000

IC [6]
 ICM: A61K031-60
 ICS: A61K031-56; A61K031-40; A61K031-37

EXF 424/9.1; 424/0.2; 436/71; 436/86; 436/129; 514/18; 514/423; 514/478;
 514/479; 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513;
 514/824; 514/825; 514/826; 514/861; 514/863; 530/331; 548/431; 558/230;
 558/235; 564/76; 565/21; 565/25

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 64 OF 98 USPATFULL on STN
 AN 1998:150994 USPATFULL
 TI Compositions and methods for treating and preventing pathologies
 including cancer
 IN Samid, Dvorit, Rockville, MD, United States
 PA The United States of America as represented by the Department of Health
 and Human Services, Washington, DC, United States (U.S. government)
 PI US 5843994 19981201 <--
 AI US 1995-478264 19950607 (8)
 RLI Division of Ser. No. US 1994-207521, filed on 7 Mar 1994, now patented,
 Pat. No. US 5605930 which is a continuation-in-part of Ser. No. US
 1993-135661, filed on 12 Oct 1993, now abandoned which is a
 continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991,
 now abandoned

DT Utility
 FS Granted
 LN.CNT 7935
 INCL INCLM: 514/510.000
 INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
 514/567.000

NCL NCLM: 514/510.000
 NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
 514/567.000

IC [6]
 ICM: A61K031-21
 ICS: A01N047-40

EXF 514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 65 OF 98 USPATFULL on STN
 AN 1998:144102 USPATFULL
 TI Amino-alcohol substituted cyclic compounds
 IN Kumar, Anil M., Seattle, WA, United States
 Michnick, John, Seattle, WA, United States
 Underiner, Gail E., Brier, WA, United States
 Klein, J. Peter, Vashon Island, WA, United States
 Rice, Glenn C., Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5837703 19981117 <--
 AI US 1993-152650 19931112 (8)
 RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
 now abandoned

DT Utility
 FS Granted
 LN.CNT 2596
 INCL INCLM: 514/183.000
 INCLS: 514/211.000; 514/228.800; 514/241.000; 514/242.000; 514/249.000;
 514/256.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000;
 514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;
 514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;
 540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;
 544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;
 546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;
 548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000

NCL NCLM: 514/183.000
 NCLS: 514/211.150; 514/228.800; 514/241.000; 514/242.000; 514/249.000;
 514/256.000; 514/266.200; 514/266.300; 514/270.000; 514/274.000;
 514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;
 514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;

544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;
546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;
548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000

IC [6]
ICM: A61K031-55
ICS: A61K031-515; A61K031-445; A61K031-52
EXF 544/276; 544/272; 544/216; 544/257; 544/285; 544/286; 544/301; 544/311;
544/335; 514/263; 514/183; 514/211; 514/228.8; 514/241; 514/242;
514/249; 514/256; 514/259; 514/270; 514/274; 514/309; 514/312; 514/315;
514/348; 514/357; 514/374; 514/400; 514/418; 514/425; 514/427; 540/467;
540/544; 546/96; 546/141; 546/142; 546/157; 546/246; 546/296; 546/334;
548/215; 548/340.1; 548/485; 548/546; 548/561
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 66 OF 98 USPATFULL on STN
AN 1998:128265 USPATFULL
TI Substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5824677 19981020 <--
AI US 1995-474816 19950607 (8)
RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented,
Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US
1993-152650, filed on 12 Nov 1993, now patented, Pat. No. US 5801181 And
Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US
5470878, said Ser. No. US -152650 And Ser. No. US -164081, each
Ser. No. US - which is a continuation-in-part of Ser. No. US
1993-40820, filed on 31 Mar 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3136
INCL INCLM: 514/222.500
INCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800;
514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000;
514/249.000; 514/255.000; 514/258.000; 514/274.000; 514/301.000;
514/303.000; 514/311.000; 514/351.000; 514/360.000; 514/361.000;
514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000;
514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000;
514/378.000; 514/379.000; 514/380.000; 514/387.000; 514/395.000;
514/415.000; 514/418.000; 514/424.000; 514/425.000; 514/433.000;
514/452.000; 514/432.000; 514/438.000; 346/113.000; 346/114.000;
346/164.000; 346/300.000; 549/014.000; 549/050.000; 549/075.000;
549/367.000; 549/368.000; 544/002.000; 544/003.000; 544/005.000;
544/008.000; 544/053.000; 544/063.000; 544/065.000; 544/066.000;
544/067.000; 544/090.000; 544/091.000; 544/127.000; 544/128.000;
544/162.000; 544/215.000; 544/219.000; 544/229.000; 544/235.000;
544/237.000; 544/255.000; 544/278.000; 544/311.000; 544/353.000;
544/385.000; 548/123.000; 548/125.000; 548/131.000; 548/134.000;
548/143.000; 548/146.000; 548/153.000; 548/174.000; 548/207.000;
548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/228.000;
548/229.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000;
548/247.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000;
548/486.000; 548/543.000; 548/546.000

NCL NCLM: 514/222.500
NCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800;
514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000;
514/249.000; 514/255.020; 514/260.100; 514/274.000; 514/301.000;
514/303.000; 514/311.000; 514/351.000; 514/360.000; 514/361.000;
514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000;
514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000;
514/378.000; 514/379.000; 514/380.000; 514/387.000; 514/395.000;
514/415.000; 514/418.000; 514/424.000; 514/425.000; 514/432.000;
514/433.000; 514/438.000; 514/452.000; 544/002.000; 544/003.000;
544/005.000; 544/008.000; 544/053.000; 544/063.000; 544/065.000;
544/066.000; 544/067.000; 544/090.000; 544/091.000; 544/127.000;
544/128.000; 544/162.000; 544/215.000; 544/219.000; 544/229.000;
544/235.000; 544/237.000; 544/255.000; 544/278.000; 544/311.000;
544/353.000; 544/385.000; 546/113.000; 546/114.000; 546/164.000;
546/300.000; 548/123.000; 548/125.000; 548/131.000; 548/134.000;
548/143.000; 548/146.000; 548/153.000; 548/174.000; 548/207.000;
548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/228.000;
548/229.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000;
548/247.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000;

IC [6]
 ICM: A61K031-385
 ICS: A61K031-445; A61K031-47; A61K031-505
 EXF 549/75; 549/50; 549/14; 549/367; 549/368; 514/432; 514/438; 514/222.5;
 514/223.5; 514/224.5; 514/226.8; 514/227.5; 514/228.8; 514/229.2;
 514/230.5; 514/230.8; 514/237.8; 514/248; 514/249; 514/255; 514/258;
 514/274; 514/301; 514/303; 514/311; 514/351; 514/360; 514/361; 514/362;
 514/363; 514/364; 514/365; 514/367; 514/372; 514/373; 514/374; 514/375;
 514/376; 514/378; 514/379; 514/380; 514/387; 514/395; 514/415; 514/418;
 514/424; 514/425; 514/433; 514/452; 544/2; 544/3; 544/5; 544/8; 544/53;
 544/63; 544/65; 544/66; 544/67; 544/90; 544/91; 544/127; 544/128;
 544/162; 544/215; 544/219; 544/229; 544/235; 544/237; 544/255; 544/278;
 544/311; 544/353; 544/385; 546/113; 546/114; 546/164; 546/300; 548/123;
 548/125; 548/131; 548/134; 548/145; 548/146; 548/153; 548/174; 548/207;
 548/214; 548/215; 548/217; 548/221; 548/228; 548/229; 548/237; 548/240;
 548/241; 548/243; 548/247; 548/267.2; 548/303.7; 548/307.1; 548/453;
 548/486; 548/543; 548/546
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 67 OF 98 USPATFULL on STN
 AN 1998:122413 USPATFULL
 TI Substituted amino alkyl compounds
 IN Klein, J. Peter, Vashon Island, WA, United States
 Underiner, Gail E., Brier, WA, United States
 Leigh, Alistair J., Brier, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5817662 19981006 <--
 AI US 1995-468656 19950606 (8)
 RLI Division of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned
 which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9
 Nov 1992, now patented, Pat. No. US 5340813
 DT Utility
 FS Granted
 LN.CNT 1358
 INCL INCLM: 514/263.000
 INCLS: 424/824.000; 424/825.000; 424/885.000; 424/921.000
 NCL NCLM: 514/263.350
 NCLS: 424/824.000; 424/825.000
 IC [6]
 ICM: A61K031-52
 EXF 514/397; 514/263; 424/824; 424/825; 424/885; 424/921
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 68 OF 98 USPATFULL on STN
 AN 1998:115764 USPATFULL
 TI Treatment for atherosclerosis and other cardiovascular and inflammatory
 diseases
 IN Medford, Russell M., Atlanta, GA, United States
 Alexander, R. Wayne, Atlanta, GA, United States
 Parthasarathy, Sampath, Atlanta, GA, United States
 Khan, Bobby V., Dunwoody, GA, United States
 PA Emory University, Atlanta, GA, United States (U.S. corporation)
 PI US 5811449 19980922 <--
 AI US 483335& 19950607 (8)
 RLI Division of Ser. No. 317399, filed on 4 Oct 1994 which is a
 continuation-in-part of Ser. No. 240858, filed on 10 May 1994, now
 abandoned which is a continuation-in-part of Ser. No. 969934, filed
 on 30 Oct 1992, now patented, Pat. No. 5380747
 DT Utility
 FS Granted
 LN.CNT 2106
 INCL INCLM: 514/423.000
 INCLS: 514/863.000; 530/331.000; 548/431.000; 548/531.000; 549/010.000;
 558/230.000; 558/234.000; 558/235.000; 558/250.000; 562/026.000;
 562/027.000; 564/076.000
 NCL NCLM: 514/423.000
 NCLS: 424/009.100; 424/009.200; 436/071.000; 436/086.000; 436/129.000;
 514/018.000; 514/226.200; 514/477.000; 514/478.000; 514/479.000;
 514/484.000; 514/485.000; 514/487.000; 514/488.000; 514/489.000;
 514/506.000; 514/513.000; 514/517.000; 514/518.000; 514/553.000;
 514/561.000; 514/824.000; 514/825.000; 514/826.000; 514/861.000;
 514/863.000; 530/331.000; 548/431.000; 548/531.000; 549/010.000;
 558/230.000; 558/234.000; 558/235.000; 558/250.000; 562/026.000;
 562/027.000; 564/076.000; 568/021.000; 568/025.000

ICM: A61K031-40
ICS: A61K031-54; A61K031-265; A61K031-185
EXF 424/9.1; 424/9.2; 436/71; 436/86; 436/129; 514/18; 514/423; 514/478;
514/479; 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513;
514/824; 514/825; 514/826; 514/861; 514/863; 530/331; 548/431; 558/230;
558/235; 564/76; 568/21; 568/25
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 69 OF 98 USPATFULL on STN
AN 1998:115565 USPATFULL
TI Atherosclerotic plaque specific antigens, antibodies thereto, and uses
thereof
IN Ditlow, Charles C., Fremont, CA, United States
Chen, Francis W., San Francisco, CA, United States
Calenoff, Emanuel, Chicago, IL, United States
PA Charter Ventures, Palo Alto, CA, United States (U.S. corporation)
PI US 5811248 19980922 <--
AI US 1995-480434 19950607 (8)
RLI Division of Ser. No. US 1994-336525, filed on 9 Nov 1994, now abandoned
which is a continuation-in-part of Ser. No. US 1993-53451, filed on 26
Apr 1993 which is a continuation-in-part of Ser. No. US 1992-828860,
filed on 31 Jan 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1989-388129, filed on 31 Jul 1989, now abandoned which is a
continuation-in-part of Ser. No. US 1987-67995, filed on 29 Jun 1987,
now abandoned which is a continuation of Ser. No. US 1987-67993, filed
on 29 Jun 1987, now abandoned which is a continuation-in-part of Ser.
No. US 1987-67986, filed on 29 Jun 1987, now abandoned which is a
continuation-in-part of Ser. No. US 1986-876841, filed on 20 Jun 1986,
now abandoned which is a continuation-in-part of Ser. No. US
1986-871811, filed on 6 Jun 1986, now abandoned which is a
continuation-in-part of Ser. No. US 1986-846401, filed on 31 Mar 1986,
now abandoned
DT Utility
FS Granted
LN.CNT 4729
INCL INCLM: 435/007.900
INCLS: 435/007.100; 435/011.000; 435/007.920; 435/007.930; 424/009.600;
424/133.100; 424/134.100; 424/135.100; 424/178.100; 530/387.300;
530/388.100; 530/388.900; 530/391.100; 530/391.300
NCL NCLM: 435/007.900
NCLS: 424/009.600; 424/133.100; 424/134.100; 424/135.100; 424/178.100;
435/007.100; 435/007.920; 435/007.930; 435/011.000; 530/387.300;
530/388.100; 530/388.900; 530/391.100; 530/391.300
IC [6]
ICM: G01N033-574
ICS: G01N033-53; C07K016-18
EXF 435/7.1; 435/11; 435/7.9; 435/7.92; 435/7.93; 530/387.3; 530/388.1;
530/388.9; 530/391.1; 530/391.3; 530/391.7; 436/518; 424/9.6; 424/133.1;
424/134.1; 424/135.1; 424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 70 OF 98 USPATFULL on STN
AN 1998:111964 USPATFULL
TI Treatment for atherosclerosis and other cardiovascular and inflammatory
diseases
IN Medford, Russell M., Atlanta, GA, United States
Alexander, R. Wayne, Atlanta, GA, United States
Parthasarathy, Sampath, Atlanta, GA, United States
Khan, Bobby V., Dunwoody, GA, United States
PA Emory University, Atlanta, GA, United States (U.S. corporation)
PI US 5807884 19980915 <--
AI US 1994-317399 19941004 (8)
RLI Continuation-in-part of Ser. No. US 1994-240858, filed on 10 May 1994,
now abandoned which is a continuation-in-part of Ser. No. US
1992-969934, filed on 30 Oct 1992, now patented, Pat. No. US 5380747
DT Utility
FS Granted
LN.CNT 2089
INCL INCLM: 514/423.000
INCLS: 424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.210;
435/007.240; 435/007.940; 435/007.950; 436/071.000; 436/086.000;
436/129.000; 436/172.000; 436/503.000; 436/504.000; 436/548.000;
514/018.000; 514/226.200; 514/477.000; 514/478.000; 514/479.000;
514/484.000; 514/485.000; 514/487.000
NCL NCLM: 514/423.000

514/518.000; 514/553.000; 514/561.000; 514/824.000; 514/825.000;
514/826.000; 514/861.000; 514/863.000; 530/331.000; 548/431.000;
549/016.000

IC [6]

ICM: A61K031-40

ICS: A61K031-54; A61K031-265; A61K031-185

EXF 424/9.1; 424/9.2; 436/71; 436/86; 436/129; 514/18; 514/423; 514/478;
514/479; 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513;
514/824; 514/825; 514/826; 514/861; 514/863; 514/226.2; 514/477;
514/517; 514/518; 514/553; 514/561; 530/331; 548/431; 548/531; 558/230;
558/235; 558/234; 558/250; 564/76; 568/21; 568/25; 562/26; 562/27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 71 OF 98 USPATFULL on STN

AN 1998:111942 USPATFULL

TI Therapeutic compounds containing pyrimidinyl moieties

IN Klein, J. Peter, Vashon, WA, United States

Leigh, Alistair J., Brier, WA, United States

Underiner, Gail E., Brier, WA, United States

Kumar, Anil M., Seattle, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5807862 19980915 <--

AI US 1995-478112 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
now abandoned

DT Utility

FS Granted

LN.CNT 2190

INCL INCLM: 514/269.000

INCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000

NCL NCLM: 514/269.000

NCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000

IC [6]

ICM: A61K031-505

ICS: C07D239-54

EXF 514/269; 514/274; 544/309; 544/310; 544/311; 544/312

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 72 OF 98 USPATFULL on STN

AN 1998:111941 USPATFULL

TI Amine substituted xanthinyl compounds

IN Klein, J. Peter, Vashon, WA, United States

Underiner, Gail E., Brier, WA, United States

Kumar, Anil M., Seattle, WA, United States

Ridgers, Lance H., Bothell, WA, United States

Rice, Glenn C., Seattle, WA, United States

Leung, David W., Mercer Island, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5807861 19980915 <--

AI US 1995-476911 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994,
now abandoned

DT Utility

FS Granted

LN.CNT 1713

INCL INCLM: 514/263.000

NCL NCLM: 514/263.350

NCLS: 514/081.000; 514/151.000; 514/210.210; 514/263.200; 514/263.220;
514/263.230

IC [6]

ICM: A61K031-52

EXF 514/263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 73 OF 98 USPATFULL on STN

AN 1998:108415 USPATFULL

TI Therapeutic compounds containing a monocyclic five- to six- membered
ring structure having one to two nitrogen atoms

IN Underiner, Gail E., Brier, WA, United States

Porubek, David, Seattle, WA, United States

Klein, J. Peter, Vashon Island, WA, United States

Woodson, Paul, Edmonds, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5804584 19980908 <--

AI US 1995-468659 19950606 (8)

which is a continuation-in-part of Ser. No. US 1992-9/6353, filed on 16 Nov 1992, now patented, Pat. No. US 5473070

DT Utility
FS Granted
LN.CNT 1554
INCL INCLM: 514/269.000
INCLS: 544/298.000; 544/242.000; 544/301.000; 544/302.000; 514/256.000
NCL NCLM: 514/269.000
NCLS: 514/256.000; 544/242.000; 544/298.000; 544/301.000; 544/302.000
IC [6]
ICM: C07D239-54
ICS: A61K031-52
EXF 514/242; 514/243; 514/269; 544/298; 544/299
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 74 OF 98 USPATFULL on STN
AN 1998:104752 USPATFULL
TI Amine substituted compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5801182 19980901 <--
AI US 1995-485777 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1706
INCL INCLM: 514/269.000
INCLS: 514/274.000; 544/310.000; 544/311.000; 544/312.000
NCL NCLM: 514/269.000
NCLS: 514/274.000; 544/310.000; 544/311.000; 544/312.000
IC [6]
ICM: A61K031-505
ICS: C07D239-02
EXF 544/312; 514/269; 514/274; 514/310; 514/311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 75 OF 98 USPATFULL on STN
AN 1998:88470 USPATFULL
TI ***VEGF*** gene transfer into endothelial cells for vascular prosthesis
IN Pratt, Richard E., Palo Alto, CA, United States
Dzau, Victor J., Los Altos Hills, CA, United States
PA The Board of Trustees of the Leland Stanford Junior Univ., Palo Alto, CA, United States (U.S. corporation)
PI US 5785965 19980728 <--
AI US 1996-647821 19960515 (8)
DT Utility
FS Granted
LN.CNT 905
INCL INCLM: 424/093.210
INCLS: 424/093.100; 424/093.200; 435/172.300; 435/325.000
NCL NCLM: 424/093.210
NCLS: 424/093.100; 424/093.200; 435/325.000; 435/455.000; 435/456.000
IC [6]
ICM: A01N063-00
ICS: C12N015-00
EXF 600/36; 623/1; 623/11; 623/12; 435/172.3; 435/240.2; 435/320.1; 435/325; 424/93.21; 424/93.1; 424/93.2; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 76 OF 98 USPATFULL on STN
AN 1998:82763 USPATFULL
TI Hydroxyl-containing xanthine compounds
IN Underiner, Gail E., Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5780476 19980714 <--
AI US 1995-468660 19950606 (8)
RLI Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned

Nov 1992, now patented, Pat. NO. US 5473070

DT Utility
FS Granted
LN.CNT 1672
INCL INCLM: 514/263.000
INCLS: 544/267.000
NCL NCLM: 514/263.360
IC [6]
ICM: A61K031-52
ICS: C07D473-04

EXF 514/263; 514/256; 514/257; 514/258; 514/259; 514/261; 514/269; 514/270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 77 OF 98 USPATFULL on STN
AN 1998:79344 USPATFULL
TI Method for preparing substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5777117 19980707 <--
AI US 1995-472569 19950607 (8)
RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994 which is a
continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993
And Ser. No. US 1993-164081, filed on 8 Dec 1993 which is a
continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
now abandoned, said Ser. No. US -152650 which is a
continuation-in-part of Ser. No. US -40820

DT Utility
FS Granted
LN.CNT 3153
INCL INCLM: 544/267.000
INCLS: 544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000;
546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
NCL NCLM: 544/267.000
NCLS: 544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000;
546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
IC [6]
ICM: C07D473-10
ICS: C07D239-80; C07D211-94; C07D209-48

EXF 544/267; 544/257; 544/285; 544/286; 544/287; 544/311; 546/141; 546/243;
546/246; 548/477; 548/546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 78 OF 98 USPATFULL on STN
AN 1998:79342 USPATFULL
TI Acetal-and ketal-substituted pyrimidine compounds
IN Leigh, Alistair, Brier, WA, United States
Underiner, Gail, Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5777115 19980707 <--
AI US 1994-193331 19940207 (8)
RLI Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now
abandoned

DT Utility
FS Granted
LN.CNT 1632
INCL INCLM: 544/242.000
INCLS: 544/267.000; 514/269.000; 514/270.000; 514/256.000
NCL NCLM: 544/242.000
NCLS: 544/267.000
IC [6]
ICM: C07D239-26
ICS: A61K031-505

EXF 544/267; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 79 OF 98 USPATFULL on STN
AN 1998:75382 USPATFULL
TI Treatment for atherosclerosis and other cardiovascular and inflammatory
diseases
IN Medford, Russell M., Atlanta, GA, United States
Alexander, R. Wayne, Atlanta, GA, United States
Parthasarathy, Sampath, Atlanta, GA, United States
Khan, Bobby V., Dunwoody, GA, United States

PI US 5773231 19980630 <--
 AI US 1995-473272 19950607 (8)
 RLI Continuation of Ser. No. US 1994-317399, filed on 4 Oct 1994 which is a
 continuation-in-part of Ser. No. US 1994-240858, filed on 10 May 1994,
 now abandoned which is a continuation-in-part of Ser. No. US
 1992-969934, filed on 30 Oct 1992, now patented, Pat. No. US 5380747
 DT Utility
 FS Granted
 LN.CNT 2092
 INCL INCLM: 435/007.240
 INCLS: 424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.210;
 435/007.940; 435/007.950; 436/071.000; 436/086.000; 436/129.000;
 436/172.000; 436/503.000; 436/504.000; 436/548.000; 514/018.000;
 514/423.000; 514/478.000; 514/479.000; 514/484.000; 514/485.000;
 514/487.000; 514/488.000; 514/489.000; 514/506.000; 514/513.000;
 514/824.000; 514/825.000; 514/826.000; 514/861.000; 514/863.000;
 530/331.000; 548/431.000; 558/230.000; 558/235.000; 564/076.000;
 568/021.000; 568/025.000
 NCL NCLM: 435/007.240
 NCLS: 514/489.000; 514/506.000; 514/513.000; 514/824.000; 514/825.000;
 514/826.000; 514/861.000; 514/863.000; 530/331.000; 548/431.000;
 558/230.000; 558/235.000; 564/076.000; 568/021.000; 568/025.000
 IC [6]
 ICM: G01N033-53
 EXF 424/9.1; 424/9.2; 436/71; 436/86; 514/18; 514/423; 514/478; 514/479;
 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513; 514/824;
 514/825; 514/826; 514/861; 514/863; 530/331; 540/431; 558/230; 558/235;
 564/76; 568/21; 568/25
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L8 ANSWER 80 OF 98 USPATFULL on STN
 AN 1998:75361 USPATFULL
 TI Treatment for atherosclerosis and other cardiovascular and inflammatory
 diseases
 IN Medford, Russell M., Atlanta, GA, United States
 Alexander, R. Wayne, Atlanta, GA, United States
 Parthasarathy, Sampath, Atlanta, GA, United States
 Khan, Bobby V., Dunwoody, GA, United States
 Emory University, Atlanta, GA, United States (U.S. corporation)
 PA US 5773209 19980630 <--
 AI US 1995-484059 19950607 (8)
 RLI Continuation of Ser. No. US 1994-317399, filed on 4 Oct 1994 which is a
 continuation-in-part of Ser. No. US 1994-240858, filed on 10 May 1994
 which is a continuation-in-part of Ser. No. US 1992-969934, filed on 30
 Oct 1992, now patented, Pat. No. US 5380747
 DT Utility
 FS Granted
 LN.CNT 2115
 INCL INCLM: 435/007.240
 INCLS: 424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.210;
 435/007.940; 435/007.950; 436/071.000; 436/086.000; 436/129.000;
 436/172.000; 436/503.000; 436/504.000; 436/548.000; 514/018.000;
 514/423.000; 514/478.000; 514/479.000; 514/484.000; 514/485.000;
 514/487.000; 514/488.000; 514/489.000; 514/506.000; 514/513.000;
 514/824.000; 514/825.000; 514/826.000; 514/861.000; 514/863.000;
 530/331.000; 548/431.000; 558/230.000; 558/235.000; 564/076.000;
 568/021.000; 568/025.000
 NCL NCLM: 435/007.240
 NCLS: 424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.210;
 435/007.940; 435/007.950; 436/071.000; 436/086.000; 436/129.000;
 436/172.000; 436/503.000; 436/504.000; 436/548.000; 514/018.000;
 514/423.000; 514/478.000; 514/479.000; 514/484.000; 514/485.000;
 514/487.000; 514/488.000
 IC [6]
 ICM: G01N033-53
 EXF 424/9.1; 424/9.2; 436/71; 436/86; 436/129; 514/18; 514/423-478; 514/479;
 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513; 514/824;
 514/825; 514/826; 514/861; 514/863; 530/331; 548/431; 558/230; 558/235;
 564/76; 568/21; 568/25
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L8 ANSWER 81 OF 98 USPATFULL on STN
 AN 1998:72620 USPATFULL
 TI Oxime substituted therapeutic compounds
 IN Klein, J. Peter, Vashon, WA, United States

PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5770595 19980623 <--
 AI US 1994-193344 19940207 (8)
 RLI Continuation of Ser. No. US 1993-6083, filed on 19 Jan 1993, now
 abandoned
 DT Utility
 FS Granted
 LN.CNT 2183
 INCL INCLM: 514/263.000
 INCLS: 544/271.000; 544/273.000
 NCL NCLM: 514/263.350
 NCLS: 514/151.000; 544/271.000; 544/273.000
 IC [6]
 ICM: M61K031-52
 EXF 514/263; 544/271; 544/273

L8 ANSWER 82 OF 98 USPATFULL on STN
 AN 1998:51651 USPATFULL
 TI Substituted amino alcohol compounds
 IN Klein, J. Peter, Vashon, WA, United States
 Underiner, Gail E., Brier, WA, United States
 Kumar, Anil M., Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5750575 19980512 <--
 AI US 1995-475721 19950607 (8)
 RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented,
 Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US
 1993-152650, filed on 12 Nov 1993 And a continuation-in-part of Ser. No.
 US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878
 which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31
 Mar 1993, now abandoned
 DT Utility
 FS Granted
 LN.CNT 3115
 INCL INCLM: 514/617.000
 INCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000
 NCL NCLM: 514/617.000
 NCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000
 IC [6]
 ICM: A61K031-165
 ICS: A61K031-135; C07C233-35; C07C215-20
 EXF 564/355; 564/182; 564/361; 514/617; 514/653
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 83 OF 98 USPATFULL on STN
 AN 1998:51434 USPATFULL
 TI Treatment for atherosclerosis and other cardiovascular and inflammatory
 diseases
 IN Medford, Russell M., Atlanta, GA, United States
 Alexander, R. Wayne, Atlanta, GA, United States
 Parthasarathy, Sampath, Atlanta, GA, United States
 Khan, Bobby V., Dunwoody, GA, United States
 PA Emory University, Atlanta, GA, United States (U.S. corporation)
 PI US 5750351 19980512 <--
 AI US 1995-474530 19950607 (8)
 RLI Continuation of Ser. No. US 1994-317399, filed on 4 Oct 1994 which is a
 continuation-in-part of Ser. No. US 1994-240858, filed on 10 May 1994,
 now abandoned which is a continuation-in-part of Ser. No. US
 1992-969934, filed on 30 Oct 1992, now patented, Pat. No. US 5380747
 DT Utility
 FS Granted
 LN.CNT 2126
 INCL INCLM: 435/007.210
 INCLS: 424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.240;
 435/007.940; 435/007.950; 436/071.000; 436/086.000; 436/129.000;
 436/172.000; 436/503.000; 436/504.000; 436/548.000; 514/018.000;
 514/226.200; 514/423.000; 514/477.000; 514/478.000; 514/479.000;
 514/484.000; 514/485.000; 514/487.000; 514/488.000; 514/489.000;
 514/506.000; 514/513.000; 514/517.000; 514/518.000; 514/553.000;
 514/561.000; 514/824.000; 514/825.000; 514/826.000; 514/861.000;
 514/863.000; 530/331.000; 548/431.000; 549/016.000; 558/230.000;
 558/234.000; 558/235.000; 558/250.000; 562/026.000; 562/027.000;
 564/076.000
 NCL NCLM: 435/007.210
 NCLS: 424/009.100; 424/009.200; 435/006.000; 435/007.200; 435/007.240;

436/172.000; 436/503.000; 436/504.000; 436/548.000; 514/018.000;
514/226.200; 514/423.000; 514/477.000; 514/478.000; 514/479.000;
514/484.000; 514/485.000; 514/487.000; 514/488.000; 514/489.000;
514/506.000; 514/513.000; 514/517.000; 514/518.000; 514/553.000;
514/561.000; 514/824.000; 514/825.000; 514/826.000; 514/861.000;
514/863.000; 530/331.000; 548/431.000; 549/016.000; 558/230.000;
558/234.000; 558/235.000; 558/250.000; 562/026.000; 562/027.000;
564/076.000

IC [6]
ICM: G01N033-53
ICS: A61K031-40; A61K031-54; A61K031-265
EXF 424/9.1; 424/9.2; 436/71; 436/86; 436/129; 514/1S; 514/423; 514/478;
514/479; 514/484; 514/485; 514/487; 514/488; 514/489; 514/506; 514/513;
514/824; 514/825; 514/826; 514/861; 514/863; 530/331; 548/431; 558/230;
558/235; 564/76; 568/21; 568/25
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 84 OF 98 USPATFULL on STN
AN 1998:7093 USPATFULL
TI Growth stimulating factors
IN Nudelman, Edward, Seattle, WA, United States
Hakomori, Sen-Itiroh, Mercer Island, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5710175 19980120 <--
AI US 1996-627623 19960404 (8)
RLI Continuation of Ser. No. US 1994-285153, filed on 3 Aug 1994, now
abandoned
DT Utility
FS Granted
LN.CNT 999
INCL INCLM: 514/547.000
INCLS: 514/549.000; 514/723.000
NCL NCLM: 514/547.000
NCLS: 514/549.000; 514/723.000
IC [6]
ICM: A01N037-02
ICS: A01N037-06; A61K031-72
EXF 514/547; 514/549; 514/723
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 85 OF 98 USPATFULL on STN
AN 97:86614 USPATFULL
TI Halogen, isothiocyanate or azide substituted xanthines
IN Leigh, Alistair, Brier, WA, United States
Michnick, John, Seattle, WA, United States
Kumar, Anil, Seattle, WA, United States
Underiner, Gail, Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5670506 19970923 <--
AI US 1993-42946 19930405 (8)
DT Utility
FS Granted
LN.CNT 1994
INCL INCLM: 514/258.000
INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
NCL NCLM: 514/141.000
NCLS: 544/267.000; 544/272.000; 544/277.000
IC [6]
ICM: A61K031-52
ICS: C07D473-00
EXF 544/267; 544/276; 544/272; 544/277; 514/258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 86 OF 98 USPATFULL on STN
AN 97:80936 USPATFULL
TI Methods for the preparation of immunostimulating agents for in vivo
delivery
IN Grinstaff, Mark W., Pasadena, CA, United States
Soon-Shiong, Patrick, Los Angeles, CA, United States
Wong, Michael, Champagne, IL, United States
Sandford, Paul A., Los Angeles, CA, United States
Suslick, Kenneth S., Champagne, IL, United States
Desai, Neil P., Los Angeles, CA, United States
PA Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S.
corporation)

AI US 1995-488804 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-200235, filed on 22 Feb 1994, now patented, Pat. No. US 5498421 which is a continuation-in-part of Ser. No. US 1993-23698, filed on 22 Feb 1993, now patented, Pat. No. US 5439686 And a continuation-in-part of Ser. No. US 1993-35150, filed on 26 Mar 1993, now patented, Pat. No. US 5362478
DT Utility
FS Granted
LN.CNT 3278
INCL INCLM: 424/450.000
INCLS: 424/451.000; 424/465.000; 424/489.000
NCL NCLM: 424/450.000
NCLS: 424/451.000; 424/465.000; 424/489.000
IC [6]
ICM: A61K009-127
EXF 424/451; 424/450; 424/465; 424/489
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 87 OF 98 USPATFULL on STN
AN 97:80935 USPATFULL
TI Methods for the preparation of pharmaceutically active agents for in vivo delivery
IN Grinstaff, Mark W., Pasadena, CA, United States
Soon-Shiong, Patrick, Los Angeles, CA, United States
Wong, Michael, Champaign, IL, United States
Sandford, Paul A., Los Angeles, CA, United States
Suslick, Kenneth S., Champaign, IL, United States
Desai, Neil P., Los Angeles, CA, United States
PA Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S. corporation)

PI US 5665382 19970909 <--
AI US 1995-485448 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-200235, filed on 22 Feb 1994, now patented, Pat. No. US 5498421 which is a continuation-in-part of Ser. No. US 1993-23698, filed on 22 Feb 1993, now patented, Pat. No. US 5439686 And a continuation-in-part of Ser. No. US 1993-35150, filed on 26 Mar 1993, now patented, Pat. No. US 5362478
DT Utility
FS Granted
LN.CNT 3304
INCL INCLM: 424/450.000
INCLS: 424/009.100; 424/488.000
NCL NCLM: 424/450.000
NCLS: 424/009.100; 424/488.000
IC [6]
ICM: A61K009-127
EXF 424/9; 424/9.1; 424/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 88 OF 98 USPATFULL on STN
AN 97:73601 USPATFULL
TI Compositions for inhibiting restenosis
IN Weisz, Paul B., State College, PA, United States
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5658894 19970819 <--
AI US 1994-345011 19941123 (8)
RLI Continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned, said Ser. No. US -900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809, issued on 2 Feb 1993
DT Utility
FS Granted
LN.CNT 1449
INCL INCLM: 514/058.000
INCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 536/103.000; 530/810.000; 530/812.000; 530/813.000
NCL NCLM: 514/058.000
NCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 530/810.000; 530/812.000; 530/813.000; 536/103.000
IC [6]

ICS: C08B037-16
EXF 514/21; 514/23; 514/54; 514/58; 514/60; 536/103; 530/810; 530/812;
530/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 89 OF 98 USPATFULL on STN
AN 97:63766 USPATFULL
TI Methods for in vivo delivery of nutraceuticals and compositions useful
therefor
IN Grinstaff, Mark W., Pasadena, CA, United States
Soon-Shiong, Patrick, Los Angeles, CA, United States
Wong, Michael, Champagne, IL, United States
Sandford, Paul A., Los Angeles, CA, United States
Suslick, Kenneth S., Champagne, IL, United States
Desai, Neil P., Los Angeles, CA, United States
PA Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S.
corporation)
PI US 5650156 19970722 <--
AI US 1995-482272 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-200235, filed on 22 Feb 1994,
now patented, Pat. No. US 5498421 which is a continuation-in-part of
Ser. No. US 1993-23698, filed on 22 Feb 1993, now patented, Pat. No. US
5439686 And Ser. No. US 1993-35150, filed on 26 Mar 1993, now patented,
Pat. No. US 5362478
DT Utility
FS Granted
LN.CNT 3310
INCL INCLM: 424/400.000
INCLS: 424/450.000; 424/451.000; 424/056.000; 424/009.400; 424/009.500;
424/009.300
NCL NCLM: 424/400.000
NCLS: 424/009.300; 424/009.400; 424/009.500; 424/056.000; 424/450.000;
424/451.000
IC [6]
ICM: A61K009-00
EXF 424/400; 424/450; 424/451; 424/9
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 90 OF 98 USPATFULL on STN
AN 97:54233 USPATFULL
TI Substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5641783 19970624 <--
AI US 1994-303842 19940908 (8)
RLI Continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993
And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No.
US 5470878
DT Utility
FS Granted
LN.CNT 3206
INCL INCLM: 514/263.000
INCLS: 514/183.000; 514/222.500; 514/223.500; 514/224.200; 514/226.800;
514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800;
514/237.800; 514/241.000; 514/242.000; 514/243.000; 514/246.000;
514/247.000; 514/248.000; 514/249.000; 514/255.000; 514/256.000;
514/258.000; 514/259.000; 514/261.000; 514/262.000; 514/263.000;
514/270.000; 514/274.000; 514/297.000; 514/300.000; 514/301.000;
514/302.000; 514/303.000; 514/306.000; 514/307.000; 514/311.000;
514/312.000; 514/315.000; 514/345.000; 514/351.000; 514/357.000;
514/359.000; 514/360.000; 514/361.000; 514/362.000; 514/363.000;
514/364.000; 514/365.000; 514/367.000; 514/369.000; 514/372.000;
514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/378.000;
514/379.000; 514/380.000; 514/381.000; 514/383.000; 514/389.000;
514/394.000; 514/395.000; 514/398.000; 514/399.000; 514/401.000;
514/404.000; 514/406.000; 514/413.000; 514/415.000; 514/416.000;
514/418.000; 514/423.000; 514/424.000; 514/425.000; 514/427.000;
514/428.000; 544/001.000; 544/002.000; 544/003.000; 544/008.000;
544/053.000; 544/063.000; 544/065.000; 544/066.000; 544/067.000;
544/090.000; 544/091.000; 544/162.000; 544/215.000; 544/216.000;
544/219.000; 544/220.000; 544/224.000; 544/235.000; 544/239.000;
544/254.000; 544/255.000; 544/257.000; 544/262.000; 544/272.000;
544/277.000; 544/278.000; 544/280.000; 544/283.000; 544/286.000;

544/353.000; 544/385.000; 544/401.000; 546/102.000; 546/113.000;
546/114.000; 546/115.000; 546/117.000; 546/118.000; 546/119.000;
546/122.000; 546/138.000; 546/139.000; 546/150.000; 546/153.000;
546/157.000; 546/164.000; 546/176.000; 546/178.000; 546/242.000;
546/243.000; 546/246.000; 546/264.000; 546/300.000; 546/334.000;
548/100.000; 548/123.000; 548/125.000; 548/127.000; 548/128.000;
548/131.000; 548/134.000; 548/146.000; 548/153.000; 548/179.000;
548/186.000; 548/207.000; 548/214.000; 548/215.000; 548/217.000;
548/221.000; 548/225.000; 548/228.000; 548/229.000; 548/235.000;
548/237.000; 548/240.000; 548/241.000; 548/243.000; 548/247.000;
548/252.000; 548/267.200; 548/267.800; 548/303.700; 548/306.400;
548/307.100; 548/309.700; 548/319.100; 548/323.500; 548/340.100;
548/348.100; 548/349.100; 548/356.100; 548/370.100; 548/375.100;
548/379.400; 548/452.000; 548/453.000; 548/470.000; 548/482.000;
548/485.000; 548/486.000; 548/491.000; 548/503.000; 548/532.000;
548/543.000; 548/546.000; 548/550.000; 548/565.000; 548/566.000

NCL

NCLM:

NCLS:

514/263.350
514/183.000; 514/222.500; 514/223.500; 514/224.200; 514/226.800;
514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800;
514/237.800; 514/241.000; 514/242.000; 514/243.000; 514/246.000;
514/247.000; 514/248.000; 514/249.000; 514/252.160; 514/256.000;
514/259.500; 514/264.100; 514/266.300; 514/270.000; 514/274.000;
514/297.000; 514/300.000; 514/301.000; 514/302.000; 514/303.000;
514/306.000; 514/307.000; 514/311.000; 514/312.000; 514/315.000;
514/345.000; 514/351.000; 514/357.000; 514/359.000; 514/360.000;
514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000;
514/367.000; 514/369.000; 514/372.000; 514/373.000; 514/374.000;
514/375.000; 514/376.000; 514/378.000; 514/379.000; 514/380.000;
514/381.000; 514/383.000; 514/389.000; 514/394.000; 514/395.000;
514/398.000; 514/399.000; 514/401.000; 514/404.000; 514/406.000;
514/413.000; 514/415.000; 514/416.000; 514/418.000; 514/423.000;
514/424.000; 514/425.000; 514/427.000; 514/428.000; 544/001.000;
544/002.000; 544/003.000; 544/008.000; 544/053.000; 544/063.000;
544/065.000; 544/066.000; 544/067.000; 544/090.000; 544/091.000;
544/162.000; 544/215.000; 544/216.000; 544/219.000; 544/220.000;
544/224.000; 544/235.000; 544/239.000; 544/254.000; 544/255.000;
544/257.000; 544/262.000; 544/272.000; 544/277.000; 544/278.000;
544/280.000; 544/283.000; 544/286.000; 544/301.000; 544/311.000;
544/335.000; 544/336.000; 544/350.000; 544/353.000; 544/385.000;
544/401.000; 546/102.000; 546/113.000; 546/114.000; 546/115.000;
546/117.000; 546/118.000; 546/119.000; 546/122.000; 546/138.000;
546/139.000; 546/150.000; 546/153.000; 546/157.000; 546/164.000;
546/176.000; 546/178.000; 546/242.000; 546/243.000; 546/246.000;
546/264.000; 546/300.000; 546/334.000; 548/100.000; 548/123.000;
548/125.000; 548/127.000; 548/128.000; 548/131.000; 548/134.000;
548/146.000; 548/153.000; 548/179.000; 548/186.000; 548/207.000;
548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/225.000;
548/228.000; 548/229.000; 548/235.000; 548/237.000; 548/240.000;
548/241.000; 548/243.000; 548/247.000; 548/252.000; 548/267.200;
548/267.800; 548/303.700; 548/306.400; 548/307.100; 548/309.700;
548/319.100; 548/323.500; 548/340.100; 548/348.100; 548/349.100;
548/356.100; 548/370.100; 548/375.100; 548/379.400; 548/452.000;
548/453.000; 548/470.000; 548/482.000; 548/485.000; 548/486.000;
548/491.000; 548/503.000; 548/532.000; 548/543.000; 548/546.000;
548/550.000; 548/565.000; 548/566.000

IC

[6]

ICM: A61K031-415

ICS: A61K031-42; A61K031-425; A61K031-52

EXF

544/272; 514/263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 91 OF 98 USPATFULL on STN

AN 97:16085 USPATFULL

TI Compositions and methods for treating and preventing pathologies
including cancer

IN Samid, Dvorit, Rockville, MD, United States

PA The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. government)

PI US 5605930 19970225 <--

AI US 1994-207521 19940307 (8)

RLI Continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993
which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21
Oct 1991

DT Utility

FS Granted

INCL INCLM: 514/510.000
INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000
NCL NCLM: 514/510.000
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;
514/567.000
IC [6]
ICM: A61K031-21
ICS: A01N037-00; A01N047-40; A01N047-46
EXF 514/538; 514/563; 514/567; 514/510; 514/513; 514/515; 514/529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 92 OF 98 USPATFULL on STN
AN 96:46169 USPATFULL
TI Olefin substituted long chain compounds
IN Underiner, Gail, Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon, WA, United States
Eiseman, Elisa, Seattle, WA, United States
Leigh, Alistair, Brier, WA, United States
Kumar, Anil, Seattle, WA, United States
Michnick, John, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5521315 19960528 <--
AI US 1993-59697 19930510 (8)
RLI Continuation-in-part of Ser. No. US 1993-3372, filed on 12 Jan 1993, now
patented, Pat. No. US 5354756
DT Utility
FS Granted
LN.CNT 2761
INCL INCLM: 546/243.000
INCLS: 546/242.000; 544/285.000
NCL NCLM: 546/243.000
NCLS: 544/285.000; 546/242.000
IC [6]
ICM: C07D211-88
ICS: C07D239-80
EXF 548/545; 548/546; 548/547; 546/243; 544/285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 93 OF 98 USPATFULL on STN
AN 96:19104 USPATFULL
TI Inhibition of insulin-induced adiposis
IN Alexander-Bridges, Maria C., Newtonville, MA, United States
Zhao, Hui-Fen, Brookline, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S.
corporation)
PI US 5496831 19960305 <--
AI US 1994-242409 19940513 (8)
DT Utility
FS Granted
LN.CNT 1269
INCL INCLM: 514/290.000
INCLS: 514/294.000
NCL NCLM: 514/290.000
NCLS: 514/294.000
IC [6]
ICM: A01N043-42
EXF 514/290; 514/294
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 94 OF 98 USPATFULL on STN
AN 95:105868 USPATFULL
TI Cell signaling inhibitors
IN Michnick, John, Seattle, WA, United States
Underiner, Gail E., Brier, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5470878 19951128 <--
AI US 1993-164081 19931208 (8)
RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
now abandoned
DT Utility
FS Granted

INCL INCLM: 514/558.000
INCLS: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000;
514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000;
514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000;
544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000;
548/486.000; 548/556.000; 554/055.000; 554/061.000; 554/108.000;
554/213.000; 560/130.000; 560/145.000; 562/553.000; 562/567.000;
564/183.000; 564/197.000; 564/198.000; 564/201.000; 564/506.000
NCL NCLM: 514/558.000
NCLS: 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000;
514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000;
514/626.000; 514/629.000; 514/669.000; 544/254.000; 544/285.000;
544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000

IC [6]
ICM: A61K031-20
ICS: C07C233-00

EXF 554/51; 554/61; 554/55; 554/108; 554/213; 564/224; 564/506; 564/198;
564/215; 564/201; 564/197; 514/625; 514/629; 514/613; 514/558; 514/552;
514/529; 514/561; 514/626; 514/669; 560/130; 560/145; 562/553; 562/567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 95 OF 98 USPATFULL on STN
AN 94:113002 USPATFULL
TI Methods for treating renin-related disorders with amylin antagonists
IN Young, Andrew A., San Diego, CA, United States
Rink, Timothy J., La Jolla, CA, United States
PA Amylin Pharmaceuticals, Inc., San Diego, CA, United States (U.S.
corporation)

PI US 5376638 19941227 <--
AI US 1992-939106 19920901 (7)
DT Utility
FS Granted

LN.CNT 1037
INCL INCLM: 514/012.000
INCLS: 514/011.000; 514/013.000
NCL NCLM: 514/012.000
NCLS: 514/011.000; 514/013.000

IC [5]
ICM: A61K037-02
ICS: C07K007-10

EXF 514/11-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 96 OF 98 USPATFULL on STN
AN 94:93338 USPATFULL
TI Methods for treating arteriosclerosis
IN Halperin, Jose, Brookline, MA, United States
Brugnara, Carlo, Newton Highlands, MA, United States
PA President and Fellows of Harvard University, Cambridge, MA, United
States (U.S. corporation)

PI US 5358959 19941025 <--
AI US 1993-18835 19930218 (8)
DT Utility
FS Granted

LN.CNT 539
INCL INCLM: 514/396.000
INCLS: 514/399.000; 514/824.000
NCL NCLM: 514/396.000
NCLS: 514/399.000; 514/824.000

IC [5]
ICM: A61K031-415
EXF 514/396; 514/399; 514/824

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 97 OF 98 USPATFULL on STN
AN 91:84437 USPATFULL
TI Method for preventing tissue damage after an ischemic episode
IN Sheffield, Warren D., Lebanon, NJ, United States
PA Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)
PI US 5057494 19911015 <--
AI US 1988-227579 19880803 (7)

DT Utility
FS Granted
LN.CNT 487
INCL INCLM: 514/012.000

NCL NCLM: 514/012.000
NCLS: 514/021.000
IC [5]
ICM: A61K037-02
ICS: A61K037-36
EXF 514/12; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 98 OF 98 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2000-256866 [22] WPIDS
DNC C2000-078440
TI Hydrogel compositions useful for controlled delivery of ***growth***
factors e.g. in treatment of ischemia and in wound healing.
DC A11 A25 A96 B04 B07
IN JENNINGS, R N; PROTTER, A A; WANG, Y J; YANG, B
PA (SCIO-N) SCIOS INC
CYC 87
PI WO 2000013710 A2 20000316 (200022)* EN 27 A61K047-10 <--
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT UA UG US UZ VN YU ZA ZW
AU 9959095 A 20000327 (200032) <--
EP 1107791 A2 20010620 (200135) EN A61K047-10
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI
US 6331309 B1 20011218 (200205) A61F013-00
JP 2002524425 W 20020806 (200266) 33 A61K038-22
AU 758178 B 20030320 (200329) A61K047-10
ADT WO 2000013710 A2 WO 1999-US20382 19990903; AU 9959095 A AU 1999-59095
19990903; EP 1107791 A2 EP 1999-946759 19990903, WO 1999-US20382 19990903;
US 6331309 B1 Provisional US 1998-99168P 19980904, US 1999-390164
19990903; JP 2002524425 W WO 1999-US20382 19990903, JP 2000-568516
19990903; AU 758178 B AU 1999-59095 19990903
FDT AU 9959095 A Based on WO 2000013710; EP 1107791 A2 Based on WO 2000013710;
JP 2002524425 W Based on WO 2000013710; AU 758178 B Previous Publ. AU
9959095, Based on WO 2000013710
PRAI US 1998-99168P 19980904; US 1999-390164 19990903
IC ICM A61F013-00; A61K038-22; A61K047-10
ICS A61K009-10; A61K009-70; A61K038-18; A61K047-26; A61K047-32;
A61K047-34; A61K047-36; A61P009-10; A61P017-02

=> S CPK-MB
43 FILES SEARCHED...
L9 1514 CPK-MB

=> S L1 AND L9
60 FILES SEARCHED...
L10 120 L1 AND L9

=> DUP REM L10
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L10
L11 90 DUP REM L10 (30 DUPLICATES REMOVED)

=> D L11 1-90

L11 ANSWER 1 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 1
AN 2004:323387 BIOSIS
DN PREV200400325165
TI Methods of use of fibroblast growth factor, vascular endothelial growth
factor and related proteins in the treatment of acute and chronic heart
disease.
AU Franco, Wayne P. [Inventor, Reprint Author]
CS 500 Cold Spring Rd., No. E217, Rocky Hill, CT, 06067, USA
PI US 6759386 July 06, 2004
SO Official Gazette of the United States Patent and Trademark Office Patents,
(July 6 2004) Vol. 1284, No. 1. <http://www.uspto.gov/web/menu/patdata.html>

ISSN: 0098-1133 (ISSN print).
DT Patent
LA English
ED Entered STN: 21 Jul 2004
Last Updated on STN: 21 Jul 2004

L11 ANSWER 2 OF 90 USPATFULL on STN
AN 2004:203948 USPATFULL
TI Rifalazil compositions and therapeutic regimens
IN Cabana, Bernard E., Montgomery Village, MD, UNITED STATES
Michaelis, Arthur F., Devon, PA, UNITED STATES
Magnant, Gary P., Topsfield, MA, UNITED STATES
Sayada, Chalom B., Luxembourg City, LUXEMBOURG
PI US 2004157840 A1 20040812
AI US 2003-668792 A1 20030923 (10)
PRAI US 2002-412958P 20020923 (60)
DT Utility
FS APPLICATION
LN.CNT 1369
INCL INCLM: 514/229.500
NCL NCLM: 514/229.500
IC [7]
ICM: A61K031-538

L11 ANSWER 3 OF 90 USPATFULL on STN
AN 2004:152127 USPATFULL
TI Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
IN Franco, Wayne P., Rocky Hill, CT, UNITED STATES
PI US 2004116349 A1 20040617
AI US 2003-730831 A1 20031209 (10)
RLI Division of Ser. No. US 2001-828330, filed on 6 Apr 2001, PENDING
PRAI US 2000-195624P 20000406 (60)
DT Utility
FS APPLICATION
LN.CNT 2885
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC [7]
ICM: A61K038-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 90 USPATFULL on STN
AN 2004:101741 USPATFULL
TI Triple therapy of angiotensin converting enzyme inhibitor epoxy-steroidal aldosterone antagonist and diuretic or digoxin for treatment of cardiovascular disease
IN Alexander, John C., Princeton, NJ, UNITED STATES
Roniker, Barbara, Chicago, IL, UNITED STATES
Desai, Subhash, Wilmette, IL, UNITED STATES
PA G.D. Searle & Co., Chicago, IL (U.S. corporation)
PI US 2004077611 A1 20040422
AI US 2003-440691 A1 20030519 (10)
RLI Continuation of Ser. No. US 2000-518854, filed on 3 Mar 2000, ABANDONED
PRAI US 1999-122997P 19990305 (60)
US 1999-122998P 19990305 (60)
DT Utility
FS APPLICATION
LN.CNT 4409
INCL INCLM: 514/171.000
INCLS: 514/423.000
NCL NCLM: 514/171.000
NCLS: 514/423.000
IC [7]
ICM: A61K031-58
ICS: A61K031-401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 90 USPATFULL on STN
AN 2004:83262 USPATFULL
TI Targeted therapeutics and uses thereof
IN Michaelis, Arthur F., Devon, PA, UNITED STATES
Maulding, Hawkins V., Mendham, NJ, UNITED STATES
Sayada, Chalom, Luxembourg City, LUXEMBOURG

PI US 2004063718 A1 20040401
AI US 2002-302409 A1 20021121 (10)
PRAI US 2002-358881P 20020222 (60)
US 2001-332264P 20011121 (60)

DT Utility
FS APPLICATION
LN.CNT 1997
INCL INCLM: 514/252.130
INCLS: 540/457.000
NCL NCLM: 514/252.130
NCLS: 540/457.000

IC [7]
ICM: A61K031-496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 90 USPATFULL on STN
AN 2004:45028 USPATFULL
TI Intravenous rifalazil formulation and methods of use thereof
IN Michaelis, Arthur F., Devon, PA, UNITED STATES
Sayada, Chalom, Luxembourg City, LUXEMBOURG
Cabana, Bernard E., Montgomery Village, MD, UNITED STATES

PI US 2004034021 A1 20040219
AI US 2003-453155 A1 20030603 (10)
PRAI US 2002-385532P 20020603 (60)
US 2002-406873P 20020829 (60)
US 2002-412958P 20020923 (60)
US 2003-444570P 20030203 (60)

DT Utility
FS APPLICATION
LN.CNT 1942
INCL INCLM: 514/229.500
NCL NCLM: 514/229.500
IC [7]
ICM: A61K031-538

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 90 USPATFULL on STN
AN 2004:31721 USPATFULL
TI Methods of use growth factors for treating heart disease
IN Franco, Wayne P., Rocky Hill, CT, UNITED STATES

PI US 2004023863 A1 20040205
AI US 2003-239902 A1 20030123 (10)
WO 2001-US11205 20010406
PRAI US 2000-60195624 20000406

DT Utility
FS APPLICATION
LN.CNT 2837
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC [7]
ICM: A61K038-18

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 90 USPATFULL on STN
AN 2004:19446 USPATFULL
TI Metal complexes and formulations of rifamycin analogues and uses thereof
IN Michaelis, Arthur F., Devon, PA, UNITED STATES
Maulding, Hawkins V., Mendham, NJ, UNITED STATES
Sayada, Chalom, Luxembourg City, MA, UNITED STATES
Eisenstein, Barry, Chestnut Hill, MA, UNITED STATES

PI US 2004014750 A1 20040122
AI US 2002-318998 A1 20021212 (10)
PRAI US 2001-341591P 20011213 (60)
US 2002-382805P 20020523 (60)
US 2002-385532P 20020603 (60)
US 2002-406873P 20020829 (60)
US 2002-412958P 20020923 (60)

DT Utility
FS APPLICATION
LN.CNT 2451
INCL INCLM: 514/224.500
INCLS: 514/229.500
NCL NCLM: 514/224.500
NCLS: 514/229.500
IC [7]

ICS: A61K031-538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 90 USPATFULL on STN
AN 2004:19445 USPATFULL
TI Sulfhydryl rifamycins and uses thereof
IN Michaelis, Arthur F., Devon, PA, UNITED STATES
Maulding, Hawkins V., Mendham, NJ, UNITED STATES
Sayada, Chalom, Luxembourg City, LUXEMBOURG
Eisenstein, Barry, Chestnut Hill, MA, UNITED STATES
Geiss, William B., Athens, NY, UNITED STATES
Raker, Joseph, Delmar, NY, UNITED STATES
PI US 2004014749 A1 20040122
AI US 2002-318582 A1 20021212 (10)
PRAI US 2001-341130P 20011213 (60)
US 2002-382805P 20020523 (60)
US 2002-385532P 20020603 (60)
US 2002-406873P 20020829 (60)
US 2002-412958P 20020923 (60)
DT Utility
FS APPLICATION
LN.CNT 2259
INCL INCLM: 514/224.500
INCLS: 514/229.800; 540/457.000
NCL NCLM: 514/224.500
NCLS: 514/229.800; 540/457.000
IC [7]
ICM: A61K031-542
ICS: A61K031-538; C07D498-14; C07D491-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 1040203293 JICST-EPlus
TI Plain Computed Tomography Is Useful for Assessment of Coronary
Microvascular Damage in Infarction Area After Recanalization Therapy
AU KATO M; DOTE K; SASAKI S; TAKEMOTO H; HABARA S; HASEGAWA D
CS Hiroshima City Asa Hospital, Hiroshima
SO Circ J, (2004) vol. 68, no. Supplement 1, pp. 543. Journal Code: F0908A
ISSN: 1346-9843
CY Japan
DT Journal; Preprint
LA English
STA New

L11 ANSWER 11 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2004:244431 BIOSIS
DN PREV200400243343
TI Should patients with severe aortic stenosis and ***coronary***
artery ***disease*** undergoing percutaneous coronary
intervention prior to aortic valve replacement?
AU Kuchulakanti, Pramod K. [Reprint Author]; Rha, Seung-Woon [Reprint
Author]; Gevorkian, Natalie [Reprint Author]; Abbott, Maureen C. [Reprint
Author]; Pichard, Augusto D. [Reprint Author]; Satler, Lowell F. [Reprint
Author]; Kent, Kenneth M. [Reprint Author]; Suddath, William O. [Reprint
Author]; Waksman, Ron [Reprint Author]
CS Washington Hospital Center, Washington, DC, USA
SO Journal of the American College of Cardiology, (March 3 2004) Vol. 43, No.
5 Supplement A, pp. 440A. print.
Meeting Info.: 53rd Annual Scientific Session of the American College of
Cardiology. New Orleans, LA, USA. March 07-10, 2004. American College of
Cardiology.
ISSN: 0735-1097 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 6 May 2004
Last Updated on STN: 6 May 2004

L11 ANSWER 12 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 1040202388 JICST-EPlus
TI The relationships between coexisting inflammation and no/slow-flow
phenomenon during directional coronary atherectomy
AU MIURA E; HIROSAKA A; TAKEDA H; NIITSUMA T; UEKITA H; ENDOH N
OHWADA K
MARUYAMA Y

Onta Memorial Hospital Onta General Hospital Foundation, Koriyama
 Fukushima Medical Coll., Fukushima
 SO Circ J, (2004) vol. 68, no. Supplement 1, pp. 317. Journal Code: F0908A
 ISSN: 1346-9843
 CY Japan
 DT Journal; Preprint
 LA English
 STA New

L11 ANSWER 13 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 1040387728 JICST-EPlus
 TI Nocturnal Hypoxemic Episodes After Acute Myocardial Infarction
 AU SASAMOTO SHUICHI; SASAO KEN'ICHIRO; UNO NARIAKI; HONDA MITSURU; IGARASHI
 MASAKI; YOSHIHARA KATSUNORI; KOYAMA NOBUYA
 CS Toho Univ., Omori Hosp.
 SO Nippon Kyukyu Igakkai Zasshi (Journal of Japanese Association for Acute
 Medicine), (2004) vol. 15, no. 4, pp. 135-140. Journal Code: L1136A (Fig.
 2, Tbl. 3, Ref. 8)
 ISSN: 0915-924X
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 14 OF 90 USPATFULL on STN
 AN 2003:283399 USPATFULL
 TI Screening test and procedure using apocrine sweat
 IN Berlin, Stuart M., Thousand Oaks, CA, UNITED STATES
 PI US 2003199743 A1 20031023
 AI US 2003-463465 A1 20030616 (10)
 RLI Continuation-in-part of Ser. No. US 2001-994535, filed on 26 Nov 2001,
 GRANTED, Pat. No. US 6585646
 PRAI US 2000-250206P 20001129 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 822
 INCL INCLM: 600/346.000
 NCL NCLM: 600/346.000
 IC [7]
 ICM: A61B005-05

L11 ANSWER 15 OF 90 USPATFULL on STN
 AN 2003:244880 USPATFULL
 TI Dose of an angiogenic factor and method of administering to improve
 myocardial blood flow
 IN Hung, David T., Belmont, CA, UNITED STATES
 Annex, Brian H., Durham, NC, UNITED STATES
 Landolfo, Kevin P., Chapel Hill, NC, UNITED STATES
 Kavanaugh, W. Michael, Mill Valley, CA, UNITED STATES
 PA Chiron Corporation, Emeryville, CA, UNITED STATES (U.S. corporation)
 PI US 2003171294 A1 20030911
 AI US 2003-395541 A1 20030324 (10)
 RLI Continuation of Ser. No. US 2000-637471, filed on 11 Aug 2000, PENDING
 PRAI US 1999-148746P 19990813 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2868
 INCL INCLM: 514/012.000
 NCL NCLM: 514/012.000
 IC [7]
 ICM: A61K038-18

L11 ANSWER 16 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 1040000525 JICST-EPlus
 TI Emergency Coronary Artery Bypass Grafting for Acute Coronary Syndrome with
 Preoperative Intraaortic Balloon Pumping; Comparative Surgical Outcome and
 Long-term Results
 AU KAMOHARA KEIJI; YOSHIKAI MASARU; YUNOKI JUNJI; FUMOTO HIDEMASA
 ITO TSUBASA; MURAYAMA JUN'ICHI; HAMADA MASAKATSU
 CS Tenjinkai Shinkogaboyin Shinzokekkangeka
 Sagadai Kyobugeka
 SO Kyobu Geka (Japanese Journal of Thoracic Surgery), (2003) vol. 56, no. 13,
 pp. 1075-1084. Journal Code: Z0662A (Fig. 2, Tbl. 4, Ref. 22)
 ISSN: 0021-5252
 CY Japan

LA Japanese
 STA New

L11 ANSWER 17 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN DUPLICATE 2
 AN 2003358169 EMBASE
 TI A case of acute myocardial infarction due to vasospasm related to marked
 coronary inflammation.
 AU Kawakami H.; Matsuoka H.; Koyama Y.; Matsunaka T.; Aono J.; Ito T.
 SO Respiration and Circulation, (1 Sep 2003) 51/9 (943-948).
 Refs: 7
 ISSN: 0452-3458 CODEN: KOJUA
 CY Japan
 DT Journal; Article
 FS 018 Cardiovascular Diseases and Cardiovascular Surgery
 037 Drug Literature Index
 LA Japanese
 SL English; Japanese

L11 ANSWER 18 OF 90 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
 AN 2004:195912 SCISEARCH
 GA The Genuine Article (R) Number: 773UF
 TI Noninvasive characterization of myocardium after transmyocardial laser
 revascularization
 AU Jones J W (Reprint); Richman B W; Baldwin J C; Losanoff J E
 CS Univ Missouri, Sch Med, Hlth Sci Ctr M580, Dept Surg, 1 Hosp Dr, Columbia,
 MO 65212 USA (Reprint); Univ Missouri, Sch Med, Hlth Sci Ctr M580, Dept
 Surg, Columbia, MO 65212 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth
 Med Sch, Hanover, NH 03756 USA
 CYA USA
 SO JOURNAL OF CARDIOVASCULAR SURGERY, (DEC 2003) Vol. 44, No. 6, pp. 681-684.
 Publisher: EDIZIONI MINERVA MEDICA, CORSO BRAMANTE 83-85 INT JOURNALS
 DEPT., 10126 TURIN, ITALY.
 ISSN: 0021-9509.
 DT Article; Journal
 LA English
 REC Reference Count: 20
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L11 ANSWER 19 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 AN 2004:17492 BIOSIS
 DN PREV200400014437
 TI Diagnostic implications of release of myocardial necrosis markers in
 patients with acute pulmonary edema.
 AU Pena-Gil, C. [Reprint Author]; Figueras, J.; Ferreira, I.; Soler-Soler, J.
 CS Cardiology, Hospital Clinico de Santiago, Santiago de Compostela, Spain
 SO European Heart Journal, (August-September 2003) Vol. 24, No. Abstract
 Supplement, pp. 260. print.
 Meeting Info.: Congress of the European Society of Cardiology. Vienna,
 Austria. August 30-September 03, 2003. European Society of Cardiology.
 ISSN: 0195-668X (ISSN print).
 DT Conference; (Meeting)
 Conference; (Meeting Poster)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 24 Dec 2003
 Last Updated on STN: 24 Dec 2003

L11 ANSWER 20 OF 90 USPATFULL on STN DUPLICATE 3
 AN 2002:214528 USPATFULL
 TI Screening test and procedure using skin patches
 IN Berlin, Stuart, Thousand Oaks, CA, UNITED STATES
 PI US 2002115921 A1 20020822
 US 6585646 B2 20030701
 AI US 2001-994535 A1 20011126 (9)
 PRAI US 2000-250206P 20001129 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 854
 INCL INCLM: 600/362.000
 NCL NCLM: 600/362.000
 NCLS: 600/306.000; 600/309.000; 600/573.000
 IC [7]
 ICM: A61B005-00

AN 2002:112871 USPATFULL
TI Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
IN Franco, Wayne P., Rocky Hill, CT, UNITED STATES
PI US 2002058612 A1 20020516
US 6759386 B2 20040706
AI US 2001-828330 A1 20010406 (9)
PRAI US 2000-195624P 20000406 (60)
DT Utility
FS APPLICATION
LN.CNT 2636
INCL INCLM: 514/002.000
INCLS: 424/043.000
NCL NCLM: 514/002.000
NCLS: 514/002.000; 514/008.000; 514/012.000; 514/014.000; 530/300.000
IC [7]
ICM: A61L009-04
ICS: A61K038-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 2003058936 EMBASE
TI [Use of a combination of enoxaparin or unfractionated Heparin and abciximab during percutaneous coronary interventions: A randomized pilot study].
UTILIZACION DE ENOXAPARINA O HEPARINA NO FRACCIONADA EN COMBINACION CON ABCIXIMAB DURANTE LA INTERVENCION CORONARIA PERCUTANEA: ESTUDIO PILOTO ALEATORIZADO.
AU Galeote G.; Hussein M.; Sobrino N.; Calvo L.; Sanchez-Recalde A.; Sobrino J.A.
CS Dr. G. Galeote, Unidad Med.-Quirurgica Cardiologia, Hospital Universitario La Paz, P de la Castellana 261, 28046 Madrid, Spain.
guigaleote@teleline.es
SO Revista Espanola de Cardiologia, (1 Dec 2002) 55/12 (1261-1266).
Refs: 23
ISSN: 0300-8932 CODEN: RCDOAM
CY Spain
DT Journal; Article
FS 006 Internal Medicine
018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
038 Adverse Reactions Titles
LA Spanish
SL Spanish; English

L11 ANSWER 23 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN DUPLICATE 5
AN 2002233738 EMBASE
TI Sustained ventricular tachycardia as a marker of inadequate myocardial perfusion during the acute phase of myocardial infarction.
AU Fiol Sala M.; Perez Barcena J.; Ayestaran Rota J.I.; Velasco Roca J.; Carrilo Lopez A.; Raurich Puigdevall J.M.; Guindo Soldevilla J.; Bayes de Luna A.
CS Dr. J. Perez Barcena, Calle Andrea Doria 55, 07014 Palma de Mallorca, Spain. ucoro@hsd.es
SO Clinical Cardiology, (2002) 25/7 (328-334).
Refs: 35
ISSN: 0160-9289 CODEN: CLCADC
CY United States
DT Journal; Article
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
LA English
SL English

L11 ANSWER 24 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:190135 BIOSIS
DN PREV200100190135
TI Coronary artery calcification in patients with acute chest pain.
AU Alexopoulos, Dimitris [Reprint author]; Stathopoulos, Christos [Reprint author]; Hahalis, George [Reprint author]; Chiladakis, John A. [Reprint author]; Kotsaridis, Abraham [Reprint author]; Manolis, Antonis S. [Reprint author]
CS Patras University, Patras, Greece

No. 2 Supplement A, pp. 377A. print.
Meeting Info.: 50th Annual Scientific Session of the American College of
Cardiology. Orlando, Florida, USA. March 18-21, 2001. American College of
Cardiology.

CODEN: JACCDI. ISSN: 0735-1097.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 20 Apr 2001

Last Updated on STN: 18 Feb 2002

L11 ANSWER 25 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

AN 2001088181 EMBASE

TI Myocardial bridging of the left anterior descending coronary artery in
acute inferior wall myocardial infarction.

AU Yano K.; Yoshino H.; Taniuchi M.; Kachi E.; Shimizu H.; Watanuki A.;
Ishikawa K.

CS Dr. K. Ishikawa, Second Dept. of Internal Medicine, Kyorin University
School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan

SO Clinical Cardiology, (2001) 24/3 (202-208).

Refs: 37

ISSN: 0160-9289 CODEN: CLCADC

CY United States

DT Journal; Article

FS 006 Internal Medicine

014 Radiology

018 Cardiovascular Diseases and Cardiovascular Surgery

037 Drug Literature Index

LA English

SL English

L11 ANSWER 26 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN DUPLICATE 6

AN 2001360365 EMBASE

TI Direct coronary stenting without balloon or device pretreatment: Acute
success and long-term results.

AU Stys T.; Lawson W.E.; Liuzzo J.P.; Hanif B.; Bragg L.; Cohn P.F.

CS Dr. W.E. Lawson, Division of Cardiology, State Univ. New York at Stony
Brook, HSC T-17-020, Stony Brook, NY 11794, United States.

wlawson@ts.uh.sunysb.edu

SO Catheterization and Cardiovascular Interventions, (2001) 54/2 (158-163).

Refs: 19

ISSN: 1522-1946 CODEN: CARIF2

CY United States

DT Journal; Article

FS 018 Cardiovascular Diseases and Cardiovascular Surgery

036 Health Policy, Economics and Management

LA English

SL English

L11 ANSWER 27 OF 90 USPATFULL on STN

AN 2000:161050 USPATFULL

TI Method of improving outcome of cardiopulmonary bypass surgery

IN Holtz, Russell R., 3305 N. 18.sup.th St., Tacoma, WA, United States
98406

PI US 6153654 20001128

WO 9824381 19980611

AI US 1999-319405 19990604 (9)

WO 1997-US22103 19971204

19990604 PCT 371 date
19990604 PCT 102(e) date

DT Utility

FS Granted

LN.CNT 557

INCL INCLM: 514/652.000

NCL NCLM: 514/652.000

IC [7]

ICM: A61K031-135

EXF 514/652

L11 ANSWER 28 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

AN 2001:189978 BIOSIS

DN PREV200100189978

TI Profile of patients with nonobstructive ***coronary*** ***artery***

AU Mani, A. [Reprint author]; Karatepe, M. [Reprint author]; Kreps, E.
 [Reprint author]; Collins, M. [Reprint author]; Moses, J. [Reprint
 author]; Coplan, N. [Reprint author]; Moussa, I. [Reprint author]
 CS Lenox Hill Heart and Vascular Institute, New York, NY, USA
 SO American Journal of Cardiology, (October 16, 2000) Vol. 86, No. Suppl. 8A,
 pp. 100i-101i. print.
 Meeting Info.: Twelfth Annual Symposium on Transcatheter Cardiovascular
 Therapeutics. Washington, D. C., USA. October 17-22, 2000.
 CODEN: AJCDAG. ISSN: 0002-9149.
 DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 20 Apr 2001
 Last Updated on STN: 18 Feb 2002

L11 ANSWER 29 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 1000366354 JICST-EPlus
 TI An autopsy case of the incarceration of a free-floating ball thrombus in
 the left atrium into mitral valve.
 AU KAWABE TETSUYA; YAMAMOTO KATSUHIRO; SHIOTANI MASAHIKO; SATANI OSAMU; HANO
 TAKUZO; NISHIO ICHIRO
 CS Wakayama Med. Coll.
 SO Wakayama Igaku (Journal of the Wakayama Medical Society), (2000) vol. 51,
 no. 1, pp. 73-77. Journal Code: F0546A (Fig. 5, Tbl. 1, Ref. 14)
 CODEN: WKMIAO; ISSN: 0043-0013
 CY Japan
 DT Journal; Short Communication
 LA Japanese
 STA New

L11 ANSWER 30 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN DUPLICATE 7
 AN 2000077979 EMBASE
 TI Adenosine for cardioplegic induction: A comparison with St Thomas
 solution.
 AU Chauhan S.; Wasir H.S.; Bhan A.; Rao B.H.; Saxena N.; Venugopal P.
 CS Dr. S. Chauhan, Department of Cardiac Anaesthesia, Cardiothoracic Centre,
 All India Inst. of Medical Sciences, New Delhi 110029, India
 SO Journal of Cardiothoracic and Vascular Anesthesia, (2000) 14/1 (21-24).
 Refs: 13
 ISSN: 1053-0770 CODEN: JCVAEK
 CY United States
 DT Journal; Article
 FS 018 Cardiovascular Diseases and Cardiovascular Surgery
 024 Anesthesiology
 030 Pharmacology
 037 Drug Literature Index
 LA English
 SL English

L11 ANSWER 31 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 2000126248 EMBASE
 TI The effects of endotracheal intubation and laryngeal mask airway on the
 risk of myocardial ischemia in cardiac patients.
 AU Ay B.; Eti Z.; Fak A.S.; Umuroglu T.; Gogus F.Y.
 CS B. Ay, Dept. Anesthesiology Reanimation, School of Medicine, Marmara
 University, Istanbul, Turkey
 SO Marmara Medical Journal, (2000) 13/1 (15-18).
 Refs: 20
 ISSN: 1019-1941 CODEN: MMJOF4
 CY Turkey
 DT Journal; Article
 FS 018 Cardiovascular Diseases and Cardiovascular Surgery
 024 Anesthesiology
 037 Drug Literature Index
 LA English
 SL English

L11 ANSWER 32 OF 90 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
 AN 1999:419986 SCISEARCH
 GA The Genuine Article (R) Number: 199XY
 TI Sleep apnoea syndrome and the extent of atherosclerotic lesions in
 middle-aged men with myocardial infarction
 AU Aboyans V (Reprint); Lacroix P; Virot P; Tapie P; Cassat C; Rambaud G;

CS HOP DUPOUYTREN, SERV CTCV & ANGIOL, 2 AVE MARTIN LUTHER, F-87042 LIMOGES, FRANCE (Reprint); SUPUYTRENS UNIV HOSP, DEPT THORAC & CARDIOVASC SURG & ANGIOL, LIMOGES, FRANCE

CYA FRANCE

SO INTERNATIONAL ANGIOLOGY, (MAR 1999) Vol. 18, No. 1, pp. 70-73.
 Publisher: EDIZIONI MINERVA MEDICA, CORSO BRAMANTE 83-85 INT JOURNALS
 DEPT., 10126 TURIN, ITALY.
 ISSN: 0392-9590.

DT Article; Journal

FS CLIN

LA English

REC Reference Count: 17
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L11 ANSWER 33 OF 90 USPATFULL on STN

AN 1998:122391 USPATFULL

TI Methods of preventing tissue damage associated with decreased blood flow by administration of AICA riboside compounds

IN Gruber, Harry E., Rancho Santa Fe, CA, United States
 Mullane, Kevin M., Del Mar, CA, United States
 Laikind, Paul K., San Diego, CA, United States

PA Gensia Pharmaceuticals, San Diego, CA, United States (U.S. corporation)

PI US 5817640 19981006

AI US 1995-443245 19950516 (8)

RLI Continuation of Ser. No. US 1994-296266, filed on 25 Aug 1994, now abandoned which is a continuation of Ser. No. US 1992-949101, filed on 21 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-770023, filed on 30 Sep 1991, now abandoned

DT Utility

FS Granted

LN.CNT 1645

INCL INCLM: 514/046.000
 INCLS: 514/045.000; 514/821.000; 514/822.000; 514/824.000; 514/885.000;
 514/886.000; 435/975.000

NCL NCLM: 514/046.000
 NCLS: 435/975.000; 514/045.000; 514/821.000; 514/822.000; 514/824.000;
 514/885.000; 514/886.000

IC [6]
 ICM: A61K031-70

EXF 514/45; 514/46; 514/821; 514/822; 514/824; 514/861; 514/885; 514/886;
 435/975

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 34 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN

AN 990445094 JICST-EPlus

TI Surgical Results of Postinfarction Ventricular Septal Rupture.

AU FUNAKI SHIGEKI; KOYAMA TERUYUKI; OKADA TADAHICO; TAKEI HIROSHI; YAMATE NOBORU
 KAWADA TADANORI
 HIEKATA TOMIZO; OGAWA NOBORU; ABE HIROYUKI

CS St. Marianna Univ.
 Showa Univ., Sch. of Med.
 Yokohama-shi Seibu Hosp., St. Marianna Univ.

SO Sei Marianna Ika Daigaku Zasshi (St. Marianna Medical Journal), (1998) vol. 26, no. 6, pp. 755-760. Journal Code: Z0605A (Fig. 3, Tbl. 4, Ref. 18)
 ISSN: 0387-2289

CY Japan

DT Journal; Article

LA Japanese

STA New

L11 ANSWER 35 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN

AN 980876199 JICST-EPlus

TI Clinical advantages and myocardial protection of normothermal CPB. Comparison with hypothermal CPB.

AU UNO YOSHIMASA; HORIKOSHI SHIGEKI; EMOTO HIDETO; MIYAMOTO HISAKI; SUZUKI HIROYUKI

CS Jikei Univ. Kashiwa Hosp.

SO Jpn J Thorac Cardiovasc Surg, (1998) vol. 46, no. 8, pp. 671-676. Journal Code: Z0767A (Fig. 6, Tbl. 1, Ref. 12)
 ISSN: 0369-4739

CY Japan

DT Journal; Article

LA Japanese

L11 ANSWER 36 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 990111671 JICST-EPlus
 TI The Clinical Assessment of the Nutritional and the Metabolic Changes in Patients with AMI.
 AU SUGIMOTO KATSUHIKO; ARUGA TOORU
 KATO CHII; AOKI YAYOI; KONDO ETSUKO; AOYAMA NAOYOSHI; ASARI YASUSHI; OWADA TAKASHI; KUROSAWA TOSHIRO
 CS Showa Univ., Sch. of Med.
 Kitasato Univ., Hosp.
 SO Geka to Taisha, Eiyo (Japanese Journal of Surgical Metabolism and Nutrition), (1998) vol. 32, no. 6, pp. 343-350. Journal Code: Y0699A (Fig. 5, Tbl. 4, Ref. 23)
 ISSN: 0389-5564
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 37 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 980739086 JICST-EPlus
 TI Intra-coronary Shunt for Coronary Artery Revascularization in the Beating Heart.
 AU SOGAWA MASAKAZU; SAITO AKIRA; NAMURA OSAMU; OZEKI HAJIME; MORO HISANAGA; HAYASHI JUN'ICHI
 CS Niigata Univ., Sch. of Med.
 SO Nippon Shinzo Kekkan Geka Gakkai Zasshi (Japanese Journal of Cardiovascular Surgery), (1998) vol. 27, no. 4, pp. 222-226. Journal Code: Y0192A (Fig. 4, Ref. 12)
 ISSN: 0285-1474
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 38 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 970731490 JICST-EPlus
 TI Urgent coronary artery bypass surgery by only arterial graft for acute myocardial infarction.
 AU HAYASHI SAIHO; SASAKI MASARU; KAWAMOTO JUN
 CS Chugoku Rosai Hosp.
 SO Nippon Kyobu Geka Gakkai Zasshi (Journal of the Japanese Association for Thoracic Surgery), (1997) vol. 45, no. 7, pp. 935-939. Journal Code: Z0767A (Tbl. 1, Ref. 27)
 ISSN: 0369-4739
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 39 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 970699865 JICST-EPlus
 TI A Case of Acute Myocardial Infarction during Intravenous Ritodrine Treatment for Preterm Labor.
 AU SAIJO YASUAKI; MATSUZAKA TOMOYUKI; HONDA HAJIME; NORO TADATAKA; KOMORI HARUMI; NAKATA TOSHIYUKI
 CS Enaru Kosei Hosp.
 SO Kokyu to Junkan (Respiration and Circulation), (1997) vol. 45, no. 8, pp. 825-828. Journal Code: Z0660A (Fig. 4, Tbl. 1, Ref. 9)
 ISSN: 0452-3458
 CY Japan
 DT Journal; Short Communication
 LA Japanese
 STA New

L11 ANSWER 40 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN DUPLICATE 8
 AN 97267119 EMBASE
 DN 1997267119
 TI Transmyocardial laser revascularisation combined with coronary artery bypass grafting without cardiopulmonary bypass.
 AU Trehan N.; Mishra M.; Bapna R.; Mishra A.; Maheshwari P.; Karlekar A.
 CS M. Mishra, Escorts Heart Inst, Research Centre, Okhla Road, New Delhi-110 025, India
 SO European Journal of Cardio-thoracic Surgery, (1997) 12/2 (276-284).

ISSN: 1010-7940 CODEN: EJCSE7
PUI S 1010-7940(97)00098-5
CY Netherlands
DT Journal; Article
FS 009 Surgery
018 Cardiovascular Diseases and Cardiovascular Surgery
LA English
SL English

L11 ANSWER 41 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 9
AN 1997:176416 BIOSIS
DN PREV199799468129
TI Indications and problems of coronary artery bypass grafting without
cardiopulmonary bypass.
AU Kondo, Keiichiro [Reprint author]; Minohara, Seiichiro; Sawada, Yoshihide;
Irie, Hiroshi; Okamoto, Ken; Kinugasa, Seiji; Nakao, Masatomo; Sasaki,
Shinjiro
CS Dep. Thoracic Surgery, Osaka Med. College, 2-7 Daigaku-cho, Takatsuki
City, Osaka 569, Japan
SO Surgery Today (Tokyo), (1997) Vol. 27, No. 3, pp. 202-206.
DT Article
LA English
ED Entered STN: 24 Apr 1997
Last Updated on STN: 24 Apr 1997

L11 ANSWER 42 OF 90 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 97:211222 SCISEARCH
GA The Genuine Article (R) Number: WM022
TI Indications and problems of coronary artery bypass grafting without
cardiopulmonary bypass
AU Kondo K (Reprint); Minohara S; Sawada Y; Irie H; Okamoto K; Kinugasa S;
Nakao M; Sasaki S
CS OSAKA MED COLL, DEPT THORAC SURG, 2-7 DAIGAKU CHO, TAKATSUKI, OSAKA 569,
JAPAN (Reprint)
CYA JAPAN
SO SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, (FEB 1997) Vol. 27, No. 3,
pp. 202-206.
Publisher: SPRINGER VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010.
ISSN: 0941-1291.
DT Article; Journal
FS CLIN
LA English
REC Reference Count: 9
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L11 ANSWER 43 OF 90 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1997-43118 DRUGU T
TI The effect of prolonged low-dose nitroglycerin infusion on left
ventricular diastolic function early after myocardial infarction.
AU Piszczek I; Grajek S; Skorupski W; Taronka A; Grygier M; Prech M; Popiel
M; Mularek Kubzdela T; Kowal J; Cieslinki A
LO Poznan, Pol.
SO Eur.Heart J. (18, Abstr.Suppl., 172, 1997) 1 Tab.
CODEN: EHJODF ISSN: 0195-668X
AV University School of Medical Sciences, Cardiology Department, Poznan,
Poland.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L11 ANSWER 44 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 97171174 EMBASE
DN 1997171174
TI Metabolic and hemodynamic effects of unilateral tourniquet application on
lower extremities of the patients with ***coronary*** ***artery***
disease
AU Erol U.; Ay B.; Dogu D.
CS U. Erol, Dept. Anesthesiology and Reanimation, Faculty of Medicine,
Marmara University, Istanbul, Turkey
SO Marmara Medical Journal, (1997) 10/2 (91-99).
Refs: 12
ISSN: 1019-1941 CODEN: MMJOF4

DT Journal; Article
FS 009 Surgery
018 Cardiovascular Diseases and Cardiovascular Surgery
024 Anesthesiology
033 Orthopedic Surgery
LA English
SL English

L11 ANSWER 45 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 97145902 EMBASE
DN 1997145902
TI Perioperative risk of coronary patients undergoing major urological
operations. The role of prophylactic administration of Diltiazem.
AU Hatziantoniou G.P.; Tassiopoulos P.A.; Fakiolas C.N.; Foussas S.G.;
Lykourinas M.G.
CS G.P. Hatziantoniou, Tzanio Hospital, Cardiology Department, Piraeus,
Greece
SO Hellenic Journal of Cardiology, (1997) 38/1 (28-34).
Refs: 14
ISSN: 1011-7970 CODEN: HLKEAE
CY Greece
DT Journal; Article
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
028 Urology and Nephrology
030 Pharmacology
037 Drug Literature Index
LA Greek
SL Greek; English

L11 ANSWER 46 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 960687559 JICST-EPlus
TI Study on variation of serum enzymes during and after extracorporeal
circulation. Relationship with intraoperative factors.
AU MATSUI YOSHIRO; ISHII KOJI; SHIYA NORIHIKO; MURASHITA TOSHIFUMI; SASAKI
SHIGEYUKI; SAKUMA MAKOTO; YASUDA KEISHU
CS Hokkaido Univ.
SO Jinko Zoki, Nippon Jinko Zoki Gakkai (Japanese Journal of Artificial
Organs), (1996) vol. 25, no. 1, pp. 60-62. Journal Code: Z0557B (Fig. 4,
Ref. 8)
ISSN: 0300-0818
CY Japan
DT Journal; Article
LA Japanese
STA New

L11 ANSWER 47 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 960128779 JICST-EPlus
TI A Case of Shower Embolism Using IABP on a Patient Undergoing Hemodialysis
Who Had Acute Myocardial Infarction.
AU KISHI HISAYO; HIROOKA KEIJI; YASUDA TAKENORI; TANIGUCHI TOKUSHI; OKADA
TAKEO; IKE SHINPEI; CHIN WAKATOMI; ASAO MASATO; HAYASHI TOORU
CS Osaka National Hospital
SO Iryo (Japanese Journal of National Medical Services), (1995) vol. 49, no.
12, pp. 1033-1035. Journal Code: F0707A (Fig. 2, Tbl. 1)
CODEN: IRYOAV; ISSN: 0021-1699
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L11 ANSWER 48 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 950516483 JICST-EPlus
TI Clinical Evaluation of Prophylactic Nitroglycerin Infusion during Coronary
Artery Bypass Grafting.
AU AMANO HOMARE; OKUDA MASAHIRO; FURUHASHI KAZUHISA; UTSUNOMIYA HIROFUMI;
NAKAI YASUSHI; MUNEYUKI MANNOSUKE
CS Mie Univ., Sch. of Med.
SO Masui (Japanese Journal of Anesthesiology), (1995) vol. 44, no. 4, pp.
594-596. Journal Code: F0838A (Fig. 2, Tbl. 2, Ref. 4)
CODEN: MASUAC; ISSN: 0021-4892
CY Japan
DT Journal; Article
LA Japanese
STA New

L11 ANSWER 49 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 960306626 JICST-EPlus
 TI A Case with Cardiac Ischemia Induced by Mesenteric Traction.
 AU SUYAMA HIDEMICHI; KAWAMOTO MASASHI; YAMANOUE TAKAO; OKADA KUNIKO; YUGE
 OSAFUMI
 CS Univ. Med. Hosp. Hiroshima Univ.
 SO Masui to Sosei (Hiroshima Journal of Anesthesia), (1995) vol. 31, no. 4,
 pp. 265-266. Journal Code: S0305A (Fig. 1, Ref. 8)
 ISSN: 0385-1664
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 50 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 950199532 JICST-EPlus
 TI A Case of Acute Myocardial Infarction Associated with Myocardial Bridge.
 AU YOSHIDA TOORU; KARASAWA NAOKO; SADA HIDEO; KAWABATA KAZUTO
 MURAMATSU JUN; KIKAWADA RYUICHI
 CS Keisukai Kanazawabyoin
 Kitasato Univ., Sch. of Med.
 SO Kokyu to Junkan (Respiration and Circulation), (1995) vol. 43, no. 2, pp.
 201-204. Journal Code: Z0660A (Fig. 3, Ref. 12)
 ISSN: 0452-3458
 CY Japan
 DT Journal; Short Communication
 LA Japanese
 STA New

L11 ANSWER 51 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 940955444 JICST-EPlus
 TI The efficacy of both antegrade and retrograde cardioplegia in coronary
 artery bypass surgery.
 AU YAMAGUCHI AKIMITSU; KITAMURA NOBUO; KIMURA SHUN'ICHI; IRIE HIROSHI; KO
 TOKUMITSU; SHUNTO KEISUKE
 CS Osaka National Hospital
 SO Nippon Kyobu Geka Gakkai Zasshi (Journal of the Japanese Association for
 Thoracic Surgery), (1994) vol. 42, no. 10, pp. 1916-1924. Journal Code:
 Z0767A (Fig. 6, Tbl. 3, Ref. 32)
 ISSN: 0369-4739
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 52 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 940582670 JICST-EPlus
 TI Serum cardiac markers in hemodialysis patients.
 AU TERAOKA SETSUO; NAKAO TOSHIYUKI
 CS Tokyo Medical College
 SO Nippon Toseki Igakkai Zasshi (Journal of Japanese Society for Dialysis
 Therapy), (1994) vol. 27, no. 6, pp. 955-960. Journal Code: X0954A (Fig.
 3, Tbl. 3, Ref. 16)
 ISSN: 1340-3451
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 53 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN DUPLICATE 10
 AN 940331084 JICST-EPlus
 TI Coronary Artery Spasm after Mitral Valve Replacement: A Case Report.
 AU KANNO MEGUMU; KURIHARA HISAO; SATO MASATO; HAMAWAKI MASAYOSHI; HONDA
 MASATOMO
 CS Hondakinen Tohokujunkankikabyoin
 SO Kyobu Geka (Japanese Journal of Thoracic Surgery), (1994) vol. 47, no. 4,
 pp. 315-318. Journal Code: Z0662A (Fig. 6, Ref. 8)
 ISSN: 0021-5252
 CY Japan
 DT Journal; Commentary
 LA Japanese
 STA New

L11 ANSWER 54 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN DUPLICATE 11
 AN 940297383 JICST-EPlus

artery bypass surgery.

AU MOIZUMI YOSHIMASA; OSAKA KENSHI; AKASAKA JUN'ETSU; KONDO SHUN'ICHI;
SHIMIZU MASAYUKI; UCHIYAMA TETSUYUKI; IMAI YOSHIMICHI; KUMAGAI TOMOKO;
SUZUKI ICHIRO

CS Sendai City Medical Center

SO Nippon Kyobu Geka Gakkai Zasshi (Journal of the Japanese Association for
Thoracic Surgery), (1994) vol. 42, no. 2, pp. 198-205. Journal Code:
Z0767A (Fig. 6, Tbl. 4, Ref. 25)
ISSN: 0369-4739

CY Japan

DT Journal; Article

LA Japanese

STA New

L11 ANSWER 55 OF 90 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN

AN 1994-01792 DRUGU T S

TI Possible Myocardial Toxicity Associated with Interleukin-4 Therapy.

AU Trehu E G; Isner J M; Mier J W; Karp D D; Atkins M B

CS Univ.Tufts

LO Boston, Massachusetts, United States

SO J.Immunother. (14, No. 4, 348-51, 1993) 2 Fig. 26 Ref.

AV Division of Hematology-Oncology, New England Medical Center, Box 245, 750
Washington St., Boston, MA 02111, U.S.A. (M.B.A.).

LA English

DT Journal

FA AB; LA; CT

FS Literature

L11 ANSWER 56 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

AN 93338913 EMBASE

DN 1993338913

TI Is continuous normothermic blood cardioplegia really a practical way of
myocardial preservation? Comparison with intermittent cold crystalloid
cardioplegia.

AU Demirtas M.; Dagsali S.; Tarcan S.; Sungu U.

CS Ahmet Celebi M., Sumbulzade S., 20/3-81160 Uskudar, Istanbul, Turkey

SO Thoracic and Cardiovascular Surgeon, (1993) 41/5 (284-289).
ISSN: 0171-6425 CODEN: TVCHAF

CY Germany

DT Journal; Article

FS 018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index

LA English

SL German; English

L11 ANSWER 57 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN

AN 930378675 JICST-EPlus

TI A clinical trial of recombinant human superoxide dismutase for myocardial
protection.

AU TAKEMURA TAKAHIRO

CS Tokyo Women's Medical College, Heart Inst. of Japan

SO Nippon Kyobu Geka Gakkai Zasshi (Journal of the Japanese Association for
Thoracic Surgery), (1993) vol. 41, no. 2, pp. 247-253. Journal Code:
Z0767A (Fig. 8, Tbl. 1, Ref. 22)
ISSN: 0369-4739

CY Japan

DT Journal; Article

LA Japanese

STA New

L11 ANSWER 58 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN

AN 930681045 JICST-EPlus

TI Effect of the Myocardial Protection Method in Patients with Ischemic Heart
Disease: Relation of Duration of Aortic Cross Clamping to the
Postoperative Severity of Myocardial Damage and Left Ventricular
Impairment.

AU TAMURA SUSUMU

CS Toho Univ., School of Medicine, Ohashi Hospital

SO Toho Igakkai Zasshi (Journal of the Medical Society of Toho University),
(1993) vol. 40, no. 2, pp. 196-209. Journal Code: G0654A (Fig. 8, Tbl. 11,
Ref. 28)
CODEN: TOIZAG; ISSN: 0040-8670

CY Japan

DT Journal; Article

STA New

L11 ANSWER 59 OF 90 PHIN COPYRIGHT 2004 PJB on STN

AN 92:6000 PHIN
DN S00308044
DED 23 Apr 1992
TI Acadesine beneficial in Coronary Artery Bypass Graft (CABG) surgery
SO Scrip (1992) No. 1713 p23
DT Newsletter
FS FULL

L11 ANSWER 60 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 12

AN 1993:71410 BIOSIS
DN PREV199395035910
TI Cardiac isoenzymes following heart transplantation.
AU Ladowski, Joseph S. [Reprint author]; Sullivan, Margaret; Schatzlein, Michael H.; Peterson, Alan C.; Underhill, David J.; Scheeringa, Ronald H.
CS Indiana/Ohio Heart, 7910 West Jefferson Blvd., Fort Wayne, Indiana 46804, USA
SO Chest, (1992) Vol. 102, No. 5, pp. 1520-1521.
CODEN: CHETBF. ISSN: 0012-3692.
DT Article
LA English
ED Entered STN: 26 Jan 1993
Last Updated on STN: 27 Jan 1993

L11 ANSWER 61 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN

AN 930210051 JICST-EPlus
TI The effect of human superoxide dismutase on reperfusion injury in clinical cases.
AU TAKATA KOJI
CS Okayama Univ., School of Medicine
SO Okayama Igakkai Zasshi, (1992) vol. 104, no. 11-12, pp. 1127-1134. Journal Code: Z0158B (Fig. 5, Tbl. 3, Ref. 31)
ISSN: 0030-1558
CY Japan
DT Journal; Article
LA Japanese
STA New

L11 ANSWER 62 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN

AN 920133701 JICST-EPlus
TI A Case of Acute Severe Myocarditis with Myocardial Infarction Like ECG Findings. The Investigation of Myocardial Interstitial Fibrosis by the Monoclonal Antibodies to Collagen Fiber Subtypes (Type I, III, IV).
AU SUZUKI HIROYUKI; UEMURA SHIGERU; MINAMI YORIAKI; NERAI HIROYUKI; KOIKE MICHIO; MAEDA JIRO; OSHIMA AKIRA
MIYASHIRO EIKICHI
CS Wakayama Medical College
Wakayama Rosai Hospital
SO Nippon Shoni Junkanki Gakkai Zasshi (Acta Cardiologica Paediatrica Japonica), (1992) vol. 7, no. 4, pp. 560-565. Journal Code: X0809A (Fig. 5, Tbl. 2, Ref. 26)
ISSN: 0911-1794
CY Japan
DT Journal; Article
LA Japanese
STA New

L11 ANSWER 63 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN

AN 920367194 JICST-EPlus
TI A Case of Unstable Angina Pectoris Associated with an Active Phase of Polymyositis.
AU YASU TAKANORI
NONOGI HIROSHI; OSHIMA SHUICHI; DAIKOKU SATOSHI; HAZE KAZUO
CS Jichiidai Omiyaiyose
National Cardiovascular Center
SO Kokyu to Junkan (Respiration and Circulation), (1992) vol. 40, no. 5, pp. 491-494. Journal Code: Z0660A (Fig. 3, Ref. 9)
ISSN: 0452-3458
CY Japan
DT Journal; Article
LA Japanese

L11 ANSWER 64 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 920587221 JICST-EPlus
 TI Coronary air embolism during the mitral regurgitation tests.
 AU IMOTO YUTAKA; SESE AKIRA; UENO YASUTAKA; TODOROKI HARUTOMO; OE MASAHIRO;
 TANAKA KEN'ICHIRO; MASAKI HIDETO
 CS Kyushu Kosei Nenkin Hospital
 SO Kosei Nenkin Byoin Nenpo (Annual Bulletin of Kosei-Nenkin Hospitals),
 (1992) vol. 18(1991), pp. 103-108. Journal Code: Y0366A (Fig. 2, Tbl. 1,
 Ref. 6)
 ISSN: 0388-2314
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 65 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
 DUPLICATE 13
 AN 1991:428389 BIOSIS
 DN PREV199192084554; BA92:84554
 TI INCIDENCE OF ABNORMAL RNA STUDIES AND DYSRHYTHMIAS IN PATIENTS WITH BLUNT
 CHEST TRAUMA.
 AU MCLEAN R F [Reprint author]; DEVITT J H; DUBBIN J; MCLELLAN B A
 CS DEP ANESTHESIA, SUNNYBROOK HEALTH SCI CENT, 2075 BAYVIEW AVE, TORONTO,
 ONTARIO M4N 3M5, CAN
 SO Journal of Trauma, (1991) Vol. 31, No. 7, pp. 968-970.
 CODEN: JOTRA5. ISSN: 0022-5282.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 26 Sep 1991
 Last Updated on STN: 26 Sep 1991

L11 ANSWER 66 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 910934341 JICST-EPlus
 TI Diagnosis of Acute Myocardial Infarction Using Dual SPECT (99mTc PYP and
 201Tl Cl) Method: Diagnostic Availability and Quantitative Assessment of
 Infarct Area.
 AU HONDA NORIBUMI; ABE MASAHIRO; TAYA KOICHI; TAKADA YOSHIFUMI; OGAWA
 TAKASHI; INUZUKA HIROSHI; ABE TOSHIHIRO; NAGAI YOSHIKAZU
 CS Tokyo Medical College
 SO Tokyo Ika Daigaku Zasshi (Journal of Tokyo Medical College), (1991) vol.
 49, no. 5, pp. 652-660. Journal Code: F0570A (Fig. 7, Tbl. 4, Ref. 20)
 CODEN: TIDZAH; ISSN: 0040-8905
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 67 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 930153803 JICST-EPlus
 TI Evaluation of healing process in myocardial infarction by the time course
 of serum myosin light chain I. The effects of early reperfusion.
 AU ASAJI TAKAYOSHI; MURAKAMI EIJI; TAKEKOSHI NOBORU
 CS Kanazawa Medical Univ.
 SO J Cardiol, (1991) vol. 21, no. 3, pp. 579-587. Journal Code: Y0264A (Fig.
 4, Tbl. 2, Ref. 20)
 ISSN: 0914-5087
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 68 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 910363292 JICST-EPlus
 TI Ischemic myocardial disorder in acute phase subarachnoid hemorrhage:
 Clinical study of 52 patients.
 AU MATSUMURA HAJIME; IWAI FUMIHARU; ICHIKIZAKI KIYOSHI
 CS Second Tokyo National Hospital
 SO Neurol Surg, (1991) vol. 19, no. 4, pp. 349-357. Journal Code: Z0684A
 (Fig. 9, Tbl. 10, Ref. 16)
 ISSN: 0301-2603
 CY Japan
 DT Journal; Article
 LA Japanese

L11 ANSWER 69 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 910461437 JICST-EPlus
 TI Clinical application of Indium-111 antimyosin antibody and Thallium-201 dual nuclide single photon emission computed tomography in acute myocardial infarction.
 AU YOSHIDA H; MOCHIZUKI M; KAINOUCHI M; ISHIDA T; SAKATA K; YOKOYAMA S; HOSHINO T; TAKEZAWA M; KABURAGI T
 CS Shizuoka General Hospital, Shizuoka, JPN
 SO Ann Nucl Med, (1991) vol. 5, no. 1, pp. 41-46. Journal Code: X0838A (Fig. 3, Tbl. 2, Ref. 15)
 CODEN: ANMEEEX; ISSN: 0914-7187
 CY Japan
 DT Journal; Article
 LA English
 STA New

L11 ANSWER 70 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 900873002 JICST-EPlus
 TI Granulocytes cause reperfusion injury after 180 minute hypothermic cardioplegic arrest in dogs.
 AU ISEKI HARUKAZU; SOUMA YASUHIRO; ONOYUCHI KATSUHISA; SHIMIZU HIDEYUKI; INOUE TADASHI
 CS Keio Univ., School of Medicine
 SO Nippon Geka Gakkai Zasshi (Journal of Japan Surgical Society), (1990) vol. 91, no. 9, pp. 1417-1420. Journal Code: Z0009B (Fig. 4, Ref. 9)
 ISSN: 0301-4894
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 71 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 900511151 JICST-EPlus
 TI Serial changes of enzymes, CPK & LDH and their isoenzyme pattern, in anterior and posterior papillary muscle of left ventricle produced by ischemia.
 AU HOSAKA HIDEAKI; YAMASAWA IKUHIRO; KIYOMI SADAMICHI; AOKI MAKOTO; KASAI RYUTARO; TSUMAKI NANAE; CHIYOTANDA SHIGERU; ICHIKI TAKEO; RAKUE HIROYUKI
 CS Tokyo Medical College
 SO Tokyo Ika Daigaku Zasshi (Journal of Tokyo Medical College), (1990) vol. 48, no. 2, pp. 148-157. Journal Code: F0570A (Fig. 9, Ref. 21)
 CODEN: TIDZAH; ISSN: 0040-8905
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 72 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 900029057 JICST-EPlus
 TI Basic studies in relation between metabolic changes and rate pressure products on ischemic myocardium treated with ulinastatin.
 AU YADA HIROAKI; YAMASAWA IKUHIRO; KIYOMI SADAMICHI; IKEBE NOBUHIKO; USUI MIKIO; NAKAGAWA NORIO; KASAI RYUTARO; TSUMAKI NANAE; ICHIKI TAKEO
 CS Tokyo Medical College
 SO Tokyo Ika Daigaku Zasshi (Journal of Tokyo Medical College), (1989) vol. 47, no. 5, pp. 768-778. Journal Code: F0570A (Fig. 10, Tbl. 3, Ref. 19)
 CODEN: TIDZAH; ISSN: 0040-8905
 CY Japan
 DT Journal; Article
 LA Japanese
 STA New

L11 ANSWER 73 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 900442718 JICST-EPlus
 TI Evaluation of myocardial protection with DBcAMP in crystalloid cardioplegic solutions.
 AU ISHIKURA YOSHIYA; ODAGIRI SHIGETO; SHIMAZU AKIRA; TOKUNAGA HIROYUKI; SHIMOKAWAJI MASATAKE; YOSHIMATSU HIROSHI
 CS Univ. of Occupational and Environmental Health
 SO Rinsho Kyobu Geka (Japanese Annals of Thoracic Surgery), (1989) vol. 9, no. 6, pp. 559-563. Journal Code: Y0501A (Fig. 4, Tbl. 3, Ref. 17)
 ISSN: 0389-7893
 CY Japan
 DT Journal; Article

STA New

L11 ANSWER 74 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 890480721 JICST-EPlus
TI Report of a case of lung cancer with metastasis to the myocardium which showed electrocardiographic findings similar to acute myocardial infarction and intramyocardial mass on echocardiography.
AU DAZAI YASUNOBU; KATO ICHIJIRO; SUEDA SHOUZO; KATO TOSHIKAZU; YOSHIDA RYOICHI
FUJII MASAFUMI
KAZATANI SACHIO
CS Yawatahama City General Hospital
National Shikoku Cancer Center Hospital
Ehime Univ., School of Medicine
SO Kokyu to Junkan (Respiration and Circulation), (1989) vol. 37, no. 4, pp. 461-465. Journal Code: Z0660A (Fig. 5, Ref. 18)
ISSN: 0452-3458
CY Japan
DT Journal; Article
LA Japanese
STA New

L11 ANSWER 75 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 14
AN 1989:309468 BIOSIS
DN PREV198988023198; BA88:23198
TI CARDIAC COMPLICATIONS OF ANEURYSM REPAIR.
AU CAMPBELL J B [Reprint author]; BAKER J; MORRIS D M
CS 1038 MAPLE AVE, ZANESVILLE, OH 43701, USA
SO Southern Medical Journal, (1989) Vol. 82, No. 4, pp. 458-461.
CODEN: SMJOAV. ISSN: 0038-4348.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 30 Jun 1989
Last Updated on STN: 30 Jun 1989

L11 ANSWER 76 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 890429460 JICST-EPlus
TI Serum ***CPK*** /- ***MB*** activities in meconium aspiration syndrome, neonatal transient tachypnea and neonatal transient myocardial ischemia.
AU TAKECHI TETSUHISA; FUNAMOTO JIN'ICHI; OZAKI HITOSHI; FUJITA KEINOSUKE; SHINO KAZUKO
CS Osakashikinmuishikaishinseijijunkandotaikenkyuhan
SO Osakashi Kinmu Ishikai Kenkyu Nenpo, (1989) no. 17(1987), pp. 93-96.
Journal Code: Y0666A (Tbl. 6, Ref. 4)
ISSN: 0289-4521
CY Japan
DT Journal; Article
LA Japanese
STA New

L11 ANSWER 77 OF 90 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1989-09773 DRUGU T S
TI Myocardial Toxic Effects During Recombinant Interleukin-2 Therapy.
AU Nora R; Abrams J S; Tait N S; Hiponia D J; Silverman H J
LO Baltimore, Maryland, Rockford, Illinois, United States
SO J.Natl.Cancer Inst. (81, No. 1, 59-63, 1989) 4 Tab. 20 Ref.
CODEN: JNCIAM
AV University of Maryland Cancer Center, 22 South Greene St., Baltimore, MD 21201, U.S.A. (Abrams J S).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L11 ANSWER 78 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 880497628 JICST-EPlus
TI Sequelae mitral regurgitation and myocardial damage in a case of Kawasaki disease with early regression of coronary aneurysms.
AU TAKECHI TETSUHISA; TANI YOSHITAKA; OZAKI MARIKO; SANO YOSHIKO; KIDERA KATSUHIKO
TADA AKIO; SHOUJU YASUO
SAKAI YOSHIO

Osaka City Univ., Medical School
Izumi Municipal Hospital

SO Prog Med, (1988) vol. 8, no. 7, pp. 1743-1749. Journal Code: F0664B (Fig. 7, Ref. 10)
ISSN: 0287-3648
CY Japan
DT Journal; Article
LA Japanese
STA New

L11 ANSWER 79 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 890208376 JICST-EPlus

TI The efficacy of myocardial protection with prolonged aortic cross-clamping.

AU FUJIOKA YASUTADA; SONEDA JUN'ICHI; BAN TOSHIHIKO; OKAMOTO YOSHIFUMI; MATSUDA TOSHIHIKO; HIRATA KAZUO; KIYOTA YOSHIHARU; JINNO KIMIO; OGINO HITOSHI

CS Kyoto Univ., Faculty of Medicine, Hospital

SO Rinsho Kyobu Geka (Japanese Annals of Thoracic Surgery), (1988) vol. 8, no. 2, pp. 170-173. Journal Code: Y0501A (Fig. 2, Tbl. 3, Ref. 5)
ISSN: 0389-7893

CY Japan
DT Journal; Article
LA Japanese
STA New

L11 ANSWER 80 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 880053884 JICST-EPlus

TI Intravenous short-term coronary thrombolysis by a high-dose urokinase in aged patients with acute myocardial infarction.

AU SAKAI MAKOTO; UEDA KEIJI; KURAMOTO KIZUKU
MATSUSHITA SATORU

CS Tokyotorojin'iryose

SO Tokyo Metrop. Tama Geriatric Hospital

Nippon Ronen Igakkai Zasshi (Japanese Journal of Geriatrics), (1987) vol. 24, no. 4, pp. 354-360. Journal Code: Z0680A (Fig. 4, Tbl. 2, Ref. 13)
ISSN: 0300-9173

CY Japan
DT Journal; Article
LA Japanese
STA New

L11 ANSWER 81 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 880320268 JICST-EPlus

TI Assessment by total released ***CPK*** - ***MB*** in patients with acute myocardial infarction.

AU KOBAYASHI TOYOKAZU; ISHIKAWA NOBORU; KIMPARA TOSHIYUKI; KITAYAMA MASAHIKO; MIURA AKIRA; INAGAKI MASAO; NISHIOKA AKINORI; WADA TAIZO; KOTOURA HAJIME

CS Wakayama Red Cross Hospital

SO Med J Wakayama Red Cross Hosp, (1987) vol. 5, pp. 92-97. Journal Code: G0717B (Fig. 4, Ref. 22)
ISSN: 0289-1026

CY Japan
DT Journal; Article
LA Japanese
STA New

L11 ANSWER 82 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 870072364 JICST-EPlus

TI Myocardial microinfarction in a dog.

AU MACHIDA N; YAMAGA Y; YASUDA J; TOO K

CS Hokkaido Univ., Sapporo, JPN

SO Jpn J Vet Sci, (1986) vol. 48, no. 5, pp. 1057-1062. Journal Code: F0905A (Fig. 5, Tbl. 1, Ref. 20)
CODEN: NJUZA9; ISSN: 0021-5295

CY Japan
DT Journal; Short Communication
LA English
STA New

L11 ANSWER 83 OF 90 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 850350256 JICST-EPlus

TI Introduction of ***CPK*** - ***MB*** (myocardial type).

AU SUGISAKA SHIZUO; KAWAUCHI TERUMI; SAWADA TAEKO
CS Yachiyo Hospital

CY Japan
DT Journal; Article
LA Japanese
STA New

L11 ANSWER 84 OF 90 USPATFULL on STN
AN 84:56652 USPATFULL
TI Heart attack screening method, apparatus and kit for same
IN Kiyasu, John Y., 94 Meadow St., Garden City, NY, United States 11530
PI US 4476016 19841009
AI US 1982-360951 19820323 (6)
RLI Continuation of Ser. No. US 1980-177669, filed on 13 Aug 1980, now abandoned which is a continuation-in-part of Ser. No. US 1978-922885, filed on 10 Jul 1978, now abandoned which is a continuation-in-part of Ser. No. US 1976-730102, filed on 6 Oct 1976, now patented, Pat. No. US 4105499
DT Utility
FS Granted
LN.CNT 1395
INCL INCLM: 210/198.200
INCLS: 422/070.000; 210/927.000
NCL NCLM: 210/198.200
NCLS: 210/427.000; 422/070.000
IC [3]
ICM: B01N015-08
EXF 210/198.2; 210/446; 210/472; 210/DIG.24; 210/927; 055/386; 422/58; 422/59; 422/61; 422/70; 422/101; 422/104; 422/99; 435/17; 435/194; 435/803; 435/815; 435/816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 85 OF 90 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 15
AN 1984:256373 BIOSIS
DN PREV198477089357; BA77:89357
TI RELATIVE EFFICACY OF LEFT VENTRICULAR VENTING AND VENOUS DRAINAGE TECHNIQUES COMMONLY USED DURING CORONARY ARTERY BYPASS GRAFT SURGERY.
AU ROBERTS A J [Reprint author]; FARO R S; WILLIAMS L A; COHEN J A; KNAUF D K; ALEXANDER J A
CS DIV THORACIC AND CARDIOVASCULAR SURGERY, J HILLIS MILLER HEALTH CENTER, UNIV FLORIDA, GAINESVILLE, FL 32610, USA
SO Annals of Thoracic Surgery, (1983) Vol. 36, No. 4, pp. 444-452.
ISSN: 0003-4975.
DT Article
FS BA
LA ENGLISH

L11 ANSWER 86 OF 90 MEDLINE on STN
AN 84140881 MEDLINE
DN PubMed ID: 6608040
TI Myocardial revascularization by laser: a clinical report.
AU Mirhoseini M; Fisher J C; Cayton M
SO Lasers in surgery and medicine, (1983) 3 (3) 241-5.
Journal code: 8007168. ISSN: 0196-8092.
CY United States
DT (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198403
ED Entered STN: 19900319
Last Updated on STN: 19900319
Entered Medline: 19840330

L11 ANSWER 87 OF 90 USPATFULL on STN
AN 82:32825 USPATFULL
TI Heart attack screening method and process
IN Kiyasu, John Y., 94 Meadow St., Garden City, NY, United States 11530
PI US 4338396 19820706
AI US 1980-177662 19800813 (6)
RLI Continuation-in-part of Ser. No. US 1978-922885, filed on 10 Jul 1978, now abandoned which is a continuation-in-part of Ser. No. US 1976-730102, filed on 6 Oct 1976, now patented, Pat. No. US 4105499
DT Utility

LN.CNT 1138
INCL INCLM: 435/017.000
INCLS: 210/635.000; 210/927.000; 435/194.000; 435/803.000; 435/815.000;
435/816.000
NCL NCLM: 435/017.000
NCLS: 210/635.000; 435/194.000; 435/803.000; 435/815.000; 435/816.000
IC [3]
ICM: C12Q001-50
ICS: B01D015-08
EXF 435/17; 435/194; 435/803; 435/816; 435/815; 023/230B; 210/198.2;
210/635; 210/656; 210/927
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 88 OF 90 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 74140012 EMBASE
DN 1974140012
TI Intraoperative detection of myocardial damage during coronary artery
surgery by plasma creatine phosphokinase isoenzyme analysis.
AU Oldham Jr H.N.; Roe C.R.; Young Jr W.G.; Dixon Jr S.H.
CS Dept. Surg., Duke Univ. Med. Cent., Durham, N.C., United States
SO Surgery, (1973) 74/6 (917-925).
CODEN: SURGAZ
DT Journal
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
029 Clinical Biochemistry
LA English

L11 ANSWER 89 OF 90 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:204960 FEDRIP
NR CRISP 5M01RR00052-42 0753
TI OUTCOME--EARLY DETECTION/THERAPY OF MYOCARDIAL ISCHEMIA
SF Principal Investigator: MARTINEZ, ELIZABETH A; JOHNS HOPKINS MED
INSTITUTIONS, 2024 E MONUMENT ST, SUITE 2-600
CSP JOHNS HOPKINS UNIVERSITY, BALTIMORE, MARYLAND
CSS Supported By: NATIONAL CENTER FOR RESEARCH RESOURCES
DB 2010 (/01/75)
FYR 2003
DE 2011 (/30/04)
FU Noncompeting Continuation (Type 5)
FS National Institutes of Health

L11 ANSWER 90 OF 90 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:52483 FEDRIP
NR VA 137414
NC 0025, 544
TI A Rnd, Dbl-Bld, Plcb Cntl Trial of the Eff of Weekly Azithromycin on the
Incidence of Cor Artery Dis in Subjs w/ Evid of Exp to C. pneumoniae
SF Principal Investigator: Hassapoyannes, Constantine A., M.D.
CSP Department of Veterans Affairs, Medical Center, Columbia, SC
CSS Supported By: Department of Veterans Affairs. Research and Development
(15), 810 Vermont Ave. N.W., Washington, D.C., 20420, United States of
America
DB Nov 16, 2000
FS Department of Veterans Affairs
STN INTERNATIONAL LOGOFF AT 13:48:20 ON 13 AUG 2004